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
Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality
approach, depending on the stage and biology of the tumour and the acceptance and tolerance
of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy,
chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation
planning and delivery, and genomics, and the development of novel systemic therapy agents alongside
their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this
Special Issue entitled, ‘Treatment strategies and survival outcomes in breast cancer’, a number of
original research articles are included covering a diversity of studies, from pre-clinical and translational
biomarker studies to clinical trials and population-based studies. They evaluated survival and other
outcomes, including quality of life, in the context of pre-diagnosis (screening), as well as early and
advanced stages of breast cancer.
With the established survival benefits of prophylactic mastectomy in women with BRCA genetic
mutations, the procedure is increasingly being performed on the contralateral breast following diagnosis
of breast cancer. Teoh et al. conducted a review of the literature which mostly consisted of retrospective
studies with less than optimal data quality [1]. The evidence suggests a reduction of incidence of
contralateral breast cancer following the procedure in those with ‘high risk’, notably those with BRCA
genetic mutations, whereas survival benefits are uncertain. The overall benefits in other risk categories
are even more doubtful. In the area of pre-invasive cancer, Sieuwerts et al. observed in cases of ductal
carcinoma in situ an upregulation of APOBEC3B, which was previously seen in invasive carcinoma and
known to be associated with poor prognosis, suggesting its potential role in early carcinogenesis [2].
There are two studies on screening. Heller looked at approximately 993,000 individuals using a
national database, aiming to see why screening did not appear to decrease the incidence of stage IV
breast cancer [3]. They found that among those diagnosed up front with stage IV disease, 37.6% had
aggressive tumours as compared to 5.1% in those with stage 1 disease, suggesting that the two groups
are from different populations with different tumour phenotypes. Regarding screening, over-diagnosis
has been coined as the main concern. Fann et al. evaluated the 15-year adjusted cumulative survival of
breast cancer in a cohort in Sweden, and noted that the majority of survivors could be attributed to cure
arising from screening and subsequent treatments [4]. According to their interpretation, over-diagnosis
had minimal contribution.
For primary breast cancer, Corradini et al. analysed the oncological outcomes of 7565 cases
of breast cancer in a case-controlled cohort study comparing breast conserving surgery followed
by radiotherapy with mastectomy, showing that the former was associated with better recurrence
control and survival, and as such recommended physicians to encourage women to receive such
treatment [5]. While the findings are interesting, provocative and continue to be reassuring in terms
of the efficacy of breast conserving surgery, their applications must be cautioned. The findings have
not been consistently shown by randomised controlled trials and must be further investigated before
a change in practice is implemented. This Special Issue also contains a few studies related to breast
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cancer in older patients. In a population-based registry study in the Netherlands, survival in these
patients was found to be poorer when compared to their younger counterparts, and the observation
was shown to be associated with a proportionately reduced use of surgery and increased use of primary
endocrine therapy [6]. As discussed by the researchers, this phenomenon has been picked up in
other studies and changes in treatment guidelines have since been made. While surgery is now the
primary treatment of choice in this population as in the younger one, alternative treatments such as
primary endocrine therapy may still be appropriate, especially in patients with competing causes of
death due to significant comorbidities. Given this, and other needs to appropriately select treatments,
including primary and adjuvant therapies in this challenging population, biomarker studies play a
very important role in translational research. Three such biomarkers—LKB1 [7] and cytoplasmic cyclin
E [8] (poor prognostic in the older (>70 years) population), and HDAC5 [9] (poor prognostic in the
very young (<35 years) patients)—have been found to be associated with age. Furthermore, other
conventional and emerging prognostic and predictive factors were investigated and reported in this
Special Issue. Kim et al. highlighted the use of high lymph-node ratio following axillary surgery as an
indicator of poor prognosis and the need for radiotherapy to the supraclavicular fossa in a retrospective
study [10]. However, sentinel node biopsy has now become the standard axillary staging procedure,
making the precise calculation of the ratio difficult. As a result, its potential clinical application is likely
to be limited. In addition, Abdel-Fatah studied an emerging biomarker, ERCC1, a DNA excision repair
protein, and noted its potential prognostic significance and ability to predict response in neoadjuvant
chemotherapy [11]. In a different study using a cell line model, Gaule et al. identified the potential role
of combining dasatinib and a c-Met inhibitor, in order to combat dasatinib resistance in triple negative
breast cancer [12].
In the context of metastatic breast cancer, the Special Issue contains two pieces of work focusing on
important new targeted therapies currently licensed for clinical use, CDK4/6 inhibitors and anti-HER2
therapies. Rossi et al. carried out a network meta-analysis comparing the combination use of individual
CDK4/6 inhibitors with fulvestrant or an aromatase inhibitor [13]. They found that CDK4/6 inhibitors
have similar efficacy when combined with an aromatase inhibitor in the first-line treatment of hormone
receptor positive disease, and are superior to either endocrine agent as monotherapy, regardless of any
other patient or tumour characteristics. While this may be seen as reassuring for those who are strong
supporters of using such a combination despite the concerns on increased toxicity, the authors admitted
the limitations of their meta-analysis, including not using actual patient data, the lack of uniformity
in terms of prior use of endocrine therapy, and the fact that some trials employed non-standard
fulvestrant dose (250 mg, rather than 500 mg). On the other hand, the PRAEGNANT Real-World Breast
Cancer Registry study reviewed the landscape of using anti-HER2 therapies [14]. Both novel therapies
(pertuzumab/trastuzumab and T-DM1) are utilised in a high proportion of HER2 positive breast cancer
patients. Most patients were found to receive T-DM1 after pertuzumab/trastuzumab in a real-world
setting. The Special Issue contains two other interesting studies regarding this disease stage. Keup et al.
advocated a ‘comprehensive’ liquid biopsy, including both cell-free DNA mutational and circulating
tumour cell transcriptional analyses, which could increase the chance of identifying actionable targets
at which to direct therapeutic strategies [15]. Pelizzari identified the change in plasma LDH levels as a
potential cost-effective biomarker of prognosis in the early course of systemic therapy [16]. According
to the results of their study, patients who maintained elevated LDH levels after 12 weeks of first-line
treatment experienced worse survival outcomes when compared to those with stable normal LDH
levels, even after adjustment for other prognostic factors.
Finally, as opposed to survival outcomes, Hong et al. carried out a systematic review and
meta-analysis of randomised controlled trials to investigate quality of life as another important
treatment outcome for breast cancer [17]. Their work showed that exercise interventions improved
quality of life and that the ‘time of session’ (longer than 45 minutes) appeared to be crucial in achieving
significant improvement.
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	

Abstract: The uptake of contralateral prophylactic mastectomy is rising with increasing trends that
are possibly highest in the USA. Whilst its role is generally accepted in carriers of recognized high-risk
predisposition genes such as BRCA1 and BRCA2 when the affected individual is premenopausal,
controversy surrounds thebenefit in less understood risk-profile clinical scenarios. This comprehensive
review explores the current evidence underpinning the role of contralateral prophylactic mastectomy
and its impact on contralateral breast cancer risk and survival in three distinct at-risk groups affected
by unilateral breast cancer: known genetic carriers, thosewith strong familial risk but no demonstrable
genetic mutation and women who are of young age at presentation. The review supports the role of
contralateral prophylactic mastectomy in “high risk” groups where the evidence suggests a reduction
in contralateral breast cancer risk. However, this benefit is less evident in women who are just
young at presentation or those who have strong family history but no demonstrable genetic mutation.
A multidisciplinary and personalized approach to support individuals in a shared-decision making
process is recommended.
Keywords: contralateral prophylacticmastectomy; contralateral breast cancer; BRCA; CHEK2; PALB2;
ATM; mutation carriers; family history; survival
1. Introduction
The incidence of women with breast cancer who elect to undergo contralateral prophylactic
mastectomy is steadily increasing, with preponderance amongst Caucasians, young women, and those
with a higher socioeconomic status [1,2]. A study of 496,488 women with unilateral Stage I–III breast
cancer, from the Surveillance, Epidemiology, End Results (SEER) Program database demonstrated an
increase in contralateral prophylactic mastectomy rates performed for unilateral invasive breast cancer
from 3.9% in 2002 to 12.7% in 2012 [3]. This effect was reproduced in a National Cancer Database
review of 553,593 patients, showing an increase in contralateral prophylactic mastectomies from 4.1%
in 2003 to 9.7% in 2010. This finding was most marked in young women, where those <45 years
(n = 73,888) showed an increase from 9.3% in 2003 to 26.4% in 2010 [4].
Factors that contribute to this decision include patient age, disease stage, previous breast biopsies,
genetic predisposition or family history of breast cancer, fear of recurrence, concern with cosmetic
symmetry and physician recommendation [1,5–8].
Patients tend to overestimate their risk of developing a contralateral breast cancer [9,10] as well as
the extent of risk reduction conferred by contralateral prophylactic mastectomy [9,11]. Interestingly,
Cancers 2020, 12, 140; doi:10.3390/cancers12010140 www.mdpi.com/journal/cancers5
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whilst 43.9% ofwomenwith breast cancer considered contralateral prophylacticmastectomy, only 38.1%
were aware that it did not improve survival, highlighting the importance of patient education [12].
Improvements in modern multidisciplinary management have led to a reduction in the incidence
of contralateral breast cancer from approximately 0.6% to 0.2–0.5%/year [13]. Consequently, the role of
contralateral prophylactic mastectomy and the context in which it is supported is debatable.
This comprehensive review explores the current evidence underpinning the role of contralateral
prophylactic mastectomy and its impact on contralateral breast cancer risk and survival in three
high-risk groups affected by breast cancer: (i) genetic carriers, (ii) strong family history with no
demonstrable mutation, and (iii) young women.
2. Methods
A comprehensive literature review was performed, assessing all studies published in the English
literature from 1974 to March 2019 across Embase and Medline search engines. Search terms
“contralateral prophylactic mastectomy”, “unilateral breast cancer”, “BRCA”, “TP53”, “PALB2”,
“CHEK2”, “ATM”, “mutation carrier”, “family history”, “young women”, “non-genetic carriers”,
“overall survival”, “disease-free survival”, “contralateral breast cancer” and “risk” were included.
Relevant references from identified papers were also included.
3. BRCA 1/2 Carriers with Breast Cancer
3.1. BRCA 1/2 Carriers and Contralateral Breast Cancer Risk
BRCA carriers with breast cancer carry a higher risk of contralateral breast cancer, 23.7% (95% CI
17.6–30.5), compared with non-carriers, 6.8% (95% CI 4.2–10), respectively, (RR 3.56, 95% CI 2.50–5.08;
p < 0.001). This risk was higher in BRCA1 compared to BRCA2 carriers (RR 1.42, 95% CI 1.01–1.99;
p = 0.04) [14]. In a Dutch multicentre study of 6294 invasive breast cancer patients ≤50 years, the risk
of contralateral breast cancer for BRCA1/2 carriers at a median follow-up of 12.5 years was shown to
be 2–3 times higher compared to non-carriers (HR 3.31, 95% CI 2.41–4.55; p < 0.001 and 2.17, 95% CI
1.22–3.85; p = 0.01 respectively). The 10-year cumulative contralateral breast cancer risk following the
initial breast cancer diagnosis was 21.1% for BRCA1, 10.8% for BRCA2 and 5.1% for non-carriers [15].
These findings were confirmed in a recent multicentre study where the 10-year cumulative risk was
25.1% (95% CI 19.6–31.9) for BRCA1, 13.5% (95% CI 9.2–19.1) for BRCA2 and 3.6% (95% CI 2.2–5.7) for
non-carriers [16].
The age of first breast cancer diagnosis is a significant predictor of contralateral breast cancer
risk in BRCA carriers [17–19]. Risk estimates vary in the literature, ranging from 23.7–30.7% in young
women (<40 years) across BRCA1/2 carriers combined (BRCA1: 24–32%; BRCA2: 17–29%) [19–24].
This risk is lower in the >40 years age group, ranging from 8.4–21% (BRCA1: 11–52%; BRCA2:
7–18%) [15,17,19–22,24,25]. Similar results were shown in another study demonstrating a 10-year
cumulative contralateral breast cancer risk of 23.9% (BRCA1: 25.5%; BRCA2: 17.2%) in patients
<41 years, compared to 12.6% in the 41–49 year group (BRCA1 15.6%; BRCA2 7.2%) [15].
In a retrospective study of 1042 BRCA1/2 carriers with breast cancer, Graeser demonstrated
that the 25-year cumulative contralateral breast cancer risk for BRCA1 carriers with the first breast
cancer diagnosis at age <40years, 40–50 years and >50 years, was 62.9% (95% CI 50.4–75.4), 43.7%
(95% CI 24.9–62.5) and 19.6% (95% CI 5.3–33.9) respectively. In BRCA2 carriers, the corresponding rates
were 63% (95% CI 32.8–93.2), 48.8% (95% CI 22.7–74.9) and 16.7% (95% CI 1.0–32.4) for the respective
age groups [19].
3.2. Contralateral Prophylactic Mastectomy and Risk of Contralateral Breast Cancer
Contralateral prophylactic mastectomy reduces the risk of contralateral breast cancer in BRCA
mutation carriers [14,26,27]. This risk reduction has been reported to be in the range of 91% [27]. This
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is further supported by a meta-analysis showing that contralateral prophylactic mastectomy resulted
in a 93% reduction in contralateral breast cancer risk (RR 0.072; 95%CI 0.035–0.588) [26].
3.3. Contralateral Prophylactic Mastectomy and Survival
There is conflicting evidence on whether contralateral prophylactic mastectomy improves survival
in BRCA carriers with breast cancer [14,26–31] (Table 1). In a multicenter, retrospective study of 242
BRCA carriers with breast cancer, contralateral prophylactic mastectomy was associated with improved
overall survival on multivariate analysis, having adjusted for risk-reducing salpingo-oophorectomy
(HR 0.49, 95% CI 0.29–0.82) [30]. Similar findings have been reported in other cohort studies [27,29–31].
Table 1. Studies looking at the impact of CPM on CBC risk and survival in BRCA1/2 mutation carriers.
Author Year Study Type Follow up Patient Findings
Li [26] 2016
Meta-analysis
(2 RC/1 PC/1
RCC)
n/a 4/4574 studies(1672 individuals)
CPM significantly decreased CBC risk
in BRCA1/2 mutation carriers
(RR 0.072; 95% CI, 0.035–0.148).
CPM is associated with a decrease in
“all–cause” mortality
(HR 0.512; 95% CI 0.368–0.588)
Valachis [14] 2014 Meta-analysis(1 RCC/1 RC) n/a 2/13 studies
CPM was not associated with a benefit
in BCSS
HR 0.78 (95% CI 0.44–1.39, p = 0.40)
Copson [32] 2018 Prospectivecohort
Median 8.2
years
21 BRCA
carriers/10
non-carriers, with
TNBC
CPM conferred no difference in 5-year
OS between BRCA carriers and
non-carriers with TNBC
83% (95% CI 74–89) vs. 74%
(95% CI 69–78)
HR 0.98 (95% CI 0.58–1.65), p = 0.94
Heemskerk-Gerritsen
[30] 2015
Multicentre
retrospective
cohort
Median 11.4
years
242/583(52%)
carriers with BC
who underwent
CPM
CPM improved OS
HR 0.49 (0.29–0.82)
Metcalfe [29] 2014 Retrospectiveobservational
Median follow
up 14.3 yrs
(0.1–20.0)
390 BRCA1/BRCA2
carriers with a
positive family
history
At 20 years follow up, CPM was
associated with a 48% reduction in
death from breast cancer (HR 0.52;
p = 0.03).
* Not significant on propensity score
adjusted analysis
Evans [31] 2013 Retrospectivecase-control
Median 9.7
years
105/698 (15%)
BRCA 1/2 carriers
with BC who
underwent CPM
CPM improves OS
89% (CPM) vs. 71% (non-CPM) at 10
year follow up (p < 0.001)
Van Sprundel [27] 2005 Retrospectivecohort Mean 3.5 years
69/148 (47%) BRCA
1/2 carriers with BC
who underwent
CPM
CPM reduced the risk of CBC in
BRCA1/2 carriers by 91%
No significant difference in OS between
CPM and non-CPM group
HR 0.35, p = 0.14 (adjusted for
prophylactic oophorectomy)
Brekelmans [28] 2007 Retrospectivecase-control
Median 4.3
years
260 BRCA 1/2
carriers with BC vs.
759 non-carriers
CPM conferred no difference in BCSS
HR 0.98 (95% CI 0.5–0.91, p = 0.96)
RC: retrospective cohort; RCC: Retrospective case-control; PC: prospective cohort; BCCS: breast-cancer-specific; OS
overall survival; CPM: contralateral prophylactic mastectomy; BC: breast cancer; CBC: contralateral breast cancer;
TNBC: triple negative breast cancer; HR: hazard ratio.
In a retrospective study by Van Sprundel, contralateral prophylactic mastectomy was associated
with superior overall survival compared to active surveillance at 5-year follow up (94% vs 77%,
p = 0.03). However, this difference was not significant once adjusted for prophylactic oophorectomy
(HR 0.35, p = 0.14) [27]. Notably, Metcalfe observed a survival benefit only in the second decade of
follow-up following initial breast cancer diagnosis (HR 0.52, 95% CI 0.29–0.93) but not during the first
10 years of follow-up (HR 0.65, 95% CI 0.34–1.22) [29].
A meta-analysis by Valachis demonstrated no difference in breast-cancer-specific survival between
BRCA carriers who underwent contralateral prophylactic mastectomy against those who did not (HR
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0.78, 95% CI 0.44–1.39; p = 0.40) [14]. However, a meta-analysis including two additional studies
demonstrated a decrease in “all-cause” mortality [26]. To further add to the ambiguity, a recent
prospective study showed that contralateral prophylactic mastectomy conferred no benefit in 5-year
overall survival between BRCA carriers and non-carriers with triple negative breast cancer [32].
The available findings should be interpreted with caution as they are mostly based on retrospective
studies that may contain recognized and unrecognized biases.
4. “Other” Genetic Carriers (CHEK2, TP53, ATM, PALB2, PTEN, CDH1) with Breast Cancer
Mutations in CHEK2, TP53, ATM, PALB2, PTEN, and CDH1 account for a small fraction of
familial breast cancers. The available studies are sparse and primarily family-based, with potential
ascertainment bias. It should be noted that the existing literature focusses mainly on relative rather
than absolute risk estimates.
4.1. “Other” Genetic Carriers and Contralateral Breast Cancer Risk
4.1.1. CHEK2 Mutation Carriers and Contralateral Breast Cancer Risk
In a recent meta-analysis, Akdeniz demonstrated an increased contralateral breast cancer risk for
CHEK2* 1100delC carriers (RR 2.75, 95% CI 1.77–4.27) [33]. This mutation is associated with bilateral
disease and an increased risk of bilateral breast cancer which varies between two to six-fold [15,34–40]
(Table 2). It has been suggested that CHEK2 carriers may be more sensitive to ionizing radiation
that may contribute to contralateral breast cancer rates in patients receiving adjuvant radiotherapy
following breast conserving surgery [40,41]. The true impact of radiation in this context is questionable
as consistently increased contralateral breast cancer risk has been demonstrated in patients treated with
or without radiotherapy (HR 4.12, 95% CI 2.49–6.83 and HR 3.17, 95% CI 1.36–7.35, respectively) [39,41].
4.1.2. TP53 Mutation Carriers and Contralateral Breast Cancer Risk
There are no studies estimating contralateral breast cancer risk in TP53 carriers with breast cancer.
4.1.3. ATM Mutation Carriers and Contralateral Breast Cancer Risk
In a multicentre, population-based, case-control study, Concannon suggested that four common
variants of ATM (c.1899-55T>G; c.3161C>G; c.6348-54T>C and c.5558A>T) were associated with a lower
contralateral breast cancer risk (overall RR 0.8, 95% CI 0.6–0.9) compared to those with rare, missense
ATM mutations. The protective mechanisms may occur through an alteration in ATM activity as an
initiator of DNA damage response or through its role in TP53 regulation [42]. Bernstein suggested that
common ATM variants may exert a protective effect and reduce contralateral breast cancer risk, while
rare ATM missense, deleterious variants may act synergistically with radiation exposure to increase this
risk [43]. In this study, the variants: c.1899-55T>G (RR 0.5, 95% CI 0.3–0.8), c.3161C>G (RR 0.5, 95% CI
0.3–0.9), c.5558A>T (RR 0.2, 95% CI 0.1–0.6), and c.6348-54T>C (RR 0.2, 95% CI 0.1–0.8) were associated
with significantly reduced risk. On the other hand, female carriers of any rare missense ATM variant,
who received radiation therapy for their first breast cancer, had a significantly elevated contralateral
breast cancer risk compared to unexposed women (RR = 2.8 for <1.0 Gy dose and RR = 3.3 for ≥1.0 Gy
dose to the contralateral breast).
The direct relationship between the presence of ATM variants and the overall risk of contralateral
breast cancer remains controversial, although the combination of radiotherapy and certain ATM
missense variants appears to accelerate tumour development [44].
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Table 2. Studies looking at CBC risk and survival in CHEK2* 1100delC mutation carriers.
Author Year Study MedianFollow up N Findings
Akdeniz [33] 2019 Meta-analysis N/A 68 studies
CBC risk by mutation carriers
BRCA1 RR 3.7 (95% CI, 2.8–4.9)
BRCA2 RR 2.8 (95% CI, 1.8–4.3)
CHEK2* 1100delC RR 2.7
(95% CI, 2.0–3.7)
Kriege [39] 2014
Retrospective,
multicentre
cohort study
6.8 years
193/4722 (4.1%) BC
patients with
CHEK2* 1100delC
mutation
Higher risk of CBC
HR 3.97 (95% CI 2.59–6.07)
10-year risk of CBC is 28.9%
Weischer [37] 2012 Meta-analysis 6 years
459/25571 (1.8%)
BC patients with
CHEK2* 1100delC
mutation
20-year cumulative risk of developing
BC is 25–30% (HR 3.52)
No comment on CBC rates
Mellemkjaer [40] 2008
Population
based,
multicentre
cohort study
N/A
17/2103 (0.8%) BC
patients with
CHEK2* 1100delC
No significant association between
CHEK2* 1100delC mutation and CBC
Broeks [41] 2004 Case study N/A
15/233 (6.4%)
CHEK2* 1100delC
mutation carriers
with BBC
2/191 (1%) CHEK2*
1100delC mutation
carriers with UBC
Increased risk of CBC in carriers
OR 6.5 (95% CI 1.5–28.8, p = 0.005)
Schmidt [36] 2007 Retrospectivecohort study
Median 10.1
years
54/1479 (3.7%)
pre-menopausal
BC patients with
CHEK2* 1100delC
mutation
CHEK2* 1100delC mutation carriers:
Increased risk of ipsilateral second
breast cancer HR 2.1 (95% CI 1.0–4.3;
p = 0.049)
Increased risk of CBC
HR 1.7 (95% CI 1.2–2.4)
Worse breast-cancer-specific survival
HR 1.4 (95% CI 1.0–2.1; p = 0.072)
Worse recurrence- free survival
HR 1.7 (95% CI 1.2–2.4; p = 0.06)
De Bock [45] 2004 Prospectivecohort
Median 3.8
years
34 BC patients with
CHEK2* 1100delC
mutation; 102 BC
patients with no
mutation
Compared to non-carriers, CHEK2*
1100delC mutation carriers:
Increased risk of CBC compared
RR = 5.74 (95% CI 1.67–19.65)
Increased risk of distant metastasis
RR 2.81 (95% CI 1.2–6.58)
Worse DFS
RR = 3.86 (1.91–7.78)
No difference in overall survival.
Mutation carriers more frequently had
a 1st or 2nd degree female relative with
breast cancer (p = 0.03)
BC: breast cancer; CBC: contralateral breast cancer; BBC: bilateral breast cancer; UBC: unilateral breast cancer; RR:
relative risk; DFS: disease-free survival; ER: oestrogen receptor; HR: hazard ratio.
4.1.4. PALB2 Mutation Carriers and Contralateral Breast Cancer Risk
There are no studies estimating contralateral breast cancer risk in PALB2 carriers with breast cancer.
4.1.5. CDH1 Mutation Carriers and Contralateral Breast Cancer Risk
There are no studies on the risk of contralateral breast cancer in CDH1 carriers.
4.1.6. PTEN Mutation Carriers and Contralateral Breast Cancer Risk
There are no studies estimating contralateral breast cancer risk in PTEN carriers with breast cancer.
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4.2. Contralateral Prophylactic Mastectomy and Risk of Contralateral Breast Cancer
No studies have investigated the role of contralateral prophylacticmastectomy in the risk reduction
of contralateral breast cancer in patients with a diagnosis of breast cancer that harbor a genetic mutation
in non-BRCA1/2 genes (CHEK2, TP53, ATM, PALB2, CDH1 and PTEN).
4.3. Contralateral Prophylactic Mastectomy and Survival
There is no data to support any survival benefit from contralateral prophylactic mastectomy in
this group of patients (“other” genetic carriers). This would be even more challenging in those with
TP53, CDH1 and PTEN mutations because of the additional competing cancer risk. In view of the
limited evidence, no further comment can be made, except to reinforce that contralateral prophylactic
mastectomy should be considered on an individual basis for women with unilateral breast cancer in
this group.
5. Familial Breast Cancers with no Demonstrable Genetic Mutations
5.1. Familial Breast Cancers with No Demonstrable Genetic Mutation and Contralateral Breast Cancer Risk
A positive family history remains a strong risk factor for contralateral breast cancer, even after
excluding mutation carriers [46–48]. Table 3 summarizes the current literature on the impact of positive
family history on contralateral breast cancer risk and survival. In a multicentre, population-based,
case-control study of 1521 contralateral breast cancer cases against 2212 matched controls of unilateral
breast cancer, Reiner demonstrated that non-mutation carriers with any 1st or 2nd degree relative of
breast cancer had a nearly two-fold increased contralateral breast cancer risk (RR 1.8, 95% CI 1.3–2.4),
compared to individuals without a family history. This risk is similar to that shown in previous
studies [49,50]. In this non-mutation carrier group, a 1st degree family history of bilateral breast
cancer increased the contralateral breast cancer risk by more than three-fold (RR 3.4, 95% CI 1.5–7.4).
Where there is only an affected 2nd degree relative, the individual is at a 40% increased risk compared
to an individual without a family history. The 10-year absolute contralateral breast cancer risk in
non-mutation carriers with a 1st or 2nd degree family history is 8.3% (95% CI 5.5–12.6) and 6.6% (95%
CI 4.4–10) respectively [46].
10
Cancers 2020, 12, 140
Ta
bl
e
3.
St
ud
ie
s
lo
ok
in
g
at
th
e
im
pa
ct
of
po
si
ti
ve
FH
of
br
ea
st
ca
nc
er
on
C
BC
ra
te
s,
di
se
as
e-
fr
ee
an
d
ov
er
al
ls
ur
vi
va
l.
T
he
Im
pa
ct
of
Po
si
ti
ve
FH
of
B
re
as
tC
an
ce
r
on
C
B
C
R
at
es
,D
is
ea
se
-F
re
e
an
d
O
ve
ra
ll
Su
rv
iv
al
A
ut
ho
r
Ye
ar
St
ud
y
Ty
pe
Fo
ll
ow
up
Pa
ti
en
ts
Fi
nd
in
gs
R
ei
ne
r
[4
6]
20
18
M
ul
ti
ce
nt
re
,p
op
ul
at
io
n-
ba
se
d,
ca
se
-c
on
tr
ol
st
ud
y
N
ot
st
at
ed
15
21
C
BC
ca
se
s
w
it
h
22
12
U
BC
co
nt
ro
ls
A
1s
td
eg
re
e
re
la
ti
ve
w
it
h
BC
co
nf
er
s
in
cr
ea
se
d
ri
sk
of
C
BC
R
R
1.
9
(9
5%
C
I1
.6
–2
.3
)
A
1s
td
eg
re
e
re
la
ti
ve
w
it
h
BB
C
co
nf
er
s
th
e
hi
gh
es
tr
is
k
of
C
BC
R
R
3.
4
(9
5%
C
I2
.4
–5
)
A
2n
d
de
gr
ee
re
la
ti
ve
in
cr
ea
se
s
th
e
ri
sk
of
C
BC
R
R
1.
4
(9
5%
C
I1
.2
–1
.7
)
A
ny
1s
td
eg
re
e
re
la
ti
ve
w
it
h
br
ea
st
ca
nc
er
co
nf
er
s
a
10
-y
ea
r
A
R
of
de
ve
lo
pi
ng
C
BC
of
8.
1%
(9
5%
C
I6
.7
–9
.8
).
Th
e
10
-y
ea
r
A
R
in
cr
ea
se
s
to
13
.5
%
(9
5%
C
I8
.8
–2
0.
8)
if
th
is
re
la
tiv
e
w
as
<
40
ye
ar
s
at
ag
e
of
di
ag
no
si
s.
Th
e
10
-y
ea
r
A
R
is
hi
gh
es
ta
t3
6%
(9
5%
C
I1
4.
5–
90
.5
)i
ft
he
fir
st
de
gr
ee
re
la
ti
ve
w
as
di
ag
no
se
d
w
it
h
BB
C
at
ag
e
<
40
ye
ar
s.
O
n
su
bg
ro
up
an
al
ys
is
an
d
ex
cl
us
io
n
of
m
ut
at
io
n
ca
rr
ie
rs
i.e
.,
BR
C
A
,
A
TM
,P
A
LB
2
an
d
C
H
EK
2,
th
e
in
cr
ea
se
d
10
-y
ea
r
A
R
as
so
ci
at
ed
w
it
h
a
1s
td
eg
re
e
re
la
ti
ve
an
d
a
1s
td
eg
re
e
re
la
ti
ve
w
it
h
BB
C
re
m
ai
ne
d
si
gn
ifi
ca
nt
si
m
ila
r
to
ab
ov
e-
re
po
rt
ed
.
K
uc
he
nb
ae
ck
er
[2
0]
20
17
Pr
os
pe
ct
iv
e,
m
ul
ti
ce
nt
re
,c
oh
or
t
st
ud
y
M
ed
ia
n
4
ye
ar
s
(2
–7
)
38
86
el
ig
ib
le
fo
r
br
ea
st
ca
nc
er
an
al
ys
is
BR
C
A
1
(n
=
22
76
);
BR
C
A
2
(n
=
16
10
)
In
cr
ea
se
d
ri
sk
if
≥t
w
o
1s
to
r
2n
d
de
gr
ee
re
la
ti
ve
s
w
it
h
br
ea
st
ca
nc
er
co
m
pa
re
d
to
no
fa
m
ily
hi
st
or
y
of
BC
;H
R
1.
99
D
id
no
te
va
lu
at
e
th
e
eff
ec
to
fF
H
on
C
BC
ri
sk
Be
rn
st
ei
n
[5
1]
19
92
Pr
os
pe
ct
iv
e
co
ho
rt
st
ud
y
M
ea
n
52
m
on
th
s
13
6/
45
50
(2
.9
%
)p
at
ie
nt
s
w
ith
C
BC
an
d
va
ry
in
g
fa
m
ili
al
ri
sk
C
om
pa
re
d
w
it
h
no
FH
of
br
ea
st
ca
nc
er
:
In
cr
ea
se
d
ri
sk
of
C
BC
~2
x
w
it
h
a
1s
td
eg
re
e
re
la
ti
ve
w
it
h
BC
In
cr
ea
se
d
ri
sk
of
C
BC
~3
x
if
1s
td
eg
re
e
re
la
ti
ve
w
as
di
ag
no
se
d
at
a
yo
un
g
ag
e
(<
35
ye
ar
s)
Ji
[5
2]
20
07
Po
pu
la
ti
on
ba
se
d,
na
ti
on
al
da
ta
ba
se
st
ud
y
N
ot
st
at
ed
56
19
0
in
va
si
ve
an
d
68
41
in
si
tu
BC
pa
ti
en
ts
T
he
ri
sk
of
m
et
ac
hr
on
ou
s
C
BC
m
ea
su
re
d
by
SI
R
s
w
as
hi
gh
er
w
it
h
pr
im
ar
y
in
si
tu
di
se
as
e
co
m
pa
re
d
to
in
va
si
ve
ca
nc
er
.
SI
R
fo
r
m
et
ac
hr
on
ou
s
C
BC
in
w
om
en
di
ag
no
se
d
w
it
h
in
va
si
ve
BC
:
<
45
ye
ar
s:
5.
12
(9
5%
C
I4
.4
7–
5.
85
)
45
–5
5
ye
ar
s:
1.
95
(9
5%
C
I1
.7
6–
2.
16
)
>
55
ye
ar
s:
1.
49
(9
5%
C
I1
.3
7–
1.
61
)
SI
R
fo
r
m
et
ac
hr
on
ou
s
C
BC
in
w
om
en
di
ag
no
se
d
w
it
h
1s
ti
nv
as
iv
e
BC
an
d
ha
ve
:
A
po
si
ti
ve
FH
2.
74
(9
5%
C
I2
.3
–3
.2
3)
N
o
FH
1.
85
(9
5%
C
I1
.7
5–
1.
96
)
SI
R
fo
r
m
et
ac
hr
on
ou
s
C
BC
in
w
om
en
di
ag
no
se
d
w
it
h
in
si
tu
di
se
as
e:
<
45
ye
ar
s:
5.
12
(9
5%
C
I4
.4
7–
5.
85
)
45
–5
5
ye
ar
s:
1.
95
(9
5%
C
I1
.7
6–
2.
16
)
>
55
ye
ar
s:
1.
49
(9
5%
C
I1
.3
7–
1.
61
)
11
Cancers 2020, 12, 140
Ta
bl
e
3.
C
on
t.
T
he
Im
pa
ct
of
Po
si
ti
ve
FH
of
B
re
as
tC
an
ce
r
on
C
B
C
R
at
es
,D
is
ea
se
-F
re
e
an
d
O
ve
ra
ll
Su
rv
iv
al
A
ut
ho
r
Ye
ar
St
ud
y
Ty
pe
Fo
ll
ow
up
Pa
ti
en
ts
Fi
nd
in
gs
N
ar
od
[5
3]
20
16
Po
pu
la
ti
on
ba
se
d,
na
ti
on
al
da
ta
ba
se
st
ud
y
N
ot
st
at
ed
48
39
C
BC
pa
ti
en
ts
ou
to
f8
48
19
pa
ti
en
ts
w
it
h
BC
*
(5
.7
%
)
Yo
un
g
ag
e
at
1s
tB
C
di
ag
no
si
s
an
d
a
m
at
er
na
lc
an
ce
r
hi
st
or
y
in
cr
ea
se
s
th
e
ri
sk
of
C
BC
T
he
15
-y
ea
r
cu
m
ul
at
iv
e
ri
sk
of
C
BC
w
as
:
8.
8%
(9
5%
C
I8
.5
–9
.1
)i
n
th
e
ge
ne
ra
lp
op
ul
at
io
n
(r
eg
ar
dl
es
s
of
m
at
er
na
l
BC
st
at
us
)
12
%
(9
5%
C
I1
1–
13
)i
n
m
at
er
na
lU
BC
13
%
(9
5%
C
I9
.5
–1
7)
in
m
at
er
na
lB
BC
A
m
at
er
na
lc
an
ce
r
hi
st
or
y
of
U
BC
at
an
ea
rl
y
ag
e
co
nf
er
re
d
th
e
da
ug
ht
er
a
lif
et
im
e
C
BC
ri
sk
of
35
%
(9
5%
C
I2
5–
46
)
*
M
ut
at
io
n
ca
rr
ie
rs
no
te
xc
lu
de
d
as
in
fo
rm
at
io
n
no
ta
va
ila
bl
e
fr
om
ca
nc
er
re
gi
st
ry
V
ai
tt
in
en
[5
4]
20
00
Po
pu
la
ti
on
ba
se
d,
na
ti
on
al
da
ta
ba
se
st
ud
y
N
ot
st
at
ed
25
29
/7
2,
09
2
(3
.5
%
)C
BC
pa
ti
en
ts
.
14
7
(5
.8
%
)o
fC
BC
ca
se
s
w
it
h
1s
t
de
gr
ee
re
la
ti
ve
M
od
es
te
le
va
ti
on
in
C
BC
ri
sk
fo
r
w
om
en
w
it
h
an
aff
ec
te
d
1s
td
eg
re
e
re
la
ti
ve
R
R
of
1.
53
Bo
ug
he
y
[5
5]
20
10
R
et
ro
sp
ec
ti
ve
co
ho
rt
M
ed
ia
n
17
.3
ye
ar
s
38
5
pa
ti
en
ts
w
it
h
a
po
si
ti
ve
FH
;
38
5
m
at
ch
ed
co
nt
ro
ls
Pa
ti
en
ts
w
it
h
st
ag
e
Io
r
II
BC
an
d
a
po
si
ti
ve
fa
m
ily
hi
st
or
y
w
ho
un
de
rw
en
tC
PM
ha
d:
A
95
%
re
du
ct
io
n
in
C
BC
ra
te
s;
ad
ju
st
ed
H
R
0.
05
(9
5%
C
I0
.0
1–
0.
19
,
p
<
0.
00
01
)
C
P
M
:c
on
tr
al
at
er
al
p
ro
p
hy
la
ct
ic
m
as
te
ct
om
y;
B
C
:b
re
as
tc
an
ce
r;
B
B
C
:b
ila
te
ra
lb
re
as
tc
an
ce
r;
C
B
C
:c
on
tr
al
at
er
al
br
ea
st
ca
nc
er
;U
B
C
:u
ni
la
te
ra
lb
re
as
tc
an
ce
r;
A
R
:a
bs
ol
u
te
ri
sk
;S
IR
:
St
an
da
rd
iz
ed
in
ci
de
nc
e
ra
ti
o;
FH
:f
am
ily
hi
st
or
y;
R
D
:r
is
k
di
ff
er
en
ce
;H
R
:h
az
ar
d
ra
ti
o.
12
Cancers 2020, 12, 140
In a retrospective study of 6230 women from high risk families, with or without a known BRCA1/2
mutation, Rhiem observed a cumulative contralateral breast cancer risk, 25 years after a first breast
cancer diagnosis of 44.1% (95% CI 37.6–50.6) in BRCA1 positive families, 33.5% (95% CI 22.4–44.7) in
BRCA2 positive families and 17.2% (95% CI 14.5–19.9) in BRCA1/2 negative families [56]. This effect
was previously demonstrated in smaller cohort studies linking a higher contralateral breast cancer risk
with a family history with and without a young age of first breast cancer diagnosis [51,53].
The age at which the affected relative is diagnosed with their first breast cancer and the presence
of bilateral disease impacts on contralateral breast cancer risk. Rhiem further observes that patients
diagnosed with breast cancer at age <40 years had a cumulative risk 25 years from primary diagnosis
of 55.1% and 38.4% for BRCA1 and BRCA2-positive family history, respectively. The corresponding
risk was 28.4% in patients from non-BRCA families [56].
The highest risk lies with women who have relatives with early-onset, bilateral breast
cancer [52–54,57]. The 10-year absolute risk in individuals whose 1st degree relative received a
unilateral breast cancer diagnosis at a young age (<40 years) is similar to that of an individual with
a 1st degree relative diagnosed with bilateral breast cancer (13.5% and 14.1% respectively). When
there was a combination of a family history of a 1st degree relative, an affected relative with bilateral
breast cancer or at a young age (<40 years), the 10-year contralateral breast cancer risk increased
significantly to 36% [46]. A similar cumulative risk of contralateral breast cancer by the age of 80 (32%,
95% CI 13–66) was observed in a study of 78,775 breast cancer patients, with a maternal history of
bilateral breast cancer [53].
5.2. Contralateral Prophylactic Mastectomy and Risk of Contralateral Breast Cancer
Contralateral prophylactic mastectomy may reduce the risk of contralateral breast cancer in
women with an elevated genetic or familial risk [21]. This meta-analysis demonstrated a risk reduction
in women with BRCA-positive families (HR 0.03; p = 0.0005). However, only 4% (19/430) of the
cohort were non-carriers, with the remaining 96% representing mutation carriers. Fayanju reported
a significant reduction in pooled relative (RR 0.04, 95% CI 0.02–0.09) and absolute risk (−24%,
95% CI (−35)–(−12.4)) of metachronous contralateral breast cancer amongst recipients of contralateral
prophylactic mastectomy [58]. This analysis included studies with a significant proportion of BRCA
carriers which may lead to an overestimation of risk. A case-control study of women with stage I/II
breast cancer and a positive family history reported a 95% decreased risk (HR 0.05, 95% CI 0.01–0.19;
p < 0.0001) of contralateral breast cancer following contralateral prophylactic mastectomy, at a median
follow-up of 17.3 years, compared to a matched cohort of women who did not receive mastectomy.
However, this cohort, with either an affected 1st or 2nd degree relative was not screened for mutation
status [55].
McDonnell also demonstrated a contralateral breast cancer risk reduction following contralateral
prophylactic mastectomy in pre- and postmenopausal women with a strong family history of
breast/ovarian cancer i.e., 94.4% (95% CI 87.7–97.9) and 96% (95% CI 85.6–99.5) respectively, at a median
follow up of 10 years using the Anderson model [59] to predict the risk [60]. Although the cohort
had a strong family history, the patients had not been screened for mutations. Similar to studies with
undefined gene carriers within the study population, this data should be interpreted with caution as
the effect from contralateral prophylactic mastectomy may be overestimated from competing risks
conferred by mutation carriers.
5.3. Contralateral Prophylactic Mastectomy and Survival
The evidence on the effect of contralateral prophylactic mastectomy on disease-free and overall
survival is conflicting (Table 4).
A Cochrane review of 1708 women with variable familial risk, who underwent contralateral
prophylactic mastectomy, concluded that although this decreased the incidence of contralateral breast
cancer, there was no association with survival improvement [61]. The meta-analysis conducted
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by Fayanju demonstrated no association with breast-cancer-specific and overall survival, despite
a reduction in the risk of distant metastases or recurrence [58]. The lack of survival benefit from
contralateral prophylactic mastectomy in breast cancer patients with elevated familial risk is also
reported in smaller, retrospective cohort studies [27,62,63] but with notable exceptions. Boughey
reported improved overall (HR 0.77, 95% CI 0.60–0.98; p = 0.03) and disease-free survival (HR 0.67,
95% CI 0.54–0.84) on multivariate analysis [55]. In a review of 908 patients receiving against 46,368 not
receiving contralateral prophylactic mastectomy, Herrinton demonstrated that mastectomy reduced
breast cancer mortality (HR 0.57, 95% CI 0.45–0.72) and overall mortality (HR 0.6, 95% CI 0.5–0.72)
across all levels of familial risk [64]. Furthermore, Davies demonstrated that young women (<40 years)
with unilateral, stage I disease and a 1st degree relative with bilateral breast cancer, were the only
group to have a quality-adjusted life year benefit from contralateral prophylactic mastectomy, which
was similar to that of a BRCA1/2 carrier [63].
Table 4. Studies looking at the impact of CPM on CBC and survival in BC patients with elevated
familial risk.
Author Year Study Type Follow up Patients Findings
Akdeniz [33] 2019 Meta-analysis N/A 68 studies
A positive FH of BC was associated
with increased CBC risk
RR = 1.72 (95% CI 1.15–2.57)
Engel [16] 2019
Multicentre,
prospective
cohort study
Median 2.9
years
667 BRCA1 carriers,
402 BRCA2 carriers
1924 BRCA1/2
noncarriers
(BRCA1/2-negative
families)
10-year cumulative CBC risk for
BRCA1/2 non carriers
3.6% (95 CI 2.2–5.7)
Women with ≥2 relatives with BC had
an increased risk of CBC, compared to
women without any relative affected
by BC
HR 2.35 (95% CI 1.21–4.55)
ER-negativity was not associated with
an increased CBC risk in BRCA1/2
non-carriers
Fayanju [58] 2014 Meta-analysis N/A 14/79 studies
Patients with an elevated
familial/genetic risk who had CPM (vs
no CPM):
Reduction in pooled RR of mCBC;
RR 0.04 (95% CI 0.02–0.09; p < 0.001))
Reduction in pooled AR of mCBC;
RD of −24% (95% CI −35.6 to −12.4;
p = 0.013)
Significant reduction in rates of
distant/metastatic recurrence.
CPM was not associated with improved
OS or BCSS
Boughey [55] 2010 Retrospectivecohort
Median 17.3
years
385 patients with a
positive FH; 385
matched controls
(parent, sibling or 2nd
degree relative with BC)
* no genetic screening
Patients with stage I/II BC and a
positive family history who underwent
CPM had:
A 95% reduction in CBC rates; adjusted
HR 0.05 (95% CI 0.01–0.19, p < 0.0001)
Improved OS (HR 0.77
(95% CI 0.60–0.98, p = 0.03))
Improved DFS
(HR 0.67 (95% CI 0.54–0.84))
McDonnell [60] 2001 Retrospectivecohort
Median 10
years
745 BC patients (388
premenopausal (<50 yrs);
357 postmenopausal
with a positive FH
CPM conferred a CBC risk-reduction:
In premenopausal women of 94.4%
(95% CI 87.7–97.9)
In postmenopausal women of 96%
(95% CI 85.6–99.5)
Herrinton [64] 2005 Retrospectivecohort
Median 5.7
years
1072/50,000 BC patients
undergoing CPM
Across all levels of familial risk, CPM:
Reduces breast cancer mortality
(HR = 0.57; 95% CI 0.45–0.72)
Reduces overall mortality
(HR = 0.6; 95% CI 0.5–0.72)
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Table 4. Cont.
Author Year Study Type Follow up Patients Findings
Peralta [65] 2001 Retrospectivecohort Mean 6.8 years
23/64 (36%) BC patients
undergoing CPM and
with ≥one affected 1st
degree relative (not
screened for mutations)
None of the patients undergoing CPM
developed a subsequent CBC
Kiely [62] 2010 Retrospectivecohort Median 8 years
154/1018 women who
underwent CPM, with
FH of BC ± BRCA
mutations
Reduced rate of CBC in women who
underwent CPM with no apparent
benefit in survival
CPM: contralateral prophylactic mastectomy; BC: breast cancer; CBC: contralateral breast cancer; mCBC:
metachronous contralateral breast cancer; BBC: bilateral breast cancer; UBC: unilateral breast cancer; FH: Family
history; RR: relative risk; AR: absolute risk; DFS: disease-free survival; OS: overall survival; BCSS: breast
cancer-specific survival’ ER: oestrogen receptor; HR: hazard ratio.
6. Young Women with Breast Cancer
6.1. Young Women with Breast Cancer and Contralateral Breast Cancer Risk
The definition of ‘young’ age group in the literature, varies from the “under-35”- to 50 years. Young
age at first primary breast cancer diagnosis is associated with an increased contralateral breast cancer
risk, poor prognosis and serves as an independent predictor of recurrence and breast-cancer-related
death [66–71] (Table 5). Older studies did not account for BRCAmutation carriers, which may confound
contralateral breast cancer risk and survival. Furthermore, they do not consider risk-reducing adjuvant
therapies. In a retrospective study of 652 patients ≤35 years compared to 2608 women >35 years, the
relative risk of contralateral breast cancer was 2.48 in the younger, compared to the older group [70].
This finding is supported by Li, who demonstrated an increased HR of 2.8 (95% CI 1.1–6.9), 2.1
(95% CI 1.1–4.4) and 1.9 (95% CI 1.1–3.5) in the ≤29 years, 30–34 years and 35–39 years age groups,
compared to women diagnosed at age ≥40 [67]. The contralateral breast cancer risk is further elevated
in HER2-overexpressing and triple negative subtypes [70].
Table 5. Studies looking at the impact of CPM on CBC and survival in young women with breast cancer.
Author Year Study Type MedianFollow up
Patient Demographics
(Age, CPM Status) Findings
Chen [2] 2019 Retrospectivecohort 113 months
<35 years and CPM
811/3083 (26.3%)
35–39 years and CPM
1243/5961 (20.9%)
No difference in BCSS from CPM
HR 1.209 (95% CI 0.908–1.610,
p = 0.194)
No difference in OS from CPM
HR 1.179 (95% CI 0.902–1.540,
p = 0.228)
Yu [72] 2018 Retrospectivecohort 6.9 years
910/1806 young patients
(18–50 years) with CPM
No difference in OS in women with a
young age (18–50 years) who had CPM
HR 0.93 (95% CI 0.70–1.24; p = 0.627)
Pesce [73] 2014 Retrospectivecohort 6.1 years
4338/10,289 (29.7%)
young women (<45
years) with Stage I/II
cancer with CPM
CPM provides no survival benefit in
young women (<45 years)
Compared to unilateral mastectomy
HR 0.93; p = 0.39
With early-stage (T1N0) breast cancer
HR 0.85; p = 0.37
With ER-negative breast cancer
HR 1.12; p = 0.32
Bedrosian [74] 2010
Population
based cohort
study
47 months
3731/27,336 (13.6%)
young women (18–49
years) with CPM
CPM offers benefit in BCSS for young
women (18–49 years) with early stage,
ER-negative breast cancer
HR 0.68 (95% CI 0.53–0.69), p < 0.001
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Table 5. Cont.
Author Year Study Type MedianFollow up
Patient Demographics
(Age, CPM Status) Findings
Bouchard-Fortier
[75] 2018
Population-based
cohort 11 years
81/614 (13.2%) young
women (≤35 years) with
CPM
Risk of recurrence (breast/distant) was
lower in the CPM group
HR 0.61, p = 0.02
No difference in breast cancer-specific
mortality from CPM
HR 0.73 (95% CI 0.47–1.21)
Zeichner [71] 2014 Retrospectivecohort 68 months
42/481 (8.73%) young
women (<40 years) with
CPM
CPM provides a benefit in 10-year
overall survival * HR 2.35 (95% CI
1.02–5.41, p = 0.046)
* effect not seen at 5-year overall
survival
Lazow [76] 2018 Population-basedcohort
Mean 62
months
4139/11,859 (34.9%)
young women (<40
years) with CPM
CPM improves 10-year overall survival
HR 0.75 (95% CI, 0.59–0.96) p = 0.023]
Park [77] 2017
Population
based, national
database study
Not stated
3648 DCIS patients <40
years (25.8% UM; 15.8%
CPM)
No overall survival benefit from CPM
compared to UM in the <40 years group
OS: overall survival; CPM: contralateral prophylactic mastectomy; unilateral mastectomy: BCSS:
breast-cancer-specific survival.
6.2. Contralateral Prophylactic Mastectomy and Risk of Contralateral Breast Cancer
The younger age group is generally underrepresented in studies evaluating the role of contralateral
prophylactic mastectomy. Using a Surveillance, Epidemiology, End Results database analysis of 107,106
women, of whom 8902 (8.3%) underwent contralateral prophylactic mastectomy, Bedrosian conducted
a subgroup analysis of young women (<50 years) and the risk of contralateral breast cancer after
contralateral prophylactic mastectomy, in both ER-negative and ER-positive, early-stage breast cancer.
In ER-positive disease, the cumulative incidence of contralateral breast cancer during the 6-year study
period was 0.13% vs. 0.46% (p = 0.07) in the contralateral prophylactic mastectomy vs. non-mastectomy
group, and in ER-negative disease, 0.16% vs. 0.90% (p = 0.05) respectively [74]. These results should be
interpreted with caution though as the study population was not screened for genetic carriers and also
patients with a strong family history were not excluded.
6.3. Contralateral Prophylactic Mastectomy and Survival
There is conflicting data on the impact of contralateral prophylactic mastectomy on survival in
this patient group. In a population-based study of 614 women <35 years, 81 (13.2%) of whom were
elected for contralateral prophylactic mastectomy, Bouchard-Fortier demonstrated that recurrences,
defined as local, regional or distant, were significantly fewer for patients with contralateral prophylactic
mastectomy than without (32.1% vs. 52.9%, p < 0.001; HR 0.61; p = 0.02). However, this did not
translate to an improvement in breast cancer-specific survival [75].
In an analysis of the National Cancer Database between 2004 and 2014, Lazow demonstrated
that after controlling for patient demographics, tumor grade and use of adjuvant therapies, bilateral
mastectomy in women < 40 years was associated with increased 10-year overall survival (HR 0.75,
95% CI 0.59–0.96; p = 0.023), compared to the unilateral mastectomy group [76]. This trend was also
observed in a preceding National Cancer Database review from 1998–2002, demonstrating a 5-year
overall survival benefit of 2% in young patients (adjusted HR 0.88, 95% CI 0.83–0.93; p < 0.001) between
these two groups [78]. In a retrospective study of 42/481 (8.73%) young women <40 years, who were
elected for contralateral prophylactic mastectomy, Zeicher reported that this was associated with
improved 10-year overall survival (HR 2.35, 95% CI 1.02–5.41; p = 0.046), although this effect was not
demonstrable for 5-year overall survival [71].
There is a suggestion that contralateral prophylactic mastectomy may confer benefit in young
women with early-stage, ER-negative breast cancer. In a population-based study of 107,106 breast
cancer patients, 3731 (3.48%) of whom were young (18–49 years), contralateral prophylactic mastectomy
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was associated with improved disease-specific mortality (HR 0.68, 95% CI 0.53–0.88; p = 0.004). This
effect was not reproduced in young women with early-stage, ER-positive breast cancer [74].
Other retrospective cohort or population-based studies refute the survival benefit of contralateral
prophylactic mastectomy in young women [72,73,75,77]. In a review of 9044 young women (<40 years)
with breast cancer, Chen demonstrated no improvement in overall or breast cancer-specific survival [2].
This was supported in a retrospective study of 10,226 patients with invasive lobular carcinoma,
demonstrating no overall survival benefit from contralateral prophylactic mastectomy in the 18–50
years group, at a median follow up of 6.9 years [72]. Moreover, in a review of 14,627 women and at
median follow-up of 6.1 years, having matched for tumour size/grade, ER status and nodal status,
Pesce demonstrated that contralateral prophylactic mastectomy offered no overall survival benefit, in
women aged <45 years, with stage I/II breast cancer (HR 0.93, p = 0.39) [73].
Overall, these findings should be interpreted with caution as the quality of the data does not allow
for definitive conclusions to be drawn.
7. Discussion
Contralateral prophylactic mastectomy is increasingly being performed despite an ambiguity of
evidence to support an oncological benefit. In 2007 and 2009, two studies reported that contralateral
prophylactic mastectomy rate had increased 148% and 150% among all patients diagnosed with
non-invasive and invasive breast cancer respectively [79,80]. Current trends in the U.S.A show an
absolute percentage increase in the range of 25% [81]. This trend is modest in European studies
suggesting a difference in practice and healthcare environments [82–84]. Nonetheless, this increased
utilization of contralateral prophylactic mastectomy is a cause of concern for clinicians because of
the associated surgical risks, complications, and psychological and financial burden in the absence of
robust evidence to support significant oncological benefits.
Although intuitively it is expected that contralateral prophylactic mastectomy would decrease
the risk of contralateral breast cancer, the available data only support this in patients with BRCA1/2
gene mutations [14,26,27]. In women with strong family history or young age at diagnosis, the effect
of contralateral prophylactic mastectomy is less well studied and the existing literature should be
interpreted with caution because of the potential biases. At present, there are no models that allow
for calculation of contralateral breast cancer risk in a polyfactorial model. Such a model might be
useful in stratifying risk and aiding physicians to provide precise and unbiased estimation of risk,
in order to offer individualized counselling to patients, inform decision-making and mitigate patient
overestimation of cancer risk which may drive unnecessary surgery.
Despite the potential decrease in contralateral breast cancer, the effect of contralateral prophylactic
mastectomy on oncological outcomes is debatable as studies suggest that this reduction is not
translated into survival benefit. Moreover, the role of contralateral prophylactic mastectomy per se
as a contributing factor for improved outcomes in women with unilateral breast cancer is difficult to
accurately define, as the majority of the available data is of limited quality. Meta-analyses are only as
strong as the independent studies they comprise. The majority of studies are retrospective cohorts
and based on population/family studies. Therefore, the results should be interpreted with caution
because of potential uncontrolled biases. The way to address these issues is with higher quality data
but it is unlikely that the future will harbour randomized clinical trials investigating the impact of
contralateral prophylactic mastectomy on contralateral breast cancer risk and survival due to patient
preference and ethical considerations. One proposal is to set up robust prospective registries to help
enhance our knowledge in the field. The majority of existing studies do not account for the significant
role conferred by improved systemic therapies and its effect on contralateral breast cancer risk and
improved oncological outcomes, factors that merit future research.
Recently, and in order to aid clinicians approach this controversial topic, both the American Society
of Breast Surgeons and Association of Breast Surgery published consensus statements on the utilization
of contralateral prophylactic mastectomy. Both were aligned on supporting its use in women with
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significant contralateral breast cancer risk i.e., BRCA1/2 mutations, patients with a history of mantle
field radiation to the chest before age 30 years [85,86]. However, a multidisciplinary, individualised
approach is required to help women in their informed decision-making process.
8. Conclusions
In conclusion, contralateral prophylactic mastectomy may be supported in ‘high-risk’ groups as
evidence indicates a possible reduction in contralateral breast cancer risk and also potentially improved
oncological outcomes. The evidence to demonstrate that this may confer benefit in the other risk
groups or in older patients is less established. It is therefore imperative to follow a multidisciplinary,
personalised approach, to educate women on the best available evidence and to support individuals in
a shared-decision making process.
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Abstract: The underlying mechanism of the progression of ductal carcinoma in situ (DCIS),
a non-obligate precursor of invasive breast cancer (IBC), has yet to be elucidated. In IBC,
Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B (APOBEC3B) is upregulated
in a substantial proportion of cases and is associated with higher mutational load and poor prognosis.
However, APOBEC3B expression has never been studied in DCIS. We performed mRNA expression
analysis of APOBEC3B in synchronous DCIS and IBC and surrounding normal cells. RNA was
obtained from 53 patients. The tumors were categorized based on estrogen receptor (ER), progesterone
receptor (PR), human epidermal growth factor receptor 2 (Her2) and phosphoinositide-3-kinase,
catalytic, alpha polypeptide (PIK3CA) mutation status. APOBEC3B mRNA levels were measured by
RT-qPCR. The expression levels of paired DCIS and adjacent IBC were compared, including subgroup
analyses. The normal cells expressed the lowest levels of APOBEC3B. No differences in expression
were found between DCIS and IBC. Subgroup analysis showed that APOBEC3B was the highest in
the ER subgroups of DCIS and IBC. While there was no difference in APOBEC3B between wild-type
versus mutated PIK3CA DCIS, APOBEC3B was higher in wild-type versus PIK3CA-mutated IBC.
In summary, our data show that APOBEC3B is already upregulated in DCIS. This suggests that
APOBEC3B could already play a role in early carcinogenesis. Since APOBEC3B is a gain-of-function
mutagenic enzyme, patients could benefit from the therapeutic targeting of APOBEC3B in the early
non-invasive stage of breast cancer.
Keywords: APOBEC3B; gene expression; breast cancer; ductal carcinoma in situ; infiltrating breast
cancer; PIK3CA
1. Introduction
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer (IBC) [1].
This is supported by previous studies that reported a high genomic concordance of synchronous DCIS
and IBC [2–4]. However, despite molecular similarities, recent in-depth genetic studies also reported
specific mutations that were either restricted to the in situ or the invasive component [3,5]. Increased
insight in the molecular changes during DCIS progression has the potential to reveal novel, potentially
targetable drivers of progression.
A major role of Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B
(APOBEC3B) has been reported in breast cancer and several other cancers [6–9]. This enzyme is
a member of the APOBEC family of deaminases and is involved in DNA cytosine deaminase activity,
Cancers 2019, 11, 1062; doi:10.3390/cancers11081062 www.mdpi.com/journal/cancers25
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which has diverse biological functions, including activities in the innate immune system by restricting
virus replication [10]. The upregulation of APOBEC3B is correlated with increased C-to-T transitions
and increased mutational load, including known driver mutations in PIK3CA and tumor protein
53 (TP53) [10–12]. APOBEC3B mRNA is upregulated in a substantial proportion of IBC cases and
an association with poor clinical outcome has been reported in Estrogen receptor (ER)-positive
subtypes [13]. In addition, we recently reported higher mRNA levels of APOBEC3B in breast cancer
metastasis as compared to the corresponding primary tumor, which implied that breast cancer
progression is associated with the upregulation of APOBEC3B [14].
In this study we investigated APOBEC3B mRNA expression levels in synchronous DCIS and IBC
and correlated the expression with PIK3CA mutation status in order to increase our understanding
regarding the expression levels of this enzyme during progression from the in situ to the invasive stage.
We believe this could improve breast cancer care in the future since APOBEC3B is a gain-of-function
mutagenic enzyme, so patients could potentially be treated with small molecules at a very early,
non-invasive stage.
2. Results
2.1. General Clinicopathological Data
In total, 53 patients were included. Table 1 provides an overview of the clinicopathological data
of all patients. The overall median age was 53 years (range 28–102 years). The majority of DCIS and
IBC samples were high grade (62.3 and 54.7%, respectively). There was no difference in grade between
DCIS and adjacent IBC (Fisher Exact Probability Test p = 0.92). Based on immunohistochemical
staining, IBCs were categorized into the following five breast cancer subtype categories: ER+/PR
high/Her2− (n = 13), ER+/PR− or low/Her2− (n = 12), ER+/any PR/Her2+ (n = 11), ER−/PR−/Her2+
(n = 8), or ER−/PR−/Her2− (n = 9).
Table 1. Clinicopathological features of patients with ductal carcinoma in situ (DCIS) and adjacent
invasive breast cancer (IBC) (n = 53).
Characteristic n (%)
Age at diagnosis 53
years, median (range) (28–102)
Type of surgery
Breast-conserving surgery 24 45.3
Mastectomy 29 54.7
Grade DCIS
1 1 49.1
2 19 39.6
3 33 7.5
Grade IBC
1 1 49.1
2 21 39.6
3 31 7.5
Tumor size
≤2 cm 28 49.1
>2–5 cm 21 39.6
>5 cm 4 7.5
Missing 0 3.8
Subtypes based on
immunohistochemistry
ER+/PR high/Her2− 13 24.5
ER+/PR− or low/Her2− 12 22.6
ER+/any PR/Her2+ 11 20.8
ER−/PR−/Her2+ 8 15.1
ER−/PR−/Her2− 9 17.0
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2.2. APOBEC3B Expression in Synchronous Normal, DCIS and IBC Cells
Both the Kruskal-Wallis Test and the Median Test indicated that there was a significant difference
(p < 0.001) in APOBEC3B mRNA levels between the normal controls, DCIS and IBC. APOBEC3B
mRNA was lower expressed in the normal mammary epithelial tissue adjacent DCIS and IBC (unpaired
Mann-Whitney U Test and paired Wilcoxon Signed Ranks Test p < 0.001) (Figure 1). There was no
statistically significant difference in APOBEC3B mRNA expression between DCIS and IBC (unpaired
Mann–Whitney U Test p = 0.065 (Figure 1), Wilcoxon Signed Ranks Test p = 0.082). (Figure 2).
Figure 1. Boxplots of APOBEC3B mRNA expression levels in paired normal, DCIS and IBC (n = 53).
Differences between normal, DCIS and IBC were analyzed by the Mann-Whitney U test.
Figure 2. APOBEC3B expression levels in paired DCIS and IBC (n = 53). Wilcoxon Signed Ranks Test
p = 0.082.
2.3. APOBEC3B mRNA Subgroup Analysis
Previous studies reported elevated APOBEC3B mRNA levels in breast cancers with otherwise
aggressive characteristics, including high histological grade and lack of estrogen expression [7,13,15].
For both DCIS and IBC, there was no correlation between APOBEC3B expression levels and tumor
diameter (Spearman Rank Correlation Test p > 0.05) or histological grade (Kruskal-Wallis Test p > 0.05).
Our breast cancer subtype analysis showed that the expression of APOBEC3B was the highest in the
ER− subgroup (Mann–Whitney U Test, p = 0.037) (Figure 3).
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Figure 3. Boxplots of Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B
(APOBEC3B) mRNA expression levels according to ER status. The difference between ER+ and ER−
cases was analyzed by the Mann-Whitney U test.
2.4. APOBEC3B Expression in Epithelial Versus Inflammatory Cells
Based on the positive correlation between APOBEC3B and marker for epithelial content (EPCAM)
mRNA levels (Spearman Rank Correlation test, p = 0.005 for DCIS, p = 0.001 for IBC), APOBEC3B
mRNA was mostly expressed by epithelial cells. Of note, there was no significant difference in the
levels of EPCAM mRNA between DCIS and synchronous IBC (Wilcoxon Signed Ranks Test, p = 0.18).
Since inflammatory cells also express APOBEC3B [16], we investigated whether the number of
inflammatory cells could have biased our results by comparing Protein Tyrosine Phosphatase Receptor
Type C (PTPRC, gene for the common leukocyte antigen CD45) mRNA levels from DCIS and IBC.
There was no correlation between APOBEC3B and PTPRC mRNA levels (Spearman Rank Correlation
test, p = 0.18 for DCIS and p = 0.29 for IBC). However, IBC expressed slightly higher levels of PTPRC
when compared with DCIS (Wilcoxon Signed Ranks Test, p = 0.023).
2.5. APOBEC3B Expression and PIK3CA Mutation Status
In a recently published study [17], we detected a PIK3CA somatic hotspotmutation in 24.7% (18 out
of 73) patients. For these 18 PIK3CA-positive patients, a significantly higher PIK3CA variant allele
frequency (VAF) was detected in the DCIS component (45.8%) when compared with the synchronous
IBC component (31.7%) (p = 0.007). For the n = 14 PIK3CA mutation-positive patients (26.4%) included
in the current study, a significantly higher PIK3CA VAF was also detected in the DCIS component
(52.3%) when compared with the synchronous IBC component (37.2%) (p = 0.027). The correlation
of PIK3CA VAF with APOBEC3B showed a negative Spearman Rank correlation in IBC (rs = −0.33,
p = 0.001, n = 53). For the DCIS cases, there was no such correlation (rs = 0.02, p = 0.89, n = 53).
Analyzing these data irrespective of the degree of the PIK3CA VAF levels revealed that for the 53
patients analyzed in this study, APOBEC3B mRNA levels in IBC were significantly lower in the eight
patients with exon 9 (G to A)-mutated PIK3CA when compared with the n = 39 wild-type PIK3CA
cases (Mann-Whitney U test p = 0.017). No such difference was observed for the DCIS cases (p = 0.28)
(Figure 4). Albeit not statistically significant, APOBEC3B mRNA levels were higher overall in the n = 39
PIK3CA wild-type IBC samples when compared with the PIK3CA wild-type DCIS samples (Mean ±
SEM: −4.54 ± 0.36 for IBC versus −5.38 ± 0.35 for DCIS) and lower in the n = 8 G-to-A PIK3CA-mutated
IBC samples when compared with G-to-A PIK3CA-mutated DCIS samples (Mean ± SEM: −6.52 ± 1.66
for IBC versus −6.14 ± 0.74 for DCIS). Although the majority of samples with a PIK3CA mutation were
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ER+, there was no significant interaction effect between ER status and the absence or presence of the
two types of tested PIK3CA mutations (p = 0.46 for DCIS and p = 0.20 for IBC).
Figure 4. Boxplots of APOBEC3B mRNA expression levels according PIK3CA mutation status.
The differences between wild-type (blue boxes) and mutated (red boxes) PIK3CA cases were analyzed
by the Mann-Whitney U test.
3. Discussion
APOBEC3B has been identified as an important factor in the evolution of breast cancer [8].
In a recently published pan-tissue, pan-cancer analysis of RNA-seq data specific to the seven
APOBEC3 genes in 8951 tumors, 786 cancer cell lines and 6119 normal tissues, APOBEC3B consistently
demonstrated its association with proliferative cells and processes, in contrast to other APOBEC3s,
especially APOBEC3G and APOBEC3H, which were revealed as more immune cell related [9].
Our current data showed that APOBEC3B mRNA is already upregulated in the in situ stage of
breast cancer, which is in line with the high genomic resemblances between DCIS and IBC [18]. In a
study we performed earlier, we observed higher mRNA levels ofAPOBEC3B in breast cancer metastasis
as compared to the corresponding primary tumor [14], supporting our hypothesis that, already starting
from DCIS, breast cancer progression is associated with deregulated expression of APOBEC3B.
Tumors with upregulated APOBEC3B demonstrate a higher mutational load, which could explain
the aggressive behavior of these tumors [7,12]. Two hotspot G-to-A mutations in exon 9 of the—often
mutated in breast cancer—PIK3CA gene (E542K and E545K) are thought to be generated by APOBEC3B
induced C-to-T (G-to-A) transitions [11]. Whether APOBEC3B is still needed once the mutations
are present needs further investigation. In the study of Kosumi et al., APOBEC3B expression in
esophageal squamous cell carcinoma was significantly correlated with PIK3CA mutations in exon
9 [10]. However, no correlation was found between APOBEC3B expression and PIK3CA mutations
status in a Japanese breast cancer cohort [15]. Although PIK3CA mutations are known to be more
prevalent in ER+ cases [19], and thus might have been a confounder in our analysis, we found no
significant difference in the distribution of wild-type and mutated PIK3CA in ER+ and ER− cases.
In our cohort, APOBEC3B levels were decreased in specifically the G-to-A PIK3CA-mutated IBC
samples when compared with wild-type PIK3CA IBC tumors. In the synchronous DCIS counterpart,
however, there was no difference in APOBEC3B levels between mutated and PIK3CA wild-type
tumors. This might suggest that, in contrast to DCIS, the invasive tumors no longer need APOBEC3B
to proliferate and metastasize. Previous studies reported elevated APOBEC3B mRNA levels in breast
cancers with otherwise aggressive characteristics, including high histological grade and lack of estrogen
expression [7,13,15]. This is consistent with our subgroup analysis, which showed higher APOBEC3B
levels in synchronous DCIS and IBC of ER− tumors as compared to ER+ tumors. However, in our
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study, no significant correlations were found between APOBEC3B levels and histological grade and/or
tumor diameter. This could be due to the fact that the majority of our samples were high grade.
This is the first study evaluating APOBEC3B levels within DCIS and co-existing IBC, including
different breast cancer subtypes. However, our study has several limitations, such as the relatively
small size of our cohort and the analysis of a limited mRNA panel only, with the main focus on
APOBEC3B. Since upregulated APOBEC3B is associated with higher mutational load, evaluation of
the mutational status of additional markers besides PIK3CA will be interesting. Another limitation
is that APOBEC3B is also expressed by inflammatory cells, which could have influenced our data
because we performed manual microdissection, and thus contamination with inflammatory cells was
not completely avoidable. Although IBC expressed slightly higher levels of PTPRC (the gene for
leukocyte antigen CD45) than DCIS, there was no correlation between APOBEC3B and PTPRC mRNA
levels. Based on this analysis, it seems unlikely that the number of inflammatory cells biased our data.
Increased insight in molecular mechanisms that contribute to DCIS progression will improve
the development of a personalized treatment strategy for patients with DCIS. APOBEC3B could be
a potential therapeutic target since it is non-essential, but it has an active enzymatic activity that
may be inhibited [7]. Patients with DCIS could therefore benefit from such therapeutic molecules by
inhibiting tumor evolution. Concept inhibitors have already been developed for the related enzyme
APOBEC3G [20,21]. Additional clinical and pharmaceutical assays are necessary to develop and
explore the potential benefit of APOBEC3B inhibitors.
4. Materials and Methods
4.1. Patient Materials
Fifty-three patients with synchronous DCIS and IBC were enrolled. We used coded leftover patient
material in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in the
Netherlands (http://www.federa.org/codes-conduct). This article is approved by the Medical Ethics
Committee of the Erasmus MC (approval number MEC 02.953). According to national guidelines,
no informed consent was needed for this study.
Formalin-fixed-paraffin-embedded (FFPE) hematoxylin and eosin (H&E)-stained whole sections
of excision specimens were collected and reviewed by two pathologists (Carolien H. M. van Deurzen
and Shusma C. Doebar). Histopathological features included the grade of IBC [22], IBC diameter,
ER, PR and Her2 status, and grade of DCIS [23]. Tumors were divided into subtypes based on
immunohistochemistry (ER, PR and Her2), including the following 5 categories: ER+/PR high/Her2−;
ER+/PR− or low/Her2−; ER+/any PR/Her2+; ER−/PR−/Her2+; ER−/PR−/Her2−. ER was considered
positivewhen at least 10%of the tumor cellswere positive, irrespective of intensity, according to national
guidelines (https://richtlijnendatabase.nl). Low PR was defined as ≤ 20% [24]. Immunohistochemical
HER2 expression was scored according to international guidelines [25]. Equivocal cases were evaluated
by silver in situ hybridization.
4.2. RT-qPCR
RNA was extracted from tissue areas composed of at least 50% IBC or DCIS cells and analyzed
by RT-qPCR as described before [14,17]. In brief, these cells were obtained by microdissection from
FFPE tissue, which was performed with a sterile needle under a stereomicroscope. RNA was extracted
from these cells using the Qiagen (Hamburg, Germany) AllPrep DNA/RNA FFPE Kit according the
manufacturer’s instructions. RNA concentrations were measured with a Nanodrop 2000 system. cDNA
was generated from 50 ng/μL cDNA and was generated for 30 min at 48 ◦C with the RevertAid H minus
kit (Thermo Fisher Scientific, Breda, The Netherlands) and gene-specific pre-amplified with Taqman
PreAmp Master mix (Thermo Fisher Scientific) for 15 cycles, followed by Taqman probe based real-time
PCR according to the manufacturer’s instructions in a MX3000P Real-Time PCR System (Agilent,
Amsterdam, TheNetherlands). The following intron-spanning gene expression assays (all fromThermo
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Fisher Scientific) were evaluated: APOBEC3B, assay ID: hs00358981_m1; EPCAM, hs00158980_m1, and
PTPRC, hs00236304_m1. Messenger RNA levels were quantified relative to the average expression of 2
reference genes (GUSB, hs9999908_m1 and HMBS, hs00609297_m1) using the delta Cq (average Cq
reference genes −Cq target gene) method. According GeNorm and NormFinder, the average of these
two reference genes was the most stable expressed across our samples (M-value = 0.59, SD = 0.29).
Also, when taking the different groups into account, the inter and intra variation was the lowest for the
average of our 2 reference genes (SD = 0.19 for the NormFinder analysis across the control, DCIS and
IBC groups and SD = 0.24 for the NormFinder analysis across the ER/PR/Her2 groups). Samples with
an average reference gene expression of Cq > 25 were considered to be of insufficient RNA quality and
excluded from further analysis, together with their paired samples. A serially diluted RNA pool of
FFPE breast tumor samples was included in each experiment to evaluate the linear amplification and
efficiencies for all genes included in the panel and absence of amplification in the absence of reverse
transcriptase. All gene transcripts were equally efficient amplified (range 94–106%) and were negative
in the absence of reverse transcriptase. A summary of the performance of our assays on these serially
diluted samples is shown in Supplementary Table S1.
4.3. PIK3CA Mutation Status
PIK3CA mutation status and VAFs were measured as described before [17]. In brief, DNA was
extracted from the same micro-dissected FFPE tissues used for RNA extraction using the Qiagen
(Hamburg, Germany) AllPrep DNA/RNA FFPE Kit. The SNaPshot Multiplex System for SNP
Genotyping (Thermo Fisher Scientific) was used to identify samples positive for PIK3CA hotspot
mutations in exon 9 and exon 20. Next, we used digital PCR (dPCR) to validate the SNaPshot results
and quantify the relative number of PIK3CA-mutated copies (of E542K, E545K in exon 9 and H1047R
and H1047L in exon 20) in both the DCIS and IBC component of those patients with a PIK3CA mutation
identified by SNaPshot analysis.
4.4. Statistical Analyses
GeNorm and NormFinder [26,27], present in GenEx qPCR data analysis software (version 6.1,
MultiD, Götenborg, Sweden), were used to assess the stability of our reference genes. SPSS version
24 was used for the statistical analyses. Because our APOBEC3B mRNA data were not normally
distributed (skewness −1.01 ± 0.33 and −1.75 ± 0.33, kurtosis 0.80 ± 0.64 and 3.60 ± 0.64 for DCIS and
IBC, respectively), we only used non-parametric tests. The Wilcoxon Signed Ranks Test was used to
compare levels in paired DCIS and IBC and unpaired analyses were performed using the Wilcoxon or
Mann-Whitney U Test or the Fisher Exact Probability Test for contingency tabled data. Continuous
variables were analyzed by the Spearman Rank Correlation test. p-values ≤ 0.05 were considered
statistically significant.
5. Conclusions
In conclusion, our results indicate that APOBEC3B mRNA is similarly upregulated in DCIS and
IBC, but declines in PIK3CA-mutated IBC, which suggests that APOBEC3B plays a role in the early
stages of breast carcinogenesis. Since APOBEC3B is a gain-of-function mutagenic enzyme, it could be
a candidate for therapeutic targeting in an early, non-invasive stage of breast cancer.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/8/1062/s1,
Table S1: Performance of the Taqman mRNA assays used in this study.
Author Contributions: Conceptualization, A.M.S., S.C.D. and C.H.M.v.D. Methodology, A.M.S., S.C.D., E.I.V.,
V.d.W., C.M.B., M.C.A. and C.H.M.v.D.; Formal analysis, A.M.S.; Validation, S.C.D., C.H.M.v.D. Writing—Original
Draft Preparation, A.M.S. and S.C.D.; Writing—Review and Editing, A.M.S., S.C.D., J.M.W.M. and C.H.M.v.D.;
Visualization, A.M.S.; Supervision, J.W.M.M. and C.H.M.v.D. All co-authors have read and approved of the
manuscript and acknowledge their contributions.
31
Cancers 2019, 11, 1062
Funding: This research was funded by KWF-EMCR-2016-10270 “The role of APOBEC3B in breast cancer therapy
resistance”.
Acknowledgments: A.M.S. was supported by Cancer Genomics Netherlands (CGC.nl) funded by the Netherlands
Organization for Scientific Research (NWO).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Cowell, C.F.; Weigelt, B.; Sakr, R.A.; Ng, C.K.; Hicks, J.; King, T.A.; Reis-Filho, J.S. Progression from ductal
carcinoma in situ to invasive breast cancer: Revisited. Mol. Oncol. 2013, 7, 859–869. [CrossRef] [PubMed]
2. Casasent, A.K.; Edgerton, M.; Navin, N.E. Genome evolution in ductal carcinoma in situ: Invasion of the
clones. J. Pathol. 2017, 241, 208–218. [CrossRef] [PubMed]
3. Kim, S.Y.; Jung, S.H.; Kim, M.S.; Baek, I.P.; Lee, S.H.; Kim, T.M.; Chung, Y.J.; Lee, S.H. Genomic differences
between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Oncotarget 2015, 6, 7597–7607. [CrossRef] [PubMed]
4. Casasent, A.K.; Schalck, A.; Gao, R.; Sei, E.; Long, A.; Pangburn, W.; Casasent, T.; Meric-Bernstam, F.;
Edgerton, M.E.; Navin, N.E. Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell
Sequencing. Cell 2018, 172, 205–217.e12. [CrossRef] [PubMed]
5. Hernandez, L.; Wilkerson, P.M.; Lambros, M.B.; Campion-Flora, A.; Rodrigues, D.N.; Gauthier, A.; Cabral, C.;
Pawar, V.; Mackay, A.; A’Hern, R.; et al. Genomic and mutational profiling of ductal carcinomas in situ and
matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.
J. Pathol. 2012, 227, 42–52. [CrossRef] [PubMed]
6. Smith, H.C.; Bennett, R.P.; Kizilyer, A.; McDougall, W.M.; Prohaska, K.M. Functions and regulation of the
APOBEC family of proteins. Semin. Cell Dev. Biol. 2012, 23, 258–268. [CrossRef] [PubMed]
7. Roberts, S.A.; Lawrence, M.S.; Klimczak, L.J.; Grimm, S.A.; Fargo, D.; Stojanov, P.; Kiezun, A.; Kryukov, G.V.;
Carter, S.L.; Saksena, G.; et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human
cancers. Nat. Genet. 2013, 45, 970–976. [CrossRef]
8. Harris, R.S. Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer.
Breast Cancer Res. 2015, 17, 8. [CrossRef]
9. Ng, J.C.F.; Quist, J.; Grigoriadis, A.; Malim, M.H.; Fraternali, F. Pan-cancer transcriptomic analysis dissects
immune and proliferative functions of APOBEC3 cytidine deaminases. Nucleic Acids Res. 2019, 47, 1178–1194.
[CrossRef]
10. Kosumi, K.; Baba, Y.; Ishimoto, T.; Harada, K.; Nakamura, K.; Ohuchi, M.; Kiyozumi, Y.; Izumi, D.;
Tokunaga, R.; Taki, K.; et al. APOBEC3B is an enzymatic source of molecular alterations in esophageal
squamous cell carcinoma. Med. Oncol. 2016, 33, 26. [CrossRef]
11. Henderson, S.; Chakravarthy, A.; Su, X.; Boshoff, C.; Fenton, T.R. APOBEC-mediated cytosine deamination
links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep.
2014, 7, 1833–1841. [CrossRef] [PubMed]
12. Burns,M.B.; Lackey, L.; Carpenter,M.A.; Rathore,A.; Land,A.M.; Leonard, B.; Refsland, E.W.; Kotandeniya,D.;
Tretyakova, N.; Nikas, J.B.; et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature
2013, 494, 366–370. [CrossRef] [PubMed]
13. Sieuwerts, A.M.; Willis, S.; Burns, M.B.; Look, M.P.; Meijer-Van Gelder, M.E.; Schlicker, A.; Heideman, M.R.;
Jacobs, H.; Wessels, L.; Leyland-Jones, B.; et al. Elevated APOBEC3B correlates with poor outcomes for
estrogen-receptor-positive breast cancers. Horm. Cancer 2014, 5, 405–413. [CrossRef]
14. Sieuwerts, A.M.; Schrijver, W.A.; Dalm, S.U.; de Weerd, V.; Moelans, C.B.; Ter Hoeve, N.; van Diest, P.J.;
Martens, J.W.; van Deurzen, C.H. Progressive APOBEC3B mRNA expression in distant breast cancer
metastases. PLoS ONE 2017, 12, e0171343. [CrossRef] [PubMed]
15. Tsuboi, M.; Yamane, A.; Horiguchi, J.; Yokobori, T.; Kawabata-Iwakawa, R.; Yoshiyama, S.; Rokudai, S.;
Odawara, H.; Tokiniwa, H.; Oyama, T.; et al. APOBEC3B high expression status is associated with aggressive
phenotype in Japanese breast cancers. Breast Cancer 2016, 23, 780–788. [CrossRef] [PubMed]
16. Siriwardena, S.U.; Chen, K.; Bhagwat, A.S. Functions and Malfunctions of Mammalian DNA-Cytosine
Deaminases. Chem. Rev. 2016, 116, 12688–12710. [CrossRef] [PubMed]
32
Cancers 2019, 11, 1062
17. Agahozo, M.C.; Sieuwerts, A.M.; Doebar, S.C.; Verhoef, E.; Beaufort, C.M.; Ruigrok-Ritstier, K.; de Weerd, V.;
Sleddens, H.; Dinjens, W.N.; Martens, J.; et al. PIK3CA mutations in ductal carcinoma in situ and adjacent
invasive breast cancer. Endocr. Relat. Cancer 2019, 26, 471–482. [CrossRef] [PubMed]
18. Aubele, M.; Mattis, A.; Zitzelsberger, H.; Walch, A.; Kremer, M.; Welzl, G.; Hofler, H.; Werner, M. Extensive
ductal carcinoma In situ with small foci of invasive ductal carcinoma: Evidence of genetic resemblance by
CGH. Int. J. Cancer 2000, 85, 82–86. [CrossRef]
19. Pang, B.; Cheng, S.; Sun, S.P.; An, C.; Liu, Z.Y.; Feng, X.; Liu, G.J. Prognostic role of PIK3CA mutations and
their association with hormone receptor expression in breast cancer: A meta-analysis. Sci. Rep. 2014, 4, 6255.
[CrossRef]
20. Olson, M.E.; Harris, R.S.; Harki, D.A. APOBEC Enzymes as Targets for Virus and Cancer Therapy. Cell Chem.
Biol. 2018, 25, 36–49. [CrossRef]
21. Li, M.; Shandilya, S.M.; Carpenter, M.A.; Rathore, A.; Brown, W.L.; Perkins, A.L.; Harki, D.A.; Solberg, J.;
Hook, D.J.; Pandey, K.K.; et al. First-in-class small molecule inhibitors of the single-strand DNA cytosine
deaminase APOBEC3G. ACS Chem. Biol. 2012, 7, 506–517. [CrossRef] [PubMed]
22. Elston, C.W.; Ellis, I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in
breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991, 19, 403–410.
[CrossRef] [PubMed]
23. Consensus Conference Committee. Consensus Conference on the classification of ductal carcinoma in
situ. Thomas Jefferson University in Philadelphia, Pennsylvania, USA, Nov 1. Cancer 1997, 80, 1798–1802.
[CrossRef]
24. Prat, A.; Cheang, M.C.; Martín, M.; Parker, J.S.; Carrasco, E.; Caballero, R.; Tyldesley, S.; Gelmon, K.;
Bernard, P.S.; Nielsen, T.O.; et al. Prognostic significance of progesterone receptor-positive tumor cells within
immunohistochemically defined luminal A breast cancer. J. Clin. Oncol. 2013, 31, 203–209. [CrossRef]
[PubMed]
25. Wolff, A.C.; Hammond, M.E.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.;
Bartlett, J.M.; Bilous, M.; Fitzgibbons, P.; et al. Recommendations for human epidermal growth factor
receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists
clinical practice guideline update. J. Clin. Oncol. 2013, 31, 3997–4013. [CrossRef] [PubMed]
26. Andersen, C.L.; Jensen, J.L.; Orntoft, T.F. Normalization of real-time quantitative reverse transcription-PCR
data: A model-based variance estimation approach to identify genes suited for normalization, applied to
bladder and colon cancer data sets. Cancer Res. 2004, 64, 5245–5250. [CrossRef] [PubMed]
27. Wang, Q.; Ishikawa, T.; Michiue, T.; Zhu, B.L.; Guan, D.W.; Maeda, H. Stability of endogenous reference
genes in postmortem human brains for normalization of quantitative real-time PCR data: Comprehensive
evaluation using geNorm, NormFinder, and BestKeeper. Int. J. Legal Med. 2012, 126, 943–952. [CrossRef]
[PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
33

cancers
Article
Why Has Breast Cancer Screening Failed to Decrease
the Incidence of de Novo Stage IV Disease?
Danielle R. Heller 1, Alexander S. Chiu 1, Kaitlin Farrell 2, Brigid K. Killelea 2 and
Donald R. Lannin 2,*
1 Department of Surgery, Yale School of Medicine, New Haven, CT 06520, USA; d.heller@yale.edu (D.R.H.);
alex.chiu@yale.edu (A.S.C.)
2 The Breast Center/Section of Surgical Oncology, Department of Surgery, Yale School of Medicine, New
Haven, CT 06520, USA; kaitlinfarrell10@gmail.com (K.F.); Brigid.killelea@yale.edu (B.K.K.)
* Correspondence: Donald.lannin@yale.edu; Tel.: +1-203-200-1518; Fax: +1-203-200-2503
Received: 18 February 2019; Accepted: 3 April 2019; Published: 8 April 2019
	

Abstract: Background: Despite screening mammography, the incidence of Stage IV breast cancer (BC)
at diagnosis has not decreased over the past four decades. We previously found that many BCs
are small due to favorable biology rather than early detection. This study compared the biology
of Stage IV cancers with that of small cancers typically found by screening. Methods: Trends in
the incidence of localized, regional, and distant female BC were compared using SEER*Stat. The
National Cancer Database (NCDB) was then queried for invasive cancers from 2010 to 2015, and
patient/disease variables were compared across stages. Biological variables including estrogen
receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her2), grade,
and lymphovascular invasion were sorted into 48 combinations, from which three biological subtypes
emerged: indolent, intermediate, and aggressive. The distributions of the subtypes were compared
across disease stages. Multivariable regression assessed the association between Stage IV disease
and biology. Results: SEER*Stat confirmed that the incidence of distant BC increased between 1973
and 2015 (annual percent change [APC] = 0.46). NCDB data on roughly 993,000 individuals showed
that Stage IV disease at presentation is more common in young, black, uninsured women with
low income/education and large, biologically aggressive tumors. The distribution of tumor biology
varied by stage, with Stage IV disease including 37.6% aggressive and 6.0% indolent tumors, versus
sub-centimeter Stage I disease that included 5.1% aggressive and 40.6% indolent tumors (p < 0.001).
The odds of Stage IV disease presentation more than tripled for patients with aggressive tumors
(OR3.2, 95% CI 3.0–3.5). Conclusions: Stage I and Stage IV breast cancers represent very different
populations of biologic tumor types. This may explain why the incidence of Stage IV cancer has not
decreased with screening.
Keywords: breast cancer; stage IV; incidence; tumor biology; NCDB; SEER
1. Introduction
Despite widespread breast cancer screening in the United States, the incidence of de novo Stage
IV breast cancer has not decreased. Esserman and colleagues called attention to this irregularity in
2009, showing that localized breast cancer incidence surged with the introduction of disease screening
in the 1980s, without a corresponding decrease in distant disease [1]. Works by Bleyer and colleagues
have reinforced the conclusion that screening is not meaningfully lowering the incidence of advanced
disease [2,3].
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The reasons underlying this problem are still unknown. Esserman presciently cited tumor
biological factors as likely determinants of disease screenability, calling for the incorporation of such
factors into screening and treatment guidelines [1]. Recently, Lannin and Wang showed that small
tumors—the majority of which are found on mammography screening—have a distinctly favorable
biological profile that dictates an indolent growth pattern [4]. Along similar lines, we hypothesized
that de novo Stage IV breast cancer may have a uniquely aggressive biology, granting it growth
properties that allow it to escape detection by screening. The purpose of this study was to compare
the tumor biology of de novo Stage IV breast cancer with that of small cancers typically detected by
screening mammography.
2. Methods
2.1. Data and Patient Selection
Data for this study were drawn from both the Surveillance, Epidemiology, and End Results
database (SEER,November 2017 submission) and theNational CancerDatabase (NCDB2015 Participant
User File, downloaded 15 December 2017). The original SEER 9 registry data, spanning 1973–2015,
were used to analyze long-term population-based incidence trends of the various disease stages. SEER
was chosen over NCDB for this analysis, since it contains many more years of incidence data and is
population-based and age-adjusted.
NCDB data from 2010 to 2015 were used to explore patient and disease characteristics of Stage
IV disease in a large modern population, as well as to compare the tumor biological profiles of
Stages I–IV. NCDB was chosen over SEER for this analysis since it contains more robust data on
disease characteristics and captures a larger population of breast cancer patients in the United States.
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and
the American Cancer Society. The data used in this study were derived from a de-identified NCDB
file. The American College of Surgeons and the Commission on Cancer have not verified and are not
responsible for the analytic or statistical methodology employed nor for the conclusions drawn from
these data by the investigators.
Included in this study were female patients with invasive breast cancer with known disease stage
(in situ and American Joint Committee on Cancer [AJCC] Stage 0 excluded). The analyses of the
incidence and patient/disease factors were conducted using targeted statistical methods and software,
as outlined below.
2.2. Incidence
To identify long-term breast cancer incidence trends by disease stage, the SEER 9 registry data
were queried for cases of localized, regional, and distant breast cancer (SEER Historic Stage A variable)
from 1973 to 2015. The Historic Stage A variable is traditionally used for analyses prior to 1988, when
recoding for AJCC stage was unavailable in SEER. Localized disease includes cancer confined to the
breast. Regional disease refers to contiguous organ spread, including regional lymph nodes and
the chest wall. Distant disease denotes remote organ metastasis detected at the time of diagnosis.
SEER*Stat software (Version 8.3.5, accessed on 20 April 2018) was used to calculate population-based
incidence rates and annual percent change (APC). The two-sided p-values were set at <0.05.
2.3. Patient and Tumor Characteristics
The NCDB was queried for cases from 2010 to 2015 of “NCDB Analytic Stages I–IV,” which
uses the AJCC 7th edition pathologic stage classification to collapse sub-stages into their broader
designations. Stages I–III cases were consolidated and compared with Stage IV in the univariable
analysis of patient characteristics, including race/ethnicity, age, insurance, median household income,
and education level, as well as disease characteristics, including histology, tumor size, estrogen receptor
(ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 status (Her2),
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grade, and lymphovascular invasion (LVI). Nodal status was not included in this analysis, as debate
exists as to whether lymph node spread marks biological predisposition versus a tumor’s natural
history when left untreated. All patients with known disease stage, including those with other missing
variables, were included in this analysis, totaling 992,687 patients. Chi-squared testing was used to
detect differences in patient and disease variables between Stage IV and non-Stage IV cancer, with
statistical significance set at p < 0.05.
Five markers of biological activity reported in the NCDB were found to be associated with Stage
IV in the univariable analysis: ER, PR, Her2, grade, and LVI. Their values were recombined into 48
possible permutations, generating a spectrum of tumor biology across 740,246 patients for whom
these data were available. The rates of Stage IV disease were calculated across the permutation
groups, which were then ranked in order of increasing Stage IV percentage. We aimed to cluster these
groups into three subtypes of increasing biological aggressiveness, with up to 25% at the extremes,
and the remainder intermediately aggressive. After testing multiple Stage IV percentage cut points
in sensitivity analyses, we ultimately classified 22.3% of patients as “indolent,” 61.7% of patients as
“intermediate,” and 16.0% of patients as “aggressive.” This process of classification is summarized in
Table 1.
Table 1. Classification system of breast cancer biological subtypes. ER: estrogen receptor, PR:
progesterone receptor, HER2: human epidermal growth factor receptor 2, LVI: lymphovascular invasion.
Group n ER PR HER2 Grade LVI Row % with Stage IV N Subtype Subtype
1 119 − + − 1 − 0
165,150 Indolent
2 7 − + − 1 + 0
3 3 − + + 1 + 0
4 146,900 + + − 1 − 0.006
5 12,409 + − − 1 − 0.01
6 3917 + + + 1 − 0.012
7 1795 − − − 1 − 0.013
8 204,447 + + − 2 − 0.014
456,894 Intermediate
9 726 + − + 1 − 0.018
10 691 − + − 2 − 0.019
11 21,860 + − − 2 − 0.022
12 12,597 − − − 2 − 0.022
13 52,160 − − − 3 − 0.022
14 9908 + + − 1 + 0.022
15 18,147 + + + 2 − 0.026
16 48,280 + + − 3 − 0.026
17 3123 − + − 3 − 0.026
18 373 − − + 1 − 0.027
19 754 + − − 1 + 0.027
20 14,045 + − − 3 − 0.029
21 98 + − + 1 + 0.031
22 49,161 + + − 2 + 0.031
23 15,296 + + + 3 − 0.033
24 5228 + − + 2 − 0.034
37
Cancers 2019, 11, 500
Table 1. Cont.
Group n ER PR HER2 Grade LVI Row % with Stage IV N Subtype Subtype
25 5224 − − + 2 − 0.038
118,202 Aggressive
26 14,608 − − + 3 − 0.038
27 6336 + − + 3 − 0.042
28 23 − + + 1 − 0.043
29 949 − + + 3 − 0.044
30 2805 − − − 2 + 0.045
31 411 + + + 1 + 0.046
32 5502 + + + 2 + 0.046
33 318 − + + 2 − 0.047
34 4922 + − − 2 + 0.048
35 28,757 + + − 3 + 0.051
36 17,799 − − − 3 + 0.056
37 6178 + − − 3 + 0.059
38 8808 + + + 3 + 0.059
39 1031 − + − 3 + 0.065
40 147 − − − 1 + 0.068
41 1468 + − + 2 + 0.068
42 473 − + + 3 + 0.068
43 175 − + − 2 + 0.069
44 3168 + − + 3 + 0.083
45 7249 − − + 3 + 0.086
46 1665 − − + 2 + 0.091
47 72 − − + 1 + 0.097
48 114 − + + 2 + 0.114
Frequencies of the above biological subtypes were calculated for all the staged breast cancer
cases with known biological data, and their distributions were compared across Stages I–IV. Stage I
was divided into tumors measuring 0.1–1.0 cm and 1.1–2.0 cm, in order to compare the biology of
tiny tumors almost exclusively found on screening mammography with Stage IV biology. Patients
without known tumor size or other demographic or disease variables were excluded from the analysis,
resulting in 718,118 patients included. Chi-squared testing was used to detect differences in tumor
biology across Stages I–IV, with statistical significance set at p < 0.05.
Finally, multivariable logistic regression using backward elimination tested Stage IV cases for
significant associations with the demographic variables, including race/ethnicity, age, insurance, and
median household income, as well as with disease variables, including histology, size, and biological
category. Only the patients with known demographic and disease variables were included, again
totaling 718,118 patients. Type I error was set at p = 0.05. The analyses were performed using SPSS
Statistics software (IBM Version 25, Armonk, NY, USA).
3. Results
3.1. Breast Cancer Incidence Trends, 1973–2015
Age-adjusted population-based incidence trends for localized, regional, and distant disease are
depicted in Figure 1. Based on SEER 9 registry data, the overall incidence of invasive breast cancer
increased between 1973 and 2015. The localized disease rate per 100,000 persons increased from 39.0
in 1973 to 85.9 in 2015, generating an APC of 1.20 (95% CI 0.87–1.53). The regional disease rate per
100,000 slightly decreased from 36.9 in 1973 to 34.7 in 2015, with a negative APC of −0.47 (95% CI −0.61
to −0.34). The distant disease rate per 100,000 was lowest but experienced an overall increase from 6.2
in 1973 to 8.7 in 2015, with an APC of 0.46 (95% CI 0.32–0.60).
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Figure 1. Age-adjusted incidence of localized, regional, and distant breast cancer in women, from 1973
to 2015 (SEER 9). APC: annual percent change.
3.2. Demographic and Disease Characteristics of Stage IV Patients
Between 2010 and 2015, there were 992,687 women in the NCDB with staged invasive breast
cancer. Of these, 939,903 (94.7%) were Stages I–III, and 52,784 (5.3%) were Stage IV. Univariable analysis
of the demographic and tumor characteristics is depicted in Table 2. Analysis of demographic data
showed that women with Stage IV disease were more likely to be black, younger than 40 years of age,
uninsured or on Medicaid, and living in zip codes where median household income was <$48,000,
and where ≥13% of adult residents did not have a high school degree. Strikingly, Stage IV disease
affected 8.0% of blacks, 8.8% of women under 30 years of age, and 14.2% of uninsured. Analysis of
tumor data showed that women with Stage IV were more likely to have larger tumors, non-ductal or
lobular undifferentiated histologies (“Other”), negative ER or PR status, positive Her2 status, LVI, and
poorly differentiated grade. Conspicuously, Stage IV affected 19.0% of tumors > 5cm and 10.9% of
tumors with undifferentiated histologies.
3.3. Tumor Biology Distribution by Stage
As mentioned in Methods, 740,264 patients had known tumor biology characteristics, including
hormone receptor and Her2 status, LVI status, and grade. Of this cohort, 718,118 of patients had known
tumor size and other demographic and disease characteristics, without missing data. These patients
were included in the analysis of the tumor biological subtypes by stage.
Using the tumor biology classification shown in Table 1, a majority of the cohort, 61.7%,
had intermediate biology, while 22.7% had indolent biology and 15.6% had aggressive biology.
The distribution of biological categories varied tremendously by disease stage (p < 0.001 for all stages),
as shown in Figure 2. Patients presenting with Stages III and IV disease had similar tumor biology and
had over eight times the fraction of aggressive tumors and one-seventh the fraction of indolent tumors
as patients with small Stage I tumors ≤1 cm.
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Table 2. Univariable analysis of demographic and disease variables for American Joint Committee on
Cancer Stages I–III and Stage IV. HS: high school.
Demographic/Disease Variables Stages I–III N (Row%) Stage IV N (Row%) p-Value
Race/Ethnicity
<0.001
White 738,416 (95.1%) 38,453 (4.9%)
Black 103,646 (92.0%) 8988 (8.0%)
Asian 31,843 (95.6%) 1455 (4.4%)
Hispanic 50,958 (94.5%) 2983 (5.5%)
Missing 15,040 (94.3%) 905 (5.7%)
Age
<0.001
<30 4594 (91.2%) 446 (8.8%)
30–39 36,589 (93.5%) 2560 (6.5%)
40–49 141,714 (95.6%) 6553 (4.4%)
50–59 223,898 (94.6%) 12,803 (5.4%)
60–69 259,993 (94.8%) 14,212 (5.2%)
≥70 273,115 (94.4%) 16,210 (5.6%)
Insurance
<0.001
None 17,883 (85.8%) 2961 (14.2%)
Private 467,639 (95.9%) 20,062 (4.1%)
Medicaid 59,468 (90.2%) 6476 (9.8%)
Medicare 368,966 (94.5%) 21,609 (5.5%)
Other Government 9705 (95.9%) 411 (4.1%)
Unknown 16,242 (92.8%) 1265 (7.2%)
Median Household Income
<0.001
≤$38,000 136,807 (93.2%) 9982 (6.8%)
$38,000–$47,999 197,306 (94.3%) 11,842 (5.7%)
$48,000–$62,999 251,060 (94.7%) 13,934 (5.3%)
≥$63,000 351,943 (95.5%) 16,758 (4.5%)
Missing 2787 (91.2%) 268 (8.8%)
Median Education (No HS Diploma)
<0.001
≥21% 136,597 (93.3%) 9811 (6.7%)
13–20.9% 221,484 (94.1%) 13,914 (5.9%)
7–12.9% 309,839 (94.9%) 16,810 (5.1%)
<7% 269,536 (95.7%) 12,002 (4.3%)
Missing 2447 (90.8%) 247 (9.2%)
Size (cm)
<0.001
0.1–2.0 606,385 (98.7%) 8052 (1.3%)
2.1–5.0 268,290 (93.5%) 18,615 (6.5%)
>5.0 56,294 (81.0%) 13,216 (19.0%)
Missing 8934 (40.9%) 12,901 (59.1%)
Histology
<0.001
Ductal 704,671 (95.5%) 33,525 (4.5%)
Lobular 90,608 (94.2%) 5623 (5.8%)
Mixed Ductal/ Lobular 49,264 (96.3%) 1912 (3.7%)
Other 95,360 (89.1%) 11,724 (10.9%)
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Table 2. Cont.
Demographic/Disease Variables Stages I–III N (Row%) Stage IV N (Row%) p-Value
ER
<0.001Negative 155,062 (92.9%) 11,810 (7.1%)
Positive 771,633 (95.5%) 36,720 (4.5%)
Missing 13,208 (75.6%) 4254 (24.4%)
PR
<0.001Negative 243,415 (93.0%) 18,354 (7.0%)
Positive 681,482 (95.8%) 29,586 (4.2%)
Missing 15,006 (75.6%) 4844 (24.4%)
Her2
<0.001Negative 763,436 (91.5%) 33,677 (4.2%)
Positive 119,352 (91.5%) 11,146 (8.5%)
Missing 57,115 (87.8%) 7961 (12.2%)
Grade
<0.001
Well-Differentiated 212,301 (98.6%) 3107 (1.4%)
Moderately Differentiated 398,667 (96.1%) 16,333 (3.9%)
Poorly Differentiated 270,103 (93.4%) 18,953 (6.6%)
Missing 58,832 (80.3%) 14,391 (19.7%)
LVI
<0.001
Negative 628,236 (98.1%) 12,155 (1.9%)
Positive 154,951 (95.0%) 8237 (5.0%)
Missing 156,716 (82.9%) 32,392 (17.1%)
Figure 2. Tumor biology by AJCC 7th edition stage.
3.4. Multivariable Analysis of Demographic and Disease Characteristics
In the multivariable logistic regression model, many demographic and disease variables that
were associated with Stage IV disease in univariable analysis remained significantly associated, as
shown in Table 3. Large tumor size, aggressive biological subtype, and no insurance were the strongest
predictors. Tumors with size >5 cm were more than 15 times as likely to predict Stage IV disease as
tumors with size ≤2 cm (OR 15.6, 95% CI 14.9–16.5), and tumors with aggressive biology were more
than 3 times as likely to present with Stage IV disease as indolent tumors (OR 3.22, 95% CI 2.99–3.47).
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Race/ethnicity, age, household income, and histology remained significant in the model, but their
effects were fairly minor.
Table 3. Multivariable logistic regression demonstrating the strength of association between Stage IV
disease and demographic and disease factors.
Demographic/Disease Factors Stage IV (De Novo) Odds Ratio 95% Confidence Interval
Race/Ethnicity
White Reference Reference
Black 1.09 1.04–1.15
Asian 0.78 0.71–0.86
Hispanic 0.71 0.66–0.77
Age
<30 1.38 1.17–1.63
30–39 1.08 0.99–1.18
40–49 0.87 0.81–0.93
50–59 1.07 1.01–1.14
60–69 1.06 1.01–1.12
≥70 Reference Reference
Insurance
None Reference Reference
Private 0.43 0.39–0.46
Medicaid 0.74 0.67–0.81
Medicare 0.51 0.47–0.56
Other Government 0.41 0.34–0.50
Unknown 0.57 0.49–0.68
Median Household Income
≤$38,000 1.12 1.06–1.18
$38,000–$47,999 1.09 1.04–1.14
$48,000–$62,999 1.04 0.99–1.08
≥$63,000 Reference Reference
Size (cm)
0.1–2.0 Reference Reference
2.1–5.0 4.40 4.21–4.60
>5.0 15.6 14.9–16.5
Histology
Ductal Reference Reference
Lobular 0.83 0.78–0.88
Mixed Ductal/Lobular 0.82 0.75–0.88
Other 0.84 0.79–0.89
Biological Subtype
Indolent Reference Reference
Intermediate 2.05 1.91–2.20
Aggressive 3.22 2.99–3.47
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4. Discussion
Multiple studies have shown that, despite widespread screening programs in the United States,
the incidence of Stage IV breast cancer has remained stable or increased over time [1–3,5,6]. In this
study, we analyzed the most recent and comprehensive population-based SEER data and showed that
the incidence of Stage IV disease has indeed been gradually increasing in recent decades.
Esserman and colleagues elegantly delineated this issue in 2009, contrasting the expected
stage-based incidence of a theoretically effective disease-screening program with the actual breast
cancer incidence trends since the rise of screening in the early 1980s. They highlighted that, while
successful screening programs are able to downstage incident cancers over time, breast cancer screening
has generated more localized disease diagnoses without congruently diminishing the incidence of
advanced cancer [1].
Welch and colleagues pointed out that since the advent of widespread mammography screening,
small cancers under 2 cm have increased in incidence over three times more than large tumors over
2 cm have decreased [7]. The clear implication is that not all small cancers are destined to become
large cancers, and this leads to overdiagnosis. Lannin and Wang provided an explanation for this by
comparing the biology of small and large cancers [4,8]. They found that many breast cancers are small,
not because they are detected early, but because they have favorable biology. The current study is
an extension of that work and shows that cancers presenting with distant metastases are a distinct
subpopulation with a biology much more aggressive than that of the small tumors found by screening
mammography. Only a small fraction of the tumors found by screening mammography have the
biological profile that puts them at risk for de novo Stage IV disease.
Of course, there are other possible explanations for increasing Stage IV incidence. One contributing
factor could be stagemigration, the phenomenonwhereby the use of high-resolution imaging, including
positron emission/computed tomography scans and magnetic resonance imaging, leads to more
frequent discovery of distant disease [9–11]. It seems unlikely, however, that this would precisely
counterbalance a decline in advanced cancer diagnoses that might otherwise be seen from early
mammographic detection.
Our data complement the body of literature suggesting that Stage IV cancers arise in unscreened
and underprivileged populations, including the very young, the very old, and the disadvantaged with
respect to healthcare access and quality. In our analyses, women younger than 40 years and older than
70 years of age had higher rates of Stage IV disease when compared to women aged 40–69 years, who
are known to have the highest rates of disease screening [12]. Black women, known to suffer disparate
breast cancer outcomes, had significantly higher rates of Stage IV disease than white women [13,14].
Those without health insurance and with Medicaid, as well as from regions in the lowest brackets for
income and education—all of which imply low resource settings—also disproportionately presented
with Stage IV disease [15–17]. These statistics must be interpreted cautiously, however, as NCDB
data are not population-based and thus do not differentiate between higher incidence of Stage IV
disease versus relatively lower incidence of Stages I–III disease. In fact, Welch and colleagues used
population-based SEER data to show that poorer counties with less mammographic screening have
lower overall breast cancer incidence but similar Stage IV disease incidence and cancer mortality
compared with wealthier counties [18,19].
Even when adjusting for demographic and socioeconomic factors, our data support the concept
that Stage IV tumors represent a unique subpopulation and are biologically distinct from the small,
indolent tumors usually detected by mammography. Other studies have postulated that breast cancer
presenting at an advanced stage may be innately endowed with biologic machinery that promotes swift
growth and spread during the 12–24 months interval between mammograms [1,20,21]. Our findings
give credence to this theory by highlighting the uniquely aggressive features of Stage IV disease.
In a previous study, Lannin used ER, PR, and grade to stratify patients into three prognostic
groups based on breast cancer-specific survival, terming the groups “favorable”, “intermediate”, and
“unfavorable”. In this study, we added two additional variables to the model—Her2 and LVI—and
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used de novo Stage IV disease as the target outcome. These five tumor characteristics were specifically
chosen to reflect the biological behavior that predicts distant metastases, thus the group names were
changed to “aggressive”, “intermediate”, and “indolent”.
Her2 is a well-known marker for biological aggressiveness and was formerly associated with
poor prognosis. With effective targeted therapy, it currently confers a better than average prognosis
and yet it is strongly associated with Stage IV disease [22–26]. LVI similarly marks aggressive growth
patterns [27,28]. Unfortunately, its status was missing in nearly 20% of the dataset and well over half
of Stage IV cases. This may be explained by the fact that many patients with Stage IV disease undergo
needle biopsy only, and pathologists are either unable or unmotivated to evaluate for LVI. Despite
missing data, we included LVI in our model, as it was highly informative of biology when known. As
shown in Table 1, 18 of 19 groups with the highest rate of Stage IV disease presentation were positive
for LVI. All 24 groups included in the “aggressive” category were positive for either LVI or Her2. The
most biologically unfavorable cancers from the earlier prognostic-based model—triple negative with
grades 2 and 3—only cluster to the current “aggressive” category when positive for LVI.
Tumor biology is evolving to become a critical factor in estimating prognosis and guiding treatment.
In the AJCC 8th edition disease staging system, anatomical features like tumor size and nodal status
are considered insufficient to accurately inform the stage and treatment plan, particularly in the
developed world where testing for biomarkers is ubiquitous. The variables used in this study are
primitive measures of tumor biology compared to molecular and genomic assays such as OncotypeDx
or Mammaprint [4,29–31]. However, they are readily available in large datasets like SEER and the
NCDB for use in estimating population trends in tumor biology. Future studies will likely elucidate
more sophisticated biological mechanisms responsible for aggressive Stage IV tumors. It seems likely
that these differing biological characteristics will explain why the incidence of Stage IV breast cancer
has not decreased with screening mammography.
5. Conclusions
The incidence of denovoStage IVbreast cancer is increasing in theUnited States despitewidespread
mammography screening. This is likely related to the differing populations of biologic tumor types that
comprise Stage IV tumors versus early-stage tumors commonly found on mammography. Our analysis
demonstrates that aggressive tumor biology accounts for nearly 40% of advanced-stage tumors, versus
only 5% of tiny early-stage tumors. Conversely, indolent biology is rarely associated with advanced
disease. Aggressive biology resulting in insidious growth patterns may explain why the incidence of
Stage IV cancer has not decreased with screening.
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Abstract: Elucidating whether and how long-term survival of breast cancer is mainly due to cure after
early detection and effective treatment and therapy or overdiagnosis resulting from the widespread
use of mammography provides a new insight into the role mammography plays in screening,
surveillance, and treatment of breast cancer. Given information on detection modes, the impact of
overdiagnosis due to mammography screening on long-term breast cancer survival was quantitatively
assessed by applying a zero (cured or overdiagnosis)-inflated model design and analysis to a 15-year
follow-up breast cancer cohort in Dalarna, Sweden. The probability for non-progressive breast
cancer (the zero part) was 56.14% including the 44.34% complete cure after early detection and initial
treatment and a small 11.80% overdiagnosis resulting from mammography screening program (8.94%)
and high awareness (2.86%). The 15-year adjusted cumulative survival of breast cancer was dropped
from 88.25% to 74.80% after correcting for the zero-inflated part of overdiagnosis. The present
findings reveal that the majority of survivors among women diagnosed with breast cancer could be
attributed to the cure resulting from mammography screening and accompanying effective treatment
and therapy and only a small fraction of those were due to overdiagnosis.
Keywords: overdiagnosis; mammography screening; invasive breast cancer; zero-inflated Poisson
regression model
1. Introduction
While the prognosis of breast cancer (BC) has been substantially improved due to early detection
of breast cancer attributed to the widespread use of mammography, the issue of overdiagnosis resulting
from mammography screening has been debated over the past decade [1–5]. As these overdiagnosed
Cancers 2019, 11, 325; doi:10.3390/cancers11030325 www.mdpi.com/journal/cancers47
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cases are biologically indolent and non-progressive they would have never progressed to clinical
phase and caused death due to breast cancer during the patients’ lifetime, implying that any treatment
was unnecessary and would not have been administered had screening not been applied to these
women [6–10].
The previous studies on the extent of overdiagnosis were estimated by excess incidence due to
screening compared with background incidence derived from randomized control trials or predicted
incidence extrapolated from previous unexposed epochs, making allowance for lead-time [2,9,11,12].
Note that these previous methods, while estimating the proportion of overdiagnosis, require individual
normal and incident breast cancer data and also a strong assumption of lead-time distribution.
These traditional approaches cannot be used for assessing the impact of overdiagnosis on long-term
survival when only information on breast cancer cases and deaths from breast cancer is available.
Here, we propose a new approach to estimating overdiagnosis using information on the
survival of breast cancer detected by different modalities (detection modes) together with prognostic
factors with the premise that overdiagnosis of BC would not result in deaths from breast cancer.
However, the survivors of these overdiagnosed BCs are often indistinguishable from those with of
non-overdiagnosed BC cases but without potential of dying from breast cancer due to effective initial
treatment and therapy, namely the completely cured. Both types are regarded as non-progressive
BC with zero-probability of dying from BC but have manifestly different causes. To distinguish
the completely cured patients from overdiagnosed ones requires information on detection mode
such as screen-detected cases, interval cancers, and cancers in non-participants. The overestimation
of cumulative survival due to the zero-probability of dying from breast cancer resulting from
overdiagnosis would be expected if these overdiagnosed cases cannot not be separated from the
completely cured.
Moreover, the non-progressive BCs indicated above would also be mixed up with progressive
BC patients still alive at each specific follow-up timepoint. Whether and when these progressive
cases would die from BC is highly dependent on subsequent treatments and therapies and prognostic
factors [13–18]. However, only relying on these prognostics may not be sufficient to distinguish
between progressive and non-progressive BC because excellent survival tumors with good prognostic
factors may also be a consequence of overdiagnosis due to mammography [19].
The aim of this study is therefore to apply the zero-inflated regression model to estimate the
proportion of overdiagnosis resulting from mammography screening separated from the proportion of
the completely cured due to effective treatment and therapy. We also assess the cumulative survival
after correction for the zero-inflated part of overdiagnosis.
2. Materials and Methods
2.1. Study Subjects and Design
We quantified the respective contributions of overdiagnosis attributable to mammography and
cures due to early detection and effective treatment by using a cohort composed of 1346 patients
diagnosedwith invasive BC at Falun Central Hospital of Dalarna County in Sweden in two periodswith
available information on prognostic factors, from 1996 to 1998 and from 2006 to 2010, in combination
with a zero-inflated model design and analysis. The main reason of selecting two periods is mainly
due to available information on immunohistochemical (IHC) markers, particularly HER2, which had
not been widely tested before 2005. The period of 1996–1998 was a pilot phase for collecting such
information. The two cohorts were followed over time until the end of 2010. Note that breast cancer
service screening program with mammography has been offered since 1985 at the close of the Swedish
Two-county randomized controlled trial [20].
In addition to longitudinal follow-up data, the current study design illustrated in Figure 1 is
based on the concept of the zero-inflated model for solving the problem of being unable to distinguish
between overdiagnosed cases from cured cases due to effective treatment and therapies as mentioned in
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the introduction. All diagnosed breast cancers are classified into three types according to the potential
for progression and the cure after initial treatment. The top left circle represents overdiagnosed
cases (blue) with zero probability of dying from breast cancer mainly resulting from mammography
screening. The dotted box is composed of those breast cancers with potential of progression, which are
further divided into two types, the cured after initial treatment (green) and the cured after subsequent
therapies during 15-year follow-up (red). The final column is the estimated attributable proportions
among three types of survivors of breast cancer. If there is a lack of information on detection mode it is
very difficult to distinguish the cured from the overdiagnosed. The screened cohort together with the
collection of these prognostic factors provide an opportunity to distinguish overdiagnosis from the
cured. The derivation of percentages among breast cancer cases delineated in Figure 1 is elaborated in
the Statistical Analysis section and Appendix
Figure 1. Study design for estimating the proportion of breast cancer survivors attributed to
overdiagnosis, the completely cured after initial treatment, and the curation after subsequent therapies
during 15-year follow-up.
2.2. Detection Mode Related to Curation and Overdiagnosis
There are three detection modes, screen-detected cases, interval cancers, and cancers from
non-participants or outside the age ranges of screening. Here we assume overdiagnosis of BC due to
mammography screening can only result from screen-detected cases as they were detected though
mammography. Interval cancers after the exposure to a previous screen with negative findings were
detected either through possible self-referral of patients or due to the presence of symptoms and signs.
Cancers from non-participants or outside screening were diagnosed due to the presence of symptom
and signs. In this sense, interval cancers would enhance awareness of being diagnosed as BC compared
to cancers from non-participants. This can be supported by the fact that interval cancers have higher
survival than cancers from non-participants [21]. Suppose treatment and therapies were administered
to three groups according to the indication for the choice of treatment modality based on significant
prognostic factors. The difference of zero probability on death from BC between screen-detected
cancers and interval cancers would provide information on excess zeros due to overdiagnosis resulting
from mammography. The difference of zero probability between interval cancers and cancers from
non-participant offers information on overdiagnosis due to increased awareness. Details of the
calculation are given in the statistical section.
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2.3. Prognostic Factors
We collected factors responsible for progressive BCs including conventional tumor attributes
(size, lymph node involvement, and histological grade), three immunohistochemical markers
(ER, PR, HER2), triple negative (defined by these three IHC markers), surgical treatment and
adjuvant therapy. Conventional tumor attributes have been collected since the dawn of the service
screening. Surgical treatment (breast-conserving surgery, mastectomy, or others), and adjuvant therapy
(radiotherapy, chemotherapy, or hormone therapy) had been collected since 1996.
Data on tumor phenotypes related to IHC markers including ER, PR and HER2 status were
collected retrospectively for the period of 1996 to 1998 by standard antibody staining in the largest
invasive tumor component for each patient and was described in full in previous studies [22].
The antibodies (supplier, type, dilution) used for staining are delineated as follows: ER (clone SP1;
Ventana Medical Systems, Tucson, AZ, USA; 1:200 dilution), PR (clone PgR 636; Dako, Glostrup,
Denmark; 1:50 dilution), and HER2 (code A 0485; Dako; 1:250 dilution). The cut-off point for ER and
PR positivity is nuclear staining >10% of tumor cells. The criteria of HER2 positivity was offered by
manufacturer. Triple negative BC is defined as a breast tumor with all ER, PR, and HER2 being negative.
2.4. Statistical Analysis
Descriptive data are presented with frequency and percentage. For categorical data, the chi-square
test was used to compare the difference between groups and the Fisher Exact test was used if any count
was less than 5. We first applied the Poisson regression model assuming the number of BC deaths
follows a Poisson distribution. We estimated follow-up women years from the date of diagnosis as
BC to the date of death from BC, loss of follow-up, or the end of this study as the offset in Poisson
regression model. The value of deviance divided by degree of freedom provides an indicator to assess
the extent of over-dispersion and under-dispersion for the specified Poisson regression model. For the
elucidation of overdiagnosis in BC, we applied the zero-inflated Poisson (ZIP) regression model [23],
which is a mixture of a Poisson regression model (count part) and a logistic regression model (zero part)
as derived in Appendix A. The former model (Poisson regression model, count part) was used to
evaluate the prognostic factors for progressive BCs. The prognostic factors included three conventional
tumor attributes and treatment and therapies (surgery, chemotherapy, radiotherapy, hormone therapy).
The latter model (logistic regression model, zero part) was used to estimate the probability of zero
part (including overdiagnosis cases or cure after initial treatment and therapies) for non-progressive
BCs. We used the detection mode of cancers as covariates to distinguish two types in the zero part
(Appendix A). We then used the regression coefficients of logistic regression part in the ZIP model to
calculate the probability of zero among all BCs and respective probabilities of zero by detection mode
as detailed in Appendix A. The probability of overdiagnosis due to mammography screening and
enhanced awareness is calculated as follows:
The probability of overdiagnosis due to mammography screening =
((The probability of zero for screen-detected - the probability of zero for interval cancer)
× The probability of zero among all BCs)
(1)
The probability of overdiagnosis due to awareness
= ((the probability of zero for interval cancers - the probability of zero for cancers from non-participants)
× the probability of zero among all BCs)
(2)
The probability of cure due to treatment = The probability of zero among all BCs - ((1) + (2)) (3)
We further derive 15-year cumulative survival curves with and without correcting for
overdiagnosis by using the hazard rate derived from the ZIP model and the corresponding figure
from the conventional Poisson regression model without considering overdiagnosis as described in
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Appendix A). Two-sided p-value less than 0.05 was treated as statistical significance. All analyses were
conducted with SAS version 9.4 (SAS Institute, Cary, NC, USA).
2.5. Ethics Approval
This study was approved by the Joint Institutional Review Board of Taipei Medical University
(TMU-JIRB, approval numbers N201607008).
3. Results
Table 1 shows the frequencies of age at diagnosis, first generation prognostic factors (tumor size,
node status, histologic malignancy grade), IHC markers (ER, PR, HER2, triple negative), and treatment
and therapies by BC death. The distribution of age at diagnosis was similar between women who
died from BC and those who did not. The distributions of tumor size, status of node involvement,
histological grade, ER, PR, triple negative, surgery, and hormonal therapy were significantly different
(p-value < 0.05) according to BC death. Women who had tumor size larger than 20 mm, positive nodes,
grade 3, ER(−), PR(−), and triple negative were more likely to die from BC.
Table 1. The distribution of age at diagnosis, conventional tumor attributes, IHC markers (ER, PR,
HER2, Triple negative), mammographic appearance, and treatment by status of breast cancer death.
Variable/Level
Breast Cancer Death p-Value
No (n = 1228) % Yes (n = 118) %
Age at diagnosis 0.345
<50 202 92.7 16 7.3
50–69 596 91.8 53 8.2
70+ 430 89.8 49 10.2
Size *, mm <0.001
1–9 233 98.3 4 1.7
10–14 273 96.1 11 3.9
15–19 260 95.2 13 4.8
20–29 263 87.4 38 12.6
≥30 155 83.8 30 16.2
Nodes * <0.001
Negative 805 95.4 39 4.6
Positive 390 87.2 57 12.8
Grade * <0.001
1 284 97.3 8 2.7
2 633 93.6 43 6.4
3 263 85.4 45 14.6
ER * <0.001
Negative 174 84.1 33 15.9
Positive 990 94.6 57 5.4
PR * <0.001
Negative 448 87.3 65 12.7
Positive 714 96.6 25 3.4
HER2 * 0.8771
Negative 1018 92.9 78 7.1
Positive 149 92.5 12 7.5
Triple negative * <0.0001
Yes 115 81.6 26 18.4
No 1046 94.2 64 5.8
51
Cancers 2019, 11, 325
Table 1. Cont.
Variable/Level
Breast Cancer Death p-Value
No (n = 1228) % Yes (n = 118) %
Surgery * <0.0001
MA 452 87.8 63 12.2
BCS 538 95.9 23 4.1
Others 238 88.1 32 11.9
Chemotherapy 0.2018
Yes 270 89.4 32 10.6
No 958 91.8 86 8.2
Radiotherapy 0.8979
Yes 632 91.3 60 8.7
No 596 91.1 58 8.9
Tamoxifen 0.0061
Yes 480 93.9 31 6.1
No 748 89.6 87 10.4
Abbreviations: ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; IHC markers:
immunohistochemical markers; PR: progesterone receptor; BCS: breast conserving surgery; MA: mastectomy.
* 66 subjects had no information on tumor size (44 survivors, 22 deaths), 55 subjects had no information on nodal
involvement (33 survivors, 22 deaths), 70 subjects had no information on histological grade (48 survivors, 22 deaths),
92 subjects had no information on ER status (64 survivors, 28 deaths), 94 subjects had no information on PR status
(66 survivors, 28 deaths), 89 subjects had no information on HER2 status (61 survivors, 28 deaths), 95 subjects had
no information on triple negative status (67 survivors, 28 deaths).
Table 2 shows that conventional tumor attributes were significant predictors in both univariate
and multivariable models. The crude RR was significantly higher for tumor with size 20–29 mm
(9.32; 95% CI, 3.33–26.13) and 30 mm+ (13.65; 95% CI, 4.81–38.74) compared with size 1–9 mm, tumor
with node positive (3.70; 95% CI, 2.46–5.57) compared with node negative, tumor with grade 3 (2.97;
95% CI, 1.99–4.43) compared with grade 1/2, and triple negative (3.32; 95% CI, 2.11–5.24) compared
with non-triple negative cancers. In the multivariable analysis, tumor with size 20–29 mm (aRR = 2.63;
95% CI, 1.38–5.02) and 30+ mm (aRR = 2.39; 95% CI, 1.19–4.80) were at greater risk than those with size
1–9 mm. Positive node led to an elevated risk (aRR = 1.86; 95% CI, 1.18–2.94) as opposed to negative
node after adjusting for variables related to treatment such as surgery, chemotherapy, radiotherapy,
and hormonal therapy. Interpretation of effect size on treatment and therapies should be taken with
great caution as they are not a reflection of efficacy of treatment and therapies but an indication for
treatment and therapies according to tumor attributes. These accounted for the findings that those with
mastectomy and radiotherapy had higher hazard of dying from breast cancer and insignificant effective
chemotherapies and tamoxifen therapy even after adjustment for other significant prognostic factors.
The value of deviance divided by the degree of freedom, an indicator for assessing the level of
over-dispersion, was about 0.46–0.59 in the univariate model and 0.49 in the multivariable model.
As this value was less than 1, it strongly suggests the problem of under-dispersion (excess zeros).
We used data with complete information (n = 1233) on conventional tumor attributes,
variables related to surgery and adjuvant therapy, and detection mode of BCs for the ZIP model
analysis. The larger the value of odds ratio (OR), the higher probability to be cured after initial
treatment or overdiagnosis. The larger the value of relative risk (RR), the higher the risk of dying from
BC. Table 3 shows the estimated parameters, ORs, and RRs for the ZIP model.
Tumor size, node status, grade were significant factors related to risk of dying from BC after
considering treatment. Compared with non-participants and outside screening of BCs, screen detected
cancers and interval cancers were with higher odds (OR = 2.38, 95% CI: 0.97–5.85 and OR = 1.23, 95%
CI: 0.48–3.17, respectively) of being zero.
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Table 2. The univariate and multivariable analysis of Poisson regression model for predicting breast
cancer death by conventional tumor attributes and other predictors.
Variable/Level
Univariate Multivariable
cRR (95% CI) p-Value Deviance/df. aRR (95% CI) p-Value Deviance/df.
Tumor size, mm <0.001 0.46 <0.001
0.49
10–14 vs. 1–9 2.53 (0.80–7.93) 1.01 (0.45–2.24)
15–19 vs. 1–9 3.12 (1.02–9.56) 1.12 (0.52–2.43)
20–29 vs. 1–9 9.32 (3.33–26.13) 2.63 (1.38–5.02)
30+ vs. 1–9 13.65 (4.81–38.74) 2.39 (1.19–4.80)
Node (+) vs. (−) 3.70 (2.46–5.57) <0.001 0.46 1.86 (1.18–2.94) 0.007
Grade 3 vs. 1/2 2.97 (1.99–4.43) <0.001 0.48 1.32 (0.84–2.07) 0.228
Triple negative
Yes vs. No 3.32 (2.11–5.24) <0.001 0.47 1.53 (0.89–2.63) 0.132
Surgery MA vs.
BCS 4.02 (2.49–6.48) <0.001 0.55 2.79 (1.56–4.98) <0.001
Chemotherapy
Yes vs. no 1.58 (1.05–2.37) 0.027 0.59 0.83 (0.51–1.38) 0.474
Radiotherapy Yes
vs. no 0.71 (0.50–1.02) 0.063 0.59 1.39 (0.82–2.37) 0.215
Tamoxifen Yes vs.
no 0.96 (0.64–1.45) 0.849 0.59 0.89 (0.56–1.42) 0.633
Abbreviations: aRR: adjusted relative risk; cRR: crude relative risk; df.: degree of freedom; MA: Mastectomy; BCS:
Breast-conserving surgery.
The probability of zero part among all non-progressive BC was 56.14%. The corresponding
probabilities for screen detected cancer, interval cancer, and refuser/outside screening cancers were
66.42%, 50.50%, and 45.40% respectively, which gave 8.94% overdiagnosis due to mammography
screening and 2.86% due to high awareness for those interval cancers but exposed to mammography
screening based on the equation (1) and (2). The probability of zero due to the curation resulting from
early detection and effective treatment was 44.34% (Figure 1, green).
The 15-year prognosis-adjusted cumulative survival of BC after correcting for overdiagnosis
fell from 88.25% (Figure 2, cross mark) to 74.80% (Figure 2, hollow circle) after further adjustment
for prognostic factors in the count part of progressive BC (Figure 1, red). The 15-year survival rate
among 43.86% progressive BC after subsequent treatments and adjuvant therapies was 32.11% after
adjustment for significant prognostic factors (Figure 1, pink).
Table 3. The regression coefficient of Zero-inflated Poisson regression model and overdiagnosis rate.
Variable RegressionCoefficient S.E. RR/OR (95% CI) p-Value
Count Part RR
Intercept −6.216 0.830
Size, mm 0.015
10–14 vs. 1–9 1.307 0.808 3.69 (0.76–18.01)
15–19 vs. 1–9 1.348 0.802 3.85 (0.80–18.53)
20–29 vs. 1–9 2.329 0.769 10.26 (2.27–46.33)
30+ vs. 1–9 2.246 0.791 9.45 (2.01–44.49)
Node (+) vs. (−) 0.877 0.315 2.40 (1.30–4.45) 0.005
Grade 3 vs. 1/2 0.484 0.276 1.62 (0.94–2.79) 0.080
Surgery MA vs. BCS 0.651 0.360 1.92 (0.95–3.88) 0.071
Triple Negative Yes vs.
No 0.914 0.311 2.49 (1.36–4.59) 0.003
Chemotherapy Yes vs.
No −0.238 0.319 0.79 (0.42–1.47) 0.456
Radiotherapy Yes vs. No 0.210 0.367 1.23 (0.60–2.53) 0.568
Tamoxifen Yes vs. No −0.054 0.281 0.95 (0.94–1.64) 0.847
Zero Part OR
Intercept −0.185 0.381
Detection mode 0.041
SD vs. RF 0.867 0.459 2.38(0.97–5.85)
IC vs. RF 0.205 0.484 1.23(0.48–3.17)
Abbreviations: S.E.: Standard error; MA: Mastectomy; BCS: Breast-conserving surgery; SD: screen detected cancer;
IC: interval cancer; RF: refuser & outside screening cancers.
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Figure 2. Cumulative survival of breast cancer-based models with and without
considering overdiagnosis.
4. Discussion
The long-term prognosis of BC has been substantially improved over the past three decades due
to early detection, mainly through mammographic screening. However, the harm of overdiagnosis is
a concomitant risk of the benefit of mammography screening and it has now become a debatable issue
and concern for population-based mammography screening over the past decade [1–5]. For breast
cancer cases with overdiagnosis, there is 0% probability of dying from BC and treatment is unnecessary
for them. It may also result in the overestimation of cumulative survival attributed to effective
treatment and therapies in accompany with early detection of mammography screening. The survival
of BC would thus be artificially inflated if such zero-inflated overdiagnosis is included. Estimating the
quantity of overdiagnosis separated from the cured due to treatment is intractable but indispensable
and can be truly a reflection of early detection and effective treatment and therapy. Our novel approach
with the zero-inflated design and model for separating the cured from the overdiagnosed provides
a solution but the conventional statistical model could not distinguish the completed cured after initial
treatment (green, Figure 1) and the curation after subsequent therapies during 15-year follow-up
(red, Figure 1). From the viewpoint of methodology, the use of the zero-inflated model enables us to
separate the zero part with potential of progression but completely cured after initial treatment from
the non-zero part with potential of progression but cured after subsequent therapies during 15-year
follow-up particularly when tumor attributes related to breast cancer progression were considered in
the non-zero (progressive) part.
In addition to the assessment of the impact of overdiagnosis on long-term survival, our proposed
zero-inflated model also provides an insight into the proportion of overdiagnosis resulting from
mammography screening that has been well studied in previous studies using excess incidence
approach with lead-time adjustment [2,9,11,12]. After reviewing the primary articles that estimated
the overdiagnosis level in European population-based mammography screening programs, Puliti et al.
found that the rates of overdiagnosis of invasive BCs due to mammography screening varied from
0 to 54% [11]. Morrel et al. reported lower estimated baseline incidence resulted in higher level of
overdiagnosis (42% vs. 30%) [24]. They also reported that longer lead-time (5 years vs. 2.5 years)
contributed to lower extent of overdiagnosis (42% vs. 51%) [24]. Different background incidence
rates and the assumption of lead-time distribution may account for such a wide range of estimates on
overdiagnosis reported before. Several studies reported that the overdiagnosis rate was different by
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age [25,26]. In addition to the disparity in the methodology of lead-time adjustment and the extent of
mammography screening, variation of overdiagnosis across age may also be explained by the fact that
background incidence rate and the distribution of lead-time also vary with age [2,9,11,12].
Our proposed alternative approach to evaluating the extent of overdiagnosis dispenses with
background incidence of BC and the assumption of lead-time distribution. We only used empirical data
on BCs with available information on detection mode, treatment and therapies, and prognostic factors
collected from an organized service screening program after population-based randomized controlled
trial on mammography screening since 1977 in Falun (also known as Dalarna now, and Kopparberg
in the 1990s), Sweden [27]. This empirical data is well suited to estimate the overdiagnosis from
mammography screening and enhanced awareness as the attendance rate of mammography screening
was over 80% and women in this county were also with high awareness of being diagnosed as BC
through interval cancers [4,6]. Information on BCs with various detection modes is therefore useful for
separating the completed cured from overdiagnosis.
It is very interesting to note that the probability of being zero part among interval cancers was
higher than refuser/outside screening BCs. The difference might result from high awareness of
detecting BCs through interval cancers because they had been exposed to mammography screening.
Our result showed about 3% overdiagnosis due to enhanced awareness of detecting BC through
interval cancers.
There are two limitations of the current study. Although the application of ZIP enables us to
estimate the attributable proportions of three types of breast cancer survivors, personalized prediction
for three types cannot be achieved without more updated information on molecular and imaging
biomarkers can be included in the zero part and non-zero part, respectively. The second is related to
the validation of this zero-inflated model by the application of the proposed model together with the
estimated parameters to independent prospective follow-up data of this cohort in the future and also
to data outside this country. We therefore strongly suggest here that our proposed zero-inflated model
had better be applied to other countries in Europe where mammography screening programs have been
widely served since the 1990s and the screening rate was also high in order to see whether and how the
cure, overdiagnosis, and the survival of progressive BCs vary with different service screening programs.
We also suggest that our model can be applied to regions with lower mammography screening rates
and lower awareness of detecting BC in contrast to the current data with high careening rate and
enhanced awareness in order to test the generalizability of our proposed zero-inflated regression.
5. Conclusions
In conclusion, the zero-inflated model design is a novel approach to correcting cumulative survival
of early-detected BC inflated due to the zero part of overdiagnosis. Application of this model to the
Dalarna breast cancer service screening program revealed that, among all breast cancers detected
from this program, there were 76% survivors (44% completely cured and 32% still alive) due to early
detection of mammography and effective treatment after 15 years of follow-up and overdiagnosis
accounted for 12% of survivors.
Author Contributions: Study concept and design: H.-H.C.; Acquisition and interpretation of data: W.-H.K.,
C.-P.Y., K.-J.C., L.T.; Literature search: K.-J.C., W.-H.K., C.-P.Y., J.C.-Y.F.; Drafting of the manuscript: J.C.-Y.F.,
C.-Y.H., K.-J.C., H.-H.C.; Critical revision of the manuscript for important intellectual content: L.T., K.-J.C.,
H.-H.C.; Statistical analysis: C.-Y.H., J.C.-Y.F., S.L.-S.C., A.M.-F.Y.; Obtained funding: S.L.-S.C., A.M.-F.Y., H.-H.C.;
Administrative, technical, or material support: A.M.-F.Y., S.L.-S.C.
Funding: Ministry of Science and Technology Grant; Ministry of Education Grant. H.H.C.,
A.M.F.Y., S.L.S.C., and C.Y.H. are supported by the Ministry of Science and Technology grant (grant
number MOST 106-2118-M-002-006-MY2; MOST 106-2118-M-038-002-MY2; MOST 106-2811-M-002-075;
MOST 107-3017-F-002-003). H.H.C. is supported by The Featured Areas Research Center Program within the
framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (NTU-107L9003).
The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
55
Cancers 2019, 11, 325
Acknowledgments: This work was financially supported by the “Innovation and Policy Center for Population
Health and Sustainable Environment (Population Health Research Center, PHRC), College of Public Health,
National Taiwan University” from The Featured Areas Research Center Program within the framework of the
Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.
Conflicts of Interest: The authors declare no conflict of interest.
Appendix A Zero-Inflated Poisson Regression Model
Let Y denote the random variable representing the observed counts of breast cancer death.
The effect of demographic factors, tumor attributes, IHC (immunohistochemical markers), type of
treatments and therapies for progressive BCs can be evaluated by using Poisson regression model
specified as follows. The number of breast cancer death (Y) following Poisson distribution,
the probability of having observation on Y = y (say 118 death cases in Table 1) is written as follows:
Pr(Y = y; μ) =
e−μμy
y!
, y = 0, 1, 2, . . . , μ > 0. (A-1)
The Poisson model can be extended to the zero-inflated Poisson (ZIP) model to account for the
zero part (non-progressive BC), including the completely cured and over-diagnosis as diagrammed
in Figure 1. By in introducing the mixture probability, say π, of being non-progressive (zero-part)
extended from (1), the ZIP is specified by:
Pr(Y = y; μ, π) =
{
π + (1− π)e−μ when y = 0
(1− π) e−μμyy! when y = 1, 2, 3 . . .
(A-2)
μ > 0, 0 ≤ π ≤ 1
The probability of having the observation on breast cancer death (y = 1,2, . . . ) for progressive
BCs is thus (1− π) e−μμyy! , subject to the premise that the women must belong to the progressive breast
cancer type with the probability specified by (1 − π). For women who would not die from breast cancer
(y = 0), there are two possibilities, the zero part (complete cure and over-diagnosis) and progressive
ones but who haven’t died at the specified follow-up time. The former is specified by the probability
π and the latter is thus the product of the complement scenario and survival probability written as
(1 − π) e−μ. Based on such a specification of the ZIP model, the effect of detection mode denoted by
two dummy variables, SD and IC as follows:
logit(π) = log (
π
1− π ) = γ0 + γ1SD+ γ2 IC (A-3)
For a screen-detected subject, the vector of covariate is specified as (SD = 1, IC = 0) and the vector
of (SD = 0, IC = 1) is thus for an interval cancer case. Due to our use of refuser as the reference group,
the covariate vector of (SD = 0, IC = 0) is specified for such type of case. The probability for being zero
(non-progressive BC) is thus:
πi =
exp(γ0 + γ1SDi + γ2 ICi)
1+ exp(γ0 + γ1SDi + γ2 ICi)
(A-4)
The probability of being zero among all BCs without considering the covariate of detection
mode was estimated as 56.14% using only the intercept term. Following the same rationale,
the probability of being zero (non-progressive breast cancer) with the incorporation of detection
mode was estimated as 66.42% for screen-detected, 50.50% for interval cancer, and 45.40% for cancers
form non-participants or outside screening. According to the Equation (1) and (2) in the text of
statistical section, 8.94% and 2.86% were estimated for over-diagnosis resulting from mammography
and enhanced awareness, respectively.
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In order to compare two cumulative survival curves as shown in Figure 2, we need to derive
two annual death rates by using the ZIP model (λ) and the conventional Poisson model (λ’). For the
ZIP model, number of breast cancer death is originated from the non-zero part with the following
regression form:
log(μ) = log(PY) + β0 + β1x1 + β2x2 . . .+ βpxp (A-5)
The average counts of breast cancer death, say μ, which can be further decomposed into the
product of death rate (λ) and the person-year of the breast cancer cases under follow up (PY), is written
as μ = λ × PY. By using log link, the association between average number of breast cancer death
and breast cancer death rates and observed person-years is decomposed into log(μ) = log(λ) + log(PY).
Breast cancer cases with certain characteristics such as large tumor size, higher grade of malignancy,
positive lymph node involvement, triple negative cancer, etc., may have unfavorable prognosis
and a higher rate of progression to breast cancer death. We denote these characteristics including
demographic factors, tumor attributes, IHC markers, type of treatments and detection modes of a
breast cancer case by vector X (X = (X1, X2, X3, . . . , Xp)). The effect of these P characteristics on breast
cancer case fatality rate can be incorporated by using log function written as follows:
log(λ) = β0 + β1x1 + β2x2 . . .+ βpxp, (A-6)
Based on the adjusted death rate derived from equation (A-6), the prognosis-adjusted survival
with the ZIP model is derived by using S(t) = exp{−λ x t} where t is the follow-up time (in years) and
S(t) is the survival function for cumulative survival making allowance for overdiagnosis.
A similar logic can be applied to deriving prognosis-adjusted annual death rates (λ’) using
the conventional Poisson regression model without considering the zero-inflated part in the light
of S’(t) = exp{−λ’ x t} where t is the follow-up time (in years) and S’(t) is the survival function.
The comparison of prognosis-adjusted 15-year cumulative survival between the model with and
without adjusting for over-diagnosis was made and plotted in the Figure 2 of the main text.
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Abstract: Although the organ preservation strategy by breast-conserving surgery (BCS) followed by
radiation therapy (BCT) has revolutionized the treatment approach of early stage breast cancer (BC),
the choice between treatment options in this setting can still vary according to patient preferences.
The aim of the present study was to compare the oncological outcome of mastectomy versus
breast-conserving therapy in patients treated in a modern clinical setting outside of clinical trials.
7565 women diagnosed with early invasive BC (pT1/2pN0/1) between 1998 and 2014 were included
in this study (median follow-up: 95.2 months). In order to reduce selection bias and confounding,
a subgroup analysis of a matched 1:1 case-control cohort consisting of 1802 patients was performed
(median follow-up 109.4 months). After adjusting for age, tumor characteristics and therapies,
multivariable analysis for local recurrence-free survival identified BCT as an independent predictor
for improved local control (hazard ratio [HR]:1.517; 95%confidence interval:1.092–2.108, p = 0.013)
as compared to mastectomy alone in the matched cohort. Ten-year cumulative incidence (CI) of
lymph node recurrences was 2.0% following BCT, compared to 5.8% in patients receiving mastectomy
(p < 0.001). Similarly, 10-year distant-metastasis-free survival (89.4% vs. 85.5%, p = 0.013) was
impaired in patients undergoing mastectomy alone. This translated into improved survival in
patients treated with BCT (10-year overall survival (OS) estimates 85.3% vs. 79.3%, p < 0.001),
which was also significant on multivariable analysis (p = 0.011). In conclusion, the present study
showed that patients treated with BCS followed by radiotherapy had an improved outcome compared
to radical mastectomy alone. Specifically, local control, distant control, and overall survival were
significantly better using the conservative approach. Thus, as a result of the present study, physicians
should encourage patients to receive BCS with radiotherapy rather than mastectomy, whenever it is
medically feasible and appropriate.
Keywords: breast cancer; breast-conserving therapy; mastectomy; outcome; comparative effectiveness
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1. Introduction
In the early 1980s, large randomized studies first proved that breast-conserving surgery (BCS)
followed by postoperative radiotherapy (breast-conserving therapy, BCT) was a valid therapeutic
alternative to radical mastectomy in women with early breast cancer (BC) [1,2]. Nowadays, in this
setting, breast organ preservation by BCT has become the treatment of choice, due to the excellent
outcome and optimal tolerability. Nevertheless, various population-based studies showed that
mastectomy is still considered a concrete treatment option and continues to be chosen by several
patients with BC in daily clinical practice [3–6].
Treatment of early-stage breast cancer can be considered as a preference-sensitive setting,
where decision-making between treatment options can change according to patient preferences [7].
Typical factors able to influence the therapeutic choice in favor of mastectomy include: (i) concerns
regarding cancer recurrence, (ii) perception that health outweighs breast retention [8], or (iii) perceived
consequences of BCT, including potential adverse effects of radiation therapy [7,9]. Moreover, a renewed
interest and trend towards mastectomy has recently emerged, with an increased use of skin-sparing
or nipple-sparing mastectomies with immediate breast reconstruction [10–12]. This treatment strategy
provides superior aesthetic and quality-of-life outcomes when compared to radical mastectomy.
Nevertheless, long-term oncologic outcomes of these new surgical approaches are currently not
provided and only retrospective studies were available as evidence. Moreover, the demand for more
radical surgical therapies has recently gained wide public attention, as prophylactic mastectomy in
BRCA gene mutation positive celebrities attracted notable media interest [13]. The prominence of this
issue in the media might also have influenced oncologic patient´s preferences regarding their choice of
surgical management. In fact, shared decision-making in daily clinical practice is strongly influenced by
a number of confounding factors, including clinician preferences and trade-offs regarding toxicity risks
or comorbidities [14].
BC management has changed dramatically over time, and local recurrence rates after BCT
have decreased significantly [15]. The impact of mammography screening in downward stage
migration resulted in smaller tumor sizes and less extensive nodal involvement and is accompanied
by improvements in adjuvant treatments, tailored to disease biology.
Therefore, the aim of the present study was to compare the oncological outcome of mastectomy
versus breast-conserving therapy in patients treated in “real life”, in a modern clinical setting outside
of clinical trials.
2. Results
2.1. Baseline Patient Characteristics
The final study cohort consisted of 7565 women and the subgroup analysis of the matched cohort
included 1802 patients. Patient and treatment characteristics for both cohorts are summarized in
Table 1. Overall, 84.8% (6412/7565) of patients were treated with BCS and postoperative RT, while
15.2% (1153/7565) a received mastectomy. A significant decrease of mastectomy was documented over
time. While in 1998 approximately 21% of patients received a mastectomy, the proportion decreased to
12% in 2014.
Patients treated with BCT were significantly younger, with a median age at diagnosis of 58.2 years
in the BCT group, as compared to 59.3 years in the mastectomy group (p < 0.001). Furthermore, patients
treated with mastectomy presented with more high-risk features such as tumor size ≥20 mm (43.1%),
positive lymph nodes (31.4%), high tumor grade (27.3%) and negative hormone receptor status (12.0%)
than patients receiving BCT. Moreover, mastectomy patients received less adjuvant endocrine therapy
(52.0% vs. 43.5%, p < 0.001). In the matched cohort, we controlled for all these imbalances.
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Table 1. Patient and tumor characteristics for the entire cohort and the case control cohort.
Variable
Entire Cohort (n = 7565) Case Control Cohort (n = 1802)
BCS + RT Mastectomy p-Value BCS + RT Mastectomy p-Value
n (%) * n (%) * n (%) * n (%) *
All 6412 (84.8) 1153 (15.2) 929 (50.0) 929 (50.0)
Age at diagnosis <0.001 n.s.
<40 years 353 (5.5) 102 (8.8) 68 (7.5) 62 (6.9)
40–49 years 1193 (18.6) 221 (19.2) 201 (22.3) 184 (20.4)
50–59 years 1880 (29.3) 282 (24.5) 241 (26.7) 234 (26.0)
60–69 years 2043 (31.9) 258 (22.4) 215 (23.9) 225 (25.0)
>70 years 943 (14.7) 290 (25.2) 176 (19.5) 196 (21.8)
median (years) 58.2 59.3 58.6 58.8
Lateralisation 0.007 n.s.
right 3181 (49.6) 522 (45.3) 414 (45.9) 414 (45.9)
left 3231 (50.4) 631 (54.7) 487 (54.1) 487 (54.1)
Tumour size <0.001 n.s.
pT1 4790 (74.7) 656 (56.9) 514 (57.0) 514 (57.0)
pT2 1622 (25.3) 497 (43.1) 387 (43.0) 387 (43.0)
Nodal status <0.001 n.s.
pN0 4904 (76.5) 791 (68.6) 646 (71.7) 646 (71.7)
pN+ (1–3 LN) 1508 (23.5) 362 (31.4) 255 (28.3) 255 (28.3)
Tumor stage <0.001 n.s.
T1N0 3860 (60.2) 492 (42.7) 395 (43.8) 395 (43.8)
T2N0 1044 (16.3) 299 (25.9) 251 (27.9) 251 (27.9)
T1N1 930 (14.5) 164 (14.2) 119 (13.2) 119 (13.2)
T2N1 578 (9.0) 198 (17.2) 136 (15.1) 136 (15.1)
Resection status n.s. n.s.
R0 5769 (98.1) 922 (98.2) 812 (98.5) 740 (98.5)
R1/R2 112 (1.9) 17 (1.8) 12 (1.5) 11 (1.5)
[unknown] 531 (8.2) 214 (18.5) 77 (8.5) 150 (16.6)
Grade <0.001 n.s.
G1 1248 (19.9) 98 (9.1) 77 (8.5) 77 (8.5)
G2 3610 (57.6) 684 (63.6) 599 (66.5) 599 (66.5)
G3/4 1411 (22.5) 294 (27.3) 225 (25.0) 225 (25.0)
[unknown] 143 [2.3] 77 [6.6]
Hormone receptor
positive 5674 (90.2) 986 (88.0) 0.038 83 (9.2) 83 (9.2) n.s.
negative 613 (9.8) 135 (12.0) 818 (90.8) 818 (90.8)
[unknown] 125 [1.9] 32 [2.7]
Chemotherapy n.s. n.s.
no 4581 (71.4) 855 (74.2) 660 (73.3) 660 (73.3)
yes 1831 (28.6) 298 (25.8) 241 (26.7) 241 (26.7)
Endocrine therapy <0.001 n.s.
no 3076 (48.0) 651 (56.5) 485 (53.8) 485 (53.8)
yes 3336 (52.0) 502 (43.5) 416 (46.2) 416 (46.2)
* Percentages of the presented subcategories are related to the sum of each item with available data; missing values
are not taken into account. Hormone receptor positive: estrogen and/or progesterone positive (>1%). BCS: breast
conserving surgery, RT: radiotherapy, n.s.: not significant.
2.2. Outcome
The median follow-up for the entire cohort was 95.2 months (95%CI: 92.5–97.9) and 109.4 months
(95% CI: 104.3–114.5) for the matched cohort. Of the 7565 BC patients, 521 (6.9%) developed local
recurrences, 160 (2.1%) lymph node recurrences, and 607 (8.0%) distant metastases.
The cumulative incidence of local recurrence (LR) for the BCT group was 3.2% after 5 years and
8.2% after 10 years. In contrast, the mastectomy group had significantly higher local failure rates with
5.0% 5-year LR and 12.6% 10-year LR rates, respectively (p < 0.001, Table 2).
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Table 2. Cumulative incidence of local recurrences (LR) and lymph node recurrences (LNR) and
Kaplan-Meier estimates of distant recurrence-free survival (DRFS) and overall survival (OS) for
patients of the different cohorts. BCS + RT: breast-conserving surgery with postoperative radiotherapy;
Mastectomy: mastectomy without radiotherapy; y: years.
Outcome Treatment Modality
Entire Cohort Case Control Cohort
Diagnosis 1998–2014 Diagnosis 1998–2014
7565 Patients 1802 Patients
5 y (%) 10 y (%) p 5 y (%) 10 y (%) p
LR <0.001 0.025
BCS + RT 3.2 8.2 4.6 9.4
Mastectomy 5.0 12.6 4.8 12.9
LNR <0.001 <0.001
BCS + RT 0.9 2.2 0.7 2.0
Mastectomy 2.6 5.7 2.5 5.8
DRFS <0.001 0.013
BCS + RT 94.5 90.2 93.8 89.4
Mastectomy 92.0 84.8 93.1 85.5
OS <0.001 <0.001
BCS + RT 95.2 86.7 93.8 85.3
Mastectomy 90.5 77.6 92.2 79.3
Multivariable Cox analysis for local recurrence-free survival identified mastectomy (hazard ratio
[HR], 1.476; 95% confidence interval [CI], 1.164–1.872, p < 0.001) as a significant predictor for local
failure. Table 3 summarizes other classic prognostic risk factors that had a significant impact on LR
risk at multivariable analysis, including young age <40 years (p < 0.001), higher tumor stage (p < 0.001),
high tumor grade (p < 0.001) and negative hormone receptor status (p = 0.012). In the matched cohort,
type of local treatment, age at diagnosis, and tumors stage confirmed their significant impact on LR
risk estimates.
Table 3. Multivariable Cox regression analysis for local recurrence free survival.
Variable
Entire Cohort (n = 7565)
Local Recurrence Free Survival
Case Control Cohort (n = 1802)
Local Recurrence Free Survival
Hazard Ratio
HR 95% CI p-Value
Hazard Ratio
HR 95% CI p-Value
Local therapy <0.001 0.013
BCS + RT 1 1
Mastectomy 1.476 1.164-1.872 1.517 1.092–2.108
Age at diagnosis <0.001 <0.001
<40 years 1 1
40–49 years 0.931 0.671–1.291 0.802 0.475–1.353
50–59 years 0.521 0.370–0.732 0.309 0.172–0.554
60–69 years 0.393 0.274–0.565 0.360 0.199–0.651
≥70 years 0.357 0.228–0.561 0.168 0.075–0.379
Tumour stage <0.001 0.020
T1N0 1 1
T2N0 1.177 0.899–1.541 0.916 0.584–1.434
T1N1 1.147 0.855–1.538 1.014 0.601–1.712
T2N1 2.091 1.565–2.795 1.969 1.204–3.220
Resection status 0.604 0.330
R0 1 1
R1/R2 0.808 0.360–1.812 1.773 0.560–5.618
Grade <0.001 0.320
G1 1 1
G2 2.063 1.438–2.959 1.719 0.821–3.599
G3/4 2.415 1.619–3.601 1.526 0.676–3.444
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Table 3. Cont.
Variable
Entire Cohort (n = 7565)
Local Recurrence Free Survival
Case Control Cohort (n = 1802)
Local Recurrence Free Survival
Hazard Ratio
HR 95% CI p-Value
Hazard Ratio
HR 95% CI p-Value
Hormone receptor 0.012 0.104
positive 1 1
negative 1.466 1.087–1.975 1.575 0.911–2.721
Chemotherapy 0.402 0.462
yes 1 1
no 1.110 0.870–1.417 1.172 0.768–1.789
Endocrine therapy 0.382 0.955
yes 1 1
no 0.808 0.360–1.812 1.010 0.706–1.447
Similarly, lymph node recurrences (LNR) were more frequent in patients undergoing mastectomy
only. The cumulative incidence of LNR at 5 and 10 years in the BCT group were 0.9% and 2.2%,
respectively, compared to 2.6% and 5.7% in patients receiving mastectomy (p < 0.001). This observation
was still significant on multivariable analysis. Type of local therapy (mastectomy HR 2.442; 95% CI,
1.675–3.560, p < 0.001), higher tumor stage (p = 0.006) and high tumor grade (p < 0.001) did significantly
affect the risk of LNR. Focusing on the impact of the type of local treatment in the matched cohort,
mastectomy was also correlated with an increased rate of LNR (HR 1.517; 95% CI, 1.092–2.108, p = 0.013,
Table 4).
Table 4. Multivariable Cox regression analysis for lymph node recurrence-free survival (LNRFS).
Variable
Entire Cohort (n = 7565)
Lymph Node Recurrence-Free Survival (LNRFS)
Case Control Cohort (n = 1802)
Lymph Node Recurrence-Free Survival (LNRFS)
Hazard Ratio
HR 95% CI p-Value
Hazard Ratio
HR 95% CI p-Value
Local therapy <0.001 0.013
BCS + RT 1 1
Mastectomy 2.442 1.675–3.560 1.517 1.092–2.108
Age at diagnosis 0.025 0.030
<40 years 1 1
40–49 years 1.795 0.857–3.762 1.758 0.576–5.361
50–59 years 1.143 0.539–2.423 0.715 0.215–2.376
60–69 years 1.399 0.661–2.960 0.871 0.262–2.890
≥70 years 0.603 0.238–1.526 0.286 0.058–1.411
Tumor stage 0.006 0.331
T1N0 1 1
T2N0 1.754 1.130–2.724 1.175 0.535–2.584
T1N1 1.274 0.749–2.168 1.433 0.593–3.463
T2N1 2.300 1.383–3.825 2.186 0.931–5.134
Resection status 0.366
R0 1 1
R1/R2 0.403 0.056–2.888 NA *
Grade <0.001 0.082
G1 1 1
G2 1.451 0.755–2.787 1.121 0.327–3.840
G3 3.651 1.841–7.242 2.284 0.623–8.371
Hormone receptor 0.120 0.973
positive 1 1
negative 1.523 0.897–2.586 0.982 0.342–2.819
Chemotherapy 0.221 0.593
yes 1 1
no 1.303 0.853–1.990 1.223 0.585–2.557
Endocrine therapy 0.193 0.702
yes 1 1
no 0.770 0.520–1.141 0.885 0.475–1.652
* NA: not applicable, HR not estimable because no event in the R1/2 group.
63
Cancers 2019, 11, 160
Ten-year distant metastasis-free survival (DMFS) in the entire cohort was statistically different in
the univariate analysis—with 90.2% DMFS in the BCT group, compared to 84.8% in the mastectomy
group (p < 0.001). This was also seen in a comparable magnitude in the matched cohort (p = 0.013).
Overall, patients treated with postoperative radiotherapy after BCS showed improved distant control,
independent from other covariates in multivariable Cox regression analysis (mastectomy HR 1.257;
95% CI, 1.006–1.570, p = 0.044). Other factors correlated with poor DMFS in this cohort were advanced
tumor stage (p < 0.001), high tumor grade (p < 0.001) and negative hormone receptor status (p = 0.050).
Also in the matched cohort, the positive effect of BCT on DMFS was observed (p = 0.008, Table 5).
Table 5. Multivariable Cox regression analysis for distant metastasis free survival.
Variable
Entire Cohort (n = 7565)
Distant Metastasis Free Survival
(DMFS)
Case Control Cohort (n = 1802)
Distant Metastasis Free Survival
(DMFS)
Hazard Ratio
HR 95% CI p-Value
Hazard Ratio
HR 95% CI p-Value
Local therapy 0.044 0.008
BCS + RT 1 1
Mastectomy 1.257 1.006–1.570 1.537 1.121–2.107
Age at diagnosis 0.677 0.053
<40 years 1 1
40–49 years 0.860 0.608–1.216 0.600 0.351–1.027
50–59 years 0.826 0.592–1.153 0.497 0.292–0.845
60–69 years 0.785 0.556–1.106 0.437 0.246–0.777
≥70 years 0.891 0.601–1.321 0.592 0.314–1.118
Tumor stage <0.001 0.001
T1N0 1 1
T2N0 1.895 1.489–2.411 1.258 0.820–1.932
T1N1 1.577 1.196–2.080 1.520 0.933–2.477
T2N1 3.755 2.930–4.812 2.516 1.608–3.936
Resection status 0.209 0.587
R0 1 1
R1/R2 1.445 0.813–2.568 1.377 0.435–4.364
Grade <0.001
G1 0.215 0.141–0.327 NA *
G2 0.514 0.421–0.629 NA
G3 1 1
Hormone receptor 0.050 0.706
positive 1 1
negative 1.327 1.000–2.586 1.110 0.646–1.907
Chemotherapy 0.656 0.517
yes 1 1
no 0.951 0.762–1.186 0.874 0.583–1.312
Endocrine therapy 0.013 0.174
yes 1 1
no 0.770 0.627–0.946 0.782 0.549–1.114
* NA: not applicable, HR not estimable because no event in the R1/2 group.
Among patients treated with BCS plus RT, 10-year OS estimates were 86.7%, and for those treated
with mastectomy 77.6% (p < 0.001). In multivariable Cox regression analysis, the use of mastectomy was
again independently associated with less favorable outcome, with an HR of 1.268 (95% CI, 1.055–1.525,
p = 0.011). Further risk factors correlated with poor OS in this cohort were older age (p < 0.001),
advanced tumor stage (p < 0.001), and high tumor grade (p < 0.001). This effect could be confirmed in
multivariable analysis for the matched cohort, where type of local treatment (mastectomy HR 1.452;
95% CI, 1.124–1.875, p = 0.004, Table 6), older age (p < 0.001), advanced tumor stage (p < 0.001), and high
tumor grade (p = 0.033) were independent risk factors.
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Table 6. Multivariable Cox regression analysis for overall survival.
Variable
Entire Cohort (n = 7565)
Overall Survival (OS)
Case Control Cohort (n = 1802)
Overall Survival (OS)
Hazard Ratio
HR 95% CI p-Value
Hazard Ratio
HR 95% CI p-Value
Local therapy 0.011 0.004
BCS + RT 1 1
Mastectomy 1.268 1.055–1.525 1.452 1.124–1.875
Age at diagnosis <0.001 <0.001
<40 years 1 1
40–49 years 1.011 0.674–1.517 0.439 0.240–0.804
50–59 years 1.273 0.870–1.861 0.599 0.346–1.038
60–69 years 1.757 1.203–2.565 0.854 0.494–1.476
≥70 years 4.552 3.089–6.710 2.335 1.342–4.065
Tumor stage <0.001 <0.001
T1N0 1 1
T2N0 1.763 1.446–2.150 1.633 1.175–2.270
T1N1 1.529 1.214–1.925 1.375 0.887–2.130
T2N1 2.892 2.337–3.580 2.589 1.786–3.753
Resection status 0.608 0.712
R0 1 1
R1/R2 1.144 0.685–1.911 1.184 0.484–2.896
Grade <0.001 0.033
G1 1 1
G2 1.406 1.100–1.798 1.968 1.028–3.768
G3 2.165 1.645–2.848 2.432 1.227–4.820
Hormone receptor 0.076 0.606
positive 1 1
negative 1.254 0.986–1.612 1.135 0.702–1.834
Chemotherapy 0.481 0.708
yes 1 1
no 1.075 0.880–1.313 1.075 0.736–1.570
Endocrine therapy 0.662 0.709
yes 1 1
no 1.039 0.876–1.232 0.946 0.708–1.26
3. Discussion
The present study showed that patients treated with BCS followed by radiotherapy (RT) in a
population reflecting “real life” in this clinical setting, had an improved outcome regarding local control,
distant control, and overall survival compared to those who underwent a mastectomy. These findings
were also confirmed in the matched cohort after adjusting for confounders.
The results presented here are in line with those of other studies investigating the same clinical
setting. A population-based analysis of van Maaren et al. [4] of 37,207 breast cancer patients treated in
the Netherlands between 01/2000 and 12/2004 obtained similar results. BCS was associated with a
significantly improved 10-year overall survival (HR 0.81, 95% CI: 0.78–0.85, p < 0.0001). Furthermore, in
a representative cohort of patients diagnosed in 2003, BCT had a significant impact on relative survival
(HR 0.76, 95% CI: 0.64–0.91, p = 0.003). In contrast to the present analysis, distant metastasis-free
survival (HR 0.88, 95% CI: 0.77–1.01, p = 0.070) was not significantly different in the Dutch cohort, with
exception of the T1N0 subgroup (HR 0.60, 95% CI: 0.42–0.85, p = 0.004). Yet, in the present analysis,
the occurrence of lymph node metastases and distant metastases were both decreased in patients
treated with breast-conserving surgery and radiotherapy compared to mastectomy.
Although locoregional and distant control rates are lacking in most of the published
experiences [16–19], two studies addressed these issues in a similar BC cohort as in the present
study [20,21]. An analysis of the prospective Swedish Multicenter Cohort Study including 2767 patients
compared BCS with postoperative RT and mastectomy without RT. Similar to the present analysis,
the axillary recurrence-free survival rate at 13 years was significantly reduced after mastectomy without
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irradiation as compared to BCS (98.3% versus 96.2%, p < 0.001) [21]. Moreover, locoregional recurrence
was a strong independent predictor of breast cancer death, (HR: 4.28, 95% CI: 2.55–7.17) and overall
survival (HR: 2.64, 95% CI: 1.66–4.19).
The axillary recurrence rates decrease after BCS with RT in comparison to mastectomy, which may
have different explanations. Of note, in the present study, 23.5% of patients treated in the BCT group
had a positive nodal status with 1–3 involved lymph nodes. While after the AMAROS trial [22],
the debate about the role of regional nodal irradiation continues, results from the ACOSOG Z0011
trial [23] and the IBCSG 23-01 trial [24] demonstrated that patients with low-volume nodal disease who
are treated with BCS and whole breast RT, can safely avoid axillary lymph node dissection without
affecting locoregional control or survival rates [25]. The potential rationale behind this observation is
that radiation originating from whole-breast tangential field RT after BCS could exert some protective
effect on axillary recurrence rates by controlling the minimal residual disease [21]. It is noteworthy,
that the dose to axillary lymph node levels I and II usually is significantly lower than the prescribed
dose and can range from 5% to 80% of the prescribed dose (mean value 48.7%). Even in patients
receiving regional nodal irradiation of 50 Gray (Gy) to the supra-/infraclavicular lymph node levels
(corresponding to levels IV, III and interpectoral lymph nodes), level I receives a reduced dose coverage
of mean 41.3 Gy [26,27]. The potential influence of whole breast irradiation, especially in cases of pN+,
needs further evaluation in randomized studies.
Regarding distant control, in a single center experience of 6137 cases, Wang et al. [20] observed
that patients undergoing BCS plus RT showed a significantly increased 5-year metastasis-free survival
(p < 0.003) and overall survival (p < 0.036) compared with mastectomy. But how could these results be
interpreted? Is RT able to add something more than just improved locoregional control? The EBCTCG
meta-analysis [28] proved a concrete direct relationship between improved local control and favorable
breast cancer specific survival outcome. Nevertheless, the underlying biological mechanisms remain
unclear. The oncological community has generated various hypotheses regarding the heterogeneous
biology of BC and the impact of available treatment options. A commonly accepted hypothesis is
that the addition of RT represents an effective curative treatment for a selected subset of patients who
would otherwise have relapsed locally and subsequently would have developed metastases. The fact
that the survival benefit only occurs in the framework of successful local control, indicates that RT
is involved in events occurring within the treated radiotherapy fields. RT prevents local recurrences
through the successful eradication of residual tumor clones or tumor cell clusters within the breast,
which are not detected at primary diagnosis. Regarding the beneficial effect on distant tumor control,
this interpretation assumes that the metastatic process consists of different waves of cell migration and
metastases with differing invasive properties [29]. Hence, RT appears to have unique biological effects
to prevent early distant dissemination of cancer cells to distant organs. Furthermore, several potential
interactions with the immune system are advocated, including radiation-induced tumor-specific
immunity capable of rejecting the colonizing clonogenic cells [29]. Nevertheless, it remains challenging
to assess the relative contribution of the interactions between systemic and locoregional treatments on
the outcome, as well as that of the individual drugs and RT volumes [15].
The present results of patients treated in a “real life” clinical setting are different from those
reported from historical randomized trials of the 1980s, which described similar survival for BCT
and mastectomy [30,31]. A key to interpreting these different findings could be that the management
of breast cancer has changed considerably over time. Fisher et al. [31] documented a 5-year local
recurrence rate of 7.7% for the BCT group and 14.3% in the twenty-year follow-up of the NSABP
trial B-06. The 5-year and 10-year cumulative incidence of local recurrences in the present analysis
were 3.2% and 8.2%, respectively, suggesting improved local control rates with modern breast cancer
therapy, even in the setting outside of randomized trials. The modern multimodal treatment approach,
including diagnostics, surgery, systemic therapy, and RT procedures, has improved significantly over
the last decades and might explain the survival difference in patients treated with breast-conserving
surgery plus radiotherapy as compared to patients treated with mastectomy. [15] The 10-year overall
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survival was significantly improved for patients receiving BCS plus radiotherapy: 86.7% with BCT
and 77.6% with mastectomy alone (p < 0.001). This difference was also observed in the matched
cohort (p < 0.001). Improved breast cancer specific and overall survival have been found in several
population-based cohorts studies [3,5,32–37]. Regarding early-stage breast cancer, Hwang et al. [32]
analyzed patients diagnosed with stage I or II breast cancer between 1990 and 2004 and reported
improved OS and DSS compared to patients with mastectomy (adjusted hazard ratio for OS entire
cohort = 0.81, 95% CI: 0.80–0.83). A registry-based study in Norway also showed comparable results to
the present analysis [5]. In multivariate analysis, patients who underwent mastectomy for T1-2/N0-1
BC had an adjusted hazard ratio of 1.65 (95% CI: 1.50–1.82) for OS compared to those who underwent
BCT. Similarly, in the present matched cohort, the outcome in terms of OS for patients receiving BCS
plus RT was improved (HR: 1.452, 95%CI: 1.124–1.875). Onitilo et al. [35] also compared BCS ± RT
versus mastectomy. While overall survival was similar for BCS alone and mastectomy, BCS plus
radiation was superior compared to mastectomy alone. The authors concluded, that the survival
benefit was not only related to the surgical approach itself but that the addition of adjuvant RT results
in a prognostic advantage of BCS plus radiation over mastectomy [35].
We controlled for all variables available in the registry. Unfortunately, we could not account for
host-related factors like comorbidities, performance status, or clinician- and patient-related preferences,
which may have influenced the clinical treatment decision-making process. It is known that older
patients or patients with comorbidities often receive non-standard treatments. A recent analysis of
7581 early stage BC patients diagnosed in 9 European countries analyzed the influence of comorbidities
on receiving standard treatments and found that mastectomy was mainly given to elderly women and
women with comorbidities [38]. There are several other limitations to effectiveness research due to
unpredictable confounding factors and consequently, misinterpretations of treatment and mortality
effects should be avoided [39]. In fact, the present observational study may suffer from a “confounding
by severity” [40], considering that the severity of the disease (e.g., high-risk factors, tumor biology)
could be a potential confounder influencing the indication for mastectomy. Furthermore, survival
estimates might be affected by non-tumor-related factors such as age or comorbidities, which could
lead to more non-breast cancer deaths. However, we conducted a matched cohort analysis to directly
address these concerns and control for these imbalances. Finally, we want to underline that patients of
the present study were treated at two specialized breast cancer centers, which in general could have
improved outcomes as compared to other settings.
Many previous studies have performed similar analyses with comparable results [4,20,21].
However, a specific characterizing element of the present study is the additional matched case
control analysis. This methodology was not used in previously published experiences, which further
strengthens the evidence that breast-conserving therapy should be the preferred treatment for patients
with early-stage breast cancer when it is medically feasible and appropriate. More specifically, in the
present study, we could show that breast-conserving therapy had improved outcome regarding local
control, distant control and overall survival as compared to mastectomy alone–even in the matched
cohort. Patients were matched regarding a number of variables in order to reduce confounding: 1:1
match for tumor lateralization, tumor size, lymph node status, tumor grade, hormone receptor status,
administration of chemotherapy/endocrine therapy and age match with a tolerance of ±2 years for
age at diagnosis. This resulted in a cohort, where for each mastectomy patient an exactly matched
BET patient with exactly the same tumor formula and treatment history was present. Even in this
matched cohort analysis, the effect of the choice of surgical treatment on oncologic outcome remained
statistically significant.
Since many people still believe that mastectomy may be a better choice, we recommend generating
more external validity, such as this retrospective study, in order to gain wide public attention. It is
well known that there are a number of barriers to compliance with treatment recommendations,
including lack of outcome expectancy. If a physician believes that a treatment will not lead to an
improved outcome, he is less likely to follow the treatment recommendations. Another explanation for
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the widespread underuse of treatments that were beneficial in controlled trials could be the lack of
consideration of external validity [14]. In general, we hope that the present study contributes to the
existing evidence regarding the effectiveness of BCS and radiotherapy in this setting.
4. Materials and Methods
For the present analysis, all female patients with a first primary unilateral invasive breast cancer
diagnosed between 1998 and 2014 and treated at two Breast Cancer Centers (Red Cross Hospital or
LMU Munich, München, Germany) were identified. All data were retrieved from the Munich Cancer
Registry. The cancer registry routinely collects data on patient’s demographics, primary tumor site,
the extent of disease (TNM), histology, treatment, and follow-up. Survival information was obtained
systematically through death certificates of health offices. Patients were considered eligible after
receiving mastectomy without postoperative radiotherapy (RT) or breast-conserving surgery followed
by RT. Patients were excluded if they received neoadjuvant chemotherapy, or in case of histology of
ductal carcinoma in situ (n = 1.412), lymphoma (n = 10) or sarcoma (n = 57), or in case of unknown date
of initial diagnosis (e.g., tumors from death certificate information only [DCO], n = 58). Patients were
also excluded if surgery information or pathologic tumor stage was incomplete or missing.
For the present study, women with tumor stages pT1pN0, pT2pN0, pT1pN1 and pT2pN1 (all M0)
were selected. For comparison of the standard BCT and mastectomy approaches, we excluded patients
with tumor stage ≥pT3 or more than 3 positive lymph nodes (pN2), as postmastectomy RT (PMRT)
would have been routinely recommended in these high-risk patients.
Over the last decades, the use of PMRT was under debate for most intermediate risk patients
with small tumor size and limited nodal disease (1–3 positive lymph nodes). Although previous
studies provided evidence for a possible survival benefit in intermediate-risk patients [41], PMRT was
not uniformly recommended at that time. The standard RT regimen at the Department of Radiation
Oncology of the LMU Munich during the observation period was whole-breast irradiation following
BCS (50.4 Gy in 28 fractions) using a 3-dimensional conformal tangential field technique with a photon
or electron boost of 10–16 Gy to the tumor bed [42].
In order to reduce selection bias and confounding, a subgroup analysis of a matched cohort
was performed. To compare treatment outcomes within a set of similar patients, 1:1 case-control
matching on the following variables was performed: age at diagnosis, tumor lateralization, tumor
size, lymph node status, tumor grade, hormone receptor status, administration of chemotherapy and
endocrine therapy. The Hormone receptor was defined positive if estrogen and/or progesterone were
positive (>1%).
Statistical analyses were conducted using IBM SPSS Statistics version 24.0 (IBM, Amonk, NY,
USA). Frequency data were analyzed using the Chi-Square test. Tolerances values of the case-control
matching were set to 2 years for age at diagnosis and 0 (exact matches) for all other above-mentioned
variables. Cumulative incidence analysis (CI) was used to calculate the time to LR and LNR and
the differences were assessed using the Gray’s test for equality of cumulative incidence functions
and was performed using R environment for statistical computing and visualization (version. 3.4.0).
Distant metastasis-free survival (DMFS) and overall survival (OS) were estimated by the Kaplan-Meier
method and tested using the log-rank test. The observation period began after diagnosis of the invasive
tumor and ended at the date of distant metastasis occurrence or date of death or the last follow-up for
cases without events. In addition, Cox proportional hazards models were used to identify independent
prognostic factors related to local recurrence-free survival (LRFS), lymph node recurrence-free survival
(LNRFS), DMFS and OS for the different cohorts. The significance level in all analyses was set at 5%.
5. Conclusions
In contrast to the highly selected and homogeneous study populations of randomized trials, this
observational analysis included a large patient cohort reflecting “real-life” clinical practice involving a
more diverse population, including elderly patients. A fundamental finding of the present study was
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that patients treated with BCS followed by RT had improved outcome in clinical practice regarding local
control, distant control and overall survival as compared to mastectomy alone. Even if randomized
trials provide the least biased estimates to compare treatments and remain the gold standard of
efficacy research in oncology, observational data should be appreciated when weighing treatment
options for breast cancer surgery. As a result of the present study, it seems advisable to continue to
encourage future patients to receive BCS with RT rather than mastectomy when it is medically feasible
and appropriate.
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Abstract: Previous studies showed substantial improvement of survival rates in patients with cancer
in the last two decades. However, lower survival rates have been reported for older patients compared
to younger patients. In this population-based study, we analyzed treatment patterns and the survival
of patients with breast cancer (BC) and colorectal cancer (CRC). Patients with stages I–III BC and
CRC and diagnosed between 2003 and 2012 were selected from the Netherlands Cancer Registry
(NCR). Trends in treatment modalities were evaluated with the Cochran-Armitage trend test. Trends
in five-year overall survival were calculated with the Cox hazard regression model. The Ederer II
method was used to calculate the five-year relative survival. The relative excess risk of death (RER)
was estimated using a multivariate generalized linear model. During the study period, 98% of BC
patients aged <75 years underwent surgery, whereas for patients ≥75 years, rates were 79.3% in 2003
and 66.7% in 2012 (p < 0.001). Most CRC patients underwent surgery irrespective of age or time
period, although patients with rectal cancer aged ≥75 years received less surgery or radiotherapy
over the entire study period than younger patients. The administration of adjuvant chemotherapy
increased over time for CRC and BC patients, except for BC patients aged ≥75 years. The five-year
relative survival improved only in younger BC patients (adjusted RER 0.95–0.96 per year), and was
lower for older BC patients (adjusted RER 1.00, 95% Confidence Interval (CI) 0.98–1.02, and RER
1.00; 95% CI 0.98–1.01 per year for 65–74 years and ≥75 years, respectively). For CRC patients, the
five-year relative survival improved over time for all ages (adjusted RER on average was 0.95 per
year). In conclusion, the observed survival trends in BC and CRC patients suggest advances in cancer
treatment, but with striking differences in survival between older and younger patients, particularly
for BC patients.
Keywords: breast cancer; colorectal cancer; relative survival; older patients; geriatric oncology;
cancer treatment
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1. Introduction
Together with the aging of the population in Western countries, the number of older people with
cancer has increased considerably in the last decade [1]. In the Netherlands, breast cancer (BC) is the
most common cancer inwomen, with an estimated incidence rate of 66 new cases per 100,000women [2].
The incidence of BC is highest in patients aged 70–74 years (212 per 100,000 women) [2]. One of the
most common cancers in both men and women is colorectal cancer (CRC), with an estimated incidence
of 65 new cases per 100,000 persons. Its incidence increases with age (415 per 100,000 per persons in
those aged 75–79 years) [2].
Though the group of older patients has increased considerably, evidence to guide treatment of
these patients remains limited [3]. Many clinical trials exclude older patients from participating [4],
and older patients who do participate in clinical trials may not be representative of the general older
population, as clinical trials often exclude older patients with comorbidities or poor overall health [5].
Several population-based studies showed that the survival rate of BC patients has improved
substantially in the last two decades [1,6–8]. This has been attributed particularly to mammographic
screening programs [9] and advances in treatment (e.g., improved radiotherapy techniques and
new systemic therapeutic agents such as third-generation chemotherapy, aromatase inhibitors, and
HER2-targeted therapies). Clinical guidelines, as well as international position papers, state that
surgery is recommended for early-stage BC patients [3,10]. Adjuvant chemotherapy is recommended
for node-positive or high-risk node-negative disease, and endocrine therapy is recommended for
high-risk receptor-positive disease [3,10]. However, population-based studies showed that older BC
patients are less likely to receive standard care, which has been linked to lower survival rates in older
patients [6,8,11].
Surgery is recommended in early-stage CRC patients. To reduce the risk of recurrence after
surgery, clinical guidelines recommend that all lymph node-positive patients should be considered
for adjuvant treatment, e.g., radiotherapy, or chemotherapy [12,13]. Several population-based studies
showed that the administration of adjuvant chemotherapy has increased considerably in recent years,
and that this is associated with improved survival [14,15]. However, the administration of adjuvant
chemotherapy is considerably less common in older patients [14].
Several studies state that age should not be a contraindication for surgery or adjuvant
chemotherapy [16]. Trends in survival and treatment have been published before, but this has
not clarified the differences in survival rates between cancers. The aim of this study was to investigate
trends in survival rates and treatment patterns over time for older versus younger patients with BC
and CRC in the Netherlands.
2. Results
Between 2003 and 2012, 127,146 patients were diagnosed with stages I–III BC in the Netherlands,
while 85,629 patients were diagnosed with stages I–III CRC (Table 1). The median age of patients with
BC was 60 years (range 18 to 103), and the median age of patients with CRC was 71 years (range 18
to 102).
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Table 1. Clinical characteristics of 127,146 breast cancer (BC) and 85,629 colorectal cancer (CRC) patients,
diagnosed in 2003–2012.
Characteristics
BC CRC
n % n %
Gender
Male - 45,783 53.5
Female 127,146 100 39,846 46.5
Age (years)
15–44 15,206 12 2077 2.4
45–54 30,539 24 6457 7.5
55–64 31,830 25 17,969 21
65–74 27,095 21.3 26,839 31.3
≥75 22,476 17.7 32,287 37.7
Year of diagnosis
2003 11,669 9.2 7367 8.6
2004 11,848 9.3 7813 9.1
2005 11,845 9.3 7877 9.2
2006 12,264 9.6 8190 9.6
2007 12,725 10 8510 9.9
2008 12,836 10.1 8713 10.2
2009 12,999 10.2 8877 10.4
2010 13,102 10.3 9135 10.7
2011 13,838 10.9 9486 11.1
2012 14,020 11 9661 11.3
Stage
I 56,579 44.5 19,453 22.7
II 52,049 40.9 33,363 39
III 18,518 14.6 32,813 38.3
2.1. Stage at Diagnosis
The stages at diagnosis according to age are presented in Figure 1. BC patients aged ≤45 or
≥75 years were more often diagnosed with stage II or III cancer compared to those aged 45–75 years
(p < 0.001). Stage II was diagnosed in 51.7% and stage III in 17.9% of the BC patients aged ≥75 years.
The percentage of CRC patients with stage II disease steadily increased with age (32.5% in CRC patients
aged 45–54 years, and 44.3% in CRC patients aged ≥75 years), while stage III decreased with age (46.7%
in CRC patients aged 45–54 years, and 33.3% in CRC patients aged ≥75 years, p < 0.001).
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Figure 1. Tumor stage by age at diagnosis: (a) breast cancer, and (b) colorectal cancer.
2.2. Trends in Treatment
The time trends for all treatments for BC patients between 2003 and 2012 are presented in Figure 2.
Over the entire study period, 98.0% of patients with stages I–III BC who were younger than 75 years
underwent surgery, whereas for those aged 75 years or over, surgery rates declined from 79.3% in
2003 to 66.7% in 2012 (p < 0.001, Figure 2a). The proportion of BC patients undergoing lymph node
dissection for node-positive disease decreased over time for all age groups (Figure 2b). The use of
radiotherapy after breast-conserving surgery increased significantly for all age groups but was lowest
among patients aged 75 years and older (73.6% in 2003 vs. 84.1% in 2012, p < 0.001) and highest among
patients aged 45–54 years (84.4% in 2003 vs. 96.2% in 2012, p < 0.001, Figure 2c). Primary endocrine
therapy as a monotherapy in BC patients was almost exclusively used for patients aged 75 years or
over, and increased significantly over time (16.5% in 2003 and 28.7% in 2012, p < 0.001, Figure 2d). The
use of adjuvant chemotherapy in stages II and I BC patients increased significantly over time for all age
groups, except for patients aged 75 years or older. Its use was associated with age, with more than 90%
of patients younger than 55 years and less than 9% of patients aged 65 years or older in 2012 receiving
it, and hardly any patients aged 75 years or older (Figure 2e,f).
As CRC patients are treated according to tumor location, i.e., colon cancer (CC) or rectal cancer
(RC), we report the treatments received for CC and RC separately (Figure 3). In CC, the number of
patients aged 75 years or older who underwent surgery declined significantly over time (98.1% in 2003
vs. 94.2% in 2012, p < 0.001, Figure 3a). The percentage of chemotherapy treatment in stage III CC
patients aged 55 years or older increased significantly over time (Figure 3b), although the percentage of
those aged 75 years or older who received chemotherapy remained considerably lower (16.3% in 2003
vs. 23.5% in 2012, p < 0.001). The percentage of RC patients aged 45 years or older who underwent
surgery declined significantly over time, the greatest decrease being observed in RC patients aged
75 years or older (from 91.8% in 2003 to 81.1% in 2012, p < 0.001) (Figure 3c). The use of radiotherapy
in stage III RC increased significantly over time for all age groups but became less frequent with
increasing age (91.8% of patients aged 55–64 years compared to 80.2% of patients aged 75 years or older
in 2012, Figure 3d). The number of RC patients aged 75 years or older undergoing surgery was lower
than that of younger patients. The percentage of I-III RC patients aged 75 years or older who received
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primary radiotherapy as a single treatment modality increased significantly, from 3.8% in 2003 to 9.4%
in 2013 (p < 0.001, Figure 3e). The use of chemoradiation in stage II RC patients increased significantly
in all age groups, ranging from 19.8% to 71.6% in 2012, but again this was highly dependent on age,
with the lowest use in the age group of 75 years and older (Figure 3f).
Figure 2. Time trends in the treatment of breast cancer (BC) patients according to age group: (a) surgery
in BC patients stages I–III, (b) lymph node dissection in BC patients stages I–III with node-positive
disease, (c) radiotherapy after breast-conserving surgery in BC patients stages I–III, (d) primary
endocrine therapy in BC patients stages I–III, (e) chemotherapy in BC patients stage II, and (f)
chemotherapy in BC patients stage III. * Significant (p < 0.05) difference in treatment over time using
the Cochran–Armitage trend test.
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Figure 3. Time trends of treatment in colon cancer (CC) and rectal cancer (RC) patients according to
age group: (a) surgery in CC patients stages I–III, (b) chemotherapy in CC patients stage III, (c) surgery
in RC patients stages I–III, (d) radiotherapy in RC patients stage III, (e) primary radiotherapy as a
single treatment modality in RC patients stage III, and (f) chemoradiation in RC patients stages II–III.
* Significant (p < 0.05) difference in treatment over time using the Cochran–Armitage trend test.
2.3. Trends in Survival
The 5-year overall survival of BC patients is presented in Figure 4. The 5-year overall survival
improved in BC patients (adjusted hazard ratio (HR) 0.78, 95% CI 0.73–0.83) in the period 2003–2012.
The 5-year overall survival improved slightly in patients aged 75 years or older (adjusted HR 0.99, 95%
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CI 0.98–0.99) and did not significantly improve in patients aged 65–74 years (adjusted HR 0.99, 95% CI
0.98–1.01). In the multivariable Cox regression analysis, the overall survival improved in the period
2003–2012 and was influenced significantly by age (Table 2). The 5-year relative survival improved
in BC patients, from 89.7% in 2003 to 93.1% in 2012 (adjusted relative excess risk (RER) 0.97, 95% CI
0.97–0.98 per year) (Figure 5). The 5-year relative survival rate improved significantly for BC patients
aged 65 years or younger over the period between 2003 and 2012. In contrast, the relative survival
for BC patients aged 75 years or older did not increase significantly over the same period (crude RER
0.99, 95% CI 0.97–1.02). After adjustment for age, stage, and treatment, the RER for BC patients aged
65–74 years was no longer significant (adjusted RER 1.00, 95% CI 0.98–1.01), and the RER for patients
aged 75 years or older remained non-significant (adjusted RER 1.00, 95% CI 0.98–1.01).
Table 2. Multivariate Cox hazard analysis of five-year overall survival.
Variable
BC CRC
HR (95% CI) a p HR (95% CI) a p
Year of diagnosis (per year) 0.98 (0.97–0.98) <0.001 0.96 (0.96–0.97) <0.001
Age <0.001 <0.001
15–44 years 1.04 (0.97–1.11) 0.87 (0.76–0.98)
45–54 years 1.00 (ref) 1.00 (ref)
55–64 years 1.35 (1.28–1.43) 1.25 (1.17–1.34)
65–74 years 2.06 (1.95–2.18) 1.81 (1.70–1.93)
≥75 years 4.89 (4.60–5.18) 3.43 (3.22–3.65)
Gender - <0.001
Male - 1.00 (ref)
Female 0.82 (0.80–0.84)
Stage <0.001 <0.001
I 1.00 (ref) 1.00 (ref)
II 1.79 (1.72–1.87) 1.50 (1.44–1.55)
III 4.14 (3.96–4.32) 2.74 (2.64–2.84)
Grade <0.001 <0.001
Well differentiated 1.00 (ref) 1.00 (ref)
Moderately differentiated 1.29 (1.22–1.35) 1.02 (0.97–1.07)
Poorly differentiated and 2.14 (2.03–2.25) 1.46 (1.38–1.55)
undifferentiated
Unknown 1.67 (1.57–1.77) 1.12 (1.06–1.19)
Surgery <0.001 <0.001
No 1.00 (ref) 1.00 (ref)
Yes 0.30 (0.28–0.32) 0.14 (0.14–0.15)
Radiotherapy <0.001 <0.001
No 1.00 (ref) 1.00 (ref)
Yes 0.63 (0.61–0.65) 0.76 (0.74–0.78)
Chemotherapy <0.05 <0.001
No 1.00 (ref) 1.00 (ref)
Yes 0.95 (0.90–0.99) 0.64 (0.62–0.66)
Hormone therapy <0.001
No 1.00 (ref) -
Yes 0.55 (0.53–0.57)
a Adjusted for all variables included in the model. HR, hazard ratio. Significant (p < 0.05) HR values are indicated
in bold. ref, reference 95% CI, 95% Confidence Interval.
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Figure 4. Five-year overall survival in BC patients over time per age group. HR indicates hazard ratio
per year, adjusted for grade, stage, and treatment. * Significant (p < 0.05).
Figure 5. Five-year relative survival in BC patients over time per age group. RER indicates relative
excess risk per year, adjusted for grade, stage, and treatment. * Significant (p < 0.05).
Similarly, the 5-year overall survival improved for all CRC patients (Figure 6). Overall survival in
CRC patients was influenced by the year of diagnoses and age. Other factors affecting 5-year overall
survival were, stage, grade, gender, and treatment. The relative survival for CRC patients improved
from 76.0% in 2003 to 80.3% in 2012 (adjusted RER 0.95, 95% CI 0.94–0.95 per year, Figure 7). Most
overall improvement was observed in the CRC patients aged 65–74 years. In this group, the 5-year
relative survival increased by 7.9% between 2003 and 2012 (adjusted RER 0.94, 95% CI 0.93–0.95). In
contrast to the BC cohort, the RERs for patients with CRC in all age groups had improved significantly
after adjustment for grade, sex, stage, and treatment (adjusted RERs varying between 0.94 and
0.96 per year).
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Figure 6. Five-year overall survival in CRC patients over time per age group. HR indicates the hazard
ratio per year, adjusted for grade, stage, gender, and treatment. * Significant (p < 0.05).
Figure 7. Five-year relative survival in CRC patients over time per age group. RER indicates the
relative excess risk per year, adjusted for grade, stage, gender, and treatment. * Significant (p < 0.05).
3. Discussion
The findings of our population-based study show that 5-year overall and relative survival
improved for BC patients and for CRC patients in the Netherlands between 2003 and 2012. The
difference in 5-year survival between older and younger CRC patients decreased during the study
period, and the greatest improvement in overall and relative survival was observed for older CRC
patients. Among BC patients, substantial improvement of 5-year relative survival was seen only for
younger BC patients. The overall and relative survival and its improvement over time were lower for
older BC patients.
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Previous population-based studies found that overall and relative survival among older BC
patients did not change in the last decade [17,18]. This lack of improvement has been attributed to
differences in the delivery of cancer care between older and younger BC patients, e.g., the influence of
comorbid conditions on the selection of cancer treatments [19,20]; the lower likelihood of receiving
breast surgery, radiotherapy, or adjuvant chemotherapy for older BC patients compared to younger BC
patients [6]; and mammographic screening being offered only to younger women [9]. The survival and
treatment differences observed in our study suggest possible limitations of cancer treatment, as well as
reticence about cancer treatment, for older BC patients.
The most notable finding was the decreasing proportion of older BC patients receiving surgery,
and the increasing proportion receiving primary endocrine therapy. Previous population-based studies
in the Netherlands confirm this finding [6,17,21]. Van de Glas et al. showed that the proportion of
older BC patients that did not receive breast surgery increased substantially from 9.2% in 1995 to 30.1%
in 2011 [17]. Moreover, previous population-based studies showed that the proportion of older BC
patients receiving primary endocrine therapy is higher in the Netherlands than in other European
countries [22–24]. The EUROCARE breast cancer group found lower survival rates in European
countries, like England and Ireland, where older BC patients are treated more often with primary
endocrine therapy omitted [22]. This increased use of primary endocrine therapy may have been
influenced by a meta-analysis, in which seven randomized controlled trials were included [25]. This
meta-analysis showed that, compared to those treated with primary endocrine therapy, surgery alone
seemed to have no beneficial impact on the overall survival rate (HR 0.98, 95% CI 0.74–1.30). However,
BC patients who underwent surgery with adjuvant endocrine therapy had a borderline significantly
improved overall survival rate (HR 0.86, 95% CI 0.73–1.00) and a significantly better disease-free
survival. The HR for endocrine therapy alone was 0.65 (95% CI 0.53–0.81) [25].
Recent reports have advocated that primary endocrine therapy should only be considered in
frail older BC patients [26]. Guidelines in the Netherlands state that patients with operable tumors
should be treated with surgery and not primary endocrine therapy, irrespective of age [10]; also, the
International Society of Geriatric Oncology (SIOG) recommends that primary endocrine therapy should
only be offered to BC patients with a life expectancy of less than three years, or who are unfit for or
refuse surgery [3]. However, as a large proportion of older BC patients are currently being treated with
primary endocrine therapy, it is not clear if this recommendation is being followed consistently. In a
small retrospective study in the Netherlands, Hamakers et al. found that the reason for not carrying
out surgery was not always clearly stated in medical charts. When documented, reasons were often
higher age, poor overall health, patient preference, and comorbidities [21]. Additionally, Sierink et al.
found in a small cohort in the Netherlands that BC patients are less likely to receive surgery when
they are older, have been diagnosed with more comorbidities, or have been diagnosed with a more
advanced disease [27]. However, other studies found that age was the most important reason for
foregoing surgery in older BC patients, even when adjustments were made for comorbidities [28–30].
Several studies found that the main factor for surgical morbidity in BC patients are comorbidities
and not age [31]. Breast surgery can be considered a low morbidity surgery [32]. Approximately one
third of BC patients develop breast and/or axillar wound infections, seromas, and hematomas after
surgery, depending on the type of surgery. These surgical morbidities are often minor and treated in
an outpatient setting [32]. Moreover, van de Glas et al. demonstrated that relative mortality was not
influenced by postoperative complications in older BC patients [33].
Our study showed that the proportion of surgery in older CRC patients remains high. Many
studies have shown that age should not prohibit surgery in CRC patients [16]. In RC, however, the
proportion of patients aged ≥75 years that received primary chemoradiation increased from 0% in 2003
to almost 20% in 2012. Recently, foregoing surgery after chemoradiation has been shown to be safe for
RC patients in whom a complete clinical response is seen [34].
In the present study, the proportion of older BC patients receiving adjuvant chemotherapy was
lower than that of younger BC patients. In Europe, different rates of adjuvant chemotherapy in BC
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patients have been reported, with lower rates in the Netherlands [22]. There has been conflicting
evidence regarding the benefits of this treatment for older BC patients. Data from the Early Breast
Cancer Trial demonstrated a decreasing benefit from adjuvant chemotherapy with age [35,36], although
relatively few BC patients aged 70 years or older have been included in clinical trials [5]. Nevertheless,
the results of this meta-analysis may have contributed to the lower use of adjuvant chemotherapy in
older BC patients [35]. Other recent studies suggest a possible benefit from adjuvant chemotherapy in
older BC patients, especially in those with HER2-positive disease [37,38]. Recently, Du et al. compared
the effectiveness of adjuvant chemotherapy between older BC and CRC patients, and found that
chemotherapy might be effective in BC patients up to the age of 79 years [39].
Possible explanations why older BC patients receive adjuvant chemotherapy less often are frailty,
poor functional status, or comorbidities. In addition, older patients are less willing to accept possible
side effects associatedwith adjuvant chemotherapy comparedwith younger patients, and are concerned
about negative influences of adjuvant chemotherapy. Most older BCpatients receive adjuvant endocrine
therapy because they are more likely to have a receptor positive disease, which tends to grow more
slowly, are usually well differentiated, and respond better to endocrine therapy. However, there are
side effects associated with endocrine therapy, like deep vein thrombosis or pulmonary emboli [40].
The 5-year overall and relative survival improved in older CRC patients in our study. In a
population-based study, Van den Broek et al. showed that 5-year relative survival had increased
significantly in CC patients aged <65 years and ≥75 years over the period from 1991 to 2005, but not
in patients aged 65–74 years [41]. In our study the greatest overall improvement of relative survival
was seen in CRC patients aged 65–74 years (74.4% in 2003 vs. 82.3% in 2012). In the ≥75 years age
group, relative survival improved significantly, but still lagged behind the survival of younger age
groups. However, the difference in survival between younger and older CRC patients reported by the
EUROCARE working group [1,7] diminished over time in our study. This improved survival could be
partly attributed to the increased use of adjuvant chemotherapy in older patients [14], but also to other
factors, such as improved preoperative staging and improved surgery [42].
This study had some limitations. Information on patient characteristics, such as comorbidities,
was not available. Furthermore, we can draw no conclusions about aspects such as quality of life,
maintaining functional status, risk of recurrence, or complications, as we had no data for these
outcomes. Although we adjusted the analyses for potential confounders, there may still have been
some confounding by other factors. Finally, we did not have data on the causes of mortality. On the
other hand, the use of data for two different tumor types means that our study does provide important
insights into the differential treatment and survival trends by age. Another strength of our study is the
large number of patients with BC and CRC included from the Netherlands Cancer Registry, with at
least 5 years of follow-up.
4. Materials and Methods
4.1. Patients
For this population-based study, we selected all patients with primary BC and CRC stages I–II
diagnosed between 2003 and 2012 from the Netherlands Cancer Registry (NCR). We only selected
patients with stages I–III, as this group could potentially be treated with curative intent. Furthermore,
only female BC patients were selected. The NCR records all newly diagnosed malignancies in the
Netherlands after notification from the nationwide automated pathological archive (PALGA). This
data is supplemented with data from the National Registry of Hospital Discharge Diagnosis. Trained
registrars from the NCR routinely collect data from medical records regarding patient, tumor, and
treatment characteristics in all Dutch hospitals.
Cancer stage was based on the pathological TNM classification applicable at the time of cancer
diagnosis. In case of a missing pathological TNM classification, the clinical TNM classification was
used instead. Data regarding the vital status of all patients was available through linkage with the
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municipal personal records database, with complete follow-up until 31 December 2017. Patients
were divided into five groups according to age: 15–44, 45–54, 55–64, 65–74, and 75 years or older.
Primary cancer treatment retrieved from the NCR included surgery, radiotherapy, endocrine therapy,
immunotherapy, and (neo-)adjuvant chemotherapy.
According to the Central Committee on Research involving Human Subjects (CCMO), this type of
study does not require approval from an ethics committee in the Netherlands. The Privacy Review
Board of the Netherlands Cancer Registry approved this study in January 2018 (K17.351).
4.2. Statistical Analyses
All analyses were performed in IBM SPSS statistics version 22.0 (SPSS, Chicago, IL, USA) or SAS
statistics version 9.4 (SAS institute, Inc., Cary, NC, USA). Statistical significance was defined as p ≤ 0.05.
TheCochran-Armitage trend testwas used to test for differences in treatment over time. Treatments
are presented as percentages per age group and period.
The Cox hazard analysis was used to calculate the overall survival. The hazard ratio (HR) was
calculated according to age group and cancer stage, and adjusted for cancer stage, grade, gender,
and treatment.
As cause of death is not available in the NCR, relative survival was used as an estimation of the
disease-specific survival, and was calculated using the Ederer II method, i.e., as the observed overall
survival of patients in the study divided by the expected overall survival in a matched group of the
general population by age, sex, and year [11]. The expected survival was obtained from national
life tables. The relative excess risk of death (RER) was estimated using a multivariate generalized
linear model with a Poisson distribution. The RER was calculated according to age and cancer type,
and adjusted for cancer stage, grade, gender, and treatment. The treatment variables were added to
investigate the effect of treatment on the RER.
5. Conclusions
In this population-based study analyzing oncological treatment patterns and relative survival
of BC and CRC patients, we observed substantial differences between younger and older patients.
Although the observed survival trends in BC and CRC patients suggest advances in cancer treatment,
we found that the survival of older BC patients in particular was strikingly lower. Moreover, the
differences in relative survival between younger and older BC patients revealed in previous studies
were found to have continued to increase in recent years. Inequalities in the provision of cancer care
to older BC patients need to be investigated in future cancer research. Selection criteria for specific
treatments could eventually lead to individualized and optimized treatment for older cancer patients.
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Abstract: Background: The role of liver kinase B1 (LKB1), a serine/threonine kinase, has been
described in the development of PeutzJagher’s syndrome, where a proportion (~45%) of patients
have developed breast cancer in their lifetime. Cell line studies have linked LKB1 with oestrogen
receptors (ER) and with the Adenosine monophosphate-activated protein kinase (AMPK) pathway
for energy metabolism. However, limited studies have investigated protein expression of LKB1 in
tumour tissues and its intracellular relationships. This study aimed to investigate the intracellular
molecular relationships of LKB1 in older women with early operable primary breast cancer and
its correlation with long-term clinical outcome. Methods: Between 1973 and 2010, a consecutive
series of 1758 older (≥70 years) women with T0-2N0-1M0 breast carcinoma were managed in a
dedicated facility. Of these, 813 patients underwent primary surgery, and 575 had good quality
tumour samples available for tissue microarray construction. LKB1 was assessed in 407 cases by
indirect immunohistochemistry (IHC). Tumours with 30% or more of cells with cytoplasmic LKB1
expression were considered positive. LKB1 expression was compared with tumour size, histological
grade, axillary lymph node stage, ER, PgR, EGFR, HER2, HER3, HER4, BRCA1&2, p53, Ki67, Bcl2,
Muc1, E-Cadherin, CD44, basal (CK5, CK5/6, CK14 and CK17) and luminal (CK7/8, CK18 and CK19)
cytokeratins, MDM2 and MDM4, and correlated with long-term clinical outcome. Results: Positive
LKB1 expression was seen in 318 (78.1%) patients, and was significantly associated with high tumour
grade, high Ki67, over-expression of HER2, VEGF, HER4, BRCA2, MDM2 and negative expression
of CD44 (p < 0.05). There was no significant correlation with tumour size, axillary lymph node
status, ER, PgR, p53, basal or luminal cytokeratins, Bcl2, Muc1, EGFR, HER3, MDM4, E-cadherin and
BRCA1. LKB1 did not show any significant influence on survival in the overall population; however,
in those patients receiving adjuvant endocrine therapy for ER positive tumours, those with positive
LKB1 had significantly better 5-year breast cancer specific survival when compared to those without
such expression (93% versus 74%, p = 0.03). Conclusion: LKB1 expression has shown association with
poor prognostic factors in older women with breast cancer. However, LKB1 expression appears to be
associated with better survival outcome among those patients receiving adjuvant endocrine therapy.
Further research is required to explore its potential role as a therapeutic target.
Keywords: LKB1; Breast Cancer; Older women; Metformin; Endocrine therapy
1. Introduction
Liver kinase B1 (LKB1) or serine/threonine kinase-11, a 436-amino acid chain protein with a
molecular weight of 49 kDa, is associated with the development of Peutz-Jeghers syndrome (PJS) [1,2].
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In addition, approximately 45% of PJS patients have been reported to develop breast cancer in their
lifetime [3]. LKB1 is known to work as a tumour suppressor gene as well as an upstream kinase which
is linked to the cellular functions during normal state and in metabolic stress response [4,5]. LKB1 is
normally located in the nucleus, however, upon activation, it is relocated to the cytoplasm, where it
acts as a co-activator of the oestrogen receptor (ER), controls the citric acid cycle (KREB’s cycle) and
cell energy metabolism via the adenosine mono-phosphate activated protein kinase (AMPK) pathway,
and inhibits the production of the aromatase enzyme [6–11]. It has also been reported to control the
cell cycle at the G0–G1 check point via the p53 pathway, to be associated with angiogenesis through
the control of Vascular Endothelial Growth Factor (VEGF) and with cell polarity [8,11,12]. A proposed
mechanism of LKB1 function in breast cancer cells is presented in Figure 1. Previously, reported
data linked LKB1 with poor prognostic factors [11]. A cell line study on MDA-MB-231 cells showed
an association of LKB1 with gemcitabine resistance [13]. Additionally, cell line studies suggested
that LKB1 is involved in DNA repair, thus deficient cells demonstrate delayed repair and respond
well to DNA-based therapy, such as PARP inhibitors [14]. Cell-based studies showed that LKB1-null
cells possess invasion and breast cancer stem cell like properties. However, LKB1 enhancing therapy
(i.e., Honokoil, a bioactive molecule) showed improving outcome by reducing cellular invasiveness
and stemness [15], thus suggesting a therapeutic significance.
 
Figure 1. Proposed intracellular mechanism of action of LKB1 as suggested in the cell line
studies [7–9,12,16]. VEGF: Vascular Endothelial Growth factor, KREB: Citric acid cycle, ER: Oestrogen
receptor, CRTC2: Creb-regulated transcription co-activator 2, MDM2/4: Mouse double minute 2/4.
Currently available literature is based on in vitro or in vivo model studies, or gene technologies,
such as Western blot. However, there is limited information available on the subject of using
immunohistochemistry (IHC), which is currently a widely used technique for analysis of therapeutic
targets in clinical practice. This study was designed to analyse the association of LKB1 with other
biological markers of known significance in breast cancer and to correlate its expression with long-term
clinical outcome in older women with primary breast cancer.
2. Materials and Methods
2.1. Patients
Over 37 years (1973–2010), 1758 older (≥70 years) women with early operable primary breast
cancer (T0-2, N0-1, M0) were managed in a dedicated facility in a single institution with clinical
information available from diagnosis till death/last follow-up. Eight hundred and thirteen patients
underwent primary surgery (with optimal adjuvant therapy as per unit policy at the time [17]) and
among them, good quality formalin-fixed paraffin-embedded surgical specimens were available from
575 patients for tissue microarray (TMA) construction. The management pattern over this period
of time was evolving, a detailed description of which was reported earlier [17]. Briefly during the
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1970s and 1980s, ER status was not available and there was no consensus on recommendations for
adjuvant systemic therapy. During the 1990s, adjuvant endocrine therapy was advised based on the
clinical judgement of the treating physician and/or the patient’s choice. In the recent decade, there
have been structured recommendations for the use of adjuvant endocrine therapy. Those patients with
ER positive tumours and Nottingham Prognostic Index (NPI) <3 (excellent prognostic group) were not
given any adjuvant systemic therapy, those with an NPI of 3–3.4 (good prognostic group) were offered
endocrine therapy and given the choice of tamoxifen or a non-steroidal aromatase inhibitor, and
those with an NPI of >3.4 (moderate to poor prognostic group) were given a non-steroidal aromatase
inhibitor. Adjuvant chemotherapy was considered in fit, relatively younger patients with moderate to
poor prognostic tumours, in particular those with ER negative tumours. Trastuzumab was considered
in relatively fit patients with HER2 positive tumours having moderate to poor prognosis.
2.2. Tissue Microarray Construction
Tissue microarrays (TMAs) of formalin-fixed paraffin-embedded tumour sections were
constructed as described [18]. Briefly, 0.6 mm-diameter cores of the representative part of the tumour
blocks were implanted in the TMA blocks using Beecher’s manual tissue microarrayer (MP06 Beecher
Instruments Inc, Sun Prairie, WI, USA).
2.3. Immunohistochemistry
LKB1 and 24 other biological markers including ER, progesterone receptor (PgR), Epidermal
Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor (HER)-2, HER3, HER4,
Breast Cancer Associated gene (BRCA)1&2, p53, Ki67, B-Cell Lymphoma (Bcl)2, Mucin (MUC)1,
E-Cadherin, basal (CK5, CK5/6, CK14 and CK17) and luminal (CK7/8, CK18 and CK19) cytokeratins,
and Mouse Double Minute (MDM)2 and MDM4 were analysed using indirect IHC by StreptAvidin
Biotin Complex and EnVision methods as described [19].
2.4. Scoring
Immunohistochemical staining of biological markers was assessed by the percentage of invasive
tumour cells stained and by McCarty’s immunohistochemical scoring (H-score) (range 0–300) [20]. The
LKB1 expression of 30% or more positive cells was considered positive (Figure 2a–d). Previously, studies
have shown that the active form of LKB1 is found in the cytoplasm and is associated with other markers
and outcome of breast cancer; thus, cytoplasmic expression of LKB1 was considered in our study [21].
 
(a)?
 
(b)?
Figure 2. Cont.
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(d)?
?Figure 2. Immunohistochemichemical expression of LKB1 in Breast cancer cells. (a–c) Positive
cytoplasmic expression, (d) LKB1 negative.
2.5. Statistical Analysis
X-tile bio-informatics software (Yale University, New Haven, CT, USA) was used to define cut-offs
for positivity of the expression of the biological markers based on breast cancer specific survival
(BCSS) [22]. The cut-offs for all the biological markers were determined by using the same metric
in X-tile. The cut-off values to define positive expression are the same as reported earlier [23]. The
Statistical Package for Social Sciences (SPSS, version 16.0, Chicago, IL, USA) was used for data
collection and analysis. A Chi-squared test was used for the analysis of the association of the LKB1
with other biomarkers in terms of expression. The clinical outcome was evaluated in terms of BCSS,
metastases free survival, local recurrence free survival and regional recurrence free survival, breast
cancer specific survival was defined as survival from the date of diagnosis till death from breast cancer;
metastases free, local recurrence free and regional recurrence free survivals were calculated from the
date of diagnosis till the appearance of the respective recurrences. Survival was analysed by using
Kaplan-Meier methods with application of log-rank and generalised Wilcoxon tests, as appropriate.
A p-value of <0.05 was considered significant.
2.6. Ethical Consideration
The study was approved by the Nottingham Research Ethics Committee 2 under ethical approval
number C2020313.
3. Results
3.1. Patients
Of the 575 patients who had TMAs constructed from surgical specimens, 168 cores were lost
during the IHC process and 407 cases had LKB1 measured. The median age of the patients was 76
(range 70–91) years, with the majority having had no axillary lymph node involvement (54.2%). Most
of the patients (n = 296 (72.7%)) underwent a mastectomy and 46.6% of patients (n = 189) received
adjuvant endocrine therapy. None of these patients received chemotherapy. The median follow-up
was 60 months (longest = 261 months).
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3.2. Pattern of LKB1 Expression and Association with Other Clinico-Pathological Parameters and
Biological Markers
Overall, 78.1% (n = 318) of patients showed positive cytoplasmic expression of LKB1 in
their tumours.
3.2.1. Pathological Parameters
The expression of LKB1 was significantly associated with high histological grade (among LKB1
positive, grade 1&2 = 44.5%, grade 3 = 55.5%; among LKB1 negative, grade 1&2 = 59.2% and grade
3 = 40.8%, p = 0.01).However there was no statistically significant correlation with tumour size(among
LKB1 positive, <3 cm = 81.7% and among LKB1 negative, <3 cm = 75.6%, p = 0.15) and axillary lymph
node status (among LKB1 positive:, stage 1&2 = 87.1%, stage 3 = 12.9%, among LKB1 negative, stage
1&2 = 89.5%, stage 3 = 10.5%, p = 0.41).
3.2.2. Biological Markers
The positive expression of LKB1 was significantly associated with positive expression of HER2
(p = 0.003), Ki67 (p = 0.01), VEGF (p = 0.002), HER4 (p = 0.001), BRCA2 (p = 0.01) and MDM2 (p < 0.001),
and negative expression of CD44 (p = 0.03). However, there was no statistically significant correlation
with, ER, PgR, p53, basal or luminal cytokeratins, Bcl2, Muc1, EGFR, HER3, MDM4, E-cadherin, and
BRCA1.A, as summarised in Table 1.
Table 1. Intracellular relationships between LKB1 with biological markers in older women with early
operable primary breast cancer.
Biomarker LKB1 Positive N (%) LKB1 Negative N (%) p-Value
ER + ve 211 (69.0) 61 (72.6) 0.30
PgR + ve 168 (55.1) 52 (61.9) 0.16
HER2 + ve 30 (9.6) 2 (2.4) 0.01
Ki67 + ve 114 (35.8) 20 (22.5) 0.01
MUC1 + ve 274 (89.0) 73 (86.9) 0.36
Bcl2 + ve 250 (83.1) 69 (83.1) 0.56
P53 + ve 123 (41.1) 31 (39.7) 0.46
CK5 + ve 104 (33.7) 21 (24.7) 0.07
CK5/6 + ve 128 (45.2) 33 (42.3) 0.37
CK7/8 + ve 301 (97.4) 84 (98.8) 0.38
CK14 + ve 73 (25.8) 15 (18.5) 0.11
CK17 + ve 70 (23.4) 14 (16.7) 0.11
CK18 + ve 286 (97.3) 81 (96.4) 0.45
CK19 + ve 291 (95.4) 79 (96.3) 0.49
EGFR + ve 65 (23.0) 12 (14.8) 0.07
BRCA2 + ve 160 (56.7) 35 (42.7) 0.01
VEGF + ve 234 (88.6) 56 (73.7) 0.002
CD44 + ve 61 (19.7) 25 (29.8) 0.03
MDM2 + ve 296 (96.7) 60 (74.1) <0.001
E-Cadherin + ve 191 (63.2) 48 (57.1) 0.18
Expression of LKB1 in molecular classes of breast cancer
Luminal A 79 (76.0) 25 (24.0)
0.09
Luminal B 56 (75.7) 18 (24.3)
Low ER Luminal 36 (81.8) 8 (18.2)
All low expression/normal like 13 (76.5) 4 (23.5)
Basal Like 19 (73.1) 7 (26.9)
HER2 positive 25 (96.2) 1 (3.8)
ER: Oestrogen receptor, HER2: Human Epidermal Receptor 2.
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3.3. Correlation with Molecular Classes of Breast Cancer
The expression of LKB1 was correlated with molecular classes (subtypes) of breast cancer found
in older women (published previously [23]). The results showed no significant difference in the
expression across them (Table 1).
3.4. Association of LKB1 with Clinical Outcome
Breast Cancer Specific Survival (BCSS)
At a median follow-up of 60 months (longest 261 months), LKB1 did not show any significant
association with BCSS (Figure 3a. However, among those who received adjuvant endocrine therapy
(n = 267), patients with ER positive disease and positive LKB1 expression (ER+/LKB1+) showed
significantly better BCSS (5-year: 93%versus 74%, p = 0.03) (Figure 3b). However, in the absence of
adjuvant endocrine therapy, LKB1 did not produce any significant impact on survival (p = 0.85). For
patients with positive LKB1, positive expression of ER (p < 0.001, Figure 4a), PgR (p = 0.001, Figure 4b),
MUC1 (p = 0.003, Figure 4c) and Bcl2 (p < 0.001, Figure 4d) was associated with significantly better
BCSS but poorer BCSS in cases of positive expression of HER2 (p < 0.001, Figure 4e), Ki67 (p = 0.01,
Figure 4f), CK17 (p = 0.02, Figure 4g) and EGFR (p = 0.03, Figure 4h).
(a) 
Figure 3. Cont.
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(b) 
Figure 3. (a) Breast cancer specific survival according to the expression of LKB1 in older women with
early operable primary breast cancer (all patients). (b) Breast cancer specific survival according to the
expression of LKB1 in older women with early operable primary breast cancer who received adjuvant
endocrine therapy.
(a) 
Figure 4. Cont.
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Figure 4. Cont.
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(e) 
Figure 4. Cont.
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(g) 
Figure 4. Cont.
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(h) 
Figure 4. Breast cancer specific survival in LKB1 positive early operable primary breast cancer in
older women: (a) Oestrogen receptor positive versus oestrogen receptor negative. (b) Progesterone
receptor(PgR) positive versus Progesterone Receptor negative, (c) Mucin (MUC)-1 positive versus
Mucin 1 negative, (d) B-Cell Lymphoma-2 (Bcl2) positive versus B-Cell Lymphoma 2 negative,
(e) Human Epidermal Growth Factor Receptor-2(HER2) positive versus Human Epidermal Growth
Factor Receptor-2 negative, (f) Ki67 positive versus Ki67 negative, (g) Cytokeratin 17(CK17) positive
versus Cytokeratin 17 negative, (h) Epidermal Growth Factor Receptor (EGFR) positive versus
Epidermal Growth Factor Receptor negative.
3.5. Recurrence Free Survival
There was no significant correlation between metastases-, local recurrence- or regional
recurrence-free survival and LKB1 expression (p > 0.05). Figure S1a–e). Nevertheless, among patients
with positive LKB1, positive expression of ER (p < 0.001, Figure 5a), PgR (p = 0.001, Figure 5b), MUC1
(p = 0.002, Figure 5c), Bcl2 (p = 0.004, Figure 5d) and negative expression of HER2 were associated with
better metastases-free survival (p = 0.01, Figure 5e). While Ki67 (Figure S2a), CK17 (Figure S2b) and
EGFR (Figure S2c) did not show any significant influence on metastases free survival.
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(e) 
Figure 5. (a) Metastasis-free survival in LKB1 positive early operable primary breast cancer in older
women: ER positive versus ER negative. (b) Metastasis-free survival in LKB1 positive early operable
primary breast cancer in older women: PgR positive versus PgR negative. (c) Metastasis-free survival
in LKB1 positive early operable primary breast cancer in older women: MUC1 positive versus MUC1
negative. (d) Metastasis-free survival in LKB1 positive early operable primary breast cancer in older
women: Bcl2 positive versus Bcl2 negative. (e) Metastasis-free survival in LKB1 positive early operable
primary breast cancer in older women: HER2 positive versus HER2 negative.
4. Discussion
Results of the analysis showed that cytosolic expression of LKB1 was associated with high-grade
tumours and positive expression of HER2, Ki67 and VEGF. Within the population with LKB1 positive
tumours, BCSS was significantly better in patients who received adjuvant endocrine therapy.
The expression of LKB1 in tumours cells was previously reported as 71%, which is slightly lower
than the expression reported in our population (78%) [24]. This could be explained by the age of
the population, as our study included patients 70 years or older, while the previously reported data
included four groups with median ages of 48, 54, 61 and 62 years [24]. In our study, the association
between LKB1 positivity and the factors mentioned above suggests its role as a possible poor prognostic
indicator. The association of LKB1 expression with high histological grade suggests a poor prognostic
indication as reported previously, where IHCwas used for the detection of LKB1 protein expression [24].
While in vitro studies reported a negative correlation between both LKB1 mutation and grade and
VEGF and a positive correlation with hormone receptor expression [1,3,12,25], these studies analysed
LKB1 using Western blot and RT-PCR [1,3,11]. A recently presented study suggested that the nuclear
location of LKB1 was associated with better survival while cytosolic expression is an indicator of poor
prognosis [25]. Another study analysed both nuclear and cytoplasmic expression (n = 32) on IHC in
early operable primary breast cancer with ER and PgR positive expression [26]. High cytoplasmic
expression was seen in 62.5% of cases, which was not associated with age, ER, PgR and HER2, but
was shown to be significantly associated with smaller tumour size [26]. In this study, the nuclear
expression was also associated with smaller tumours and better survival. A high LKB1 gene expression
has been reported to be linked to a high ER expression [24]. The expression of LKB1 has shown its
association with CD44, which is a marker of stemness in breast cancer stem cells. Previously, the
available literature showed LKB1 as a factor for maintenance of stem cells in haemopoetic cells in a
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mouse model study, where animals with LKB1 deletion had progressive pancytopenia and reduction
in haemopoetic cell proliferation [27–29]. In this study, LKB1 has also shown its significant association
with VEGF, probably linked to tumour growth and invasion. A recent study has demonstrated the
influence of LKB1 on tumour invasion and metastases in colorectal cancer and suggested it to be a
potential therapeutic marker [30].
The expression of LKB1 among molecular classes or subtypes has not been reported in the
literature. Though it did not show any remarkable findings in our data analyses, its relatively high
expression in the HER2 over-expressing class may be linked to some relationship with growth factor
pathways. As it was previously reported, it may be a potential predictor of overall survival among
HER2 positive breast cancer patients [24].
The prognostic significance of LKB1 was clinically demonstrated in the group of patients who
received adjuvant endocrine therapy. This is an interesting finding, which is in line with the data
previously reported, which suggested that within the stress environment, 17β oestradiol stimulatesthe
AMPK pathway. The same study has also suggested that LKB1 is required for the ER mediated
activation of AMPK [31,32]. The tumour analysis of the patients included in the TAMRAD randomized
GINECO trial (the trial compared tamoxifen versus tamoxifen plus everolimus in ER+ metastatic
breast cancers). It reported that the patients with a low cytoplasmic expression of LKB1 demonstrated
a 67% reduction in the risk of disease progression with everolimus (a mammalian target of rapamycin
(mTOR) inhibitor) plus tamoxifen, when compared to the tamoxifen only arm [33]. On the other hand,
high cytoplasmic expression was associated with less benefit with everolimus therapy, consistent with
our results, suggesting the predictive role of LKB1 in patients with ER positive tumours.
In addition, LKB1 has been previously reported to inhibit the aromatase enzyme via the
AMP-activated protein kinase, thus supporting its potential role in the prediction of the response to
primary endocrine therapy in older women [7,10,26].
The study has limitation of not including the comparison with the younger women and not
studying the gene expression and mutations in older women. Precisely defining an expression cut-off
based on IHC remains a challenge as this could vary between laboratories.
5. Conclusions
The available literature reported on LKB1 are primarily based on in vitro and in vivo studies using
Western blot or PCR techniques. Our work describes a novel study which analysed the relationship
between LKB1 and other biomarkers and clinical outcome in a large series of older patients with
breast cancer by using IHC. Given the availability of IHC in clinical practice, this study possesses
translational significance. The study has demonstrated significant correlations between LKB1 and
biological markers of established significance. It has also shown its significant influence on the clinical
outcome (notably BCSS) in older women receiving adjuvant endocrine therapy. Further studies are
required to investigate and compare the expression of LKB1 in and with the younger patients and
to delineate the precise role of LKB1 as a potential therapeutic target in breast cancer management.
Studies are also required to understand the detailed genetics of LKB1.
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cancer who received adjuvant endocrine therapy, Figure S2. (a) Metastases free survival in LKB1 positive early
operable primary breast cancer in older women: Ki67 positive versus Ki67 negative. (b) Metastasis-free survival
in LKB1 positive early operable primary breast cancer in older women: CK17 positive versus CK17 negative. (c)
Metastasis-free survival in LKB1 positive early operable primary breast cancer in older women: EGFR positive
versus EGFR negative.
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Abstract: Multi-cohort analysis demonstrated that cytoplasmic cyclin E expression in primary
breast tumors predicts aggressive disease. However, compared to their younger counterparts,
older patients have favorable tumor biology and are less likely to die of breast cancer. Biomarkers
therefore require interpretation in this specific context. Here, we assess data on cytoplasmic cyclin
E from a UK cohort of older women alongside a panel of >20 biomarkers. Between 1973 and 2010,
813 women ≥70 years of age underwent initial surgery for early breast cancer, from which a tissue
microarray was constructed (n = 517). Biomarker expression was assessed by immunohistochemistry.
Multivariate analysis of breast cancer-specific survival was performed using Cox’s proportional
hazards. We found that cytoplasmic cyclin Ewas the only biological factor independently predictive of
breast cancer-specific survival in this cohort of older women (hazard ratio (HR) = 6.23, 95% confidence
interval (CI) = 1.93–20.14; p = 0.002). At ten years, 42% of older patients with cytoplasmic cyclin
E-positive tumors had died of breast cancer versus 8% of negative cases (p < 0.0005). We conclude
that cytoplasmic cyclin E is an exquisite marker of aggressive tumor biology in older women. Patients
with cytoplasmic cyclin E-negative tumors are unlikely to die of breast cancer. These data have the
potential to influence treatment strategy in older patients.
Keywords: breast cancer; cyclin E; older patients; biomarker; tumor biology; prognosis; survival
1. Introduction
The prognosis for patients with primary breast cancer is a function of disease extent at
presentation and tumor biology. Time-dependent factors, including metastatic involvement of
draining axillary lymph nodes (stage) and the size of the primary tumor, indicate disease extent,
while the degree of differentiation (grade) is used as a surrogate for biological aggressiveness.
These histopathology-assessed features are classically combined into the Nottingham Prognostic Index
(NPI) [1].
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Due to comorbidities, older patients with primary breast cancer are more likely to die of non-breast
cancer-related causes when compared to their younger counterparts [2,3]. Furthermore, tumors in
older patients have distinct biological characteristics that are linked to favorable outcome, such as
a higher proportion and degree of hormone receptor (estrogen receptor (ER) and/or progesterone
receptor (PR)) positivity, and low histological grade and Ki67 proliferative index [4,5]. Biomarkers that
may influence treatment strategy therefore require interpretation in the specific clinical and biological
context of older women.
Recent developments in risk stratification, such as tumor gene expression profiling (e.g., Oncotype
Dx and MammaPrint), have focused on the biology of the primary tumor, based on the premise that
this reflects the biology of presumed micrometastatic deposits [6,7]. Adjuvant therapy is then selected
according to risk category with the aim of preventing these deposits from developing into clinically
detectable metastases, thus avoiding disease relapse.
We have previously shown that tumor biology in older (>70 years) versus younger primary breast
cancer cohorts can be distinguished by immunohistochemistry (IHC) using a panel of biomarkers,
including ER, PR, HER2, Ki67, Bcl2, BRCA1, BRCA2, E-Cadherin, EGFR, LKB1, MDM2, MDM4,
MUC1, p53, VEGF and cytokeratin markers of luminal and basal disease [4]. Differential expression
of age-associated biomarkers clustered tumors from older patients into six groups with distinct
clinical outcomes.
The current study focuses on the role of G1/S-specific cyclin-E1 (cyclin E) as a biological marker
of aggressive disease, and on its prognostic significance in the context of older women with primary
breast cancer.
In normal dividing cells, cyclin E promotes the transition from G1 to S phase by activating
cyclin-dependent kinase 2 (CDK2) [8]. In breast cancer cells, tumor-specific proteolytic processing of
cyclin E generates hyperactive low molecular weight (LMW) isoforms [9]. In contrast to full length
cyclin E, for which prognostic data have been equivocal, LMW isoforms are highly prognostic in
primary breast cancer patients [10–12]. As they lack a portion of the amino-terminus containing a
nuclear localization sequence, LMW isoforms of cyclin E preferentially accumulate in the cytoplasm
where they evade nuclear FBW-7 ubiquitin ligase that would otherwise increase their turnover [13].
In previous work using an antibody named C-19 that interacts with the carboxyl-terminus of
cyclin E (present in both full length and LMW isoforms of cyclin E), we showed that transgenic mouse
models with mammary gland expression of LMW cyclin E developed mammary tumors positive
only for cytoplasmic cyclin E [14]. Furthermore, cytoplasmic cyclin E bound to its catalytic subunit,
CDK2, in the cytoplasm of tumor cells [14]. The biological functions of cytoplasmic, LMW cyclin E are
summarized in Figure 1.
These critical findings on the biological functions of LMW cyclin E paved the way for a pivotal
study on the use of cytoplasmic expression of cyclin E (c-cyclin E) by IHC to predict recurrence in
patients with primary breast cancer [15]. Combined analysis of 2494 tumors from four cohorts of
patients (from the UK and the USA, covering all age groups) presenting with primary breast cancer
demonstrated that c-cyclin E staining is highly prognostic. These data included the current UK cohort
of older women (median age 76, versus 53–62 years in all cohorts, p < 0.0001).
We now present data on c-cyclin E exclusively from the Nottingham cohort. This paper is distinct
from the multi-cohort study as it focuses only on the older population and assesses the role of c-cyclin E
against a large panel of more than 20 disease markers. Findings are interpreted in the specific biological
and clinical context of primary breast cancer in older women, and the implications for risk stratification
and treatment decision-making in older patients are discussed.
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Figure 1. Model: Low molecular weight cyclin E (LMW-E) isoforms are generated by neutrophil
elastase-mediated proteolytic cleavage, removing the N-terminal nuclear localization signal. LMW-E
isoforms accumulate in the cytoplasm where they inappropriately interact with cytoplasmic proteins,
such as ACLY. The altered biochemistry of LMW-E results in hyperactivation of CDK2, resistance to
endogenous CDK-inhibitors (p21CIP1 and p27KIP1) and altered substrate interactions, which results in
enhanced cell cycle progression, genomic instability and other pro-tumorigenic features. Evaluation of
LMW-E by Western blot (protein size) or immunohistochemistry (cytoplasmic localization) is prognostic
of poor prognosis and predicts failure of standard treatment modalities.
2. Results
Patient clinicopathological characteristics are summarized in Table 1. Median follow-up was
6.3 years (95% CI, 6.1–7.1 years).
Table 1. Summary of patient characteristics (n = 517).
Variable Group n %
age
70 to <75 yrs 206 39.8%
75 to <80 yrs 202 39.1%
80 to <85 yrs 83 16.1%
≥85 yrs 26 5.0%
tumor size
<20 mm 153 31.7%
≥20 mm 329 68.3%
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Table 1. Cont.
Variable Group n %
stage
1 183 57.5%
2 98 30.8%
3 37 11.6%
grade
1 51 12.0%
2 169 39.8%
3 205 48.2%
ER status
negative 143 29.9%
positive 335 70.1%
HER2 status
negative 453 91.7%
positive 41 8.3%
Metastasis 1
negative 430 83.2%
positive 87 16.8%
1 at last follow-up.
2.1. Expression of Cytoplasmic Cyclin E Associates with High-Grade, ER-/PR- Breast Tumors with High Ki67
Proliferative Index
We examined the expression of c-cyclin E and a panel of biomarkers in breast tumors by IHC.
Average concordance between pathologists was 93% for the Nottingham cohort (see Table 2).
Table 2. Concordance between two independent pathologists for the Nottingham cohort (n = 516).
Pathologist B
Totalc-cyclin E+ c-cyclin E−
Pathologist A c-cyclin E+ 199 11 210
c-cyclin E− 11 295 306
516
Representative IHC staining for c-cyclin E positive and negative cases is presented in Figure 2.
To assess the potential clinical relevance of c-cyclin E, we first compared c-cyclin E expression
with clinicopathological features at initial diagnosis (age, tumor size, stage and grade) and markers of
disease biology in current clinical use, including ER, PR, HER2 and Ki67 status.
Figure 2. Representative images of positive and negative staining for cytoplasmic cyclin E using
antibody C-19.
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There was a strong association between c-cyclin E expression and higher grade (p < 0.0005,
see Table 3). In contrast, there was no association between c-cyclin E and patient age, tumor size
or stage. Cytoplasmic expression of cyclin E was significantly associated with negative ER and PR
status (p = 0.002 and p = 0.012, respectively) and high Ki67 proliferative index (p = 0.047) (Table 3).
No significant association was found between c-cyclin E and HER2 status.
Table 3. Association between tumor c-cyclin E status and clinicopathological factors.
Variable c-Cyclin E− c-Cyclin E+ p
age 70 to <80 yrs 170 (41.7%) 238 (58.3%) 0.743≥80 yrs 43 (39.4%) 66 (60.6%)
size
<20 mm 64 (41.8%) 89 (58.2%) 0.921
≥20 mm 135 (41.0%) 194 (59.0%)
stage
1 83 (45.4%) 100 (54.6%) 0.350
2 42 (42.9%) 56 (57.1%)
3 12 (32.4%) 25 (67.6%)
grade
1 33 (64.7%) 18 (35.3%) <0.0005 1
2 87 (51.5%) 82 (48.5%)
3 64 (31.2%) 141 (68.8%)
ER
negative 43 (30.1%) 100 (69.9%) 0.002 1
positive 151 (45.1%) 184 (54.9%)
PR
negative 74 (34.6%) 140 (65.4%) 0.012 1
positive 122 (46.2%) 142 (53.8%)
HER2
negative 187 (41.3%) 266 (58.7%) 0.869
positive 16 (39.0%) 25 (61.0%)
Ki67
negative 152 (44.3%) 191 (55.7%) 0.047 1
positive 61 (35.1%) 113 (64.9%)
1 Statistical significance p < 0.05, by χ2 test
Comparison of c-cyclin E status with other biomarkers revealed a positive association with VEGF
(p = 0.041), and no other significant association.
2.2. Cytoplasmic Cyclin E Expression Is Enriched in Basal Tumors
We next assessed the association between tumor c-cyclin E expression and cellular phenotype as
indicated by the expression of cytokeratin markers in the IHC protein panel.
Cytoplasmic cyclin E expression was associated with markers of basal disease (see Table 4).
Basal cytokeratin markers significantly associated with c-cyclin E included CK5 and CK17 (p = 0.001
and p = 0.036, respectively). In contrast, there was no association between c-cyclin E and the luminal
marker CK18.
Table 4. Association between tumor c-cyclin E status and clinicopathological factors.
Variable c-Cyclin E− c-Cyclin E+ p
CK5
negative 152 (45.5%) 182 (54.5%) 0.001 1
positive 43 (29.5%) 103 (70.5%)
CK5/6 negative 101 (43.3%) 132 (56.7%) 0.284
positive 78 (37.9%) 128 (62.1%)
CK14
negative 143 (43.7%) 184 (56.3%) 0.074
positive 37 (33.9%) 72 (66.1%)
CK17
negative 160 (43.1%) 211 (56.9%) 0.036 1
positive 30 (31.3%) 66 (68.8%)
CK18
negative 3 (21.4%) 11 (78.6%) 0.170
positive 187 (41.9%) 259 (58.1%)
1 statistical significance p < 0.05, by χ2 test. CK5, CK5/6 (antibody to both CK5 and CK6), CK14 and CK17 are basal
markers; CK18 is a luminal marker.
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2.3. Survival Analysis
Kaplan–Meier plots of breast cancer-specific survival (BCSS) and disease-free survival (DFS) as
a function of c-cyclin E status are shown in Figure 3. Lack of c-cyclin E was associated with good
prognosis in the patient cohort (BCSS and DFS both p < 0.0005 by logrank test). This was observed for
luminal A/B (ER+ and/or PR+), HER2+ and triple negative breast cancer subtypes (see Figure 4).
  
A B 
Figure 3. (A) Breast cancer-specific and (B) disease-free survival by cytoplasmic cyclin E status.
Figure 4. Breast cancer-specific survival by subtype: (A) hormone receptor (ER and/or PR) positive,
(B) triple negative, (C) HER2 positive.
Survival analysis of c-cyclin E alongside the full panel of biomarkers was performed using data up
to last follow-up. Due to the low proportion of low-grade tumors (grade 1, 12%), these were combined
with intermediate-grade tumors (grade 2, 40%) and used as a statistical reference for comparison with
high-grade tumors (grade 3, 48%). Multivariate analysis was performed on all clinicopathological
factors and biomarkers significantly associated with BCSS in univariate testing.
Cytoplasmic expression of cyclin E was the only independent biomarker of BCSS and had a strong
association in multivariate analysis (HR = 6.23, 95% CI 1.93–20.14; p = 0.002) (Figure 5). The only
clinicopathological factor predictive of BCSS in the multivariate analysis was axillary nodal status
(HR = 4.38, 95% CI 1.77–10.84; p = 0.001).
For the whole cohort of 517 patients, there was a strong positive association between c-cyclin
E positivity and breast cancer-specific mortality at 5 years of follow-up (p<0.0005). Multivariate
analysis demonstrates that c-cyclin E positivity is the strongest predictor of 5-year BCSS in this cohort
(HR = 9.12, 95% CI 2.22–37.40; p = 0.002)—outperforming lymph node status (HR=4.49, 95% CI
1.66–12.15; p = 0.003) and all other biological disease markers.
At ten years of follow-up, BCSS for patients with c-cyclin E-negative tumors was 92% versus
58% for those with c-cyclin E-positive tumors (HR = 6.23, 95% CI 1.92–20.14; p = 0.002 in multivariate
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analysis). At completion of follow-up, the absolute difference in median overall survival (OS) by
c-cyclin E status (positive versus negative) was 33 months (130 versus 97 months, p = 0.01 by logrank,
Mantel–Cox) (see Figure 6).
Figure 5. (A) Univariate and (B) multivariate analysis of c-cyclin E with clinicopathological and
age-associated biomarkers.
Figure 6. Overall survival (all cases) by cytoplasmic cyclin E status.
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2.4. Prognostic Value of Cytoplasmic Cyclin E in Patients Treated with Endocrine Therapy
Patients with ER+ disease received up to 5 years of adjuvant endocrine therapy according to risk
stratification by NPI (e.g., NPI > 2.4 or 3.4, according to best practice guidelines at the time of treatment).
We next explored the prognostic value of c-cyclin E and its relationship to adjuvant endocrine therapy
in patients with ER+ tumors.
In contrast to the whole cohort (where c-cyclin E was the strongest predictor of 5-year BCSS),
in patients who received up to 5 years of adjuvant endocrine therapy (n = 229), c-cyclin E was not
associated with 5-year BCSS (p = 0.323). After cessation of adjuvant endocrine therapy, c-cyclin E
reached prognostic significance (positive association with breast cancer-specific mortality) at 10 years
of follow-up (p = 0.009) (see Figure 7).
Figure 7. Adjuvant endocrine therapy negates the poor prognostic effect of c-cyclin E positivity, but
only for as long as it is given (up to 5 years).
3. Discussion
In this study of 517 older women with primary breast cancer, c-cyclin E is the only independent
biological marker of disease outcome. In terms of prognostic value, c-cyclin E status outperforms all
standard clinical and age-associated biomarkers tested in this study.
For the older population, who more often present with complex comorbidities and
psychosocial factors, considerations regarding competing causes of death are paramount in clinical
decision-making [16]. The current study presents BCSS as a surrogate measure for the impact of tumor
biology on patient mortality. Deaths due to non-breast cancer causes are excluded from the analysis.
Unlike non-modifiable and time-dependent clinicopathological disease factors, such as tumor size and
stage, those factors pertaining to tumor biology can be modified using systemic therapy.
Data from the current study supplement findings from an international study of four cohorts
(including the Nottingham cohort) and add clinical context in older women [16]. In the combined
analysis, freedom from recurrence (FFR), defined as the time between the date of diagnosis and the
date of first locoregional or distant recurrence, was the primary endpoint. Unlike BCSS and DFS,
FFR does not include death as an event, regardless of the cause of death.
In two of the other three cohorts in the combined analysis (MD Anderson (MDA) and National
Cancer Institute (NCI)), c-cyclin E expression had the strongest effect on FFR. In the Nottingham cohort,
c-cyclin E outperformed standard clinical biomarkers in terms of both FFR and BCSS.
Combined analysis of the two largest US clinical cohorts contributing to the multi-cohort study
has also been reported (MDA and NCI) [14]. Data from the Nottingham cohort are consistent with the
NCI and MDA cohorts. For example, there was 60% positive c-cyclin E staining in combined NCI/MDA
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analysis, compared to 59% in the Nottingham cohort. This demonstrates good reproducibility of
IHC measurement of cytoplasmic expression of cyclin E—an important factor when considering the
potential application of c-cyclin E status as a clinical biomarker.
In linewith theNottingham cohort, expression of c-cyclin E in the combined analysis of theNCI and
MDA cohorts was associated with tumor markers, such as grade, ER and PR, and was associated with
poor patient outcome. However, in the NCI/MDA analysis, c-cyclin E was only an independent marker
of recurrence-free and overall survival when combined with the downstream kinase, cyclin-dependent
kinase 2. In the NCI/MDA analysis, histological grade was also an independent prognostic factor.
Analysis of the Nottingham cohort of older women, in contrast, found that c-cyclin E was the
only independent prognostic biomarker, outperforming even tumor grade in terms of prognostic
value. Although c-cyclin E was not associated with age in any of the cohorts, overall findings from
the older Nottingham cohort suggest a greater biological effect of high c-cyclin E expression in the
older population. Breast cancer biology in the older population is considered more indolent, with
less aggressive phenotypic features and enrichment for ER expression. This suggests that c-cyclin
E has greater potential clinical utility in the older population and is better able to distinguish more
aggressive tumors that are likely to lead to death from breast cancer.
Findings from the current study support c-cyclin E as a robust and reproducible biomarker of an
aggressive disease course. The findings suggest that clinical outcomes of older women with primary
breast cancer can be predicted from the biology of their tumor using c-cyclin E alone. Older patients
with c-cyclin E-negative tumors are unlikely to die of their breast cancer. At ten years, only 8 patients
out of 100 will die of their breast cancer if their tumor is c-cyclin E-negative. For many older patients,
this finding will directly impact clinical decision-making.
Alongside existing clinical decision-making tools such as comprehensive geriatric assessment
scales and biomarkers of treatment response such as ER expression, there is clear potential to utilize
tumor c-cyclin E expression in the clinic. For example, c-cyclin E positivity may indicate a requirement
for an aggressive initial treatment strategy, in terms of surgical management of the primary tumor and
axillary lymph nodes, and the need for adjuvant therapy.
Although the clinical setting of the current study is patients selected to undergo initial surgery,
who are more likely to have ER-negative tumors, it may be possible to extrapolate its findings on the
value of c-cyclin E as a marker of aggressive disease biology to other clinical scenarios.
For example, ER/PR+ primary tumors that do not express c-cyclin E may be adequately treated by
primary endocrine therapy. Alongside comprehensive geriatric assessment, c-cyclin E may serve as a
biomarker in this context for patients who, because of comorbidity, psychosocial factors or individual
choice, would prefer not to undergo initial surgery. Given the high proportion of older patients already
receiving primary endocrine therapy (up to 40% of UK patients in the previous decade), there is a
compelling case to investigate this hypothesis in prospective clinical trials [17].
In adjuvant therapy decision-making, c-cyclin E could supplement or replace gene expression
predictors of chemotherapy response (e.g., Oncotype Dx and MammaPrint). Additionally, as
cyclin-dependent kinase 2-targeting treatments, e.g., dinaciclib, emerge from early phase clinical
trials, there may be a role for these drugs in older patients in preference to chemotherapy [18,19].
It is reported that c-cyclin E mediates resistance to endocrine therapy with aromatase inhibitors
(AIs) in breast cancer [20]. This study suggests that c-cyclin E may identify ER/PR+ tumors that are
unresponsive to AIs, which do not induce a cytostatic effect.
For patients with ER+ disease, evidence from the current study suggests that adjuvant endocrine
therapy negates the poor prognostic effect of c-cyclin E positivity. This implies that extending adjuvant
therapy beyond 5 years would improve long-term outcomes and would be a priority for patients with
c-cyclin E-positive tumors.
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4. Materials and Methods
Over a 37-year period (1973–2010), 1758 older (≥70 years) women with stage I–II primary breast
cancer were managed in a dedicated facility in Nottingham, as previously described [21]. Of these
patients, 813 underwent primary surgery.
Good quality formalin-fixed, paraffin embedded tissue from 575 tumors was available, from
which 517 were successfully incorporated into a tissue microarray (TMA), as previously described [22].
Briefly, representative 0.6mm diameter cores were implanted in the TMA block using Beecher’s manual
tissue microarray (MP06 Beecher Instruments Inc., Sun Prairie, WI, USA).
Clinical informationwas available fromdiagnosis to death or last follow-up. Patient clinicopathological
characteristics are summarized in Table 1. Median follow-up was 6.3 years (95% CI, 6.1–7.1 years).
The TMA was used to test expression of a panel of biomarkers by IHC, using the StreptAvidin
Biotin Complex and EnVision methods, which have been extensively described [4]. Biomarkers tested
in Nottingham included ER, PR, HER2, Ki67, Bcl2, BRCA1, BRCA2, E-Cadherin, EGFR, LKB1, MDM2,
MDM4, MUC1, p53, VEGF and cytokeratin markers CK5, CK5/6, CK14, CK17 and CK18.
Staining of the biomarker panel was assessed as previously reported [4]. Cytoplasmic staining
for cyclin E was centrally assessed at MD Anderson Cancer Center as previously described, using
Santa Cruz clone C-19 polyclonal antibody to cyclin E [15]. TMA results were interpreted by two
independent pathologists blinded to clinical outcome and assigned according to percentage of cells
stained and intensity of staining. Cut-off values for all biomarkers were as reported in our previous
studies [4,14].
Conventional pathological parameters as part of standard reporting for surgical specimens at
Nottinghamweremeasured, including size, grade andaxillary stage (regional lymphnode involvement).
The policy of axillary surgery evolved according to clinical evidence-based guidelines over the 37-year
period of sample collection, as previously described [21].
The primary endpoint was breast cancer-specific survival (BCSS), defined as time from diagnosis
to last follow-up or death from breast cancer (i.e., excluding death due to competing causes). Secondary
endpoints included disease-free survival (DFS), defined as time from diagnosis to first recurrence, and
overall survival (OS), defined as time from diagnosis to last follow-up or death from any cause.
The bioinformatics software X-Tile was used to define thresholds for biomarker positivity,
as previously described [23]. Biomarker expression was compared between groups by χ2 test.
Kaplan–Meier survival analysis was performed using logrank and generalized Wilcoxon tests.
Multivariate analysis of BCSS was performed using the Cox regression model. Statistical significance
was defined as p < 0.05. Reporting adhered to reporting recommendations for tumor marker prognostic
studies (REMARK) criteria [24].
This research was conducted in accordance with the Declaration of Helsinki. The study protocol
was approved by the Institutional Review Boards of the University of Nottingham, Nottingham
University Hospitals NHS Trust and the University of Texas MD Anderson Cancer Center (MDA ref.33).
5. Conclusions
This study highlights the clinical value of tumor c-cyclin E status as a strong predictor of the
biological course of primary breast cancer in older patients. Those who present with c-cyclin E-negative
tumors are unlikely to die of their breast cancer. Alongside existing tools such as geriatric assessment
and biomarkers of treatment response such as ER positivity, c-cyclin E status may assist initial therapy
decision-making in terms of intensity, duration and modality. These hypotheses warrant prospective
clinical evaluation in the specific clinical context of primary breast cancer in older women.
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Abstract: Background: Breast cancer in very young women (BCVY) defined as <35 years old, presents
with different molecular biology than in older patients. High HDAC5 expression has been associated
with poor prognosis in breast cancer (BC) tissue. We aimed to analyze HDAC5 expression in BCVY
and older patients and their correlation with clinical features, also studying the potential of HDAC5
inhibition in BC cell lines. Methods: HDAC5 expression in 60 BCVY and 47 older cases were analyzed
by qRT-PCR and correlated with clinical data. The effect of the HDAC5 inhibitor, LMK-235, was
analyzed in BC cell lines from older and young patients. We performed time and dose dependence
viability, migration, proliferation, and apoptosis assays. Results: Our results correlate higher HDAC5
expression with worse prognosis in BCVY. However, we observed no differences between HDAC5
expression and pathological features. Our results showed greatly reduced progression in BCVY cell
lines and also in all triple negative subtypes when cell lines were treated with LMK-235. Conclusions:
In BCVY, we found higher expression of HDAC5. Overexpression of HDAC5 in BCVY correlates with
lower survival rates. LMK-235 could be a potential treatment in BCVY.
Keywords: breast cancer; young women; histone deacetylase; HDAC5 inhibitors; LMK-235
1. Introduction
Breast cancer is the most common cancer among women worldwide [1]. As a percentage of all
cancers in young women, breast cancer rates increase during the third and fourth decades of life, from
2% at age 20 to more than 40% by age 40. This abrupt increase is attributable to routine screening
mammography. Breast cancer incidence is similar among young women in both developed and
developing countries [2], but in recent years, there has been an increase in breast cancer diagnoses
in very young women [3]. The distribution of breast cancer subtypes and grades changes with
age, with more aggressive phenotypes among young women compared with older counterparts [4].
Basal-like and Her2-enriched breast tumors are also more common in young than in older women [5].
Scientific evidence suggests that age at breast cancer diagnosis represents an independent prognostic
Cancers 2020, 12, 412; doi:10.3390/cancers12020412 www.mdpi.com/journal/cancers119
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survival factor [6]. Indeed, multiple studies conclude that early age at diagnosis of breast cancer is
highly associated with an increased risk of recurrence and death [7].
Epigenetic modifications are reported to play an important role in the onset and progression of
many diseases. Carcinogenesis can be explained by genetic alterations, but epigenetic processes such
as DNA methylation, histone modifications, and non-coding RNA deregulation are also involved [8].
Histone deacetylases are essential for global acetylation patterns in the nucleus and the epigenetic
regulation of gene expression [9]. Histone deacetylases (HDACs) have been stratified into classes I, IIA,
IIB, III, and IV and increased expression of these isoenzymes has been observed in different tumors,
also often associated with poor outcome [10–13]. It has been reported several times that their levels
vary greatly in cancer cells and differ according to tumor type. Of the 18 human HDACs, HDAC5
(a class IIa HDAC) is involved in synoviocyte activation, neural regeneration and repair, differentiation
of myoblasts, and recently, elevated expression of HDAC5 has been correlated with worse prognosis in
patients with breast cancer (BC) [14].
Histone deacetylase inhibitors (HDACi) are currently acquiring importance in cancer treatment,
being the only approved epigenetic therapy in clinics altering histone proteins to date. HDACi have been
classified into four groups depending on their structure: Hydroxamic acids, cyclic peptides, benzamides,
and short chain fatty acids. The hydroxamic acids (vorinostat, belinostat, and panobinostat) have been
approved by the FDA as anticancer treatments. However, they are limited by their nonspecificity,
affecting all HDACs [15]. These are known as pan-HDAC inhibitors and may also cause numerous
side effects due to their broader specificity. Therefore, in some cases, more selective inhibitors may be
more effective in therapy [16–19].
A previous study based on evaluation of new HDAC inhibitors identified LMK235
(N-((6-(hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide) as the most cytotoxic compound,
displaying equipotent HDAC inhibition in pan-HDAC assay when compared to vorinostat. In contrast
to vorinostat, LMK235 showed a novel HDAC isoform selectivity profile with a preference for HDAC4
and HDAC5 [20].
Previous group studies showed significant differences in miRNA expression [21] and
methylation [22] profiles among breast cancer affecting very young women (<35 years) (BCVY)
and breast cancer in older patients (>45 years) (BCO). Additionally, our group observed considerable
hypomethylation of CpG regions thatwere regulatingHDAC5 expression in BCVY, and thismethylation
was related to significant HDAC5 overexpression in BCVY patients [23]. In the present study, we
analyse HDAC5 expression in a large cohort of BC patients, to clarify the correlation between HDAC5
overexpression and relapse and survival in BCVY and BCO and the inhibitory effect of LMK-235 in
breast cancer cell lines from very young and older women with BC.
2. Results
2.1. Clinical-Pathologic Characteristics of Patients
A total of 107 patients were included, 60 were young women under 35 years (BCVY) and 47
samples from women over 45 years (BCO). The median age at breast cancer diagnosis in the young
patient’s group was 32 years (range, 20–35), and in the old patient’s group was 69 years (range,
53–94). Hereditary cases with BRCA1 and BRCA2 mutations were excluded from the study. In BCVY
cohort, the immunohistochemical analyses showed 39.9% (n = 24) of luminal patients, 11.6% (n = 7)
HER2-positive, 21.6% (n = 13) luminal/HER2 and 23.3% (n = 14) triple negative. In BCO group, 59.5%
(n = 28) of patients were luminal, 10.6% (n = 5) HER2-positive, 10.6% (n = 5) luminal/HER2 and 17%
(n = 8) presented triple negative subtype. Median follow-up was 93.4 months (Table 1).
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Table 1. Clinicopathological information of breast cancer (BC) samples and statistical results from the
study of HDAC5 expression vs. clinicopathological features by age groups.
BCVY p-Value(HDAC5 ~ CP) BCO
p-Value
(HDAC5 ~ CP)
N 60 47
Age mean (years ± SD) 32.1 ± 3.3 69.8 ± 9.3
Histological subtypes (%) 0.46 0.40
Luminal A 16.6 27.6
Luminal B 23.3 31.9
TNBC 23.3 17.0
Luminal/HER2 21.6 10.6
HER2 11.6 10.6
Unknown 3.6 2.3
ER status (%)
ER+ 60.0 0.43 74.4 0.92
ER- 33.3 21.3
Unknown 6.7 4.3
PR status (%)
PR+ 50.0 0.44 57.4 0.44
PR- 43.3 38.3
Unknown 6.7 4.3
HER2 (%)
HER2+ 31.6 0.97 21.3 0.93
HER2- 61.6 74.5
Unknown 6.8 4.2
KI67 (%) 0.56 0.07
<15% 16.6 27.7
15–30% 28.3 32.0
>30% 38.3 27.7
Unknown 16.8 12.6
Grade (%) 0.16 2.8 × 10−3 **
I 13.2 23.3
II 49.1 41.9 **
III 37.7 34.9 *
Unknown
Tumour Size (%) 0.16 0.02 *
<2 cm 35.0 59.6
2–5 cm 40.0 23.4
>5 cm 20.0 8.5
Unknown 5.0 8.5
Axillary Affection (%) 0.98 0.17
POS 38.3 29.8
NEG 56.6 63.8
Unknown 5.1 6.4
Exitus (%) 13.8 0.12 13.3 0.19
Relapse (%) 25.0 0.27 21.0 0.15
N: Sample size; SD: Standard deviation; TNBC: Triple negative subtype; ER: Estrogen receptor; PR: Progesterone
receptor; BCVY: Breast cancer in very young women; BCO: Breast cancer in older women. P-values indicate statistics
for the differences among HDAC5 expression and the different clinicopathological (CP) features included in the
table by age groups. * p-value < 0.05, ** p-value < 0.01.
2.2. HDAC5 Overexpression in BCVY Patients Correlates with Poorer Prognosis
HDAC5 was significantly overexpressed in BCVY patients (p-value = 0.04) (Figure 1A). We found
no appreciable differences among clinical features and HDAC5 expression, apart from tumor grade
in BCO patients (p-value = 2.8 × 10−3) where the lower grades presented higher HDAC5 expression
(Figure S1A). Regarding molecular subtypes, we observed higher HDAC5 expression in Luminal B
and HER2 tumors from BCVY in comparison with BCO patients from the same subgroups. While
BCO patients presented higher expression for Luminal A and Luminal/HER2 comparing to BCVY
(Figure S1B). Despite no significant association, these results agree with higher expression of HDAC5
for poor prognostic subtypes for each patient age groups in our cohort, that were HER2 for BCVY and
Luminal/HER2 for BCO patients.
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We observed similar percentages of cancer death between young and old patients, 13.8% (n = 9)
and 13.3% (n = 6), respectively. However, HDAC5 was significantly overexpressed in BCVY patients
that died in comparison with BCO (p-value = 0.04) and a significant HDAC5 overexpression was
observed for BCO patients that survive when compare with BCO patients that died (p-value = 0.01)
(Figure 1B). These results were in line with survival studies, where Kaplan–Meier curves showed a
reduced survival trend for BCVY when HDAC5 was overexpressed (Figure 2A) whereas BCO women
presented poorer survival when HDAC5 was repressed (Figure 2B). In terms of relapse, results were
not as evident as survival (results not shown). For survival and relapse studies, samples were classified
in high, medium or low, according to HDAC5 expression. Despite no significant results observed for
BCVY patients, survival studies indicated an important trend of worst survival for BCVY, contrary to
the results observed for BCO. In this regard, HDAC5 overexpression in BCVY could be related with the
poorer outcome at this age group. It is worth to mention that the number of BC patients that experience
relapse and/or death was reduced and further studies should be addressed in order to validate this
tendency observed.
Figure 1. HDAC5 expression in BCVY (n = 60) and BCO (n = 47) patients analyzed by qRT-PCR (A).
HDAC5 expression in BCVY and BCO patients regarding their status (exitus or no exitus) (B). BCVY:
Breast cancer in very young women; BCO: Breast cancer in old women. * p ≤ 0.05, ** p ≤ 0.01.
Figure 2. Association of HDAC5 expression and survival in breast cancer patients. Survival curves
for HDAC5 expression in BCVY (n = 42) (A) and BCO patients (n = 28) (B). HDAC5 expression was
classified in high (red), medium (blue) or low (green). BCVY: Breast cancer in very young women; BCO:
Breast cancer in old women. * p ≤ 0.05.
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2.3. LMK-235 Inhibitor Reduces Proliferation in BC Cell Lines
Breast cancer cell lines were exposed to increasing concentrations of HDAC5 inhibitor LMK-235
(0, 0.625, 1.25, 2.5, 5, 10, and 20 μM) for 24, 48, and 72 h. We observed that relative proliferation
decreased in a dose- and time-dependent manner for some breast cancer cell lines (Figure 3). After 48 h
treatment with low doses of LMK-235 (Figure 3A), cell viability of MDA-MB-231 and HCC1806 cell
lines was severely compromised. Additionally, viability was notably diminished in the HCC1937 cell
line after 72 h of treatment, showing similar results to MDA-MB-231 and HCC1806 cell lines (Figure 3B).
Although no significant results were obtained for HCC1500 cell line after 48 h of treatment, the young
cell line showed a 50% reduction in viability after 72 h of low dose LMK-235. Breast cancer cell lines that
experienced significant viability reduction were triple negative subtype with the exception of HCC1500
luminal cell line established from young BC patients and showed higher reduction in comparison with
the older luminal cell lines, MCF7 and BT474. Inhibitor studies reveal important response for triple
negative BC cell lines to LMK-235 and for luminal cell lines from young women with BC not observed
in older luminal cell lines.
Figure 3. Effects of LMK-235 treatments in BC cell proliferation. Cell proliferation was determined
by MTT assay for HCC1500 and HCC1937 (<35 years old) and MDA-MB-231, MCF-7, HCC1806, and
BT-474 (>45 years old) cell lines that were treated with LMK-235 (0 to 20 μM) for 48 hours (A), 72 h (B).
Points indicate the mean of at least three independent experiments and the standard deviation.
2.4. Reduced Migration of Breast Cancer Cell Lines Treated with LMK-235 Measured by Wound-Healing Assay
Wound-healing assays demonstrated that LMK-235 significantly inhibited migration in HCC1937
(p-value = 0.01), HCC1806 (p-value = 4.9 × 10−7) and MDA-MB-231 (p-value = 1.2 × 10−3) breast cancer
cell lines after 48 h of treatment. Specifically, we observed ~23% less cell migration in the HCC1937 cell
line, ~14.7% for MDA-MB-231, and also HCC1806 cell line showed a substantial reduction. HCC1500
cells treated with LMK-235 presented cell migration reduced by ~5.3%. However, the last cell line
exhibited considerable cell death at 48 h of cell treatment making wound-healing analysis difficult.
In contrast, breast cancer cell lines MCF-7 and BT474, both from luminal old BC patients, showed
insignificant cell migration reduction when cells were treated with LMK-235 (Figure 4).
These results revealed higher cell migration and proliferation reduction in cell lines from
triple negative subtypes (MDA-MB-231, HCC1806, and HCC1937), independently of age. However,
we observed markedly diminished viability in the young and luminal HCC1500 cell line treated
with HDAC5 inhibitor, which could not be detected in the luminal subtypes from older cell lines
(MCF7 and BT474).
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Figure 4. Effects of LMK-235 treatments in BC cell migration. Cell migration was assessed by scratch
wound-healing assay after treatment with LMK-235 (20 μM) for 48 h. Images of cell migration at 0 h
and 48 h after LMK-235 (20 μM) treatment (A); Percentage of wound closure after 48 h of LMK-235
(20 μM) treatment or DMSO/control. Three separate experiments were conducted, and representative
results are shown (B). Columns mean ± SD of the percentage of wound closure in the three independent
experiments. Black bars represent control DMSO cells and grey bars represent cells treated with
LMK-235. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 statistically significant. TNBC: Triple negative breast
cancer; BCVY: breast cancer in very young women; BCO: Breast cancer in old women.
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2.5. Apoptosis AfterLMK-235 Treatment
To confirm the results obtained by MTT, we performed an apoptosis assay by flow cytometry.
After 48 h of treatment, similar results to the MTT assay were observed. Results show increasingly early
apoptosis in most BC cells lines after 48 h of LMK-235 (10 and/or 20 μM) treatment. Interestingly, and
in line with previous proliferation and migration results, the most important increase in apoptosis was
observed in triple negative cell lines from both BCVY and BCO. Intriguingly, LMK-235 induced a more
profound increase in HCC1500 cell death for higher concentrations than in MTT assay (Figure 5A).
These results agree with the wound-healing assay observations, where after 48 h of treatment most of
the HCC1500 cells were dead and no wound-healing analysis could be performed.
2.6. Accumulation of Acetyl-H3 After LMK-235 Treatment in Breast Cancer Cell Lines
We observed increased HDAC5 mRNA expression in all breast cancer cell lines that were treated
with LMK-235 (Figure 5B). These results confirm that the HDACi does not act at the mRNA level, but
rather at the protein level. LMK-235 induces an increase in mRNA expression as a positive feedback
mechanism in order to increase and restore protein expression. Additionally, HDAC5 expression
was higher in control/DMSO conditions for all BC cell lines independently of their response to the
HDAC5 inhibitor.
Figure 5. Percentages of apoptosis are shown after treatment with LMK-235 (0.6 to 20 μM) or DMSO for
48 h. Apoptosis was analyzed by triplicated and SD was calculated (A); Expression of HDA5 in breast
cancer cell lines treated with LMK-235 (20 μM) and DMSO control (B); Accumulation of acetyl-histone
H3 after 48 h of LMK-235 (20 μM) treatment in breast cancer cell lines examined by western-blot.
The levels of acetyl-histone H3 were determined by western blot. GAPDH was used as a loading control
(C). Densitometry western bolt analyzed by ImageJ software (D). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
To investigatewhether the changes inHDAC5mRNA expression are reflected in persistent changes
at their protein levels, these were determined in breast cancer cell lines by western-blotting following
treatment with LMK-235 (20 μM) for 48 h. The levels of HDAC5 protein were barely detectable for
all cell lines, as previously observed in other studies [14,24] that showed the low quantity of HDAC5
protein by western blot (data not shown). Next, we measured HDAC5 activity at the acetylation of
lysine residues on histone H3 to determine the inhibitory effect of LMK-235 on HDAC5. Western-blot
studies showed accumulation of acetyl-histone H3 in breast cancer cell lines after 48 h of LMK-235
treatment (Figure 5C,D). We observed acetyl-histone H3 accumulation both in luminal breast cancer
cell lines (BT474, HCC1500 and MCF7) and in triple negative breast cancer cell lines (HCC1937 and
MDA-MB-231). These results demonstrate that LMK-235 specifically inhibits HDACs, which catalyze
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the removal of acetyl groups from N-acetyl lysine histone residues. Therefore, their inhibition produces
an accumulation of acetyl-histones and acetyl-H3 is one of the most extensively modified.
3. Discussion
BCVY can be understood as a unique and different entity from breast cancer in older people,
not only because of patients’ characteristics (where aspects such as fertility preservation must take
into account) but also in its biological and molecular tumor characteristics. Our group has focused
for years on the study of these differential molecular characteristics in breast cancer tumors of young
and old women. Previous results [23] showed us that HDAC5 was notably overexpressed in BCVY.
We validate this issue analyzing HDAC5 overexpression in a larger cohort of young patients under
35 years and over 45, as well as studying the correlation of HDAC5 expression levels with different
clinic-pathological features. Additionally, we analyzed the effects of an HDAC5 inhibitor, LMK-235,
on apoptosis, proliferation, and migration in breast cancer cell lines.
Histones are acetylated on lysine side chains, which neutralizes lysine’s positive charge, leading to
open chromatin structure by reducing interaction between histone and negatively charged DNA [25,26].
Thus, histone acetylation increases the accessibility of proteins such as transcription factors to promoters
and enhancers, thereby mediating active gene expression. Acetylated histones also function as
binding sites for numerous proteins with bromodomains, which often activate gene transcription [25].
In contrast, histone deacetylation is associated with chromatin condensation and transcriptional
repression [25]. Analogous to histone methylation, histone acetylation is reversibly controlled by two
large enzyme families: histone lysine acetyltransferases (KATs) and HDACs.
Turning to HDAC5, high expression has been correlated with poorer prognosis in patients with BC
or pancreatic neuroendocrine tumors and has been attributed to oncogenic effects [27,28]. Specifically,
HDAC5 overexpression has been correlated with triple negative BC tumors [14,29]. However, our
study showed higher HDAC5 expression in BCVY than BCO samples. Next, we wonder whether
HDAC5 overexpression was correlated with relapse and survival, and other clinical and pathological
data. BCVY patients with HDAC5 overexpression showed a higher risk of exitus, whereas results were
contrary for BCO that showed a significant risk of death when HDAC5 was repressed. In agreement
with these results, higher HDAC5 expression was observed in BCVY samples that died whereas lower
expression was found in BCO patients that die. Our results reinforce the hypothesis that HDAC5
overexpression in BCVY patients is related with a poor outcome observed in this group of age. BCVY is
not a usual diagnosis, so there is a limitation in the number of BCVY samples and the present study is
actually the first report that includes one of the highest cohort of BCVY patients in comparison with
other larger datasets (ex., TCGA and METABRIC [30,31]).
Next, we evaluated HDAC5 expression and its correlation with different clinical and pathological
features (histologic subtypes, Ki67, tumor size, grade, and axillary affection). We found no correlation
between HDAC5 expression and clinical features in BCVY. The only meaningful association observed
was between HDAC5 downregulation and higher tumor grades (II and III) in BCO. Higher tumor
grades are associated with poorer prognosis and in our study with HDAC5 repression for BCO,
which agrees with survival tendencies observed at this age group where HDAC5 repression correlates
with poorer survival in BCO.
HDAC inhibitors are the most widely investigated epigenetic drugs in clinical studies [32]. In vitro
studies suggest that the HDAC5 inhibitor LMK-235 could be a novel therapeutic strategy for BC
treatment [14]. We evaluated the inhibitory effect of LMK-235 in breast cancer cell lines from young
women and compared it with breast cancer cell lines from older counterparts. Our results demonstrated
that LMK-235 induced important reduction in progression, migration, and apoptosis, not only in triple
negative young and old but also in luminal young cell lines. Regarding that, we observed important
viability reduction under treatment conditions for the cell lines that presented significant differences in
the migration assay between control and treatment conditions. These results were observed in triple
negative cell lines (from young and old patients). Thus, the reduction in cell viability correlates with a
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reduction in cell migration under LMK-235 treatment. Interestingly, the luminal cell lines from old
patients (BT474 and MCF7) were not affected by LMK-235 inhibitor. However, the luminal young cell
line HCC1500 presented intermedium results between triple negative and luminal old cell lines. These
results point out a potential breast cancer treatment not only for triple negative breast cancer but also
for young patients from different molecular subtypes.
Additionally, LMK-235 response was lower in ER-positive cell lines, except for HCC1500 which
presented an intermedium response in comparison with the rest of ER-positive cells, as we previously
mentioned. Previous studies found LMK-235 response in triple negative BC cell lines [33–36]. However,
our results showed an important response to LMK-235 in the breast cancer cell line from young women
that present luminal subtype, as HCC1500. These results suggest an effect of ER in the LMK-235
treatment but must exist other mechanisms in young cell lines that increase the effect of LMK-235,
which are not present in older cell lines. There was a pronounced time- and dose-dependent decrease
in cell viability and migration and hence an increased apoptosis in all breast cancer cell lines from
triple negative subtypes (BCVY and BCO). Furthermore, HCC1500 luminal BCVY cell line presented
similar results, showing significant apoptosis rates and reduced cell viability, avoiding the possibility
of analyzed migration wound-healing assays. It is worth to mention that LMK-235 treatment induces
higher apoptosis in HCC1500 cell line at lower doses in comparison with the rest of cell lines. These
results suggest the existence of off-target effects that increase the apoptosis at this cell line, so further
studies are required to analyze the underlying mechanisms of LMK-235 inhibitor.
These results reinforce the hypothesis that HDAC5 is involved in tumorigenesis and cancer
progression reducing survival, specifically in BCVY. We propose studying HDAC5 inhibitors like
LMK-235 in a larger cohort of breast cancer cell lines from young and old women and from different
molecular subtypes in order to evaluate their inhibitory effect. Additionally, cell lines studies show a
significant response to HDAC5i of triple negative BCO in addition to all BCVY cell lines independently
of their molecular subtype.
4. Materials and Methods
4.1. Patient Selection
All samples included in the study were archived formalin-fixed paraffin-embedded (FFPE) BC
tissues stored at the Hospital Clínico Universitario of Valencia, Spain. We selected 60 breast cancer
samples from women under 35 years old (BCVY) and 47 samples from women over 45 (BCO).
The clinical characteristics of patients are included in Table 1. This study was approved by the
Institutional Health INCLIVA-Hospital Clínico Ethics Committee and informed consent was obtained
from all subjects. The code of the ethical committee of the Hospital Clínico Universitario of Valencia
(Spain) is 2013/128.
All patients’ clinical data and tumor pathological characteristics were collected at their first
visit and information about relapse and survival on subsequent visits. Tumor size and lymph node
involvement were assessed using the eighth edition of the American Joint Committee on Cancer staging
manual [37]. Patient clinicopathological data used in this study are shown in Table 1.
4.2. Breast Cancer Cell Lines Culture and Treatment
Breast cancer cell lines were obtained from the American Type Culture Collection (ATCC,
Rockville, MD, USA). Cell lines were cultured in RPMI 1640 or DMEM medium supplemented with 1%
L-glutamine and 10% fetal bovine serum (GIBCO, New York, NY, USA). The culture conditions were
identical in all cell lines: 37 ◦C and 5% CO2 (Table 2). Cells were seeded for 24 h before treatment with
LMK-235 (Selleck Chemicals, Houston, TX, USA) or DMSO (control) for MTT assay, wound-healing,
and apoptosis assay.
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Table 2. Cell lines characteristics and culture conditions.
Cell Line Subtype ReceptorExpression
Tumor
Type Age
Culture
Medium Conditions Supplements
HCC 1500 Luminal ER, PR IDC 32 RPMI 5% CO237 ◦C
1% L-glu
10% FBS
HCC1937 Basal EGP2 IDC 24 RPMI 5% CO237 ◦C
1% L-glu
10% FBS
MDA-MB-231 Basal EGFR,TGF-β Carcinoma 51 RPMI
5% CO2
37 ◦C
1% L-glu
10% FBS
MCF7 Luminal ER, IGFBP IDC 69 RPMI 5% CO237 ◦C
1% L-glu
10% FBS
BT474 Luminal ER, PR,HER2 IDC 60 DMEM
5% CO2
37 ◦C
1% L-glu
10% FBS
HCC1806 Basal EGP2 Carcinoma 60 RPMI 5% CO237 ◦C
1% L-glu
10% FBS
10% FBS
EGP2: Epithelial glycoprotein 2; EGFR: Epidermal growth factor receptor; TGF-β/α: transforming growth factor
β/α; ER: Estrogen receptor; PR: Progesterone receptor; HER2: Hormonal estrogen receptor 2; IGFBP: Insulin growth
factor binding protein; RPMI: RPMI 1640 medium; FBS: Fetal bovine serum; L-glu: L-glutamine; IDC: Invasive
ductal carcinoma.
4.3. Cell Proliferation Assay
The protocol used is based on a colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. We seeded and cultured 2000 cells in 96-well plates. Next, cells
were treated with a specific drug dose, and MTT assay was performed 24, 48, and 72 h after treatment.
The absorbance of this colored solution was quantified by measuring at 590 by spectrophotometer. Each
experiment was performed in triplicate and repeated at least twice. Average values for triplicates were
calculated. Absorbance observed at different drug concentrations was compared with the respective
non-treated controls and cell viability was calculated.
4.4. Scratch Wound-Healing Assay
Cells were seeded in six-well plates at a density of 5 × 105 cells/well and incubated overnight until
they reached 70% confluence. A pipette tip was used to generate a wound in the cell layer. Cells were
then treated with LMK-235 (20 μM). Each experiment was performed in triplicate and repeated at least
twice. Images were obtained at 0, 24 and 48 h at the same position and percentage of cell migration
was evaluated using ImageJ (LOCI, University of Wisconsin).
4.5. Apoptosis Assay by Flow Cytometry
We plated 100,000 cells in 12-well plates. After 48 h of treatment, trypsinized and floating cells
collected from the supernatant were centrifuged and incubated with Annexin V-FITC (BioLegend,
San Diego, California, United States) and DAPI for 15 min. Apoptosis was detected using Flow
Cytometry BD LSRFortessa™ (BD, Franklin Lake, NJ, USA).
4.6. Western Blot
We then prepared the nuclear protein fraction of breast cancer cell lines using a nuclear extraction
kit (Active Motif, Belgium, Germany). A total of 40 μg of protein were resolved by 12% SDS-PAGE and
transferred onto nitrocellulose membranes. Membranes were blocked in 5% BSA and hybridized with
antibodies against aceyl-H3 (1:1000) and GAPDH (1:1000) as a loading control. Immunoreactive bands
were visualized by chemiluminescence (GE Healthcare, Life Science, Oslo, Norway) and captured by
Image Quant™ LAS4000 (GE Healthcare, Life Science, Oslo, Norway). The band densities, normalized
to the GAPDH, were analyzed with ImageJ software.
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4.7. RNA Extraction
Total RNA from BC cell lines was isolated using the High Pure RNA Isolation Kit (Roche, Basel,
Switzerland), following the manufacturer’s protocol. Total RNA from FFPE samples was isolated
using RecoverAll Total Nucleic Acid Isolation Kit (Applied Biosystems™ by Life Technologies™,
Carlsbad, CA, USA), following the manufacturer’s protocol. RNA concentration was measured using a
NanoDrop ND 2000-UV-vis Spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE, USA).
4.8. Gene Expression by qRT-PCR
Gene expression ofHDAC5 andGAPDH as endogenous controlwas carried out by quantitative real
time-PCR (qRT-PCR) in RNA extracted from FFPE samples. We used the TaqMan®Gene Expression
Assays (Applied Biosystems™ by Life Technologies™, Carlsbad, CA, USA). Normalization was done
with GAPDH. The data were managed using the QuantStudio Desing & Analysis Software v1.4
(Applied Biosystems™ by Life Technologies™, Carlsbad, CA, USA). Relative expression was calculated
using the comparative Ct method and obtaining the fold-change value (ΔΔCt).
4.9. Statistical Analysis
All statistical analysis was performed using R Bioconductor (https://www.bioconductor.org/).
To determine differences between HDAC5 expression and breast cancer patients/cells from different
ages we performed a Wilcoxon Rank Sum test. Results were considered significant when p-value < 0.05.
OS and RFS were performed using follow-up data from BC patients to analyze the prognostic value of
HDAC5 expression in terms of relapse and survival. Patients were divided into three groups according
to the distribution of the log10HDAC5 Fold change: high expression (> 0.2 log10 Fold change), medium
(> −0.2 and <0.2) and low (< −0.2). RFS and OS studies were performed using survival R package
(https://CRAN.R-project.org/package=survival).
5. Conclusions
Taken together, the results provide insights into the biology of breast cancer in younger women
and support our hypothesis that breast tumors of younger women activate molecular pathways
related to increased aggressiveness, such as HDAC5. Our findings are consistent with those previously
published by Li et al. [14], confirming that HDAC5 promotes proliferation, invasion, and migration in
human breast cancer. We also demonstrate that HDAC5 overexpression in BCVY correlates with lower
survival rates.
In our study, we show that targeted treatment with HDAC5 inhibitor LMK-235 reduces migration
and proliferation of tumor cells and increases apoptosis in triple negative breast cancer cell lines,
as previous results demonstrated, and as a novelty in luminal cell lines from younger BC patients.
In summary, our findings show, for the first time, a potential treatment specific for breast cancer affecting
very young patients. However, more efforts should be addressed to analyze its therapeutic role.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/2/412/s1,
Figure S1: HDAC5 expression according to tumor grade in breast cancer affecting very young patients (BCVY)
and old patients (BCO) (A). HDAC5 expression according to breast cancer age groups and molecular subtypes (B).
*P ≤ 0.05, **P ≤ 0.01.
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Abstract: This study evaluated the clinical significance of the lymph-node ratio (LNR) and its
usefulness as an indicator of supraclavicular lymph-node radiation therapy (SCNRT) in pN1 breast
cancer patients with disease-free survival (DFS) outcomes. We retrospectively analyzed the clinical
data of patients with pN1 breast cancer who underwent partial mastectomy and taxane-based
sequential adjuvant chemotherapy with postoperative radiation therapy in 12 hospitals (n = 1121).
We compared their DFS according to LNR, with a cut-off value of 0.10. The median follow-up period
was 66 months (range, 3–112). Treatment failed in 73 patients (6.5%) and there was no significant
difference in DFS between the SCNRT group and non-SCNRT group. High LNR (>0.10) showed
significantly worse DFS in both univariate and multivariate analyses (0.010 and 0.033, respectively).
In a subgroup analysis, the effect of SCNRT on DFS differed significantly among patients with
LNR > 0.10 (p = 0.013). High LNR can be used as an independent prognostic factor for pN1 breast
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cancer patients treated with partial mastectomy and postoperative radiotherapy. It may also be useful
in deciding whether to perform SCNRT to improve DFS.
Keywords: breast cancer; radiotherapy; lymph-node ratio; disease-free survival
1. Introduction
In addition to surgery, chemotherapy and radiotherapy are both important in curative breast
cancer treatment. Radiotherapy has a significant role in the removal of microscopic tumor cells from
remnant breast tissue after breast-conserving surgery [1]. Radiotherapy is used to treat not only
the remaining breast tissue, but also the tumor cells in the regional lymphatic system, including
the axillar and internal mammary lymph nodes. This prevents locoregional failure in patients with
breast-conserving surgery and lymph-node metastasis after axillary-lymph-node dissection. It can
also reduce distant metastasis [2]. The Danish Breast Cancer Cooperative Group reported the benefits
of radiation therapy targeting the supraclavicular area in high-risk breast cancer patients [3,4]. The
current guidelines generally recommend that elective nodal irradiation (ENI) be applied to the regional
lymphatics as well as the whole breast in locally advanced breast cancer [5–7].
The use of ENI in pathological N1 breast cancer patients is still controversial. Taxane-based
chemotherapy has been used as an effective adjuvant therapy for breast cancer for decades, reducing
the importance of elective nodal irradiation in low-risk breast cancer [8–10]. There is no consensus
on whether ENI should be administered to patients with a low risk of regional lymphatic metastasis,
such as those with N1 breast cancer [6,11–13]. The current National Comprehensive Cancer Network
(NCCN) guidelines also recommend that ENI be strongly considered in N1 breast cancer [14].
In a study based on existingKoreanRadiationOncologyGroup (KROG) 14-18 data, supraclavicular
lymph-node radiation therapy (SCNRT) was ineffective in N1 breast cancer patients undergoing
taxane-based chemotherapy [15]. However, several studies have reported that various risk factors affect
the outcomes of patients with N1 breast cancer, and claimed that ENI can be beneficial in patients with
N1 breast cancer, depending on the risk factors present [16–18]. The lymph-node ratio (LNR), defined
as the proportion of positive axillary lymph nodes among the total number of axillary lymph nodes
removed, is recognized as one of these risk factors. Although the absolute number of axillary lymph
nodes affected by metastasis is associated with a poor prognosis in the American Joint Committee
on Cancer (AJCC) guidelines, axillary-lymph-node dissection techniques may differ across different
institutions [19]. Therefore, the number of lymph nodes removed may differ, even when patients have
the same numbers of metastatic lymph nodes [20]. Several studies have investigated whether LNR
can be used to ensure more accurate nodal staging [19–21]. In a previous single-center retrospective
study that examined the relationship between LNR and SCNRT, LNR was found to have utility as an
indicator of the suitability of SCNRT [22]. Against this background, it was investigated whether LNR
can be used as an index of the suitability of SCNRT in multicenter studies.
2. Materials and Methods
2.1. Study Design and Patients
In this study, the records of patients diagnosed with N1 breast cancer who underwent
breast-conserving surgery between January 2006 and December 2010 at one of 12 hospitals that
are members of KROG were examined. Patients who underwent Adriamycin/Taxol (AT) chemotherapy
and post-lumpectomy radiotherapy for N1 breast cancer within this period were included in this study.
The eligibility criteria were patients with N1 breast cancer who underwent breast-conserving surgery
and axillary-lymph-node dissection, who completed postoperative AT chemotherapy and radiotherapy
as planned, and for whom information regarding the pathological features of the tumor was available.
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The exclusion criteria were patients who received neoadjuvant chemotherapy or chemotherapy other
than AT, had a previous history of malignancy, or were male. Patients with fewer than 10 dissected
lymph nodes in total were also excluded from the study to ensure accurate lymph node evaluation.
The Institutional Review Board of each participating hospital approved the current study.
The patient data collected were age; the pathological features of each tumor, such as the tumor size,
number of tumors, and resection margin; number of positive lymph nodes; histological grade; presence
of lymphovascular invasion; and expression status of the estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (HER2). Positivity for ER or PR was defined
as an Allred score of 3–8 on immunohistochemistry (IHC). HER2 positivity was defined as either 3+
on IHC staining or 2+ on IHC with a positive fluorescence in situ hybridization or chromogenic in
situ hybridization signal. The molecular subtype of each breast cancer was categorized as follows:
ER+ or PR+, and HER2− (luminal A); ER+ or PR+, and HER2+ (luminal B); ER−, PR−, and HER2+
(HER2 enriched); or ER−, PR−, and HER2− (triple negative). The optimal cut-off value for LNR was
determined with an analysis of the area under the curve (AUC) of a receiver-operating characteristic
(ROC) curve. A value of 0.10, for which the sensitivity and specificity were highest, was chosen as the
optimal cut-off point for LNR.
2.2. Treatments
In this study, patients who had undergone more than 10 lymph-node dissections after
axillary-lymph-node dissection were evaluated. The patients were treated with adjuvant chemotherapy
consisting of doxorubicin and cyclophosphamide, followed by paclitaxel or docetaxel, and then by the
appropriate adjuvant hormone therapy based on the presence of hormone receptors and the HER2
receptor. All patients underwent whole-breast irradiation (WBI) and tumor-bed boost, and SCNRT
was selected according to each institution’s policy or physician’s preference.
The dose of irradiation for the whole breast was 45.0–60.4 Gy at 1.8–3.0 Gy per fraction and
the dose for the tumor bed was 4.0–19.8 Gy at 1.8–4.0 Gy per fraction. The radiation dose to the
supraclavicular lymph nodes (SCN) was 45.0–50.4 Gy at 1.8–2.0 Gy per fraction. The borders of each
field of WBI or WBI+SCNRT were defined differently in the 12 hospitals according to each institutional
policy. The axillary lymph nodes were not intentionally irradiated, but level I and a proportion of level
II axillary lymph nodes were covered during WBI while a proportion of the level II and level III axillary
lymph nodes and the SCN were irradiated during SCNRT. The inclusion of the internal mammary
lymph node in the radiation field was determined according to each hospital′s policy, considering the
location of the primary tumor, pathologic findings, and status of the metastatic lymph nodes.
2.3. Follow-Up and Endpoints
Disease-free survival (DFS) was defined as the time from the date of diagnosis to any recurrence.
Thepatientswere followedupon every 3–6months after surgerywith history andphysical examinations
in each hospital. Mammography was performed every 12 months. Additional imaging studies were
performed in patients with suspicious clinical signs or symptoms.
2.4. Statistical Analysis
Data were analyzed with SPSS ver. 20.0 for Windows (SPSS Inc., Chicago, IL, USA). The
Kaplan–Meier method was used to analyze disease-free survival (DFS) and statistical significance was
determined with a log-rank test. Cox’s stepwise regression analysis was used for the multivariable
analysis. Statistically significant variables in the univariate analysis (p < 0.05) were included in the
Cox’s regression model. Statistical significance was set at p < 0.05.
3. Results
The characteristics of the patients with pN1 breast cancer are summarized in Table 1. In total, 1121
patients satisfied the inclusion criteria for this study and were enrolled. Among them, 745 patients did
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not undergo SCNRT and 376 patients did undergo SCNRT. The presence of an extensive intraductal
component (EIC), lymphovascular invasion (LVI), number of positive lymph nodes, LNR, and the
presence of an extracapsular extension (ECE) occurred significantly more frequently in the SCNRT
group than in the non-SCNRT group. LNR was statistically independent of other prognostic factors,
such as age, type of surgery, T stage, resection margin, LVI, molecular subtype, and histological grade.
Table 1. Patient characteristics.
Characteristics
Number of Patients (%)
p ValueNon-SCNRT SCNRT
(n = 745) (n = 376)
Age (years) ≤45 442 (59.3) 221 (58.8) 0.859
>45 303 (40.7) 155 (41.2)
OP site Left 343 (46.0) 193 (51.3) 0.094
Right 402 (54.0) 183 (48.7)
Pathology IDC 702 (94.2) 346 (92.0) 0.157
Others 43 (5.8) 30 (8.0)
T stage T1 388 (52.1) 181 (48.1) 0.282
T2 351 (47.1) 192 (51.1)
T3 6 (0.8) 2 (0.5)
T4 0 (0.0) 1 (0.3)
Number of Single 615 (82.6) 318 (84.6) 0.392
tumors Multiple 130 (17.4) 58 (15.4)
Resection Clear 682 (92.2) 351 (93.9) 0.588
margin Less than 1 mm 51 (6.9) 20 (5.3)
Positive 7 (0.9) 3 (0.8)
Unknown 5 2
EIC (−) 344 (71.2) 225 (63.9) 0.025
(+) 139 (28.8) 127 (36.1)
Unknown 262 24
LVI (−) 360 (49.0) 81 (24.0) <0.001
(+) 375 (51.0) 256 (76.0)
Unknown 10 39
HG I or II 452 (61.9) 235 (63.0) 0.725
III 278 (38.1) 138 (37.0)
Unknown 15 3
Anti-HER2 (−) 678 (91.0) 339 (90.2) 0.644
therapy (+) 67 (9.0) 37 (9.8)
Dissected <20 456 (61.2) 245 (65.2) 0.197
LNs ≥20 289 (38.8) 131 (34.8)
Number of 1 509 (68.5) 121 (32.2) <0.001
positive LNs 2 161 (21.7) 145 (38.6)
3 73 (9.8) 110 (29.3)
Unknown 2 0
LNR ≤0.10 599 (80.6) 189 (50.3) <0.001
>0.10 144 (19.4) 187 (49.7)
Unknown 2 0
ECE (−) 369 (52.4) 92 (31.8) <0.001
(+) 335 (47.6) 197 (68.2)
Unknown 41 87
Hormone (−) 172 (23.1) 86 (22.9) 0.917
therapy (+) 571 (76.9) 290 (77.1)
Unknown 2 0
Molecular Luminal A 498 (67.0) 247 (65.7) 0.19
subtype Luminal B 71 (9.5) 49 (13.0)
HER2-enriched 53 (7.1) 17 (4.5)
Triple negative 122 (16.4) 63 (16.8)
Unknown 1 0
Abbreviations: SCNRT, supraclavicular lymph node radiation therapy; OP, operation; IDC, invasive ductal
carcinoma; EIC, extensive intraductal component; LVI, lymphovascular invasion; HG, histologic grade; HER2,
human epidermal growth factor receptor 2; LNR, lymph-node ratio; ECE, extracapsular extension.
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The median follow-up time was 66 months (range, 3–112). The overall 5-year DFS was 93.7%.
The 5-year DFS in the subgroup was 92.8% in the SCNRT group and 94.1% in the non-SCNRT group.
The patterns of failure are shown in Table 2. Distant metastasis was the major pattern of failure, and
regional recurrence limited to the SCN occurred in less than 1% of the total patients.
Table 2. Patterns of failure.
Outcome No. Patients (%)
Follow-up (months)
Median (range) 66 (3–112)
Patterns of failure
NED 1048 (93.5)
LR only 8 (0.7)
RR only 5 (0.4)
DM only 45 (4.0)
LR + DM 1 (0.1)
RR + DM 11 (1.0)
LR + RR + DM 3 (0.3)
Abbreviations: NED, no evidence of disease; LR, local recurrence; RR, regional recurrence; DM, distant metastasis.
A univariate analysis of DFS showed that T stage, LVI, histological grade, luminal type, and
LNR were significant factors affecting DFS. In a multivariate analysis of these factors, T stage, LVI,
histological grade, and LNR significantly affected DFS (Tables 3 and 4).
A subgroup analysis according to SCNRT was performed to analyze the risk of recurrence
according to differences in LNR. In this analysis, the risk of recurrence differed significantly according
to LNR in the non-SCNRT group, but there was no such difference in the SCNRT group (Figure 1). The
use of SCNRT reduced the difference in the incidence of recurrence according to LNR.
Table 3. Univariate analysis of disease-free survival.
Characteristics No. (%) 5-Year DFS p Value
T stage T1 569 (50.7) 97.1 <0.001
T2–4 552 (49.2) 90.2
Number of Single 933 (83.2) 93.9 0.953
tumors Multiple 188 (16.8) 93.1
Resection ≥1 mm 1033 (92.1) 93.8 0.634
margin <1 mm 81 (7.2) 92.5
EIC (−) 569 (50.8) 94.8 0.213
(+) 266 (23.7) 91.8
LVI (−) 441 (39.3) 97.0 0.001
(+) 631 (56.3) 91.4
HG I or II 687 (61.3) 96.1 <0.001
III 416 (37.1) 89.9
LNR ≤0.10 788 (70.3) 94.9 0.010
>0.10 331 (29.5) 90.8
ECE (−) 461 (41.1) 92.7 0.110
(+) 532 (47.5) 94.9
Molecular Lumimal A 463 (41.3) 96.0 0.008
Subtype Non-luminal A 657 (58.6) 82.1
Abbreviations: EIC, extensive intraductal component; LVI, lymphovascular invasion; HG, histologic grade; LNR,
lymph-node ratio; ECE, extracapsular extension.
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Table 4. Multivariate analysis of disease-free survival.
Characteristics
Cox Regression Model p Value
Hazard Ratio 95% CI
T stage T1 vs. T2–4 2.628 1.489–4.638 0.001
LVI (−) vs. (+) 1.92 1.071–3.441 0.028
HG I or II vs. III 2.288 1.349–3.880 0.002
LNR ≤0.10 vs. >0.10 1.689 1.043–2.737 0.033
Molecular subtype Luminal A vs. non-luminal A 1.029 0.695–2.121 0.496
Abbreviations: LVI, lymphovascular invasion; HG, histologic grade; LNR, lymph-node ratio.
Figure 1. Kaplan-Meier estimates of recurrent rate according to LNR in SCNRT treatment subgroups.
4. Discussion
Although many studies have reported that ENI is not required by patients with pN0 breast cancer,
it is widely accepted that postoperative locoregional radiation therapy reduces locoregional recurrence
and mortality in patients with lymph-node-positive breast cancer [23]. However, its effectiveness in
N1 breast cancer patients treated with systemic chemotherapy is still unclear [24,25]. In this context,
the NCCN guidelines recommend the use of SCNRT in patients with N1 breast cancer as for level of
evidence IIB [14].
Appropriate chemotherapy for breast cancer patients not only prevents systemic metastasis of the
cancer, but also reduces the risk of locoregional recurrence [26]. The recurrence rate after treatment has
been steadily declining with the development of surgical and adjunct therapies, and questions about
the utility of SCNRT for early breast cancer patients have begun to emerge [27]. The frequency of
adverse effects, such as lymphedema, increases when SCNRT is used with systemic chemotherapy. A
previous study based on the KROG 14–18 patient data used in the present study showed that SCNRT
was unnecessary in the N1 patient group and increased adverse effects [15,28]. In the case of another
side effect, brachial plexopathy, the risk showed 1.3% in the conventional 50 Gy SCNRT group, but the
risk was increased with adjuvant chemotherapy or total dose over 50 Gy to the brachial plexus [29].
Although the risk is low, treatment failure in N1 breast cancer occurs in regional and distant areas,
and may be related to microscopic tumor cells in the regional lymphatic system, which can be removed
with SCNRT. SCNRT still plays an important role in breast cancer treatment within this context. This
may justify the use of SCNRT in selected patients with high-risk N1 breast cancer, rather than in all
patient groups. Using SCNRT for N1 breast cancer is an interesting issue in the field of radiation
oncology, and several studies have recommended that SCNRT be performed after various risk factors
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are considered, but not in all patient groups [17,18]. SCNRT can entail radiation side effects, such as
lymphedema, brachial plexopathy, and radiation pneumonitis, so it should not be performed for small
potential benefits alone. The benefits of SCNRT and its adverse effects in N1 breast cancer patients
are highly controversial, and are affected by other modalities, such as the chemotherapy regimen and
tumor characteristics. Therefore, its benefits should be clarified in a prospective study.
In this study, the utility of LNR was investigated as a factor to be considered in selecting SCNRT as
a treatment for N1 breast cancer patients. Several studies have reported that nodal staging using LNR
can predict the prognosis more effectively than conventional AJCC nodal staging [19,20,30]. In patients
with N1 breast cancer with a relatively small number of metastatic lymph nodes, the prognosis can
vary according to the total number of dissected lymph nodes, even in patients with the same number
of metastatic lymph nodes. Therefore, this study investigated whether the utility of SCNRT can be
estimated from LNR. This study was conducted with KROG 14–18 patients, and previous studies using
the same patient group showed that SCNRT was ineffective in N1 breast cancer patients [15]. In the
present study, it was demonstrated that SCNRT may be beneficial in patients with high LNRs, despite
the use of taxane-based chemotherapy.
This study had several limitations. In addition to the limitations of all retrospective studies, there
was no definitive standard according to which all institutions decided whether or not to administer
SCNRT. Similarly, internal mammary node irradiation was also applied without clear criteria, which
blurred the conclusions of this study. The difficulty in evaluating adverse effects was another limitation
of this study. It is well known that SCNRT induces lymphedema. According to preliminary findings
reported by Coen et al., the addition of regional lymph-node radiotherapy significantly increased
the risk of lymphedema from 1.8% to 8.9% (p = 0.0001) [28]. When considering the use of SCNRT,
clinicians should weigh the potential benefits of SCNRT in disease control against the increased risk
of lymphedema. A previous study based on existing KROG 14–18 data showed that lymphedema
occurred in 16.6% of patients after WBI+ and SCNRT, but in only 10.7% of patients after WBI alone (p =
0.04) [15]. To compare the benefits of SCNRT, a prospective study is required to establish more precise
criteria. In this study, regional recurrence in the SCN, which is the main target of SCNRT, occurred in
only 1% of patients. This is a very low recurrence rate upon which to base the claim that SCNRT should
be performed in all patients. It is difficult to accept that SCNRT should be used to control recurrence,
which occurs in only 1% of patients, given its adverse effects mentioned above. This study has shown
that SCNRT also significantly reduced the risk of distant metastasis, as well as regional lymph-node
recurrence. This may be because SCNRT controls the tumor burden in the SCN region, which may be
the seed bed of distant metastases. Distant metastasis is the main failure pattern in N1 breast cancer
patients, so this study has demonstrated that SCNRT has some therapeutic benefits over and above
the control of regional recurrence. Lastly, the fact that there are characteristic differences between
SCNRT group and non-SCNRT group is a weakness of the study. These characteristics are significantly
higher in the SCNRT group and are generally known as poor prognosis factors, such as LVI, LNR,
and ECE [13]. Despite these poor prognosis factors in the SCNRT group, there was no difference in
recurrence rate between the two groups and it can be interpreted as indicating the effect of SCNRT.
Despite the several limitations described above, this multicenter study suggests that the use of
SCNRT in patients receiving taxane-based chemotherapy may be beneficial if SCNRT is performed
selectively. The study is important because it offers another direction of selective SCNRT for N1 breast
cancer. Selective SCNRT can reduce unnecessary radiation exposure in N1 breast cancer patients and
reduce the recurrence rate in appropriate patients, with a more patient-specific treatment.
5. Conclusions
In this DFS analysis, the patients with high LNR (>0.10) showed benefit with DFS outcomes by
SCNRT. This study has shown that LNR can be used as an independent prognostic factor in patients
with N1 breast cancer and as a useful index when determining whether to perform SCNRT. However,
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we did not establish whether the benefits of this treatment are sufficient to risk the associated adverse
effects. Prospective studies are required to examine these issues.
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Abstract: Genomic instability could be a beneficial predictor for anthracycline or taxane chemotherapy.
We interrogated 188 DNA repair genes in the METABRIC cohort (n = 1980) to identify genes that
influence overall survival (OS). We then evaluated the clinicopathological significance of ERCC1 in
early stage breast cancer (BC) (mRNA expression (n = 4640) and protein level, n = 1650 (test set), and
n = 252 (validation)) and in locally advanced BC (LABC) (mRNA expression, test set (n = 2340) and
validation (TOP clinical trial cohort, n = 120); and protein level (n = 120)). In the multivariate model,
ERCC1 was independently associated with OS in the METABRIC cohort. In ER+ tumours, low ERCC1
transcript or protein level was associated with increased distant relapse risk (DRR). In ER−tumours,
low ERCC1 transcript or protein level was linked to decreased DRR, especially in patients who
received anthracycline chemotherapy. In LABC patients who received neoadjuvant anthracycline, low
ERCC1 transcript was associated with higher pCR (pathological complete response) and decreased
DRR. However, in patients with ER−tumours who received additional neoadjuvant taxane, high
ERCC1 transcript was associated with a higher pCR and decreased DRR. High ERCC1 transcript was
also linked to decreased DRR in ER+ LABC that received additional neoadjuvant taxane. ERCC1
based stratification is an attractive strategy for breast cancers.
Keywords: ERCC1; anthracycline resistance; taxane sensitivity
1. Introduction
Anthracycline and taxane based adjuvant and neoadjuvant chemotherapies are standard
approaches in the management of early stage or locally advanced breast cancers to reduce distant
recurrence and improve survival [1–3]. Moreover, the recent development of multi-parameter
gene-expression assays, largely based on proliferation biomarkers, has facilitated the selection of
patients who are most likely to benefit from systemic chemotherapy [4]. However, despite the genomic
based selection, not all patients benefit from chemotherapy. In addition, chemotherapy related toxicity
(such as anthracycline induced cardiotoxicity/leukaemia and taxol induced irreversible peripheral
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neuropathy) can adversely impact overall outcomes. Therefore, the development of anthracycline
and/or taxane specific predictive biomarkers is desirable.
Chromosomal instability (CIN) that alters chromosome number or structure is a hallmark of cancer
including breast tumours [5–7]. Whilst genomic instability is a key driver of CIN, dysfunctional mitotic
mechanisms, such as defective spindle assembly checkpoints and defective sister chromatid cohesions
can also promote chromosomal instability [5–7]. Tumours with impaired DNA repair capacity and
CIN are sensitive to DNA damaging chemotherapeutics. In early breast cancer patients, duplication of
chromosome 17 centromere enumeration probe (Ch17CEP), a CIN marker, was previously shown to
be a strong predictor of benefit from anthracycline adjuvant chemotherapy in a prospective clinical
trial [8]. On the other hand, in a meta-analyses by the early breast cancer trialists collaborative group
(EBCTCG), benefit from taxanes (paclitaxel, docetaxel) based chemotherapy was most evident in
chromosomally stable low grade breast cancers [9,10]. In addition, CIN has been shown previously to
predict paclitaxel resistance in ovarian cancer patients [11].
Chemotherapy induced or radiotherapy inducedDNAdamage is processed by variousDNArepair
pathways in cells. Emerging data provides strong evidence that overexpression of DNA repair factors
can also contribute to therapeutic resistance in cancers [12]. DNA adducts induced by chemotherapy
(such as by platinum and cyclophosphamide) are processed through the nucleotide excision repair
(NER) pathway. NER is a highly conserved, versatile and robust. NER is a complex pathway requiring
several proteins and their interacting partners. Although complex, two sub-pathways of NER have
been described: The transcription-coupled nucleotide excision repair (TC-NER) pathway, that targets
lesions specifically in the transcribed strand of expressed genes, and the global genome nucleotide
excision repair (GG-NER) pathway, that deals with lesions in the rest of the genome. Although
these NER sub-pathways are complex, basic steps in GG-NER include DNA damage recognition (by
XPC-HR23B complex), lesion demarcation and verification by TFIIH complex (Cdk7, Cyclin H, MAT1,
XPB, XPD, p34, p44, p52 and p62), assembly of a pre-incision complex (RPA, XPA and XPG), DNA
opening by XPB and XPD helicases, dual incision (by ERCC1–XPF and XPG endonucleases), release of
the excised oligomer and finally repair synthesis to fill in the resulting gap (RPA, RFC, PCNA, Pol
δ/ε, and ligation by ligase I) [13,14]. In TC-NER, translocating RNA polymerase II detects lesions in
the template. A role for ERCC8 (CSA) and ERCC6 (CSB) has also been suggested in DNA damage
recognition in TC-NER. Subsequent steps in TC-NER are similar to GC-NER.
ERCC1 protein is a critical player in NER. ERCC1 is non-catalytic but associates with XPF
endonuclease (also known as ERCC4) to form the ERCC1–XPF heterodimer. The ERCC1–XPF
heterodimer cleaves and facilitates the removal of bulky lesions, such as those induced by platinum
chemotherapy [15,16]. In addition the ERCC1–XPF heterodimer also has essential roles in other DNA
repair pathways, such as DNA recombinational repair and inter-strand crosslink repair [17,18]. ERCC1
and XPF siRNA depletion was previously shown to increase cisplatin sensitivity in non-small lung [19]
and breast cancer cells [20]. In a mouse xenograph model, ERCC1-deficient melanoma cells were also
observed to be 10-fold more sensitive to cisplatin than ERCC1-proficient cells [21]. ERCC1 as a marker
of chemotherapy resistance has been well described in other solid tumours, including lung, colorectal,
head, neck, gastric, bladder and ovarian cancers [22–26]. Given the critical role of ERCC1 in genomic
integrity, in the current study, we evaluated the role of ERCC1 as a biomarker in breast cancers.
2. Results
2.1. ERCC1 Transcript Is a Predictor of Tumour Grade and Chromosomal Instability in Early Stage breast
cancers (BCs)
A large body of clinical evidence confirms that high grade BCs is associated with chromosomal
instability. Given the critical role of ERCC1 in NER, DSB repair, ICL repair and chromosomal stability,
we evaluated ERCC1 transcripts in the METABRIC Cohort. A low level of ERCC1 transcript was
significantly associated with higher grade cancer, whereas low grade tumours were common in
high ERCC1 tumours (Table 1) (p values < 0.0001). Low ERCC1 transcript was also associated with
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Ki67 positivity, ER−, PAM50 Luminal B, Pam50 Her2, Pam50 basal and Genufu ER+/HER− (high
proliferation) tumours. On the other hand, low grade, Ki67 negative, PAM50 Luminal A and Genufu
ER+/HER− (low proliferation) were more common in tumours with high ERCC1 transcript (all
p values < 0.0001). To evaluate associations with chromosomal stability we investigated ERCC1 in
various integrative molecular cluster (intClust) phenotypes described in the METABRIC cohort. Low
ERCC1 transcript was linked to genomically unstable intClust.10 phenotype whereas high ERCC1 was
associated with chromosomally stable intClust.3, 4, 7 and 8 tumours. Together, the data provides the
first clinical evidence that low ERCC1 is a marker of chromosomal instability and aggressive phenotype
in BCs.
Table 1. Clinicopathological significance of ERCC1 mRNA expression in breast cancers.
ERCC1 mRNA Expression p-Value * p-Value(Adjusted)
Low High
(A) Pathological Parameters
Tumour Size
≤1cm 43 (4.5%) 43 (4.4%)
0.481 5.2910
>1–2cm 247 (25.7%) 279 (28.8%)
>2–4cm 620 (64.5%) 601 (62.0%)
>4cm 51 (5.3%) 46 (4.7%)
Tumour Grade
1 35 (3.7%) 130 (14.1%)
4.4 × 10−37 <0.000012 305 (32.0%) 460 (49.8%)
3 612 (64.3%) 334 (36.1%)
Lymph Node Group
Negative 486 (49.8%) 528 (54.2%)
0.051 0.0623Positive 490 (50.2%) 446 (45.8%)
Histological Types
IDC-NST 837 (85.8%) 704 (72.3%)
1.33 × 10−15 <0.00001Medullary Carcinoma 20 (2.0%) 12 (1.2%)Invasive special type 104 (10.7%) 247 (25.4%)
Invasive others 15 (1.5%) 11 (1.1%)
Ki67 Expression
Negative 375 (38.4%) 600 (61.6%)
1.37 × 10−24 <0.00001Positive 601 (61.6%) 374 (38.4%)
P53 Mutation
Wild type 325 (82.9%) 383 (92.3%)
4.9 × 10−5 <0.00001Mutant 67 (17.1%) 32 (7.7%)
ER Expression
Negative 332 (34.0%) 126 (12.9%)
4.8 × 10−28 <0.00001Positive 644 (66.0%) 848 (87.1%)
PAM 50 Luminal A
Negative 770 (78.9%) 466 (48.1%)
4.45 × 10−45 <0.00001Positive 206 (21.1%) 502 (51.9%)
PAM 50 Luminal B
Negative 684 (70.1%) 775 (80.1%)
3.68 × 10−7 <0.00001Positive 292 (29.9%) 193 (19.9%)
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Table 1. Cont.
ERCC1 mRNA Expression p-Value * p-Value(Adjusted)
Low High
PAM 50 Her2
Negative 799 (81.9%) 909 (93.9%)
4.39 × 10−16 <0.00001Positive 177 (18.1%) 59 (6.1%)
PAM 50 Basal
Negative 751 (76.9%) 871 (90.0%)
1.089 × 10−14 <0.00001Positive 225 (23.1%) 97 (10.0%)
Integrative Molecular Clusters
Int Clust 1 101 (10.3%) 35 (3.6%)
1.163 × 10−60 <0.00001
Int Clust 2 41 (4.2%) 30 (3.1%)
Int Clust 3 78 (8.0%) 210 (21.6%)
Int Clust 4 144 (14.8%) 187 (19.2%)
Int Clust 5 139 (14.2%) 46 (4.7%)
Int Clust 6 52 (5.3%) 33 (3.4%)
Int Clust 7 74 (7.6%) 112 (11.5%)
Int Clust 8 77 (7.9%) 221 (22.7%)
Int Clust 9 108 (11.1%) 38 (3.9%)
Int Clust 10 162 (16.6%) 62 (6.4%)
Genufu Sub-Types
ER−/Her-2− 104 (21.4%) 44 (8.8%)
7.43 × 10−37 <0.00001ER+/Her-2– (high proliferation) 212 (43.7%) 148 (29.7%)ER+/Her-2– (low proliferation) 85 (17.5%) 281 (56.3%)
Her-2 + 84 (17.3%) 26 (5.2%)
* p values were adjusted according to Benjamini-Hochberg method.
2.2. ERCC1 Transcript and Clinical Outcomes in Patients Receiving Adjuvant Therapy
In the ER+METABRIC whole cohort, low ERCC1 transcript was associated with higher risk of
death (p = 0.0001) (Figure 1A). In patients who received endocrine therapy, similarly, low ERCC1 was
associatedwith higher risk of death (p= 0.0001) (Figure S2A). In addition, in the ER+METABRIC cohort,
we tested 188 DNA repair genes in a multivariate Cox proportional hazards model with backward
stepwise exclusion and identified ERCC1 (among seven other genes) as an independent predictor
for overall survival (OS) (Table S10). As chromosomal instability is a marker of chemo-sensitivity,
we evaluated ERCC1 in ER−METABRIC patients who received chemotherapy. Low ERCC1 mRNA
expressionwas associatedwith a decreased risk of death from BC (p= 0.05) (Figure 1B). In amultivariate
Cox regression analysis after controlling for confounders (such as endocrine therapy, chemotherapy
and other validated prognostic factors (ER, PR, HER2, grade, stage, tumour size, TP53 mutation status,
PAM50 molecular subtype and IntClust subclasses)), we confirmed that ERCC1 transcript was an
independent prognostic factor for OS (p = 0.039) and the interaction between ERCC1 and chemotherapy
was also statistically significant (p = 0.020) (Table 2). In ER− tumours, that received no chemotherapy,
ERCC1 did not influence survival (Figure S2B).
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Figure 1. ERCC1, adjuvant chemotherapy and survival. (A) Kaplan Meier curves showing BCSS (Breast
cancer specific survival) based on ERCC1 mRNA expression in ER+METABRIC cohort. (B) Kaplan
Meier curves showing BCSS (Breast cancer specific survival) based on ERCC1 mRNA expression in ER−
METABRIC cohort. (C) Kaplan Meier curves showing disease specific survival based on ERCC1 mRNA
expression in ER+Multicentre Adjuvant (Adj MC) cohort. (D) Kaplan Meier curves showing disease
specific survival based on ERCC1 mRNA expression in ER− Adj MC cohort. (E) Kaplan Meier curves
showing disease specific survival based on ERCC1 protein level in ER+ Adj MC cohort. (F) Kaplan
Meier curves showing disease specific survival based on ERCC1 protein level in ER− Adj MC cohort.
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Table 2. Multivariate Cox regression analysis for overall survival (OS) at 20 years in the
METABRIC cohort.
Variables HR
95.0% CI p Value
Lower Upper
ERCC1 mRNA expression (+) 1.43 1.02 2.01 0.039 *
ER (+) 0.75 0.38 1.49 0.411
PR (+) 0.91 0.63 1.32 0.624
HER2 overexpression 0.82 0.36 1.85 0.63
TP53 mutation 1.81 1.24 2.63 0.002 *
Tumour Size (continuous) 1.01 1.01 1.02 0.001*
Lymph node (LN) stage
1.2 × 10−6 *Negative 11–3 positive LNs 1.87 1.25 2.79
> 3 positive LNs 3.33 2.12 5.23
Histological grade
0.563
Low 1
Intermediate 0.98 0.46 2.09
High 1.2 0.55 2.62
PAM-50 subtypes
0.049 *
PAM-50-LUM A 1 0.97 2.16
PAM-50-LUM B 1.44 0.43 2.16
PAM-50-LUM HER2 0.96 0.5 3.04
PAM-50-LUM Basal 1.24 1.17 4.56
PAM-50-Normal like 2.31
IntClust Members
0.189
IntClust 1 1
IntClust 2 1.28 0.59 2.8
IntClust 3 0.56 0.25 1.24
IntClust 4 0.8 0.4 1.59
IntClust 5 2.47 0.94 6.53
IntClust 6 1.15 0.5 2.64
IntClust 7 1.08 0.49 2.38
IntClust 8 1.03 0.52 2.05
IntClust 9 1.31 0.66 2.58
IntClust 10 0.81 0.38 1.76
Hormone therapy 0.64 0.43 0.96 0.031 *
Chemotherapy 0.93 0.62 1.41 0.741
Interaction term
2.86 1.1 7.42 0.09Hormone therapy * ER (IHC)
Interaction term
2.11 1.23 3.95 0.020 *Chemotherapy * ERCC1
* significant p values.
We then validated in the Multicentre (MC)-Adjuvant cohort of 4640 patients. By using mean as
cut-off, high and low ERCC1were observed in 49% (1460/2261) and 51% (14602379) of cases, respectively.
ER and HER2 status were available for 3826 and 1727 cases; respectively. About 59% (2268/3826),
41% (1558/3826) and 26% (446/1727) of cases were ER+, ER− and HER2+, respectively (Tables S3 and
S4). Similar to the METABRIC data, in ER+ tumours, low levels of ERCC1 was associated with an
increased distant relapse DRR compared to high levels of ERCC1 [p = 0.007) (Figure 1C). However, in
ER− tumours that received adjuvant chemotherapy, low ERCC1 was associated with a reduced DRR
compared to high ERCC1 (p = 0.001) (Figure 1D). Multivariable Cox regression models confirmed that
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the low ERCC1 transcript is a poor prognostic factor for DRR after controlling with Adjuvant! Online
(AOL) (p = 0.047) and 72-proliferation-gene-signatures (p < 0.0001).
2.3. ERCC1 Protein, Clinicopathological Features and Outcomes
Using median as the cut off (H-score ≥ 130), we observed ERCC1 nuclear protein expression in
439/991 (44.3%) of breast tumours, and 55.7% (552/991) were negative for ERCC1 expression. As shown
in (Table S11), low nuclear ERCC1 level was significantly associated with aggressive phenotypes,
including high grade, no special histological type (NST), ER−, basal-like phenotype and triple negative
tumours, as well as loss of other DNA repair biomarkers (all adjusted p ≤ 0.01). In ER+ tumours,
low ERCC1 protein was linked to poor disease relapse free survival (p = 0.044) (Figure 1E). On the
other hand, in ER− tumours that received chemotherapy, low ERCC1 protein was linked to improved
disease relapse free survival (p = 0.034)) (Figure 1F). Multivariable Cox regression analysis controlling
for chemotherapy, endocrine therapy and other validated prognostic factors (stage, grade, size, ER, PR,
HER2 and BCl2), showed that ERCC1 protein expression was an independent prognostic factor for OS
(p = 0.035) and that the interaction between ERCC1 protein expression and adjuvant chemotherapy
was statistically significant (p = 0.022) (Table S12).
2.4. ERCC1 and Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy (pre-operative) is an established approach in locally advanced breast
cancers (LABC). Although current evidence suggests that patients who achieve pCR have a better
long-term clinical outcome [27,28], the development of a predictive biomarker of pCR remains a high
priority. We therefore evaluated ERCC1 transcripts in a multiple centre cohort of 2345 LABC patients
who received neoadjuvant anthracycline based combination (Neo-Adj) AC-chemotherapy (CT) + or − T
with or without Herceptin (+ or – H), including multiple clinical trials sub cohorts (MC-Neo-Adjuvant
cohort). The majority of patients (60%; 1413/2345) had received Neo-Adj AC-CT+T (taxane) whereas
29% (689/2345) and 10% (243/2345) of patients had received Neo-Adj AC-CT alone and AC-CT+T+H;
respectively. About 52% of cases were ER− (1163/2256) whereas 48% (1093/2345) and 24% (518/2163)
were ER+ and HER2+, respectively. Low and high ERCC1 transcript expressions were observed in
48% (1133/2345) and 52% (1212/2345) of cases, respectively. Out of the 2345 patients, 596 (25%) patients
had achieved pCR. Low ERCC1 transcript expression was associated with an increased proportion of
patients achieving pCR (333 (29%) of 1133 patients) compared with high ERCC1 transcript expression
(263 (22%) of 1212 patients; OR (95% CI): 1.50 (1.25–1.81, p < 0.0001).
In ER+ patients, low ERCC1 transcript expression was also associated with a higher proportion of
patients achieving pCR (80 (18%) of 442 patients) compared with high ERCC1 transcript expression
(64 (10%) of 651patients; OR (95% CI): 2.03 (1.42–2.89), p < 0.0001) especially in ER+ patients who
received either Neo-Adj AC-CT alone (21% (29/136) versus 10% (17/166); OR (95% CI): 2.38 (1.24–4.55),
p = 0.008) or Neo-Adj ACT-CT+T (15% (41/276) versus 9% (42/464); OR (95% CI): 1.75 (1.11–2.77),
p = 0.016) (Figure 2A).
In ER− patients who received Neo-Adj AC-CT alone, low ERCC1 transcript expression was also
associated with a higher proportion of patients achieving pCR (74 (33%) of 227 patients) compared with
high ERCC1 transcript expression (37 (23%) of 159 patients (OR (95% CI): 1.59 (1.01–2.53), p = 0.046)
(Figure 2B). We validated this observation in the TOP1 trial cohort of ER-negative tumours where
patients received anthracycline (epirubicin) monotherapy only. Low ERCC1 transcript expression was
associated with an increased proportion of patients achieving pCR (12 (21.4%) of 56 patients) compared
with high ERCC1 transcript expression (4 (6.9%) of 58 patients; OR (95% CI): 3.683 (1.11–12.20),
p = 0.026). Moreover, in the TOP1 cohort, low ERCC1 transcript expression was associated with 58%
lower relapse risk compared to high ERCC1, (HR (95% CI): 0.42 (0.19-0.93); p = 0.033) (Figure 2C). For
additional validation at protein level, we investigated the effect of ERCC1 protein on pCR in a series
of 120 LABC patients who received Neo-Adj AC-CT alone. 19/120 (16%) patients achieved pCR in
this cohort. Low ERCC1 protein expression was associated with an increased proportion of patients
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achieving a pCR (16 (26%) of 62 patients) compared with high ERCC1 protein expression (3 (5%) of
57 patients; OR (95% CI): 6.25 (1.89–22.73, p = 0.002).
Figure 2. ERCC1 and neoadjuvant chemotherapy. (A) Pathological complete response (pCR) based on
ERCC1 mRNA expression in ER+ tumours (neoadjuvant anthracycline based (Neo-Adj) MC cohort)
that received neoadjuvant AC or AC+T or AC+T+H chemotherapy. (B) Pathological complete response
(pCR) based on ERCC1 mRNA expression in ER− tumours (Neo-Adj MC cohort) who received
neoadjuvant AC or AC+T or AC+T+H chemotherapy. (C) Disease free survival based on ERCC1mRNA
expression in TOP1 cohort patients who received neoadjuvant AC chemotherapy. (D) Disease free
survival based in ER−Neo-Adj MC cohort who received neoadjuvant AC+T chemotherapy. (E) Disease
free survival based in ER+ Neo-Adj MC cohort who received neoadjuvant AC+T chemotherapy.
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On the other hand, in ER− patients who received Neo-Adj ACT+T, high ERCC1 transcript
expression was associated with a higher proportion of patients achieving a pCR (142 (41%) of
349 patients) compared with low ERCC1 transcript expression (110 (34%) of 323 patients; OR (95%
CI): 1.33 (0.97–1.82), p = 0.076) (Figure 2B). In addition, in ER− patients who received pre-operative
Neo-Adj ACT+T, low ERCC1 had higher relapse risk compared to high ERCC1 (HR (95% CI): 1.71
(1.12–2.60); p = 0.013) (Figure 2D). Similarly, in ER+ patients also who received Neo-Adj ACT+T, low
ERCC1 had higher relapse risk compared to high ERCC1 (hazard ratio (HR) (95% CI) = 1.71 (1.03–2.83),
p = 0.039) (Figure 2E).
Taken together, the data provides compelling evidence that ERCC1 has prognostic significance in
ER+ BCs and predict response to chemotherapy in ER− BCs.
3. Discussion
Although the efficacy of DNA damaging chemotherapy (such as anthracyclines) is influenced by
impaired DNA repair capacity, evolving evidence also suggests that mitotic spindle poisons (such as
taxanes) are more effective in low grade chromosomally stable tumours. Therefore the development
of robust DNA repair based biomarkers is highly desirable. ERCC1 is non-catalytic but partners
with XPF endonuclease to form the ERCC1–XPF heterodimer which processes abnormal DNA repair
intermediates generated during NER, double strand breaks (DSB) repair and Interstrand Cross Link
(ICL) repair [29]. Given the key role for ERCC1 in genomic integrity, we hypothesized a role for
ERCC1 in breast cancer pathogenesis and response to therapy. In the current study we show that
ERCC1 transcript expression was independently associated with OS in the METABRIC cohort. In ER+
tumours, low ERCC1 transcript or protein level was associated with increased distant relapse risk
(DRR). In ER− tumours, low ERCC1 transcript or protein level was linked to decreased DRR, especially
in patients who received anthracycline chemotherapy. In LABC patients who received neoadjuvant
anthracycline, low ERCC1 transcript was associated with higher pCR (pathological complete response)
and decreased DRR. However, in patients with ER−tumours who received additional neoadjuvant
taxane, high ERCC1 transcript was associated with a higher pCR and decreased DRR. High ERCC1
transcript was also linked to decreased DRR in ER+ LABC that received additional neoadjuvant taxane.
Taken together, the data presented here provides comprehensive clinical evidence that ERCC1 is a
predictor of anthracycline resistance and taxane sensitivity in breast cancers. ERCC1 based stratification
could be an attractive strategy in breast cancers.
Studies exploring biomarkers of response to anthracycline therapy have been limited in breast
cancers. Previous smaller studies suggest that Ki67, HER1-3 expression, TOP2A andHER-2 are potential
markers of anthracycline benefit [30]. Ch17CEP, a CIN marker, was also previously shown to predict
benefit from anthracycline adjuvant chemotherapy in a prospective clinical trial [8]. ERCC1 is a critical
factor for CIN. To the best of our knowledge, the data shown here represents the first comprehensive
evidence that ERCC1 status influences potential benefitting from anthracycline chemotherapy. The
role of ERCC1 in breast cancer pathogenesis is emerging. ERCC1 polymorphism may be associated
with increased breast cancer risk [31]. A previous, small study suggested that ERCC1 protein levels
may be low in triple negative breast cancers (TNBCs) [32,33]. In a study of fifty two TNBCs, ERCC1
positivity was associated with shorter progression free survival and poor response to neoadjuvant
chemotherapy [32]. In addition, ERCC1 genetic polymorphism also appeared to associate with
pCR in patients receiving neoadjuvant anthracycline chemotherapy [34]. Gay-Beillile et al. recently
also demonstrated that ERCC1 expression is induced in tumours that receive anthracycline based
neoadjuvant chemotherapy [35]. Previous clinical studies have evaluated the predictive significance of
ERCC1 for response to platinum chemotherapy, in various solid tumours (lung, colorectal, head and
neck, gastric and bladder cancers [36–39]. However, a major limitation has been the use of relatively
non-specific ERCC1 antibodies for immunohistochemistry in previous studies, including in a large lung
cancer clinical trial [40]. In the current study we utilised a recently generated and highly specific mouse
monoclonal antibody (clone 4F9) [41], which further strengthens our clinical data. Our study not only
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concurs with previous studies showing a link between ERCC1 overexpression and chemoresistance
but also provides additional insight suggesting that ERCC1 may also be involved in the emergence of
aggressive breast cancer phenotypes. However, a limitation to our study is that it is predominantly
retrospective. Prospective studies would be required to confirm our findings.
Currently there is no established predictive biomarker of response to taxane therapy. Previous
studies suggest that HER2, Ki67, class III β tubulin expression may influence taxane response [10].
A novel observation in the current study is that ERCC1 was also shown to influence whether taxane
chemotherapy was beneficial. Our data concurs with previous evidence demonstrating taxane benefit
in low grade, chromosomally stable tumours [9,10]. However, further prospective studies would be
required to confirm our initial findings.
Taken together, the data would support further development of ERCC1 as a biomarker of response
to chemotherapy in breast cancer.
4. Patients and Methods
4.1. Study Design and Cohorts
Study design, the patient cohorts which included 11,096 BCs and their demographics are
summarized in the consort flow diagram (Figure 3), also in Supplementary Methods and Tables.
Figure 3. Consort diagram summarizing patient cohorts investigated in the current study.
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4.2. Outcome Measurements and Patient Cohorts:
4.2.1. ERCC1 Transcript Expression Analysis
I The association of 188 DNA repair genes and prognosis (overall survival; OS) analysis:
Cohort (1): METABRIC cohort (Molecular Taxonomy of BC International Consortium)
Patient demographics are summarized in Supplementary Table S1. We investigated the association
of 188 DNA repair genes (Table S2) with OS in the METABRIC cohort (METABRIC n = 1980; median
follow-up time in years (MFUT) (inter-quantile range (IQR): 9.1 (5.2–12.9)). Univariate Cox regression
analysis was used in SPSS (Version 20, Chicago, IL, USA) and the Benjamini and Hochberg False
Discovery Rate calculation (BH FDR) was applied to account for multiple comparisons. After definition
of factors that were associated with OS after BH FDR correction, multivariate Cox proportional hazards
models (with backward stepwise exclusion of these factors, using a criterion of p < 0.05 for retention of
factors in the model) were used to identify factors that were independently associated with OS. The
statistical significance of the model was assessed based on the likelihood ratio test. The proportional
hazards assumption was tested using both standard log–log plots and by generating Kaplan–Meier
survival estimate curves, and observing that the curves did not intersect with each other. Hazard
ratios (HRs) for death risk and 95% confidence intervals were calculated from the Cox proportional
hazards analysis.
II The association of distant relapse risk (DRR)) and ERCC1 transcript after receiving systemic
adjuvant therapy (Adj-T):
Cohort (2): Multicentre (MC)-Adjuvant cohort (n = 4640)
The association between ERCC1 mRNA expression and DRR and its relationship with the received
systemic Adj-T were tested in 4640 patients with early stage BC, retrieved from 21 gene expression
databases (see Supplementary Tables S3 and S4). ERCC1 gene expression data of each database were
converted to a common scale (median equal to 0 and standard deviation equal to 1) in order to merge
all of the study data that used the same platform and to create combined cohorts. Then the data
was median centred for each gene, whereby the median of each gene was 0. Databases using the
same platform were merged and the median expression was calculated. The median expression of
ERCC1 transcription for each platform was calculated and values equal to or higher than the median
coded as +1 (overexpression). Values of less than the median were coded 0 or low ERCC1. Distal
relapse free survival follow up data were available for 3171 patients with 967 events (MFUT (IQR):
5.5 (3.0–8.7)). The systemic Adj-T information was available for 2276 patients: 45% of patients were
naïve to systemic Adj-T, whereas 49% had received Adj-endocrine therapy and 27% had received
chemotherapy. Herceptin had been offered to 156 (7%) of HER2 + patients.
III The association between ERCC1 and pathological complete response rate (pCR) analysis after
receiving neoadjuvant anthracycline based combination chemotherapy (Neo-Adj-ACT)
Cohort (3): Multicentre (MC) Neo-Adjuvant cohort (n = 2340)
Demographics summarized in Supplementary Table S5. The association between ERCC1 mRNA
expression and pCR was evaluated in 2340 patients retrieved from 15 gene expression databases that
received pre-operative anthracycline based combination (AC) with (+) or without (−) taxane (T). Out
of 2345 patients, 689 patients (29%) has received Neo-Adjuvant anthracycline based combination
chemotherapy (Neo-Adj-ACT) alone; 1413 patients (60%) received Neo-Adj-ACT with Taxane (ACT +
T) and 243 patients received Neo-Adj-ACT + T + Herceptin (ACT + T + H).
Cohort (4): NeoadjuvantTOP trial cohort (NCT00162812), inwhichpatientswithoestrogen receptor
(ER)-negative tumours were treated with anthracycline (epirubicin) monotherapy. Demographics
summarized in Supplementary Table S6.
4.2.2. Protein Expression Association Analysis
Immunohistochemical evaluation of ERCC1 protein expression was performed in three cohorts of
patients who treated at a single centre (Nottingham University Hospital (NUH)). We utilised a recently
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characterised highly specific anti-ERCC1 mouse monoclonal antibody (clone 4F9, Dako Ltd., Cheshire,
UK) [18]. We confirmed the specificity of clone 4F9, using Western Blots in breast cancer (SKBR3, T47D
and MDA-MB-231) and ovarian cancer (A2780 and A2780cis) cell lines (Supplementary Figure S1A).
Tissue culture and Western blot analyses is described in Supplementary Methods.
4.3. Adjuvant Setting
Cohort (5): NUH- early stage breast cancer (NUH-ESBC): The study was performed in a well
characterised consecutive series of 1650 patients with primary invasive breast carcinomas who were
diagnosed between 1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma
series [42] (Nottingham historical early stage cohort (NUH-ESBC); MFUT (IQR): 13.4 (10.3–16.42)).
Demographics are summarized in Supplementary Table S7. SupplementaryMethods provide a detailed
description on Tissue Microarrays (TMAs) and immunohistochemistry (IHC) evaluations (Table S8).
The association between the ERCC1 protein expression with clinicopathological parameters and DRR
were analysed in this cohort.
Cohort (6): (Nottingham ER-negative series). A series of 252 ER negative invasive breast
carcinomas diagnosed and managed at the Nottingham University Hospitals (NUH) Trust between
1999 and 2007. All patients were primarily treated with surgery, followed by adjuvant radiotherapy
and anthracycline based combination chemotherapy [43]. Demographics are shown in Supplementary
Table S9.
4.4. Neo-Adjuvant Setting
Cohort (7): Nottingham anthracycline based neo-adjuvant chemotherapy cohort (Nottingham
AC-NACT; n = 120) consisting of pre-chemotherapy core biopsies from 120 female patients with
locally-advanced primary BC treated with neo-adjuvant (Neo-Adj) anthracycline-based combination
chemotherapy (AC-CT) (Neo-Adj-AC-CT) treated at NUH between 1996 and 2012 [42].
All patients completed written informed consented, as per hospital standard of care, for excess
tumour tissue to be used in research. The study was approved by the Institutional Review Board
or Independent Ethics Committee and the Hospital Research and Innovations Department at all
participating sites. Tumour Marker Prognostic Studies (REMARK) criteria, as recommended by
McShane et al. [44] were followed throughout this study.
4.5. Power Analysis
A retrospective power analysis was conducted to determine the confidence in the calculated
hazard ratio and associated p value for 10 year survival and to ascertain how applicable the result
would be to a global population. Power of study was determined using PASS (NCSS, version 13, USA).
4.6. Statistical Analysis
Statistical analyses were performed using STATISTICA (Stat Soft Ltd., Tulsa, OK, USA) and SPSS
(version 17, Chicago, IL, USA) by the authors who were blinded to the clinical data. Where appropriate,
Pearson’s chi-squared, student’s t-test and ANOVA tests were used. Positivity for ERCC1 protein
both pre- and post-chemotherapy was calculated and compared using McNemar’s test. Cumulative
survival probabilities and 10-year BCSS and DFS were estimated using the univariate Cox proportional
hazards models and the Kaplan–Meier plot method where appropriate, and differences between
survival rates were tested for significance using the log-rank test. Multivariable analysis for survival
was performed using the Cox proportional hazard model. The proportional hazards assumption was
tested using standard log–log plots. Hazard ratios (HR) and 95% confidence intervals (95% CI) were
estimated for each variable. All tests were two-sided with a 95% CI, and a p value < 0.05 was considered
to be indicative of statistical significance. The interaction between ERCC1 and chemotherapy was
tested in the Cox proportional hazard model. For multiple comparisons, p values were adjusted
according to Benjamini–Hochberg method [45]. Tumor Marker Prognostic Studies (REMARK) criteria,
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recommended by McShane et al. [46], were followed throughout this study. Ethical approval was
obtained from the Nottingham Research Ethics Committee (C202313).
5. Conclusions
ERCC1 is non-catalytic but partners with XPF endonuclease to form the ERCC1–XPF heterodimer
which processes abnormal DNA repair intermediates generated during NER, DSB repair and ICL repair.
We provide the first comprehensive clinical evidence that ERCC1 is a key predictor of chemotherapy
response in patientswith breast cancerwho receive adjuvant or neoadjuvant chemotherapy. Importantly,
the clinical study suggests that ERCC1 based stratification is feasible in BC patients who receive
anthracycline and/or taxane chemotherapy.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/8/1149/s1,
Table S1: Clinicopathological characteristics in the METABRIC cohort, Table S2: List of DNA repair genes tested in
the METABRIC cohort, Table S3: Cohort ID and gene expression platform Multicentre (MC)-Adjuvant cohort
(n=4640), Table S4: Demographics of Multicentre (MC)-Adjuvant cohort (n=4640), Table S5: Multicentre (MC)
Neo-Adjuvant cohort (n= 2345), Table S6: Demographics in TOP trial cohort, Table S7: Clinicopathological
characteristics of Nottingham historical early, TableS8: Table of antibodies and optimisation conditions used to
immunohistochemically profile the Nottingham University Hospitals based cohorts. Detailed below are: Antigens,
primary antibodies, clone, source, optimal dilution and scoring system, used for each immunohistochemicalmarker
stage cohort (NUH-ESBC), Table S9: Clinicopathological characteristics of ER- cohort, Table S10: Multivariate
backward step-wise Cox analysis for DNA repair genes, associated with Overall Survival (OS) in ER+METABRIC
cohort, Table S11: Clinicopathological significance of ERCC1 protein expression in breast cancers, Table S12:
Multivariate Cox regression analysis for breast cancer specific survival (BCSS) at 20 years follow up in Nottingham
series including interaction terms.
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Abstract: In pre-clinical studies, triple-negative breast cancer (TNBC) cells have demonstrated
sensitivity to the multi-targeted kinase inhibitor dasatinib; however, clinical trials with single-agent
dasatinib showed limited efficacy in unselected populations of breast cancer, including TNBC.
To study potential mechanisms of resistance to dasatinib in TNBC, we established a cell line model
of acquired dasatinib resistance (231-DasB). Following an approximately three-month exposure to
incrementally increasing concentrations of dasatinib (200 nM to 500 nM) dasatinib, 231-DasB cells
were resistant to the agent with a dasatinib IC50 value greater than 5 μM compared to 0.04 ± 0.001 μM
in the parental MDA-MB-231 cells. 231-DasB cells also showed resistance (2.2-fold) to the Src kinase
inhibitor PD180970. Treatment of 231-DasB cells with dasatinib did not inhibit phosphorylation
of Src kinase. The 231-DasB cells also had significantly increased levels of p-Met compared to the
parental MDA-MB-231 cells, as measured by luminex, and resistant cells demonstrated a significant
increase in sensitivity to the c-Met inhibitor, CpdA, with an IC50 value of 1.4 ± 0.5 μM compared
to an IC50 of 6.8 ± 0.2 μM in the parental MDA-MB-231 cells. Treatment with CpdA decreased
p-Met and p-Src in both 231-DasB and MDA-MB-231 cells. Combined treatment with dasatinib and
CpdA significantly inhibited the growth of MDA-MB-231 parental cells and prevented the emergence
of dasatinib resistance. If these in vitro findings can be extrapolated to human cancer treatment,
combined treatment with dasatinib and a c-Met inhibitor may block the development of acquired
resistance and improve response rates to dasatinib treatment in TNBC.
Keywords: Src kinase; basal-like breast cancer; cMet
1. Introduction
Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER) and progesterone
receptor (PR) and exhibits overexpression of human epidermal growth factor receptor 2 (HER2).
It accounts for approximately 15% of all breast cancer cases and patients with this form demonstrate
higher rates of recurrence and shorter disease progression than those with luminal or HER2-positive
Cancers 2019, 11, 548; doi:10.3390/cancers11040548 www.mdpi.com/journal/cancers159
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tumours [1]. Treatment of TNBC predominantly relies on the use of cytotoxic chemotherapies due to
a lack of proven molecular targets [2].
We have previously shown that Proto-oncogene tyrosine-protein kinase Src (Src kinase) is
frequently expressed in TNBC and may be a rational therapeutic target for TNBC [3]. Src is
a proto-oncogene and a member of the Src family kinases (SFKs). SFKs are non-membrane-bound
tyrosine kinases consisting of nine members. Src, Yes, Fyn and Fgr belong to the Src A family subtype.
Lck, Hck, Blk and Lyn belong to Src B family subtype, with Frk in its own subfamily [4]. The SFKs
display high levels of homology to one another and are involved in propagating downstream cell
signalling to effect cellular biological functions including cell proliferation, cell migration, angiogenesis
and cell survival [5–7].
Dasatinib is a multi-targeted tyrosine kinase inhibitor whose targets include BCR/Abl and Src
family kinases. Pre-clinical studies suggested that basal-like TNBC cell lines show higher sensitivity to
dasatinib than luminal cell lines, supporting dasatinib as a potential targeted treatment for TNBC [3,8,9].
Additionally, when TNBC was further sub-classified into six molecular types, cell line models of the
mesenchymal and mesenchymal stem-like group showed greater sensitivity to dasatinib than other
cell line models [3,9,10]. However, in a phase II clinical trial, dasatinib showed limited single-agent
activity in patients with metastatic breast cancer [11] or in patients with locally advanced or metastatic
TNBC [12].
Several potential predictive biomarkers of response to dasatinib treatment have been identified [13],
and a prospective phase II trial was designed to test three predictive gene signatures, whereby patients
with metastatic breast cancer whose metastatic tumour biopsies were positive for one of the gene
signatures were treated with dasatinib [13]. However, no significant clinical benefit was observed
despite selecting patients having the highest scores for the three predictive signatures.
Thus, despite promising activity in preclinical studies, dasatinib has so far failed to produce
clinical benefits in TNBC patients. One of the limitations of the preclinical studies that showed
activity in TNBC cells, including our own [3], is that they were limited to short-term proliferation
assays. Therefore, we examined the effects of longer exposure to dasatinib on TNBC cells that are
highly sensitive to dasatinib in short-term proliferation assays. The overall aim was to identify novel
combinatorial approaches that may block the development of acquired resistance to dasatinib and
improve response rates to dasatinib treatment in TNBC.
2. Materials and Methods
2.1. Cell Lines and Reagents
MDA-MB-231 cells were obtained from the American Type Culture Collection (ATCC). 231-DasB
was developed by continuous exposure to dasatinib (Sequoia Research Products, Berkshire, UK) with
a starting concentration of 200 nM, increasing incrementally to a maximum of 500 nM dasatinib over
a period of 13 weeks. Untreated (parental) MDA-MB-231 cells were cultured in a similar manner in the
absence of drug to create an aged-matched control. Both cell lines were cultured in RPMI 1640 with
10% Foetal Bovine Serum, plus 10 nM dasatinib for 231DasB. Stock solutions (10 mM) of PD180970
(Merck, Dublin, Ireland), elacridar (Sequoia Research Products, Berkshire, UK) and Compound A
(CpdA, Amgen, Thousand Oaks, CA, USA) were prepared in DMSO.
2.2. Proliferation Assays
Proliferationwasmeasured in triplicate biological assays using an acid phosphatase assay or viable
cell count. For acid phosphatase assays, 1 × 103 cells/well were seeded in 96-well plates. Plates were
incubated overnight at 37 ◦C followed by the addition of the drug at the appropriate concentrations
and incubated for a further five days until wells were 80–90% confluent. All media were removed
and the wells were washed once with phosphate buffered solution (PBS). Paranitrophenol phosphate
(PNP) substrate (Sigma-Aldrich, Dublin, Ireland) (10 mM of PNP in sodium acetate buffer, pH 5.5) was
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added to each well and incubated at 37 ◦C for 1 h. Fifty microliters of 1 M NaOH were added and
the absorbance was read at 405 nM (reference: 620 nM). For viable cell counts, cells were trypsined
and combined in a 1:1 ratio with Viacount Flex reagent and counted using a Guava Easycyte (Merck,
Dublin, Ireland).
2.3. Doubling Time Assays
Next 2 × 103 cells were seeded in 24-well plates in 1 mL of serum-containing medium. Fresh
medium (control) or drug-containing medium was added to the cells. Assays were conducted in
triplicate. Duplicate wells per cell line for each condition (control and drug treatments) were seeded
for each time point: day 0, day 4, and day 7. Cell counts were measured using the Guava Viacount
method. Doubling times were calculated between days 4 and 7 using the formula
Doubling time (hours) = 24× log 2x(Tt− T0)
(logNt− logN0) ,
where Tt is the end time point and T0 is the beginning time point (days), which in this case were 7 and
4, respectively, and N is the average cell count on each day.
2.4. Short-Term Resistance Assay
For the short-term resistance assays, 1.5 × 104 MDA-MB-231 cells per well were seeded in two
identical 12-well plates (Plate-1 and Plate-2) in 1 mL of medium with 10% foetal bovine serum (day 1)
and allowed to adhere overnight. The cells were treated with 2.5 μM compound A and/or 50 nM
dasatinib. In addition, in plate 1, three wells were untreated as a control. In plate 2, the cells were
similarly treated with 2.5 μM compound A and/or 50 nM dasatinib. Treatment was repeated twice
weekly. After seven days, when the untreated control cells achieved confluency, the medium was
removed from the cells in plate 1 and the cells were fixed with 3:1, v:v, methanol:acetic acid, (1 min),
then washed with PBS and stained with 0.05%, w:v, crystal violet (5 min). The cells were allowed to
air dry overnight, the crystal violet was eluted in 10% acetic acid and absorbance was measured at
590 nM. After 21 days, when the dasatinib-treated cells achieved confluency, cells in plate 2 were fixed
and stained as for plate 1.
2.5. Invasion/Migration Assays
Invasion and migration assays were carried out using 5 × 104 cells in Matrigel (Corning)-coated
24-well invasion inserts (BD Biosciences) for invasion assays and uncoated inserts for migration assays.
Cells were seeded in reduced serum medium (5% foetal calf serum in RPMI-1640) and incubated for
6 h to allow cell attachment, and then treated with 100 nM dasatinib for 18 h. Cells were stained with
crystal violet and the number of invading/migrating cells was estimated by counting 10 fields of view
at 200×magnification. The average count was multiplied by the conversion factor 140 (growth area of
membrane divided by field of view area, viewed at 200×magnification) to determine the total number
of invading/migrating cells. Invasion and migration assays were carried out in triplicate.
2.6. Dasatinib Accumulation Assays
Cells were seeded at the specified numbers in T25-cm2 cell culture flasks (Thermo Fisher, Dublin,
Ireland). After 24 h, the cell culture medium was removed and cells were treated with medium (control)
or medium containing 2 μM dasatinib for 2 h. Non-adherent cells were collected and combined with
adherent cells after trypsinisation, then centrifuged at 300 g for 3 min. The supernatant was removed
and the cells were resuspended in 1 mL of ice-cold PBS. Fifty microliters of the cell suspension were
removed for cell counting using the Guava Viacount method. The cell suspension was centrifuged as
before, and the supernatant was removed. The cell pellet was stored at −20 ◦C.
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Quantification of the mass of dasatinib present in the cells collected was performed using liquid
chromatography tandemmass spectrometry (LC-MS/MS), as previously described [14]. Briefly, the drug
was extracted using a liquid-liquid extraction procedure. One hundred microliters of 500 ng/mL
lapatinib were added to an extraction tube (internal standard), along with 200 μL of 1 M Ammonium
Formate pH 3.5 buffer and 1.6 mL of extraction solvent tert-Butyl Methyl Ether (tBME)/ acetonitrile
(ACN) (3:1 v:v). The extraction tubes were vortexed and mixed on a blood tube mixer for 15 min.
The samples were centrifuged at 6500 g for 5 min; the organic layer was removed and 1.1 mL of solvent
was transferred to conical bottomed glass LC autosampler vials (Sigma-Aldrich, Dublin, Ireland).
The vials were evaporated to dryness using a Genevac EZ-2 (Ipswich, UK) evaporator at ambient
temperature, without light. The samples were reconstituted in 40 μL of acetonitrile with 20 μL injected
automatically by the autosampler. The LC-MS was run in isocratic mobile phase (54% ACN:10 mM
ammonium formate, pH 4) on a Hyperclone BDS C18 column, in multi-reaction monitoring (MRM)
positive ion mode. Analysis was performed using MRM mode with the following transitions: m/z
581→m/z 365 for lapatinib, and m/z 488→m/z (231 and 401) for dasatinib, with a dwell time of 200 ms.
Quantification was based on the integrated peak area determined by the Masshunter Quantification
Analysis software, which quantitates the peak areas of the MRM transitions of each analyte. Results
are reported as mean and standard deviation (SD) of the mass per million cells in triplicate flasks.
2.7. Protein Extraction and Western Blotting
RIPA buffer with 1× protease inhibitors, 2 mM PMSF and 1 mM sodium orthovanadate
(Sigma-Aldrich) was added to cells and incubated on ice for 20 min. Following centrifugation
at 10,000 rpm for 10 min at 4 ◦C, the resulting lysate was stored at −80 ◦C. Protein quantification
was performed using the bicinchoninic acid (BCA) assay (Pierce). Thirty micrograms of protein in
sample buffer were heated to 95 ◦C for 5 min and proteins were separated on 7.5% gels (Lonza)
or 4–12% gels (Thermo-Fischer, Dublin, Ireland). The protein was transferred to a nitrocellulose
membrane. The membrane was blocked with a blocking solution (PBS + 0.1% Tween + 5% skimmed
milk powder (BioRad, Dublin, Ireland) or a 1× NET solution buffer (0.5 M NaCl, 0.05 M EDTA, 0.1 M
Tris pH 7.8) at room temperature for 1 h, then incubated overnight at 4 ◦C in a blocking solution with
a 1:1000 antibody dilution of total Src, c-Met, p-Met Y1234/1235 (Cell Signalling Technology, Leiden,
Netherlands) or 1:500 p-Src Y419 (Merck-Millipore). The membrane was washed three times with
PBS-Tween or 1× NET, then incubated at room temperature with anti-mouse secondary antibody
(Sigma-Aldrich) at 1:1000 dilution or anti-rabbit secondary antibody (Sigma-Aldrich) at a 1:1000
dilution in blocking solution for 1 h. The membrane was washed three times with PBS-Tween/1× NET
followed by one PBS wash. Detection was performed using Luminol (Santa Cruz Biotechnology,
Heidelberg, Germany).
2.8. Luminex Magnetic Bead Assays
Magnetic bead assays were performed on the Luminex® MagPix® System (Merck Millipore
(80-073), Dublin, Ireland) using Milliplex Map Phospho Mitogenesis RTK Magnetic Bead 7-Plex Kit
(Merck Millipore 48-672 Mag) and Milliplex Map phospho Human Src Family Kinase Magnetic Bead
8-Plex kit (Merck Millipore 48-650 Mag). Protein extractions were prepared as described above. Protein
(1–10 μg) was diluted in appropriate volume of assay buffer (final volume: 25 μL/well) and the assay
was performed as per the manufacturer’s instructions.
2.9. DNA Extraction and Nested PCR Amplification of Src Exons 9–12
DNA was extracted from the parent MDA-MB-231 and the resistant 231DasB cell lines using
the QIAamp® DNA mini kit (Qiagen, Hilden, Germany). Exons 9–12 of the Src gene were amplified
using the primer sets in Table S1. The forward outer primer and the reverse primer were used in the
first PCR reaction and the forward inner primer and the reverse primer were used in the second PCR
reaction. The following PCR conditions were used for the first reaction: 5 μL 10×Amplitaq Gold Buffer
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(Thermo-Fischer, Dublin, Ireland), 3 μL 25 mM MgCl2, 1 μL 10 mM dNTPs, 5 μM each of forward and
reverse primer, 0.25 μL Amplitaq Gold DNA Polymerase (Applied Biosystems, Foster City, CA, USA)
and 50 ng of DNA made up to a volume of 50 μL with dH2O. A pre-PCR heat step of 95 ◦C for 5 min
was carried out to activate the enzyme and the DNA was amplified for 35 cycles at 95 ◦C (1 min), 56 ◦C
(1 min) and 72 ◦C (1 min) and at 72 ◦C (10 min) after the last cycle. The second PCR was carried out
as above with 1 μL of the first PCR reaction replacing the DNA. Ten microliters of the PCR product
were electrophoresed on 1% agarose gel to verify product integrity. PCR products were purified using
a QIAquick PCR purification kit (Qiagen). The DNA concentration was measured using the Nanodrop
1000 spectrophotometer (Thermo Fischer, Dublin, Ireland).
2.10. Cycle Sequencing of PCR Products
Cycle sequencing reactions were set up as follows: 2 μL of BigDye® Terminator Mix v3.1, 20 ng
amplicon DNA, 3.2 pmol of forward or reverse primer, 2 μL sequencing buffer and diluted to 20 μL
with water. A positive control was also set up to ensure the efficiency of the sequencing reaction
(1 μL pGem, 2 μL M13 primer, 2 μL of BigDye® Terminator Mix v3.1 and 2 μL sequencing buffer).
The pGem and BigDye® Terminator v3.1 mix were both sourced from Applied Biosystems (Warrington,
UK). Initial denaturation was carried out by a rapid thermal ramp to 96 ◦C (1 min), followed by
25 cycles of: rapid thermal ramp to 96 ◦C (10 s), rapid thermal ramp to 50 ◦C (5 s), rapid thermal
ramp to 60 ◦C (4 min). Unincorporated dye terminators were removed before performing capillary
electrophoresis using the DyeEx 2.0 Spinkit (Qiagen). Sequencing was performed on a 3130xl genetic
analyser (Thermo-Ficsher, Ireland, and sequencing files were analysed using the BioEdit v 7.0.8 (Tom
Hall, Ibis Biosciences, Carlsbad, CA, USA).
2.11. Statistical Analysis
Alterations in doubling times of cell lines, changes in the invasive and migratory potential of
cell lines, and alterations in proteomic signalling were measured using the Student’s t-test. Error
bars represent the standard deviation of triplicate experiments, where ‘*’/’**’indicates a p-value of
≤ 0.05/0.01, respectively, where a p-value < 0.05 was considered statistically significant.
3. Results
3.1. Dasatinib Exposure Induces a Resistant Phenotype
MDA-MB-231 cells are very sensitive to growth inhibition by dasatinib (IC50 = 40 ± 1 nM) [3].
A cell line model of acquired resistance to dasatinib, MDA-MB-231 cells, was developed by continuous
exposure to dasatinib for approximately three months. Following this treatment the IC50 value for
dasatinib increased to greater than 5 μM, confirming acquired resistance to dasatinib (IC50 > 1 μM)
(8) compared to MDA-MB-231 cells (Figure 1A). The MDA-MB-231 cells that developed acquired
resistance to dasatinib were referred to as 231 DasB.
No significant difference in growth rate was observed between the MDA-MB-231 parental cells
and the 231-DasB cells. MDA-MB-231 cells show a significant dose dependent increase in doubling
time in the presence of dasatinib, whereas the 231-DasB cells show no significant change in doubling
time in response to dasatinib (Table 1).
Table 1. Doubling time in hours (± standard deviation) of MDA-MB-231 and MDA-MB-231-Das cells
with and without dasatinib treatment. * indicates p < 0.05 calculated using the Student’s t-test.
Cell Line Control D 50 nM D 100 nM
MDA-MB-231 17.6 ± 1.2 32.2 ± 3.3* 46.8 ± 5.1*
231 DasB 19.1 ± 2.4 21.0 ± 0.2 21.2 ± 3.1
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We have previously shown that dasatinib treatment significantly decreases migration and invasion
of MDA-MB-231 cells [3]. Migration, but not invasion, was significantly increased in the 231-DasB
variant compared to the parental cell line (p = 0.009) (Figure 1B). In the 231-DasB-resistant variant,
dasatinib did not inhibit invasion (p = 0.772) (Figure 1C) or migration (p = 0.340) (Figure 1D).
 
Figure 1. Characterisation of the 231DasB cell line: (A) Proliferation assays of MDA-MB-231 and
231-DasB with serially decreasing concentrations of dasatinib from 10 μM; (B) representative images of
MDA-MB-231 and 231-DasB post-18 h 100 nM dasatinib treatment in invasion and migration assays;
(C) invasion assays and (D) migration assays of MDA-MB-231 and 231-DasB post-18 h 100 nM dasatinib
treatment. Error bars represent the standard deviation of triplicate experiments. * p ≤ 0.05. p values
were calculated using the Student’s t-test.
Dasatinib is a substrate for the drug efflux pumps BCRP and MDR-1 [15]. Therefore, in order
to determine if drug efflux pumps were involved in the resistance to dasatinib in 231-DasB cells,
we assessed the uptake of dasatinib in the parental MDA-MB-231 cells and the resistant variant,
231-DasB. Initially, dasatinib accumulation was measured using 2 μM dasatinib across a range of cell
seeding numbers. While the relative mass of drug measured increased with decreasing cell density, no
significant difference in accumulation between parental and variant cells was observed, suggesting
drug pumps do not influence resistance to dasatinib in the 231-DasB cell line (Figure S1). To confirm
this, we tested growth inhibition with dasatinib combined with the potent BCRP and MDR-1 inhibitor,
elacridar [16]. Proliferation was measured in the parental and variant cell lines treated with dasatinib
alone or in combination with a concentration of elacridar sufficient to inhibit BCRP [17] and MDR-1 [18].
The addition of elacridar did not cause a significant increase in dasatinib-induced growth inhibition in
either the parental or the variant cell line (Figure S2).
3.2. Phosphorylation of Src Is Altered in Dasatinib-Resistant Cells
The 231-DasB cells were tested for cross-resistance to the Src kinase inhibitor PD180970.
The 231-DasB cells showed a 2.2-fold increase in the PD180970 IC50 compared to the MDA-MB-231 cells
(876.1 ± 74.4 versus 400.2 ± 35.6 nM, p = 0.003), implicating Src in the resistant phenotype. Therefore,
we examined phosphorylation of Src in the resistant cells. As expected, dasatinib treatment reduced
the levels of p-Src (Y419) in MDA-MB-231 cells but no reduction in p-Src (Y419) was observed in
the 231-DasB cells following dasatinib treatment (25–200 nM) (Figure 2A). The Src family kinases
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(SFKs) consist of nine family members with high conservation between family members at tyrosine 419
(Y419). We examined the phosphorylation of seven of these proteins using magnetic multiplex assays.
Consistent with the Western blot results, MDA-MB-231 showed a significant reduction in p-Src in
response to dasatinib treatment (Figure 2B). p-FYN, p-YES and p-LYN were also significantly reduced
after treatment with dasatinib. In the 231-DasB cells, treatment with dasatinib did not decrease the
level of any of the phospho-SFK proteins examined (Figure 2B).
To determine if a mutation in the active site of Src kinase may be causing constitutive activation of
p-Src, in the presence of dasatinib, we sequenced exons 9–12 of the Src gene, which encompass tyrosine
419 and the regulatory site at tyrosine 530 [19,20], in both the MDA-MB-231 parental and 231DasB
cells. No alteration in the Src sequence was detected in the 231DasB cells (Figure S3).
 
Figure 2. (A) Levels of total Src and phosphorylated Src [pY419] in MDA-MB-231 (parental and
231-DasB cells treated with dasatinib for 6 h. (P-: phospho-; C: control (untreated); D: dasatinib (nM)).
(B) Phosphorylation of Src family kinases as determined by multiplex bead assay in MDA-MB-231 and
231-DasB cell lines with and without 6-h dasatinib treatment (100 nM). NET MFI is net median
fluorescence intensity. Error bars represent the standard deviations of triplicate independent
experiments. * indicates p < 0.05 calculated using the Student’s t-test.
3.3. cMet Signalling Is Increased in Dasatinib-Resistant Cells
To investigate the possible role of upstream receptor tyrosine kinases (RTKs) in activation of Src
kinase in the 231DasB cells, we examined the phosphorylation of a panel of RTKs using a multiplex
assay. c-Met (panTYR) was the only RTK of the five tested that was altered in the 231-DasB cells.
231-DasB cells show significantly higher levels of p-Met (p = 0.004) as determined by ELISA, compared
to the MDA-MB-231 cells (Figure 3A). We then demonstrated a non-significant 1.4-fold increase
(p = 0.08) in phosphorylation of c-Met at its activation site (Y1234/Y1235) (Figure 3B). The difference in
results between ELISA and Western blotting is likely due to the ELISA assay detecting all changes in
p-Met activation, whilst we only analysed changes in p-Met (Y1234/1235) using Western blotting.
Based on the increased levels of p-Met in the 231-DasB cells, we examined sensitivity to a c-Met
inhibitor, compound A (CpdA). The 231-DasB cells are more sensitive to CpdA, with an IC50 of
1.4 ± 0.5 μM, compared to the MDA-MB-231 cells where the CpdA IC50 is 6.8 ± 0.2 μM (Figure 3C).
Combined treatment with CpdA and dasatinib resulted in significantly decreased growth in
MDA-MB-231 (p = 0.02) (Figure 3D). In the 231-DasB cells, the combination did not enhance growth
inhibition compared to CpdA alone (Figure 3D).
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Figure 3. (A) Phosphorylation of five RTKs in the MDA-MB-231 and 231-DasB cell lines, where NET
MFI is net median fluorescence. Error bars represent the standard deviations of triplicate independent
experiments. * indicates p < 0.05. p values were calculated using the Student’s t-test. (B) Immunoblots
for p-Met (Y1234/Y1235) and total Met in MDA-MB-231 and 231-DasB cells. α-tubulin was used
a loading control. (C) MDA-MB-231 and 231-DasB dose-response curves with serially decreasing
concentrations of CpdA from 10 μM; (D) Fixed concentration proliferation assays with 100 nM dasatinib
and 5 μM CpdA in MDA-MB-231 and 231-DasB cells.
The combined treatment also significantly reduced invasion in the MDA-MB-231 cells (p = 0.002),
but not in the 231-DasB cells (Figure 4A).We examined the effects of CpdA on the phosphorylation of the
SFKs. No significant change was observed in the parental MDA-MB-231 cells following treatment with
CpdA;however, in 231-DasB cells six of the eight p-SFKs showa significant reduction inphosphorylation.
FYN, YES, LCK, LYN, FGR and BLK all show significant reductions in phosphorylation in response to
CpdA treatment (5 μM) (Figure 4B).
 
Figure 4. (A) Invasion assays in MDA-MB-231 and 231-DasB cells with/without dasatinib (100 nM)
and/or CpdA (5 μM); (B) phosphorylation of SFKs in MDA-MB-231 and 231-DasB in response to
dasatinib 100 nM and CpdA (5 μM) where NET MFI is net median fluorescence intensity. * p < 0.05,
** p < 0.01. Error bars represent the standard deviations of triplicate independent experiments. p values
were calculated using the Student’s t-test.
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3.4. cMET Inhibition Blocks Dasatinib Resistance
To determine if cMET inhibition may prevent the emergence of resistance to dasatinib in TNBC
cells, the MDA-MB-231 cells were treated with CpdA alone (2.5 μM), dasatinib alone (50 nM) or
dasatinib plus CpdA. After seven days of treatment, both CpdA and dasatinib as single agents showed
significant inhibition of growth (Figure 5). However, by day 21 cells treated with either CpdA or
dasatinib started to grow again, suggesting the emergence of resistance, whereas the cells treated with
CpdA combined with dasatinib showed no evidence of significant regrowth (Figure 5).
 
Figure 5. Short-term resistance assay in MDA-MB-231 cells treated with 2.5 μM CpdA and/or 50 nM
dasatinib for seven days and 21 days. Optical density (OD) was determined by measuring the
absorbance of the crystal violet eluted from stained cells, at 590 nM. Error bars represent the standard
deviation of triplicate experiments.
4. Discussion
Pre-clinical models of TNBC demonstrated significant sensitivity to the multi-targeted Src kinase
inhibitor dasatinib (with specificity for BCR/Abl and Src family kinases); however, clinical trials with
single-agent dasatinib showed limited efficacy in unselected populations [3,8,12]. In this study we
sought to study the effects of long-term exposure to dasatinib on MDA-MB-231 cells, which are highly
sensitive to dasatinib in three- or five-day proliferation assays [3,8]. Clinical studies indicated that
significant resistance emerged within three months of continuous exposure to physiologically relevant
concentrations of dasatinib [21,22]. Interestingly, we also demonstrated that resistance to dasatinib
developed very quickly in the MDA-MB-231 cells. In HER2 positive breast cancer cell lines, we have
found that resistance to HER2 targeted therapies generally emerges after approximately six months of
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continuous exposure [23,24]. This rapid development of dasatinib resistance may contribute to the
lack of clinical activity observed in the single-agent phase II clinical trials.
As dasatinib is a substrate for the drug efflux pumps BCRP and MDR-1 [15], we performed
accumulation assays to determine if the concentration of dasatinib achieved in the resistant cells was
lower than in the parental cells. No difference in dasatinib accumulation was observed in the resistant
cells and inhibition of MDR-1 and BCRP by elacridar did not enhance response to dasatinib in the
resistant cells. Taken together, these results suggest that neither altered drug uptake nor efflux plays
a role in the acquired dasatinib-resistant phenotype in these cells.
In the 231-DasB cells phosphorylation of Src at Y419 is not inhibited by dasatinib. This site is highly
conserved across the SFKs. Therefore, to examine if specific SFKs are altered in the resistant cells we
performed a multiplex assay for seven SFK members. Src was the only member of the SFK family that
showed increased phosphorylation in the resistant cells. While dasatinib inhibited phosphorylation of
several of the SFKs in MDA-MB-231 cells, it did not inhibit phosphorylation of any of the SFKs in the
resistant cells.
Activation of Src kinase has been documented in a number of cancer types; however, activating
mutations are rare. A truncating mutation in Src at Y530 has been identified in small subsets of
colon and endometrial cancers [20,25]. To determine if a mutation in Src could cause constitutive Src
phosphorylation in 231-DasB cells, we sequenced exons 9–12 of the Src gene, which encompass the
kinase domain and the regulatory site at tyrosine 530 [19]. No mutations were detected in the Src gene
the 231-DasB cell line.
Altered receptor tyrosine kinase signalling, in particular EGFR and c-Met signalling have been
implicated in increased pSrc signalling in cancer, particularly in lung cancer but also in breast
cancer [26,27]. Therefore, we examined whether altered RTK signalling might play a role in the
dasatinib-resistant phenotype. Of the five RTKs examined, only c-MET showed an increase in
phosphorylation in the resistant cells. Although EGFR has been implicated in cross-talk with both Src
and MET, pEGFR levels were unaltered in the 231-DasB cells suggesting that EGFR is not a mediator of
the dasatinib-resistant phenotype.
Recently another TNBC model of dasatinib resistance has been described, using the BT20 cell line.
Pinedo-Carpio et al. found that chronic exposure to dasatinib resulted in increased expression of TGFβ2
and increased resistance to a TGFβ inhibitor, with a shift towards non-canonical TGFβ signalling [28].
Zhang et al. have previously shown that non-canonical TGFβ signalling can stimulate phosphorylation
of Src at Tyr419 in a lung cancer cell line [29]. Thus, it is possible that non-canonical TGFβ signalling
may also play a role in the dasatinib resistance in our 231-DasB model. The MDA-MB-231 cell line used
in our analysis represents a post-EMT cell line [1], whilst the BT20 dasatinib-resistant model [2] is not
an epithelial-mesenchymal transition (EMT) cell line. Finn et al. reported that the majority of post-EMT
TNBC cell lines are highly sensitive to dasatinib, similar to MDA-MB-231. Pinedo-Carpio et al. [2] did
not report any changes in cMET expression as a result of acquired dasatinib resistance, indicating that
the changes we observed in cMet in the 231 DasB cells may be unique to post-EMT cells in response
to dasatinib treatment. Consistent, however, with the increased p-Met levels, the 231-DasB cells also
showed increased sensitivity to the Met inhibitor CpdA. Interestingly, the combination of CpdA and
dasatinib resulted in significantly enhanced growth inhibition in the parental cell line but not in the
231-DasB cells. Furthermore, short-term resistance assays in the MDA-MB-231 cells showed that, in
the presence of compound A, dasatinib resistance did not emerge, suggesting that c-Met inhibition
may sensitise the cells to dasatinib and prevent the delay or block the development of dasatinib
resistance. CpdA also enhanced dasatinib-mediated inhibition of invasion in the parental cells but not
in the resistant cells. In 231-DasB cells, CpdA inhibits phosphorylation of several members of the SFK
family—FYN, YES, LCK, LYN, FGR and BLK—but did not inhibit phosphorylation of Src. Our results
suggest that pSrc signalling may be critical in the development of the aggressive phenotype of TNBC,
and that the inhibition of p-Src may be required to overcome established resistance to dasatinib and
possibly the aggressive, invasive behaviour of TNBC.
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c-Met has previously been implicated in other models of acquired resistance to other small
molecule inhibitors, chemotherapy and radiotherapies. Cabozantinib, a small-molecule c-Met inhibitor,
has been shown to overcome gemcitabine resistance in pancreatic cancer and, quite encouragingly,
displayed only a very low level of acquired resistance despite long-term treatment [30]. A similar
situation was observed in two primary multiple myeloma cell lines that show increased p-Met at
the development of resistance compared to the sensitive cell lines [31]. In the MDA-MB-231 cell
line, ionising radiation increases the activation of c-Met and targeting the cells with a c-Met inhibitor
sensitises the cells to radiation therapy [32]. Met has also been implicated in the resistance to the
antiangiogenic therapy bevacizumab in glioblastomas [33]. Upregulation of c-Met was noted after
exposure to bevacizumab. Our results suggest that, while c-Met may be a potential target in the
acquired resistance setting, it may also be appropriate to target c-Met in combination with other
therapies to prevent the development of resistance.
Dasatinib has been previously tested and has failed clinical trials in breast cancer; however,
combining dasatinib with a c-Met inhibitor may be a rational therapeutic strategy to test in TNBC.
Further evaluation in preclinical models of TNBC, including in vivo, would be required to support
the progression of this combination into clinical trials. Furthermore, the evaluation of changes in
the phosphorylation of c-Met following dasatinib treatment in tumours from patients enrolled on
previous dasatinib clinical trials would be important. These trials, which included sample collection
for biomarker studies ([11], NCT00817531), would elucidate whether the increase in p-Met levels that
we observed in vitro following dasatinib treatment also occurs in TNBC cells in patients following
dasatinib exposure. If increases in p-Met were detected in dasatinib-treated tumours, it would support
clinical testing of dasatinib plus a c-Met inhibitor to block the development of dasatinib resistance.
5. Conclusions
In conclusion, our results suggest that cMet may be a rational target in triple-negative tumours
that have developed acquired resistance to dasatinib; or, perhaps a better approach may be to combine
dasatinib and cMet inhibition before metastasis occurs to improve the response to dasatinib and
potentially block the emergence of resistant cells.
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Abstract: Background:We aim tounderstandwhether all patientswith hormonal receptor (HR)-positive
(+)/human epidermal growth factor receptor-2 (HER2)-negative (−) metastatic breast cancer (MBC)
should receive cyclin D-dependent kinase (CDK) 4/6 inhibitor-based therapy as a first-line approach.
Methods: A network meta-analysis (NMA) using the Bayesian hierarchical arm-based model, which
provides the estimates for various effect sizes, were computed. Results: First-line treatment options
in HR+/HER2− MBC, including CDK 4/6 inhibitors combined with aromatase inhibitors (AIs) or
fulvestrant (F), showed a significantly longer progression-free survival (PFS) in comparison with
AI monotherapy, with a total of 26% progression risk reduction. In the indirect comparison across
the three classes of CDK 4/6 inhibitors and F endocrine-based therapies, the first strategy resulted
in longer PFS, regardless of specific CDK 4/6 inhibitor (HR: 0.68; 95% CrI: 0.53–0.87 for palbociclib
+ AI, HR: 0.65; 95% CrI: 0.53–0.79 for ribociclib + AI, HR: 0.63; 95% CrI: 0.47–0.86 for abemaciclib
+ AI) and patient’s characteristics. Longer PFS was also found in patients with bone-only and soft
tissues limited disease treated with CDK 4/6 inhibitors. Conclusions: CDK 4/6 inhibitors have similar
efficacy when associated with an AI in the first-line treatment of HR+MBC, and are superior to either
F or AI monotherapy, regardless of any other patients or tumor characteristics.
Cancers 2019, 11, 1661; doi:10.3390/cancers11111661 www.mdpi.com/journal/cancers173
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1. Introduction
Hormone receptor (HR)-positive (+) and human epidermal growth factor receptor type
(HER2)-negative (−) metastatic breast cancer (MBC) represents the most common invasive cancer
subtype in women [1]. Almost two-thirds of women with newly diagnosed MBC have HR+ tumors,
and approximately 25% of women with an early HR+ breast cancer diagnosis eventually relapse after
adjuvant treatments [2].
As the role of estrogens in etiology and breast cancer progression is well-established, the
modification of estrogen activity has represented the treatment of choice in women with HR+MBC
for several years, particularly for those with slowly progressive disease and limited tumor-related
symptoms [3]. Selective estrogen receptormodulators (such as tamoxifen) [4], selective estrogen receptor
down-regulators (SERDs, like fulvestrant [F]) [5,6] aromatase inhibitors (AIs; such asletrozole [7],
anastrazole [8] or exemestane [9]) are the mainstay of anticancer endocrine therapy (ET) [10]. The
recent addition of CDK 4/6 inhibitors to standard ET has further improved outcomes in both first- and
later-line therapy settings. CDK 4/6 inhibitors act by inactivating the complex CDK-D-type cyclins
(CCND), leading to an increase in the retinoblastoma protein (pRb), which negatively regulates E2F
transcriptional factors, eventually resulting in the inhibition of cell cycle progression and apoptosis of
tumor cells [11].
In the first-line setting, CDK 4/6 inhibitors, which mechanistically work in different ways through
estrogen receptor interference, have been studied in combination with AIs in the PALOMA-2 [12],
MONALEESA-2 [13], and MONARCH-3 studies in the context of postmenopausal women [14], as well
as in premenopausal women, in combination with either tamoxifen or an AI in the MONALEESA-7
study [15]. In particular, palbociclib, ribociclib, and abemaciclib, the three available CDK 4/6 inhibitors,
in combination with standard ET, showed progression-free survival (PFS) improvement in phase III
trials, and have been approved for use in first and in later lines of therapy in women with HR+HER2−
MBC, regardless of menopausal status, age, endocrine sensitivity and type of metastasis [12,16].
Interestingly, although the mechanism of action of these CDK 4/6 inhibitors is similar, they also present
some differences. In fact, while palbociclib and ribociclib have a similar chemical structure, abemaciclib
is 14-times more potent against CDK 4 compared with CDK 6 and presents a higher selectivity for the
complex CDK 4/cyclin D1 [11].
Despite the progress made in efficacy, combination therapy also resulted in increased toxicities,
costs, and tighter clinical monitoring for patients [17]. In addition, the improvement in PFS has not yet
translated into an increase in overall survival (OS) for all studies focusing on first-line settings [18–20].
Therefore, how and when to incorporate CDK 4/6 inhibitors in the complex management of HR+
HER2−MBC remains one of the main unmet clinical need in this setting [21].
Indeed, single-agent ET yielded a median PFS ranging from 14 to 16 months in the control arms
of the first-line trials with CDK 4/6 inhibitors. Thus, the fact that for some patients, the addition of
CDK 4/6 inhibitors might be avoided is a debated clinical topic. Moreover, according to the Fulvestrant
and Anastrozole Compared in Hormonal Therapy Naive Advanced Breast Cancer (FALCON) trial,
comparing Fwith anastrozole in the same setting, the single-agent F therapymay be a further reasonable
option for HR+/HER2−MBC patients who are ET-naïve, especially those with the non-visceral disease.
Indeed, the median PFS of 16.6 months reported in the F arm compared with 13.3 months in the
anastrozole arm, which was observed in the context of the general population, was even higher in
patients without visceral disease (22.3 versus 13.6 months; hazard ratio [HR]: 0.59; 95% CI: 0.42–0.84) [5].
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The ongoing studies, which are evaluating predictivemarkers of endocrine resistance or sensitivity,
will probably provide enough evidence for helping in the clinical decision-making and for a better
definition of the optimal ET-based strategy for this specific set of luminal breast cancer [22–24].
In the meantime, in our current daily clinical practice, also considering minor or uncertain
differences in efficacy between the available CDK 4/6 inhibitors, the choice of first-line ET strategy is
essentially based on one of the three CDK 4/6 inhibitors according to their specific toxicity profile and
patient comorbidities or preferences.
Considering the lack of formal and reliable comparisons between the three CDK 4/6 inhibitors,
in addition to the lower toxicity profile of F, the aim of this systematic review and meta-analysis is the
indirect comparison between the combination strategy, including CDK 4/6 inhibitors plus AI [12–15],
and F-based therapies for the first-line treatment of HR+/HER2−MBC [5,25–27].
2. Materials and Methods
2.1. Search Strategy and Study Selection
We followed the PRISMA statement for reporting systematic reviews and meta-analysis. Two
authors independently examined the abstracts retrieved by a search strategy in electronic databases
(MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials) from November 2011 to
June 2019. We used the following search string ((metastatic breast cancer) AND (CDK 4/6 inhibitor OR
endocrine therapy OR aromatase inhibitor OR letrozole OR anastrozole OR exemestane OR tamoxifen
OR F OR palbociclib OR everolimus OR ribociclib OR abemaciclib). The research was conducted on
5 June 2019. Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting, San
Antonio Breast Cancer Annual Symposium, and the European Society of Medical Oncology Annual
Meeting were also queried from November 2011 to June 2019 for relevant abstracts. In cases where a
report of the same trial was obtained, the most recent results were included (corresponding to longer
follow-up). Then, the authors examined full-text articles of potentially eligible studies according to
the eligibility criteria. Disagreements on the inclusion of selected trials were resolved in discussions
with another author. This article does not contain any studies with human participants or animals
performed by any of the authors. It was unnecessary, given the study does not contain any studies
with human participants or animals performed by any of the authors.
2.2. Eligibility Criteria
We decided only to include phase III randomized controlled trials (RCTs) that reported the
comparison of CDK 4/6 inhibitors plus ET or F plus or less ET versus ET treatment alone as first-line
treatment in HR+/HER2−MBC. We also excluded trials with incomplete data or different control arm.
2.3. Outcomes
The primary outcomewas PFS, calculated from the date of randomization to the date of progression
(defined by the Response Evaluation Criteria in Solid Tumors “RECIST” 1.1 criteria or death). The
secondary outcomes were: (1) objective response rate (ORR): defined as the percentage of patients
with complete or partial response as per RECIST 1.1 criteria (as assessed in all randomly assigned
patients); (2) clinical benefit (CB): defined as a confirmed complete or partial response or stable disease
lasting 24 weeks or more; (3) OS: defined as the time from randomization to death from any causes.
Subgroup meta-regression analysis was also conducted for PFS indirect comparison according to age,
Eastern Cooperative Oncology Group (ECOG) performance status, ethnicity, prior chemotherapy or
ET exposure, measurable disease at the time of metastasis occurrence, visceral or bone-only disease,
time from the initial diagnosis of breast cancer to metastasis onset.
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2.4. Data Collection and Statistical Analysis
A network meta-analysis (NMA) was carried out utilizing the method in the study by
Valkenhoef et al. [28], which performed NMA using the Bayesian hierarchical arm-based model
and provides estimates for various effect sizes. For PFS, HR and 95% credible interval (CrI) were
reported. In addition, ORR and CB rates were reported, and the results were expressed as odds ratios
(OR) with their 95% CrI. The NMA plot, in which treatments directly compared were connected with
straight line was generated. NMAs on patients’ subgroups were also performed. All analyses were
performed using R Statistical Software version 3.4.3 along with the gemtc package, which uses Markov
chain Monte Carlo (MCMC) techniques through Just Another Gibbs Sampler (JAGS) [29].
3. Results
3.1. Study Selection
Through the search strategy, we identified four phase III trials comparing 1441 patients
treated with CDK 4/6 inhibitors (palbociclib, ribociclibor, abemaciclib) in combination with an AI
(1106 patients) [12–14], an AI plus ovarian function suppression (OFS; 248 premenopausal patients),
or tamoxifen plus OFS (87 premenopausal patients) [15]. Three other phase III randomized controlled
trials (RCTs) compared 837 patients treated with F alone (230 patients) or in combination with AI
(607 patients) versus a total of 1891 patients treated with AI alone (letrozole 2.5 mg daily or anastrozole
1 mg per day on a continuous schedule), tamoxifen plus OFS (90 premenopausal patients) or AI
plus OFS (247 premenopausal) [5,25,27]. The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow diagram for study inclusion is shown in Figure 1.
 
Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
chart summarizing the process for the identification of the eligible studies.
3.2. Description of Studies and Patients
Table 1 summarizes the main characteristics and outcomes of each trial. Palbociclib and ribociclib
were tested in combination with letrozole 2.5 mg/day in PALOMA-2 and MONALEESA-2, respectively.
Abemaciclib was used in combination with anastrozole 1 mg/day (19.9%) or letrozole 2.5 mg/day
(79.1%) as per the physician’s choice in the MONARCH-3 trial. Furthermore, ribociclib was also
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studied in premenopausal patients in the context of the MONALEESA-7 trial. Specifically, in this
study, ribociclib was combined with tamoxifen plus goserelin (26%) or with letrozole 2.5 mg/day or
anastrozole 1 mg/day plus goserelin (74%). Eventually, F alone or in combination with anastrozole
1 mg/day was compared with the AI in the FALCON, Southwest Oncology Group (SWOG), and
Fulvestrant and Anastrozole Combination Therapy (FACT) trials. The primary outcome was PFS in all
trials (Table 1); secondary outcomes (ORR, CB rate, OS) in all trials were also reported in Table 1, while
the NMA core design is shown in Figure 2. The network plot in Figure 2 offers a visual representation of
the evidence. Nodes represent treatments, and edges represent the available direct comparisons—that
is, they connect treatments that are directly compared in studies.
???????????
??
???????????
???????????
??????????
Figure 2. The network meta-analysis design: Network plot of the network meta-analysis.
AI: Aromatase inhibitor.
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3.3. Outcomes
3.3.1. Progression-Free Survival
As shown in the indirect comparison between CDK 4/6 inhibitors versus F-based therapies, the
first strategy resulted in longer PFS, regardless of the specific CDK 4/6 inhibitor (HR: 0.68; 95% CrI:
0.53–0.87 for palbociclib + AI, HR: 0.65; 95% CrI: 0.53–0.79 for ribociclib + AI, HR: 0.63; 95% CrI:
0.47–0.86 for abemaciclib + AI) (Figure 3; top)
Figure 3. Forest plotswith direct comparisons against fulvestrant for progression-free survival, objective
response rate, and clinical benefit rate. AI: Aromatase inhibitor.
3.3.2. Objective Response
The CDK 4/6 inhibitors combination strategies resulted in higher RR in indirect comparison with
F (OR:1.3; 95% CrI: 0.81–2.0 from palbociclib + AI versus AI: OR:1.6; 95% CrI: 1.1–2.5 from ribociclib +
AI versus AI: OR:1.6; 95% CrI: 1.1–2.4 from abemaciclib + AI versus AI). (Figure 3; middle)
3.3.3. Clinical Benefit
The CDK 4/6 inhibitor combination strategies resulted in higher CB in indirect comparison with F
(OR: 2.1; 95% CrI: 1.3–3.3 from palbociclib + AI versus AI: OR: 1.3; 95% CrI: 0.92–1.8 from ribociclib +
AI versus AI: OR:1.2; 95% CrI: 0.81–1.8 from abemaciclib + AI versus AI). (Figure 3; bottom).
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3.3.4. Overall Survival
For overall survival (OS), no indirect comparison by NMA was performed because not all
the studies data were completely mature. Indeed, data on OS have been recently reported in the
MONALEESE-7 study where the estimated OS at 42 months was 70.2% (95% CI 63.5–76.0) in the CDK
4/6 inhibitor arm versus 46% (95% CI: 32–58.9) in the ET alone arm [18,19] In addition, also the SWOG
trial has recently shown the median OS of 49.8 months in 71% of the patients receiving F combination
strategy vs. 42 months in 76% of the patients receiving ET monotherapy alone [23].
3.3.5. Safety Profile
The main adverse effects registered in each trial are reported in Table 2.
Table 2. Main adverse effects registered in each trial.
Study Treatment AEs G3 (%) G4 (%)
PALOMA-2
Palbociclib–letrozole
Any AEs 62.2% 13.5%
Neutropenia 56.1% 10.4%
Leukopenia 24.1% 0.7%
Placebo–letrozole
Any AEs 22.1% 2.3%
Neutropenia 0.9% 0.5%
MONALEESA-2
Ribociclib–letrozole
Neutropenia 52.4% 9.6%
Abnormal LFT 8.4% 1.8%
Leukopenia 20.1% 1.2%
Placebo–letrozole
Abnormal LFT 2.4% –
Neutropenia, anemia,
arthralgia 1.2% –
MONARCH-3
Abemaciclib–nonsteroidal AI
Any AEs 51.7% 6.7%
Neutropenia 22.0% 1.8%
Leukopenia 8.3% 0.3%
ALT increase 6.1% 0.3%
Placebo–nonsteroidal AI
Any AEs 22.4% 2.5%
Neutropenia 0.6% 0.6%
MONALEESA-7
Ribociclib group
Any AEs 63% 14%
Neutropenia 51% 10%
Leukopenia 13% 1%
Placebo group Any AEs 26% 4%
Neutropenia 3% 1%
FALCON
Robertson
Fulvestrant
Arthralgia (17%)
Hot flush, fatigue, nausea (11%)
Back pain (9%)
Anastrozole Arthralgia, hot flush, nausea (10%)
SWOG
Mehta
Anastrozole
Musculoskeletal pain,
fatigue, hot flashes, mood
alterations, GI symptoms
15% (each 1–4%)
Anastrozole–fulvestrant
Musculoskeletal pain,
fatigue, hot flashes, mood
alterations, GI symptoms
13% (each 1–4%)
FACT
Bergh
Anastrozole
GI symptoms (25.2%)
Joint disorders (27.6%)
Hot flashes (13.8%)
Anastrozole–fulvestrant
GI symptoms (28.9%)
Joint disorders (26.6%)
Hot flashes (24.6%)
ALT: alanine aminotransferase; AE: adverse event; AI: aromatase inhibitor; GI: gastrointestinal; G3: grade 3; G4:
grade 4; LFT: liver function test.
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3.4. Subgroup Analyses
Table 3 summarizes the main patient’s characteristic according to subgroups analysis in each trial.
Subgroup NMA among the three classes of CDK 4/6 inhibitors and F is reported in Figure 4.
Figure 4. Forest plot on treatment effect for progression-free survival by subgroups in the indirect
comparison between CDK 4/6 inhibitors, aromatase inhibitors, and fulvestrant. AI: Aromatase inhibitor;
CT: Chemotherapy; ET: Endocrine therapy.
For PFS analysis of the seven selected phase III RCTs [5,12–15,25,27] according to prespecified
subgroups, a total of 2278 patients were in the CDK 4/6 inhibitors or fulvestrant arm and a total
of 1891 patients were in ET arm alone. Among them, 335 patients in the CDK 4/6 inhibitors and
337 patients in ET arms alone were premenopausal. The indirect comparison between CDK 4/6
inhibitors combination strategies and F-based therapies showed quite consistent PFS improvements
in favor of CDK 4/6 inhibitors in all subgroups. With reference to the most important NMA aim,
compared with F-based therapy, the CDK 4/6 inhibitor combination strategy was associated with PFS
improvement also in patients with disease limited to the bone or in non-visceral sites. Although no
statistically significant difference emerged among the three classes of inhibitors in indirect comparison,
NMA results also suggested a different potential tropism among them, which should be further
investigated in prospective clinical trials.
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4. Discussion
HR+/HER2− BC is the most common subtype of this disease, representing approximately 60–70%
of all breast tumors [1]. For many years, the sequential use of ET was the preferred approach in HR+
MBC patients due to its effectiveness and favorable toxicity profile [3,30,31]. The recent introduction
of new combinations of ET plus CDK 4/6 or phosphatidylinositol 3-kinases (PI3K) inhibitors led to
further clinical improvement in HR+MBC patients [30,31]. Regarding the first-line setting, several
randomized phase III clinical trials clearly demonstrated that the three highly selective CDK 4/6
inhibitors (palbociclib, ribociclib, abemaciclib) significantly improve ORR and CB and prolong PFS
when combined with an AI or tamoxifen, both in pre- and post-menopausal women [12–15].
Although clinical outcomes are very similar for the three CDK 4/6 inhibitors and are not influenced
by classic clinical and pathological factors, several differences were recognized concerning their toxicity
profile and mechanism of action. In the patients who received the combination CDK 4/6 inhibitor plus
ET, a higher incidence of hematologic adverse events occurred compared to control groups. The most
common hematologic adverse events with grade 3 or 4 were neutropenia (43% vs. 1%), leucopenia
(20% vs. 0.4%), anemia (5% vs. 1%), and thrombocytopenia (2% vs. 0.1%) [32]. Despite the high
incidence of neutropenia reported in the RCTs, a higher incidence of febrile neutropenia was not
recorded, which is evident just in 1.3% of patients. Unlike palbociclib and ribociclib, abemaciclib caused
low-grade diarrhea and transaminase elevation, readily managed with conventional medications
or dose reduction [17]. On the other hand, data suggest that abemaciclib has distinct single-agent
activity at the molecular level, which could reflect its unique effects and toxicity profile [33]. For
example, abemaciclib, but not ribociclib or pabociclib, is a potent inhibitor of kinases other than CDK
4/6, including CDK1/cyclin B, which appears to cause arrest in the G2 phase of the cell cycle, and
CDK2/cyclin E/A, which is implicated in resistance to palbociclib. Whereas ribociclib and palbociclib
induce cytostasis, and cells adapt to these drugs within 2–3 days of exposure, abemaciclib induces cell
death and durably blocks cell proliferation. Abemaciclib is active even in pRB-deficient cells in which
CDK 4/6 inhibition by palbociclib or ribociclib is completely ineffective [34]. In luminal tumors, some
useful biomarkers are being studied to identify the best target treatment combined with anti-hormonal
therapy and which can then determine the ideal choice for activity rather than toxicity. Recently, the
PI3K mutation presented in progressive luminal tumors from the first-line treatment with AI showed a
significant benefit in PFS when associated with F [35].
Against this background, knowing whether these three agents can be interchangeable remains an
urgent unmet clinical need [21,32,36,37]. Thus, a better understanding of molecular differences is a
relevant challenge since it could be informative for their right use in the clinical setting. Additionally,
since there are no comparative data between CDK 4/6 inhibitors and F, the hormonal agent approved
in endocrine-naïve patients with MBC for first-line setting, the identification of the most suitable
HR+ MBC patients who can benefit most from the less toxic F-based-therapy is still a significant
challenge [5,21]. Herein, we performed a meta-analysis, including only data from phase III RCTs
available concerning the same clinical scenario. This approach allows the synthesis of a large body of
evidence while retaining the benefits of randomization within each trial. Hence, we use this indirect
comparison method to investigate whether F-based ET could still play a role in some specific subgroup
of patients with HR+MBC in the first-line setting
In this meta-analysis, we found that CDK 4/6 inhibitors produced significant improvement in
ORR, CB, and PFS in all patients with HR+MBC in comparison with F-based therapies. Furthermore,
these results were independent of age, race, performance status, disease site, prior chemotherapy, prior
ET, disease-free interval after adjuvant treatment, menopausal status, type of CDK 4/6 inhibitor or
expression of the progesterone receptor. Interestingly, significant PFS improvement in favor of CDK
4/6 inhibitors was observed even in patients with bone-only disease and in non-visceral disease. Due
to the lack of convincing efficacy criteria to prefer one or the other CDK 4/6 inhibitor, the choice should
rely on the toxicity profile. It must be remembered, however, that no direct comparison has ever been
performed between the three CDK 4/6 inhibitors to allow an appropriate selection in the clinic.
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Our meta-analysis has several limitations suggesting caution in interpreting the results. First, it is
not based on individual patient data but was conducted considering the HR and 95% CIs of each study
extracted. Moreover, for some subgroups, the HRs were not reported in all studies, particularly in
F-based trials. In addition, the number of trials was relatively limited, preventing formal comparisons
among all treatment strategies for each group. Second, and this is a well-known caveat of studies with
F, not all the included studies with this compound used the now considered standard dose (500 mg
monthly plus an additional dose of 500 mg for 15 days during the first month) [25,27]. The CONFIRM
trial has revealed a superior activity of 500 mg when compared with 250 mg of F in terms of PFS and
OS [6]. Therefore, the non-standard F dose used in some trials may partially bias our findings. Third,
while the four RCTs [12–15] including CDK 4/6 inhibitors are rather homogenous in terms of inclusions
criteria and patient characteristics, the greater heterogeneity observed in F-based studies [5,25,27]
inevitably affected the pooled meta-analyses results. For instance, the line of therapy, metastatic sites,
tumor burden, prior anti-estrogen drugs, and anti-estrogen treatment sequence, previous endocrine
therapies sensitivity were also heterogeneous. Notably, F was more effective in endocrine-naïve
patients without the visceral disease [5]. As demonstrated in Table 1, the FALCON trial exclusively
included those patients who had never been exposed to ET, both in the metastatic and early settings.
By contrast, a percentage ranging from 40 to 65% of patients included in the remaining trials were
previously exposed to ET in the adjuvant or neoadjuvant settings. In addition, F efficacy in “bone-only”
limited disease was not established in all studies [27]. Finally, for peri and premenopausal patients, we
cannot rule out the possibility that the administered luteinizing hormone-releasing hormone analog
(LHRHa) may affect the final estimation, as LHRHa itself was reported as an effective endocrine
approach in breast cancer. Moreover, the limited number of peri or premenopausal patients in F-based
studies makes a comparison between F and CDK 4/6 inhibitor ET strategies unreliable in this setting of
patients. Specifically, while the FALCON and SWOG trials were enrolled merely post-menopausal
patients, in the FACT trial, premenopausal patients were also included and were treated with GnRHa.
Unfortunately, they only represented 3.1% of the experimental arm. Although previous reviews and
meta-analyses of treatments in MBC patients have been conducted, many of these studies focus on
population different from the current study. For example, Ayyagari et al. explored the safety and
efficacy of only two CDK 4/6 inhibitors (palbociclib and ribociclib) in postmenopausal women after
progression on a non-steroidal AI [35]. Ding et al. also conducted a similar NMA, focusing on the
results of all three CDK4/6 inhibitors in phase II and III trials both in the first and second lines; however,
the analysis did not include a direct comparison with F in first-line treatment [32]. Finally, El Rassy et al.
investigated which CDK4/6 inhibitor was more effective in patients with luminal breast cancer, but their
study was limited by the small sample size and lack of studies on F (1 included) [36]. Therefore, our
study specifically focused on the results of phase III studies in the first-line setting and comprised an
indirect comparison with first-line F. In addition, the present meta-analysis includes recently published
data that were not included in previous reviews, in particular, the results of MONALEESA-7 on
premenopausal women [32,36,37]. Despite the differences in study design and specific limitations, the
results of our and previous NMAs are consistent in reporting the improved clinical outcomes obtained
with CDK4/6 inhibitors compared with monotherapy [32,36,37].
5. Conclusions
In conclusion, the results of this meta-analysis confirm that CDK 4/6 inhibitors have similar
efficacy when associated with an AI in the first-line treatment of HR+MBC, and are superior to either
F or AI monotherapy, regardless of any other patients or tumor characteristics. Though all CDK 4/6
inhibitors resulted associatedwith similar outcomes, the differences in toxicity profile, drug interactions,
and patient preferences seem to be the main factors to be considered in the clinical decision-making
process. Interestingly, CDK 4/6 inhibitors with AI resulted in more effective than F-based therapies
even in patients with the bone-limited disease and, what is more, in patients without visceral disease
involvement. Hence, the use of F in the first-line setting is destined to be abandoned as a single agent,
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and its right place in HR+MBC patients management needs to be urgently refined. Based on preclinical
and early clinical trial results, its mechanism of action and pharmacokinetic properties make it an
ideal backbone for combination therapies contributing to overcome or delaying endocrine resistance.
Rational combinations with other therapies, such as PI3K inhibitors, HER2-directed therapies, and
immunotherapy, are being explored. The emerging data also suggest a potential use of CDK4/6-targeted
approaches in neoadjuvant settings (Supplementary Table S1). Different clinical trials are also ongoing
to assess the safety and efficacy of CDK4/6 inhibitors alone or in combination with chemotherapy in
different groups of patients. These trials, together with future comparative studies and biomarker
analyses, are indispensable to better select patients who derive the greatest benefit from a specific class
of CDK 4/6 inhibitors.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/11/1661/s1,
Table S1: The most important phase II or III ongoing clinical trials investigating CDK 4/6 inhibitors in breast cancer.
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Abstract: This study presents comprehensive real-world data on the use of anti-human epidermal
growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer
(MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab
(PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time,
real-world registry for MBC patients. All therapy lines are documented. This analysis describes
the utilization of anti-HER2 therapies as well as therapy sequences. Among 1936 patients in
PRAEGNANT, 451 were HER2-positive (23.3%). In the analysis set (417 patients), 53% of whom
were included in PRAEGNANT in the first-line setting, 241 were treated with H, 237 with PH,
85 with L, and 125 with T-DM1 during the course of their therapies. The sequence PH → T-DM1 was
administered in 51 patients. Higher Eastern Cooperative Oncology Group (ECOG) scores, negative
hormone receptor status, and visceral or brain metastases were associated with more frequent use of
this therapy sequence. Most patients received T-DM1 after treatment with pertuzumab. Both novel
therapies (PH and T-DM1) are utilized in a high proportion of HER2-positive breast cancer patients.
As most patients receive T-DM1 after PH, real-world data may help to clarify whether the efficacy of
this sequence is similar to that in the approval study.
Keywords: advanced breast cancer; metastatic; chemotherapy; antihormone therapy; HER2 c-erbB2;
HER2/neu; trastuzumab; pertuzumab; T-DM1; lapatinib
1. Introduction
Overexpression of human epidermal growth factor receptor 2 (HER2), or amplification of the
HER2 gene, is seen in approximately 15–25% of breast cancer (BC) patients [1]. Since the discovery in the
late 1980s of HER2 amplifications and their prognostic relevance [2], treatment for HER2-positive BC
in this subgroup of patients has greatly improved [3–6]. Adding the monoclonal anti-HER2 antibody
trastuzumab to standard chemotherapy resulted in a significant improvement in the progression-free
survival (PFS) and overall survival (OS) in patients with metastatic HER2-positive BC [7]. These results
led to the approval of trastuzumab for the treatment of HER2-positive metastatic BC.
Later, the dual tyrosine kinase inhibitor lapatinib was also analyzed in this group of patients.
Women whose cancers had progressed after treatment with an anthracycline, a taxane, and trastuzumab
were randomly assigned to therapy with capecitabine plus lapatinib or capecitabine alone. In contrast
to the monotherapy, the combination treatment led to a significantly longer PFS. Therefore, lapatinib
also became the standard of care in the early 2000s [8,9].
The CLEOPATRA study demonstrated an additional improvement in survival outcomes in
treatment-naïve (chemotherapy and biological therapy, one endocrine treatment was allowed)
HER2-positive patients with metastatic BC. Patients who were receiving docetaxel and dual HER2
blockade with trastuzumab plus pertuzumab, another monoclonal HER2 antibody, were compared
with patients receiving docetaxel plus trastuzumab alone. The improved survival results led to the
approval of pertuzumab for the first-line treatment setting. The enrolled patients were allowed to
have had (neo)adjuvant chemotherapy with or without trastuzumab. However, the observed benefit
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of the addition of palliative pertuzumab was independent of any previous (neo)adjuvant treatment
with trastuzumab [10,11].
Another HER2-targeted approved drug is trastuzumab emtansine (T-DM1), which was designed
as an antibody–drug conjugate to target specifically HER2-enriched tumor cells, and in this way,
reduce side effects in nontargeted tissue. In the EMILIA trial, the efficacy of T-DM1 was analyzed in
women with HER2-positive advanced or metastatic disease who had previously been treated with
a taxane and trastuzumab in the advanced therapy setting and were randomly assigned to second-line
or further treatment with T-DM1 versus capecitabine plus lapatinib. It was found that T-DM1 was
clearly superior with regard to survival outcomes in comparison with the control arm [12].
After the approval of T-DM1 and pertuzumab, the question arose of whether a combination of
the two might result in an additional benefit. However, the MARIANNE study showed in first-line
HER2-positive metastatic BC patients that neither T-DM1 alone nor T-DM1 in combination with
pertuzumab improved the PFS in comparison with trastuzumab plus a taxane [13]. Although the
reason for this remains unclear, there are cell line data that suggest that the correct therapy sequence
for the drugs might have an influence on the treatment response [14].
Moreover, novel substances are also being investigated to further improve outcomes for patients.
For instance, neratinib, another tyrosine kinase inhibitor, was recently approved for the adjuvant
treatment of patients with HER2-positive early BC, due to its significant improvement of five-year
disease-free survival (DFS) [15], and is currently also being analyzed in the metastatic setting. Afatinib,
however, did not show any improvement in the outcomes for patients withmetastatic BC in comparison
with trastuzumab [16]. Margetuximab has now made available a third novel HER2 antibody that
appears to enhance antibody-dependent cellular toxicity (ADCC), while at the same time being
well-tolerated [17]. Its efficacy and safety are currently being investigated in the phase III SOPHIA
trial in patients with HER2-positive metastatic BC who were previously treated with trastuzumab,
pertuzumab, and T-DM1 [14].
As more and more therapy options become available, it is possible that treatment sequences
may no longer be following the same inclusion and exclusion criteria as those that applied in the
respective clinical trials. Understanding current therapy practice may be helpful for estimating the
extent to which results from clinical trials can be generalized for specific patient populations. Therefore,
the objective of this study is to describe comprehensive real-world evidence on the use of trastuzumab,
pertuzumab, lapatinib, and T-DM1 in first-line treatment in the metastatic setting.
2. Patients and Methods
2.1. The PRAEGNANT Research Network
The PRAEGNANT study (Prospective Academic Translational Research Network for the
Optimization of the Oncological Health Care Quality in the Adjuvant and Advanced/Metastatic
Setting; NCT02338167 [18]) is an ongoing, prospective BC registry with a documentation system
similar to that of a clinical trial. The aims of PRAEGNANT are to assess treatment patterns and
quality of life, and to identify patients who may be eligible for clinical trials or specific targeted
treatments [18–21]. Patients can be included at any point in time during the course of their disease.
All of the patients included in the present study provided informed consent, and the study was
approved by the relevant ethics committees.
2.2. Patients
A total of 2379 patients with advanced or metastatic BC were registered in the PRAEGNANT
study between July 2014 and March 2018 at 52 study sites. Patients were excluded in the following
hierarchical order: 39 patients were excluded due to unknown HER2 status, as well as 53 patients due
to unknown hormone receptor status. In 138 patients, the date of the first diagnosis of a metastasis or
their birth date was missin. Therefore, these patients also had to be excluded. Male patients (n = 20)
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were also not included in the analysis. Treatment information was not available for an additional 193
women, leaving 1936 patients for whom the above-mentioned data were known. A total of 451 of
these women had HER2-positive tumors (Figure 1). For analysis, patients were divided into distinct
patient groups based on the documentation status concerning the therapy lines. Group 1 is defined as
the patient population for which only the first therapy line is documented. Group 2 is the population
for which the first and the second therapy lines are documented. Group 3 is the patient population
for which only the first, seco, nd and third therapy lines are documented. Group 4 is the patient
population for which at least the first to the forth therapy lines are documented. Each group cannot be
part of the other groups. These groups are the natural consequence of patients being treated with more
or less therapy lines in the metastatic setting.
Figure 1. Patient flow chart and patient selection.
2.3. Data Collection
The data were collected by trained staff and documented in an electronic case report form [18].
The data were monitored using automated plausibility checks and on-site monitoring. Data that
are not usually documented as part of routine clinical work are collected prospectively using
structured questionnaires completed on paper. These consist of epidemiological data, such as family
history, cancer risk factors, quality of life, nutrition and lifestyle items, and psychological health.
Supplementary Table S1 provides an overview of the collected data.
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2.4. Definition of Hormone Receptors, HER2 Status and Grading
The definition of hormone receptors, HER2 status, and grading was described previously [19].
Briefly, data about estrogen receptor status, progesterone receptor status, HER2 status, and grading
were obtained for documentation purposes for each tumor that had been biopsied. Therefore,
there could be several possible sources (right breast, left breast, local recurrence, metastatic site).
Biomarker status for ER, PR, and HER2 were determined as follows: If a biomarker assessment
of the metastatic site was available, this receptor status was used for the analysis. If there was no
information available for metastases, the latest biomarker results from the primary tumor were used.
Additionally, all patients who received estrogen therapy in the metastatic setting were assumed
to be HR-positive, and all patients who had ever received anti-HER2 therapy were assumed to
be HER2-positive. There was no central review of biomarkers. The study protocol recommended
assessing ER and PR status as positive if ≥ 1% was stained. A positive HER2 status required an
immunohistochemistry score of 3+ or positive fluorescence in situ hybridization/competitive in situ
hybridization (FISH/CISH).
2.5. Statistical Considerations
The analysis and reporting of treatments are descriptive. The total number of treatments for each
of the following four therapy lines are provided: Trastuzumab (H), trastuzumab and pertuzumab (PH),
lapatinib (L), and trastuzumab emtansine (T-DM1). It was also analyzed whether patients who had
already completed a specific number of therapy lines (1–4) received these four anti-HER2 therapies in
any therapy line. For this purpose, the patients were categorized into four distinct groups, namely:
Patients for whom only the first therapy line was documented, patients for whom the first two therapy
lines were documented, patients for whom the first three therapy lines were documented, and patients
for whom at least the first four therapy lines were documented. Similarly, the frequencies of usage of
the PH → T-DM1 and T-DM1 → PH therapy sequences were analyzed, regardless of whether these
therapies followed each other directly.
It was also analyzed whether the patients’ characteristics were associated with the frequency of
utilization of the PH → T-DM1 sequence in the first four therapy lines, again regardless of whether
these therapies followed each other directly.
With regard to the year of therapy, the patients were also categorized in relation to their first four
therapy lines. The first group consisted of patients who completed all documented therapy lines before
2013, the second group had to have had at least one treatment administered before 2013 and one in
2013 or after 2013. In the last group, all patients had to have received all treatments after 2013.
Calculations were performed using IBM SPSS Statistics, version 24 (Armonk, New York, NY, USA:
IBM Corporation).
3. Results
3.1. Patient and Disease Characteristics
A total of 451 (23.3%) patients in the registry had HER2-positive metastatic breast cancer. Figure 2
shows the frequency of HER2-positive metastatic breast cancer patients over the years. Although the
HER2 status was positive in 37% (95% CI: 26–47%) of all patients with metastases who were treated
up to 2006, HER2 positivity was seen in 25% (95% CI: 21–28%) and 22% (95% CI: 19–24%) of patients
diagnosed with metastases in 2007–2013 and after 2013, respectively (Figure 2). For further analyses,
patients with bilateral breast cancer at diagnosis and those with missing information about the stage at
initial diagnosis were excluded. The final study population comprised 417 patients, 324 of whom were
hormone receptor–positive and 93 hormone receptor–negative (Figure 1).
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Figure 2. Proportion of human epidermal growth factor receptor 2 (HER2)-positive patients with 95%
confidence intervals relative to the year in which the metastases were diagnosed.
The characteristics of the patients and diseases are listed in Table 1. Most patients entered the
study in the first-line setting, had an Eastern Cooperative Oncology Group (ECOG) score of 0, and had
visceral metastases. Approximately 40% of the patients had metastases at the time of diagnosis.
Table 1. Patient characteristics at baseline.
Characteristic n or Mean % or SD
Age at study entry 57.9 13.0
BMI 26.0 5.3
Time from diagnosis to metastasis (days) 1177.8 1743.0
Therapy situation at study entry
First-line 223 53.5
Second-line 70 16.8
Third-line 53 12.7
Fourth-line 26 6.2
Fifth-line and higher 34 8.2
Therapy situation at database closure
First-line 171 41.0
Second-line 82 19.7
Third-line 47 11.3
Fourth-line 17 4.1
Fifth-line and higher 59 14.1
Hormone receptor status
Negative 93 22.3
Positive 324 77.7
ECOG
0 196 47.0
1 155 37.2
2 35 8.4
3 12 2.9
4 2 0. 4
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Table 1. Cont.
Characteristic n or Mean % or SD
Metastasis site at study entry
Brain a 79 18.9
Visceral b 222 53.2
Bone only 58 13.9
Other c 50 12.0
Metastatic at time of diagnosis
No 244 58.5
Yes 173 41.5
BMI (body mass index) ECOG (Eastern Cooperative Oncology Group) (score); SD (standard deviation). a Patients
included in the “brain” group were allowed to have metastases at any other site. b Patients included in the “visceral”
group were allowed to have metastases at any other site except the brain. c Patients included in this group were not
allowed to have any brain, visceral, or bone metastases.
3.2. Therapies
Across all of the therapy lines (1 to 9+), 241 of the 417 patients were treated with H without
additional anti-HER2 therapy, 237 with PH, 85 with L, and 125 with T-DM1. The respective figures up
to therapy line four are 236 (H), 220 (PH), 79 (L), and 108 (T-DM1) patients.
Table 2 shows patterns of therapy utilization relative to patient groups with first-line therapy
documented, with first- and second-line therapy documented, with first- to third-line therapy
documented, and with first- to fourth-line therapy documented, relative to the treatment period.
Trastuzumab, either as a single anti-HER2 therapy or together with pertuzumab, was already
administered in over 80% of the patients for whom only the first-line was documented. PH utilization
increased across the different time periods, with approximately 60–70% of all patients already receiving
this treatment as first-line therapy. T-DM1 utilization also increased across the time periods, although
patients with a larger number of documented therapy lines had a higher frequency (approximately
52% of patients had four therapy lines documented and approximately 33% of patients had only two
therapy lines documented). Lapatinib use did not change across the time periods and was mainly
administered in later therapy lines (Table 2).
Table 2. Frequencies of patients who received the respective treatments. The patients are categorized
here into four mutually exclusive (distinct) patient groups according to the number of documented
therapy lines. The percentages of patients treated are marked in bold. The numbers and percentages
of treated patients refer to the cumulative number of patients treated up to the highest documented
therapy line. For example, in the group of patients with three therapy lines documented and treated
after 2013, 33 patients have been treated with trastuzumab in one of the first three therapy lines.
Therapy Patients Treated Before 2012 Patients Treated Crossing 2013 Patients Treated After 2013
Not Treated Treated Not Treated Treated Not Treated Treated
Trastuzumab (H)
treatments in patient group 1 a 4 (19) 17 (80.9) 0 (0) 6 (100) 28 (20.4) 109 (79.5)
treatments in patient group 2 b 0 (0) 6 (100) 2 (13.3) 13 (86.6) 11 (15) 62 (84.9)
treatments in patient group 3 c 0 (0) 4 (100) 3 (15.7) 16 (84.2) 6 (15.3) 33 (84.6)
treatments in patient group 4 d 3 (20) 12 (80) 8 (18.1) 36 (81.8) 7 (18.4) 31 (81.5)
Trastuzumab + pertuzumab (PH)
treatments in patient group 1 a 19 (90.4) 2 (9.5) 3 (50) 3 (50) 51 (37.2) 86 (62.7)
treatments in patient group 2 b 6 (100) 0 (0) 11 (73.3) 4 (26.6) 21 (28.7) 52 (71.2)
treatments in patient group 3 c 4 (100) 0 (0) 13 (68.4) 6 (31.5) 12 (30.7) 27 (69.2)
treatments in patient group 4 d 15 (100) 0 (0) 28 (63.6) 16 (36.3) 14 (36.8) 24 (63.1)
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Table 2. Cont.
Therapy Patients Treated Before 2012 Patients Treated Crossing 2013 Patients Treated After 2013
Not Treated Treated Not Treated Treated Not Treated Treated
Lapatinib (L)
treatments in patient group 1 a 20 (95.2) 1 (4.7) 5 (83.3) 1 (16.6) 134 (97.8) 3 (2.1)
treatments in patient group 2 b 6 (100) 0 (0) 12 (80) 3 (20) 65 (89) 8 (10.9)
treatments in patient group 3 c 3 (75) 1 (25) 15 (78.9) 4 (21) 30 (76.9) 9 (23)
treatments in patient group 4 d 8 (53.3) 7 (46.6) 22 (50) 22 (50) 18 (47.3) 20 (52.6)
Trastuzumab emtansine (T-DM1)
treatments in patient group 1 a 21 (100) 0 (0) 6 (100) 0 (0) 131 (95.6) 6 (4.3)
treatments in patient group 2 b 6 (100) 0 (0) 10 (66.6) 5 (33.3) 49 (67.1) 24 (32.8)
treatments in patient group 3 c 4 (100) 0 (0) 8 (42.1) 11 (57.8) 21 (53.8) 18 (46.1)
treatments in patient group 4 d 14 (93.3) 1 (6.6) 21 (47.7) 23 (52.2) 18 (47.3) 20 (52.6)
a Group 1 is the patient population for which only the 1st therapy line is documented. These patients are not part of
groups 2–4; b Group 2 is the patient population for which only the 1st and the 2nd therapy lines are documented.
These patients are not part of the other groups. c Group 3 is the patient population for which only the 1st, 2nd and
3rd therapy lines are documented. These patients are not part of the other groups. d Group 4 is the patient
population for which the 1st to the 4th therapy lines are documented. These patients are not part of the other groups.
The sequence of PH followed by T-DM1 (PH → T-DM1) was administered in 51 patients
throughout all therapy lines and in 50 patients in lines one to four. Of those 50 patients, 48 patients
were treated with the combination of PH and chemotherapy, and two with the combination of PH and
endocrine therapy. Eleven patients received a sequence of T-DM1 → PH, eight of whom were treated
within the first four therapy lines. This is equivalent to a utilization rate of PH → T-DM1 up to therapy
line four after approval of about 42%, with an increase of approximately 10% from lines two to four
per therapy line (Table 3).
Table 3. Frequencies of patients who were treated with the respective treatment sequences, irrespective
of whether the sequences were administered directly after each other. The patients are categorized
into four mutually exclusive patient groups according to the numbers of documented therapy lines.
The percentages of patients treated are marked in bold.
Therapy Patients Treated Before 2012 Patients Treated Crossing 2012 Patients Treated After 2012
Not Treated Treated Not Treated Treated Not Treated Treated
Pertuzumab/trastuzumab → trastuzumab emtansine (PH → T-DM1)
treatments in patient group 1 a 21 (100) 0 (0) 6 (100) 0 (0) 137 (100) 0 (0)
treatments in patient group 2 b 6 (100) 0 (0) 14 (93.3) 1 (6.6) 59 (80.8) 14 (19.1)
treatments in patient group 3 c 4 (100) 0 (0) 17 (89.4) 2 (10.5) 27 (69.2) 12 (30.7)
treatments in patient group 4 d 15 (100) 0 (0) 39 (88.6) 5 (11.3) 22 (57.8) 16 (42.1)
Trastuzumab emtansine → pertuzumab/trastuzumab (T-DM1 → PH)
treatments in patient group 1 a 21 (100) 0 (0) 6 (100) 0 (0) 136 (99.2) 1 (0.7)
treatments in patient group 2 b 6 (100) 0 (0) 15 (100) 0 (0) 73 (100) 0 (0)
treatments in patient group 3 c 4 (100) 0 (0) 18 (94.7) 1 (5.2) 38 (97.4) 1 (2.5)
treatments in patient group 4 d 15 (100) 0 (0) 41 (93.1) 3 (6.8) 36 (94.7) 2 (5.2)
a Group 1 is the patient population for which only the 1st therapy line is documented. These patients are not part of
groups 2–4; b Group 2 is the patient population for which only the 1st and the 2nd therapy lines are documented.
These patients are not part of the other groups. c Group 3 is the patient population for which only the 1st, 2nd and
3rd therapy lines are documented. These patients are not part of the other groups. d Group 4 is the patient
population for which the 1st to the 4th therapy lines are documented. These patients are not part of the other groups.
3.3. Predictors of the Use of a Therapy Sequence of PH Followed by T-DM1
Several patient and disease characteristics were analyzed in relation to their influence on the
utilization of the therapy sequence PH → T-DM1 (Table 4). Age, grading, and stage at the initial
diagnosis did not have any influence. Patients with higher ECOG scores appeared to be treated with
this sequence more often, as well as patients with brain or visceral metastases. One patient with
metastases only in the bone was treated with PH → T-DM1. Patients with a positive hormone receptor
status were less frequently treated with the PH → T-DM1 sequence. Although only 23.7% of patients
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with a positive hormone receptor status received this sequence up to therapy line four, hormone
receptor–negative patients were treated with this sequence in about 44% of cases.
Table 4. Frequency of patients who received the treatment sequence pertuzumab/trastuzumab →
trastuzumab emtansine (PH → T-DM1), irrespective of whether the sequences were administered
directly after each other. All patients who had at least two documented therapy lines and in whom all
treatments started after 2013 are included.
Characteristic
PH→ T-DM1
No Yes
Age
<50 28 (65.1) 15 (34.9)
50–65 53 (72.6) 20 (27.4)
>65 27 (79.4) 7 (20.6)
Eastern Cooperative Oncology Group (ECOG) score
0 59 (79.7) 15 (20.3)
1 34 (63.0) 20 (37.0)
2 6 (60.0) 4 (40.0)
3 5 (100) 0 (0)
Metastasis site at study entry
Brain a 14 (58.3) 10 (41.7)
Visceral b 56 (68.3) 23 (31.7)
Bone only c 16 (94.1) 1 (5.9)
Other d 19 (82.6) 4 (14.7)
Hormone receptor status
Negative 18 (56.3) 14 (43.8)
Positive 90 (76.3) 28 (23.7)
Grade
1 2 (100) 0 (0)
2 45 (78.9) 12 (21.1)
3 50 (64.1) 28 (35.9)
Primary metastatic
No 68 (73.9) 24 (26.1)
Yes 40 (69.0) 42 (28.0)
a Patients included in the “brain” group were allowed to have metastases at any other site. b Patients included in
the “visceral” group were allowed to have metastases at any other site except the brain. c Patients included in this
group were not allowed to have any brain, visceral, or bone metastases.
4. Discussion
This analysis of a cohort from a real-world breast cancer registry shows how frequently anti-HER2
therapies are used. Although most patients received trastuzumab, the percentage of patients who
received pertuzumab and trastuzumab, lapatinib, or T-DM1 was clearly lower. Most of the trastuzumab
and pertuzumab therapies were administered in the first-line setting, but TDM-1 was administered in
most cases between the second and fourth lines, and lapatinib more often in the third- and fourth-line
setting. The sequence of TDM-1 after trastuzumab and pertuzumab was administered in up to 40%
of patients with four therapy lines, while the sequence T-DM1 followed by pertuzumab was only
administered in about 5% of the patients.
The analysis shows that HER2-positive metastatic breast cancer is a subgroup with a clinically
relevant frequency. The frequency of HER2-positive patients in the present cohort of metastatic breast
cancer patients was 23.3%, a rate similar to the initially described frequencies of 25–30% in primary
breast cancer before the introduction of anti-HER2 therapies [2,22]. The frequency of triple-negative
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breast cancer was much lower in this cohort, at 9.1% of all cases. Looking at HER2 positivity over
the years, it seems that HER2 positivity decreased over time. One possible explanation could be the
introduction of trastuzumab in the adjuvant setting [23–25], possibly reducing the number of HER2
positive patients, who would develop a metastasis at a later timepoint. However, it should be noted
that the PRAEGNANT study has been registering patients since 2014, and data from before that year
are purely descriptive. Therefore, this trend might be the result of a bias.
Pertuzumab and T-DM1 were approved in Germany in 2013. These therapies were thus inevitably
not prevalent in the cohort before that time. Few patients were treated in clinical trials before that, and it
can be clearly seen that the use of pertuzumab and trastuzumab during the first four therapy lines
increased from 27–36% around 2013 to 63–71% after 2013. Most of these treatments were administered
as first-line therapy, which is in accordance with the current national therapy guidelines [26]. T-DM1,
which is administered after tumor progression in the metastatic setting, was already used in 23–58% of
patients around 2013 and continued to be administered in 33–53% of patients after 2013. This therapy
pattern also matched the current national therapy guidelines [26]. Most patients received T-DM1 after
pertuzumab—a sequence that is under discussion, since at the time when the EMILIA study was
conducted, only previous trastuzumab therapy was available [12]. A recent retrospective study did
not show any differences in the prognosis when patients who had been treated with T-DM1 after
pertuzumab were compared with patients who had not received previous T-DM1 treatment [27].
However, analyses of differences between subgroups with earlier and later therapy lines in which
T-DM1 was administered were inconclusive [27]. The use of lapatinib did not change much over time
in the first four therapy lines, despite the introduction of pertuzumab and T-DM1.
With regard to possible predictive factors that may have influenced physicians in deciding
to treat patients with the pertuzumab–trastuzumab sequence, it appears that patients with more
advanced disease or a less favorable prognosis were more likely to be treated with the PH → T-DM1
therapy sequence. Parameters that were associated with a higher frequency of PH → T-DM1 use were
poorer ECOG scores, brain and visceral metastases, negative hormone receptor status, and higher
grading. The higher frequency of PH → T-DM1 therapy in patients with brain metastases could
be the enrichment of patients with brain metastases in patients treated with anti-HER2 therapies,
while in patients with positive hormone receptor status, the avoidance of chemotherapy could be
a motivation behind not giving an anti-HER2 directed therapy. With regard to visceral metastasis,
its more frequent use in patients with visceral metastases could be explained with the possible need
for an effective therapy regimen including anti-HER2 treatments and chemotherapy. Moreover,
in exploratory subgroup analyses of both studies, CLEOPATRA and EMILIA patients with visceral
metastases had a larger benefit from PH or T-DM1 than the patients treated with the respective
comparator therapies [10–12].
To the best of our knowledge, no comparable data concerning this healthcare research question
was previously published. Hormone receptor status in particular appears to be of special interest,
since a desire to avoid chemotherapy in this patient group is a possible reason why specific treatment
regimens are not administered.
This study has several strengths and limitations. Although the PRAEGNANT breast cancer
registry has registered more than 2300 patients with metastatic breast cancer, only 451 of the patients
were HER2-positive. Although this is a large number in comparison with other publications reporting
on prospective or retrospective cohorts, the sample size might be low for identifying treatment
patterns and possible predictors of patient/tumor characteristics that are associated with specific
therapy sequences and possible outcomes. Clinical cancer registries might be helpful for gathering
data on larger patient populations [28], but the degree of detail in the information might be limited
in such population-based registries. Data completeness and detail are certainly strengths in the
PRAEGNANT registry, which documents therapy lines, side effects, progression, and mortality with
an approach similar to that used in clinical trials. Another fact that needs to be taken into consideration
when interpreting the data is that in real-world cohorts, not all patients enter the study or end the
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study at comparable time points. Patients in the first-line setting may therefore be overrepresented,
as patients die during the course of the disease, or may be lost to follow-up. An attempt was made
to account for this by categorizing the patients into groups for which documentation for all therapy
lines up to a specific line was available, with treatment utilization being reported for each of these
groups separately.
5. Conclusions
In conclusion, the utilization of trastuzumab appeared to be sufficiently high in this cohort of
patients with metastatic breast cancer. The utilization of the PH → T-DM1 sequence appeared to be
rather low, and the reasons for this should be analyzed in future studies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/1/10/s1,
Table S1: Data categories captured in the PRAEGNANT study.
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Abstract: Liquid biopsy analytes such as cell-free DNA (cfDNA) and circulating tumor cells (CTCs)
exhibit great potential for personalized treatment. Since cfDNA and CTCs are considered to give
additive information and blood specimens are limited, isolation of cfDNA and CTC in an “all
from one tube” format is desired. We investigated whether cfDNA variant sequencing from
CTC-depleted blood (CTC-depl. B; obtained after positive immunomagnetic isolation of CTCs
(AdnaTest EMT-2/Stem Cell Select, QIAGEN)) impacts the results compared to cfDNA variant
sequencing from matched whole blood (WB). Cell-free DNA was isolated using matched WB and
CTC-depl. B from 17 hormone receptor positive/human epidermal growth factor receptor 2 negative
(HR+/HER2−) metastatic breast cancer patients (QIAamp MinElute ccfDNA Kit, QIAGEN). Cell-free
DNA libraries were constructed (customized QIAseq Targeted DNA Panel for Illumina, QIAGEN)
with integrated unique molecular indices. Sequencing (on the NextSeq 550 platform, Illumina) and
data analysis (Ingenuity Variant Analysis) were performed. RNA expression in CTCs was analyzed
by multimarker quantitative PCR. Cell-free DNA concentration and size distribution in the matched
plasma samples were not significantly different. Seventy percent of all variants were identical in
matched WB and CTC-depl. B, but 115/125 variants were exclusively found in WB/CTC-depl.
B. The number of detected variants per patient and the number of exclusively detected variants
per patient in only one cfDNA source did not differ between the two matched cfDNA sources.
Even the characteristics of the exclusively detected cfDNA variants in either WB or CTC-depl. B
were comparable. Thus, cfDNA variants from matched WB and CTC-depl. B exhibited no relevant
differences, and parallel isolation of cfDNA and CTCs from only 10 mL of blood in an “all from
one tube” format was feasible. Matched cfDNA mutational and CTC transcriptional analyses might
empower a comprehensive liquid biopsy analysis to enhance the identification of actionable targets
for individual therapy strategies.
Keywords: metastatic breast cancer; liquid biopsy; cell-free DNA; next-generation sequencing;
circulating tumor cells
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1. Introduction
Liquid biopsies harbor great potential for personalized treatment strategies and real-time
monitoring approaches. In oncology, cell-free DNA (cfDNA) and, specifically, cell-free tumor DNA
(ctDNA), defined by the presence of variants [1], as well as circulating tumor cells (CTCs), are powerful
tools to describe tumor heterogeneity and clonal evolution [2].
High levels of ctDNA were significantly correlated with decreased overall survival (OS) in breast
cancer (BC) [2] and, more specifically, ESR1 cfDNA variants were associated with a shorter duration
of endocrine treatment effectiveness in metastatic BC (MBC) [3]. Since patients with ESR1 variants
were described to benefit from fulvestrant rather than from exemestane, compared to patients without
this alteration, ESR1 variants also have the potential to tailor treatment regiments [4]. For disease
monitoring, cfDNA concentration was shown to indicate impending relapse of primary BC earlier
than any other imaging or blood-based strategy [5] and can predate treatment response changes [6,7].
The prognostic value of CTCs was first introduced for MBC patients more than a decade ago [8].
A decreased CTC count after treatment was significantly associated with increased progression-free
survival (PFS) and OS [9]. Consequently, CTC count dynamics were proposed to be more suitable for
monitoring than radiological imaging [10]. In addition to CTC counts, the expression profiles of CTCs
were correlated with response evaluation criteria in solid tumors (RECIST) [11,12]. Positive results
for therapy decisions in BC based on the CTC count, dynamics, or molecular characteristics, however,
have until now not been convincingly examined in large randomized blinded clinical studies, but great
efforts are underway to prove the predictive value of CTCs [2].
CfDNA and CTCs isolated from the same liquid biopsy specimen can enable comprehensive
results if seen as providing complementary, rather than competitive information. CtDNA, released
mostly passively, might present dying and probably therapy-sensitive cells [5]. On the other hand,
CTCs are viable cells actively migrating into the circulation as potential seeds of metastasis and,
therefore, possibly indicating minimal residual disease. It is not only possible to conduct mutational
analysis of cfDNA and transcriptional analysis of CTCs using both analytes in parallel, but it was
already described for multiple myeloma that sequencing of cfDNA and CTCs uncovered more
mutations than analysis of either analyte alone [13]. Therefore, one might assume that parallel
cfDNA and CTC analysis is complementary rather than competitive or even redundant [14].
Practically, however, many studies comparing cfDNA and CTCs used the same patient inclusion
criteria, but different large cohorts for either cfDNA or CTC analysis [15,16]. There were a few publications
analyzing both cfDNA and CTCs from the same patients, but the cohort sizes were quite small and the
two analytes were obtained from blood samples taken at different time points [15,16]. Even if the study
design considered the same time points for withdrawal, different preservative blood tubes, e.g., Streck
and/or CellSave tubes, were mostly used [7,15,17–19]. In contrast, EDTA blood enabled parallel analysis
of cfDNA and CTC from the same blood sample [20–23], but different blood aliquots were needed
for both analyses, such that the required blood volume was around 20 mL [24]. Consequently, for
appropriate comparability and consistency, the usage of the same blood sample with minimized
volume drawn and stored/shipped under the same conditions for isolation of both analytes to reach
an unbiased comprehensive liquid biopsy in an “all from one tube” format would be desirable.
We here (1) compared the quantity and characteristics of cfDNA variants isolated from whole
blood (WB) and blood after positive immunomagnetic selection of CTCs (CTC-depleted (depl.) B),
and (2) studied the heterogeneity of cfDNA variants and CTC overexpression signals in an hormone
receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) MBC cohort.
2. Results
2.1. Patient Characteristics
The cohort was specified to only consist of patients with MBC with HR+/HER2− primary tumors.
The majority of patients were more than 50 years old, and the median follow-up time was 68 months
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(range: 12 to 322 months). Eleven of the seventeen patients were deceased at the time of analysis.
At the time of blood draw, the majority of patients had secondary metastases, received more than three
treatment lines, and exhibited progressive disease according to response evaluation criteria in solid
tumors. All patient characteristics are listed in Table S1 (Supplementary Materials).
2.2. Cell-Free DNA Concentration and Fragmentation
The used volume of the matched plasma samples was identical and ranged from 2.8 mL to 6.0 mL
(mean 4.4 mL). Cell-free DNA concentrations in the plasma of WB ranged from 4 ng/mL to 187 ng/mL
(mean 58 ng/mL), while cfDNA concentration in plasma of CTC-depl. B ranged from 5 ng/mL to
153 ng/mL (mean 61 ng/mL). Wilcoxon signed-rank test considering all 17 matched samples revealed
no significant difference of cfDNA concentration in the different plasma samples. However, in some
matched samples, the cfDNA concentration differed greatly and, importantly, a high inter-individual
variability was observed (Figure 1).
Figure 1. Inter-individual variability of cell-free DNA (cfDNA) concentration. Plasma from circulating
tumor cell (CTC)-depleted (depl.)_blood (by AdnaTest EMT-2/StemCell Select) and matched plasma
from whole blood were used in the same volume for cfDNA isolation with a QIAamp MinElute ccfDNA
Kit, and cfDNA was quantified using an Agilent High Sensitivity Chip (fragments between 100–700 bp).
Capillary electrophoresis using the Agilent High Sensitivity DNA Chip resolved the fragment
length of the cfDNA. The majority of isolated cfDNA of all patients consisted of mononucleosomal
cfDNA fragments (100–280 bp), but cfDNA fragments with a length of 280–450 bp/450–700 bp (di- or
trinucleosomal DNA) were also detectable. Size distribution was comparable in cfDNA samples from
WB and CTC-depl. B, as depicted for two exemplary patients (Figure 2). There was no difference in
high-molecular-weight DNA (700–10,000 bp) in cfDNA eluates of the two plasma sources.
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Figure 2. Size distribution of cfDNA. Matched cfDNA samples isolated from CTC-depl. blood (B,D;
CTC isolation using AdnaTest EMT-2/StemCell Select) and from whole blood (A,C) of two exemplary
patients (A + B; C + D) displayed a large mononucleosomal fraction and, in general, a similar size
distribution without high-molecular-weight DNA (700–10,000 bp). Capillary electrophoresis was
performed with an Agilent High Sensitivity Chip. (A) Cell-free DNA eluate from whole blood of
patient 2, diluted 1:40; (B) cfDNA eluate from CTC-depl. blood of patient 2, diluted 1:40; (C) cfDNA
eluate from whole blood of patient 3, diluted 1:5; (D) cfDNA eluate from CTC-depl. blood of patient 3,
diluted 1:20.
2.3. Cell-Free DNA Variants from Matched Whole Blood and Circulating Tumor Cell-Depleted Blood
Targeted deep sequencing was conducted for all cfDNA libraries >4 nM, resulting in removal
of two matched cfDNA samples from one patient (Table S2, Supplementary Materials). Sequencing
quality was guaranteed by exclusion of samples with <5 or >100 million read fragments, <400 unique
molecular indice (UMI) coverage, and if <95% of the target region was covered with at least 5% of the
mean UMI coverage, causing four samples and their matched samples to be rejected from analysis.
The mean read count of all remaining samples from twelve patients was 12.41 million, while we found
a mean of 3.5 reads per UMI and an average of 99.58% of the target region was covered with a least 5%
of the mean UMI coverage (of 2760) (Table S2, Supplementary Materials).
In total, 415 variants were detected by UMI verification and, after filtering with the Ingenuity
software, in all 24 cfDNA samples from 12 MBC patients, 175 variants were identical in the cfDNA
samples from both plasma sources, namely WB and CTC-depl. B (Figure 3A). Furthermore, 115 and
125 variants were exclusively found in WB and CTC-depl. B, respectively. Thus, the agreement was
70% with a κ-value of 0.355 (Figure 3B). Corresponding to the large overlap of identical variants found
in both plasma sources depicted in the Venn diagram (Figure 3A), the number of detected variants per
patient exhibited no significant difference between the two matched cfDNA sources (Figure 4A).
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Figure 3. Venn diagram (A) and cross table (B) of matched cfDNA variants isolated from whole
blood (light gray) and CTC-depleted blood (dark gray). Variants in all exonic regions of 17 genes
were examined in 12 metastatic breast cancer (MBC) patients with hormone receptor positive/human
epidermal growth factor receptor 2 negative (HR+/HER2−) primary tumor. Depletion of CTCs was
conducted using AdnaTest EMT-2/StemCell Select. Variant calling by verification of unique molecular
indices and filter of the Ingenuity Variant Analysis were described previously [25]. The proportional
Venn diagram was computed using the tool BioVenn [26] and displays a great overlap of identical
variants found in both cfDNA sources.
Figure 4. Boxplots describing the number of (A) detected cfDNA variants, and (B) the number of
exclusively detected cfDNA variants per patient in whole blood (gray) and CTC-depleted blood (black,
using AdnaTest EMT-2/StemCell Select). Means and standard deviations are also displayed, and the
Wilcoxon signed-rank test indicated no significant difference between both cfDNA sources.
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Additionally, the number of exclusively detected variants per patient in only one cfDNA source
was also not significantly different (Figure 4B). Despite the similar quantity of variants found in only
one of the two cfDNA sources, the characteristics of these variants might be different. Therefore, the
number of variants per patient with the most common characteristics in the categories: translation
impact, classification, gene, gene region, and allele frequency (AF) was compared in matched samples
(Figure 5). The average number of exclusive frameshift variants, BRCA2 variants, or variants with an
allele frequency between 1% and 5% was slightly higher in the cfDNA samples isolated from CTC-depl.
blood, but the Wilcoxon signed-rank test indicated no significant difference between the number of
exclusive variants with specific characteristics (frameshift, pathogenic and likely pathogenic, uncertain
significance, AR, BRCA2, MUC16, exonic, AF <1%, AF 1–5%) isolated from WB compared to variants
isolated from CTC-depl. B. Therefore, we concluded that cfDNA variants from matched WB and
CTC-depl. B harbor no differences.
Figure 5. Boxplots describing the number of exclusively detected cfDNA variants per patient
with specific characteristics in whole blood (gray) and CTC-depleted blood (black, using AdnaTest
EMT-2/StemCell Select). The averages and standard deviations are indicated. Depicted characteristics
are the major parameters of the categories: translation impact (frameshift (A)), classification (pathogenic
and likely pathogenic (B), uncertain significance (C)), gene (AR (D), BRCA2 (E), and MUC16 (F)), gene
region (exonic (G)), and allele frequency (<1% (H), 1–5% (I)). The Wilcoxon signed-rank test indicated
no significant difference between the 12 matched cfDNA sources regarding any depicted characteristic.
2.4. Clinically Relevant Characteristics of Cell-Free DNA Variants and Circulating Tumor Cell Expression
In the cohort of HR+/HER2− MBC patients, 50.0% of detected variants were located in the
MUC16 gene irrespective of the cfDNA source (Figure 6A,E). In total, 21.7%/22.5% of all variants
isolated from WB/CTC-depl. B were located in the AR gene, and the third most commonly altered
gene found was BRCA2 (Figure 6A,E). Furthermore, 54.1%/52.3% of all variants had an AF of <1%,
and 39.7%/42.0% of all variants isolated from WB/CTC-depl. B appeared with an AF of between 1%
and 5% (Figure 6B,F). Moreover, 75.2/73.0% of all variants were of uncertain significance, but 23.8/25%
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of the variants isolated from WB/CTC-depl. B were already described to be either pathogenic or likely
pathogenic (Figure 6C,G). Around 30% of these 69/75 pathogenic or likely pathogenic variants in
WB/CTC-depl. B were located in the AR or BRCA2 gene, followed by variants in BRCA1 (Figure 6D,H).
In summary, the distribution of cfDNA variants was similar in samples isolated from WB and CTC-depl.
B with most variants having a low AF, being mostly of uncertain significance and being located in the
MUC16, AR, or BRCA2 gene.
 
Figure 6. Distribution of called cfDNA variants isolated from whole blood (A–D) and CTC-depleted
blood (E–H) of HR+/HER2− MBC patients (n = 12) according to their gene location (A,D,E,H), allele
frequency (B,F), and classification (C,G). (A,E) Distribution of (exclusive (D,H)) variants according to
their gene location. Most variants were found in theMUC16 gene, while pathogenic or likely pathogenic
variants were mostly located in the AR or BRCA2 gene. (B,F) Allele frequency of all variants; 90% of all
variants showed AFs <5%. (C,G) Classification of variants according to their known impact (benign,
likely benign, uncertain significance, likely pathogenic and pathogenic) done by IVA. Nearly 25% of all
variants are known to be likely pathogenic or pathogenic. No significant different distribution was
detected for cfDNA variants from matched whole blood and CTC-depl. blood.
To confirm that CTC analysis is feasible in addition to cfDNA analysis from the same blood sample,
overexpression was examined by quantitative PCR (qPCR) in lysates of pooled CTCs. mTOR was the
most commonly overexpressed transcript in CTCs of the studied cohort (Figure S1, Supplementary
Materials). AKT2 was also commonly overexpressed with a frequency of 88% in the cohort. ERBB2,
ERBB3, ERCC1, AURKA, and SRC transcripts were overexpressed in the CTCs of more than 50% of all
patients (Figure S1, Supplementary Materials).
3. Discussion
We here demonstrate that direct comparison of cfDNA variants isolated from matched WB and
CTC-depl. B revealed no significant differences. The cfDNA concentration and size distribution, as well
as the number of detected variants, were similar for both cfDNA sources. Even the characteristics of the
exclusively detected cfDNA variants in either WB or CTC-depl. B showed no significant differences.
3.1. Cell-Free DNA Sequencing from Circulating Tumor Cell-Depleted Blood Favored in the Future
The study was conducted to question the hypothesis that differences between WB and CTC-depl.
B during cfDNA analysis occur, which were suspected to be caused by potential damage of CTCs
and/or blood cells during CTC isolation, an influence of the immunomagnetic bead cocktail used for
CTC enrichment, or an effect of additional 30-min incubation of WB at room temperature. However,
since we found no differences in quantity and characteristics of the cfDNA variants isolated from WB
versus CTC-depl. B, any systematic bias in sequencing cfDNA isolated from CTC-depl. B instead
of WB can be excluded. Furthermore, we observed an unchanged sensitivity for cfDNA analysis
using CTC-depl. B instead of WB. The blood supernatant remaining after positive immunomagnetic
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selection of CTCs using the AdnaTest EMT-2/StemCell Select procedure can, therefore, be used as
source for an additional liquid biopsy analyte. Isolation of CTCs and subsequent cfDNA isolation
from CTC-depl. B using the QIAamp MinElute cfDNA Kit, followed by UMI-confirmed sequence
analysis in a combined workflow, provide the advantage of cfDNA mutation analysis in concert with a
CTC molecular profiling from exactly the same blood sample. However, in contrast to the original
AdnaTest protocol, 5 mL of WB turned out to be not enough to obtain a CTC-depl. B volume sufficient
for the subsequent cfDNA analysis, because targeted PCR-based deep sequencing of cfDNA requires a
high input amount of cfDNA. Consequently, the CTC isolation process was conducted in duplicate
from 2 × 5 mL of WB to finally obtain minimally 4 mL of combined plasma from CTC-depl. B for
cfDNA isolation with a yield >30 ng. Thus, we describe a workflow to isolate the two liquid biopsy
analytes cfDNA and CTCs from a minimal blood volume of only 10 mL, resulting in reduction of the
burden of blood-draw volume for the patient, while simultaneously empowering a comprehensive
liquid biopsy analysis.
3.2. Additive Value of Cell-Free DNA Mutational and Circulating Tumor Cell Transcriptional Analyses
A few studies comparing cfDNA and CTC data exist. However, in contrast to our present
approach, for these studies, the blood volume needed for both analyses was additive and, thus, an
additional burden for patients. Moreover, most of the isolation protocols required different preservative
blood tubes for cfDNA and/or CTC storage. It was examined in BC patients that both total cfDNA
level and CTC count were correlated with OS [17], that cfDNA integrity was correlated with CTC
presence [20], that SOX17 promotor methylation and ESR1 methylation were highly concordant in
ctDNA and CTCs [19,23], and that cfDNA and CTCs showed overlapping mutation profiles [17].
Using cfDNA variant analysis and CTC expression analysis of the same 10 mL of blood material,
we here described the high prevalence of pathogenic or likely pathogenic AR variants (33.3%), and
38% of all 12 patients displayed an AR overexpression signal in CTCs. We conclude that AR might
be of importance in HR+/HER2− MBC patients, both on a mutational and transcriptional level, as
previously described by us in both cfDNA and CTCs in larger HR+/HER2− MBC cohorts [12,27].
Moreover, this gene is of relevance, because targeted treatment against AR is available; however, at the
moment, it is only approved for other indications [28]. Furthermore, AR was described as a potential
target in triple-negative BC patients [29,30].
Despite the similar results and consequences that can be drawn from cfDNA and CTC analysis as
described above, cfDNA and CTCs also exhibit additive value. We here showed the high prevalence
of ERBB3 (70%), ERBB2 (55%), and PIK3CA (27%) transcript overexpression in CTCs, whereas the
prevalence of cfDNA variants isolated from matched CTC-depl. B and located in ERBB3, ERBB2, and
PIK3CA genes was low (ERBB3 1.7%, ERBB2 2.2%, and PIK3CA 4.8%). This further exemplifies the
additive value of CTC expression in combination with the cfDNA analysis. The protein expression of
HER2 (encoded by ERBB2) is routinely used as a predictive marker for targeted therapy in BC [31];
therefore, the frequent overexpression of ERBB2 transcripts in CTCs of patients with HER2- primary
tumors, in line with previous results [12,32], might be relevant for treatment management in the future.
Compared to cfDNA, CTCs provide a unique opportunity to study DNA, RNA, and proteins, even
on the single-cell level, while also providing an indicator for active metastasis [33]. In particular, the
expression analysis in CTCs was shown to be relevant for prognosis [34–36], prediction [37–39], and
monitoring [11,12].
In contrast to CTC counts, ctDNA in MBC patients exhibited a greater correlation with tumor
burden, ctDNA was more frequently found, ctDNA showed a greater dynamic range, and ctDNA
described the earliest indication of response to chemotherapies [7]. Moreover, it was shown in BC
patients that sequencing of cfDNA revealed more mutations than sequencing of CTCs [17], ESR1
variant detection was more sensitive in cfDNA compared to CTCs [40], and cfDNA was correlated
in a great extent with PFS than CTC counts [18]. Here, the existence of 1.3/10.7% pathogenic or
likely pathogenic EGFR/BRCA1 cfDNA variants accompanied by 0/25% overexpression frequency of
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matched transcripts in CTCs also highlights the value of cfDNA in addition to CTC profiling. EGFR
variant detection in cfDNA was the first liquid biopsy test to be approved by the USA Food and Drug
Administration, as a companion diagnostic in non-small-cell lung cancer patients [41].
In multiple myeloma, it was shown that sequencing of both cfDNA and CTCs uncovered more
mutations than in either analyte on its own, as in some cases a subclone was only detected in one
analyte [13]. Thus, not only does the combined analysis of cfDNA variants and CTC transcriptional
profiles provide additive information, but the mutational analysis of CTCs and cfDNA—from now
on feasible using the same 10 mL of blood—is also assumed to be complementary rather than
competitive [14].
4. Materials and Methods
4.1. Patient Population Characteristics and Eligibility Criteria
The study was conducted at the Department of Gynecology and Obstetrics, in collaboration with
the Department of Medical Oncology (for specimen recruitment), both at the University Hospital Essen,
Germany, and in collaboration with QIAGEN GmbH, Hilden, Germany (for library preparation and
sequencing analysis). In accordance with the Declaration of Helsinki, written informed consent was
obtained from all participants at enrolment, and specimens were collected using protocols approved in
2012 by the institutional review board that consists of medical doctors, nurses, psychologists, welfare
workers, and a priest (12-5265-BO). In total, cfDNA from 17 MBC patients was studied between
October 2015 and June 2018. All participants were ≥18 years, had Eastern Cooperative Oncology
Group (ECOG) scores for performance status of 0–2, no severe, uncontrolled co-morbidities or medical
conditions, and no second malignancies. Prior neoadjuvant and adjuvant treatment, radiation, all
kinds of surgical intervention, or any other treatment of BC was permitted. Patients had estrogen
(ER) and/or progesterone (PR) receptor-positive primary tumors (summarized as HR+) and no
ERBB2 overamplification (n = 16). Patients with ER-positive and/or PR-positive and HER2-negative
metastases were also included if their ER, PR, and HER2 status in the primary tumor was unknown
(n = 1). Patient characteristics are listed in Table S1 (Supplementary Materials).
4.2. Sampling of Blood, Isolation of Circulating Tumor Cells and Processing of Plasma
Initially, 2 × 9 mL of EDTA blood was collected in S-Monovettes (Sarstedt AG & Co, Nuembrecht,
Germany), stored at 4 ◦C, and processed within 4 h of blood draw. Five milliliters of whole blood were
used in duplicate to isolate CTCs by positive immunomagnetic selection targeting EpCAM, EGFR,
and HER2 (AdnaTest EMT-2/StemCell Select, QIAGEN, Hilden, Germany), as described in detail
elsewhere [42]. The remaining matched whole blood not used for CTC isolation was centrifuged at
3000× g for 8 min, and plasma was frozen at −80 ◦C. This plasma sample isolated straight from whole
blood was abbreviated as WB. The CTC-depleted blood remaining after positive immunomagnetic
selection, abbreviated as CTC-depl. B, was centrifuged at 3000× g for 8 min, and plasma was frozen at
−80 ◦C.
4.3. Isolation of Cell-Free DNA
Matched plasma samples from WB and CTC-depl. B were thawed, centrifuged at 16,000× g for
10 min at 4 ◦C, and passed through a 0.8-μm pore size syringe filter (Sartorius, Goettingen, Germany).
Cell-free DNA was isolated from 2.8–6.0 mL (mean 4.4 mL; maximized plasma volume available)
plasma by affinity-based binding to magnetic beads according to the manufacturer’s instructions
(QIAamp MinElute ccfDNA Kit, QIAGEN) and as described previously [25]. The same volume of
plasma was used for isolation of matched cfDNA from WB and CTC-depl. B of the same patient.
Cell-free DNA was eluted in 22 μL of ultraclean water and stored at −20 ◦C.
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4.4. Cell-Free DNA Quantification
Diluted cfDNA (1:5 to 1:100) was applied to an Agilent Chip High Sensitivity DNA (Santa Clara,
CA, USA). Concentrations of fragments with a length between 100 and 700 bp were summed using the
2100 expert software B02.08 (Agilent) to calculate the cfDNA yield.
4.5. Library Construction
The library was constructed with a customized QIAseq Targeted DNA Panel Kit (QIAGEN), as
described in detail previously [25,27]. The input amount preferred for library preparation was in the
range of 30–60 ng, but cfDNA samples with lower input were also included in the library preparation.
The same cfDNA input amount of matched cfDNA samples from WB and CTC-depl. B was used for
the library preparation, as listed in Table S2 (Supplementary Materials). Thus, the mean cfDNA input
used across the cohort was 54.47 ng. We applied a 20 μL input volume in accordance with the protocol
previously described [25]. Briefly, end-repair and A-addition was performed while the enzymatic
fragmentation was inhibited. Subsequently, barcoded adapters including the UMI and sample-specific
indices were ligated to the fragments. DNA was purified and free adapters were depleted by magnetic
beads. The targeted enrichment was performed with a customized QIAGEN QIAseq Targeted DNA
Panel primer designed to amplify all coding regions of the following genes: AKT1, AR, BRCA1, BRCA2,
EGFR, ERBB2, ERBB3, ERCC4, ESR1, KRAS, FGFR1, MUC16, PIK3CA, PIK3R1, PTEN, PTGFR, and
TGFB1. The universal PCR amplification was followed by a magnetic bead clean-up, and the final
targeted enriched cfDNA library was eluted.
4.6. Sequencing
Libraries were quantified as published [25] by qPCR and the quality was checked using an
Agilent Chip High Sensitivity DNA (Santa Clara). Libraries were diluted to 4 nM, and libraries
with a lower yield (and matched libraries from the same patient; n = 1) were excluded. All pooled
libraries were analyzed by paired-end sequencing on the Illumina NextSeq Sequencer with a NextSeq
550 System High-Output Kit, 2× 150-bp reads using a custom sequencing primer (QIAseq A Read1
Primer, QIAGEN).
4.7. Data Analysis/Bioinformatical Analysis
Data were initially analyzed using the QIAGEN GeneGlobe Data Analysis Center. Sufficient
sequencing quality of all samples was guaranteed by exclusion of libraries with less than five million
read fragments (n = 1), a UMI coverage lower than 400 (n = 1), and if less than 95% of the target
region was covered with at least 5% of the mean UMI coverage (n = 1) [25,27]. Furthermore, libraries
with >100 million read fragments were excluded to remove highly overrepresented libraries (n = 1).
The matched libraries of the excluded ones were not analyzed to also guarantee comparison of
only matched samples. The input amount, library yield, and sequencing quality parameter of each
sample are summarized in Table S2 (Supplementary Materials). The QIAGEN Biomedical Genomics
Workbench and the Ingenuity Variant Analysis plugin (IVA; QIAGEN) were used for further annotation,
scoring, filtering (described previously [25]), and interpretation of variants detected in the UMI-based
analysis. In detail, a consensus sequence was built from all fragments with the same UMI to exclude
potential artefacts.
The IVA used five different filters for exclusion of called variants. The confidence filter excluded
all variants with a call quality below 20. Moreover, the confidence filter only kept variants that
were not located in the top 5% of the most exonically variable 100-base windows in healthy public
genomes. Variants with a prevalence of >0.5% in the normal population (reference databases: (1) Allel
Frequency Community (gnomAD&CGI), (2) 1000 Genomes Project, (3) ExAC, and (4) NHLBI ESP
exomes) were excluded, unless the variant was already known to be a pathogenic common variant, to
identify rare variants potentially associated with the evaluated condition of the tested cohort (common
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variant filter). The genetic analysis filter only kept variants that were associated with gain of function
or with the following inheritance patterns: homozygous, compound heterozygous, haplosufficient,
hemizygous, het-ambiguous, or heterozygous. Only variants located no more than 20 bases from the
intron were included, as well as those described to be pathogenic and/or likely pathogenic from the
American College of Medical Genetics and Genomics, or variants that are loss-of-function-associated,
which induce frameshift, in-frame indel, start/stop changes, missense, intronic two-bp splice-site loss,
or any splice-alteration predicted by MaxEntScan (predicted deleterious filter). The cancer driver
variant filter kept only variants that were found in (1) cancer-associated mouse knockout phenotypes,
(2) cancer-associated cellular processes with any directionality, (3) cancer-associated pathways with
any directionality, (4) cancer therapeutic targets, (5) published cancer literature variants and gene
level findings, (6) known or predicted cancer subnetwork regulatory sites, (7) COSMIC at a frequency
greater than or equal to 0.01%, and (8) TCGA at a frequency greater than or equal to 0.01%.
Original raw sequencing data were uploaded as two fastq files plus MD5 checksum per sample,
and are available at the European Nucleotide Archive with the study accession number PRJEB30449.
4.8. Messenger RNA Isolation and Quantitative PCR
Messenger RNA was isolated from the CTC lysates by oligo(dT)25-coated magnetic beads and
was reverse-transcribed (Adna-Test EMT-2/StemCell Detect, QIAGEN; [42]). The AdnaTest TNBC
Panel prototype (QIAGEN), consisting of multimarker real-time (RT)-qPCR assays, was applied to
the complementary DNA isolated from the CTCs for expression profiling of AKT2, ALK, AR, AURKA,
BRCA1, EGFR, ERCC1, ERBB2, ERBB3, KIT, KRT5, MET, MTOR, NOTCH1, PARP1, PIK3CA, SRC, and
GAPDH, in relation to the leukocyte-specific transcript CD45 and healthy donor controls. Experimental
set-up und data evaluation were described in detail previously [12].
4.9. Statistical analysis
Statistical analysis was performed using SPSS, version 11.5 (IBM, Armonk, NY, USA).
The Wilcoxon signed-rank test was used to assess whether the matched samples differed. Diagrams
were computed with GraphPad PRISM (GraphPad Software Inc., San Diego, CA, USA) and Microsoft
Excel (Microsoft Corporation, Redmond, WA, USA). Box plots display individual values for each
patient, as well as the mean and standard deviation. The Venn diagram was produced with the online
tool BioVenn [26]. The kappa-value was calculated using the GraphPad QuickCalcs website [43].
5. Conclusions
In summary, cfDNA mutational and CTC transcriptional analyses can supplement each other.
A comprehensive liquid biopsy, therefore, increases the chance for identification of actionable targets
to direct therapy strategies. Thus, the isolation of both CTCs and cfDNA, in an “all from one tube”
format without bias due to the initial CTC isolation process, as demonstrated in this research study,
might be helpful in paving a way for individual treatment decision-making.
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Abstract: Background: Elevated plasmatic lactate dehydrogenase (LDH) levels are associated with
worse prognosis in various malignancies, including metastatic breast cancer (MBC). Nevertheless, no
data are available on the prognostic role of LDH as a dynamic biomarker during first-line treatment
in unselected MBC. Methods: We reviewed data of 392 women with MBC to evaluate the association
between LDH variation after 12 weeks of first-line treatment and survival. The prognostic impact
was tested by multivariate Cox regression analysis. Results: Plasmatic LDH was confirmed as an
independent prognostic factor in MBC. Patients who maintained elevated LDH levels after 12 weeks
of first-line treatment experienced worse progression-free survival (PFS, HR 2.88, 95% CI: 1.40–5.89,
p = 0.0038) and overall survival (OS, HR 2.61, 95% CI 1.16–5.86, p = 0.02) compared to patients
with stable normal LDH levels, even after adjustment for other prognostic factors. Notably, LDH
low-to-high variation emerged as an unfavorable prognostic factor for PFS (HR 3.96, 95% CI 2.00–7.82,
p = 0.0001). Conclusions: Plasmatic LDH and its variation during first-line treatment predict PFS and
OS in MBC, providing independent prognostic information. It would be worthwhile to prospectively
evaluate the association between LDH variation and therapeutic benefit in MBC, and explore how it
may affect treatment strategies.
Keywords: metastatic breast cancer; lactate dehydrogenase; serum biomarker; LDH; monitoring
metastatic breast cancer
1. Introduction
Breast cancer (BC) is the most common cancer among women and the second leading cause of
cancer-related death [1]. About 6% of all breast tumors present with distant metastases at diagnosis,
and 30% of patients with early BC will experience local or distant recurrence [2]. BC is a heterogeneous
disease, including distinct subgroups with different prognosis based on histological and molecular
features [3]. In clinical practice, the expression of the estrogen receptor (ER), progesterone receptor
Cancers 2019, 11, 1243; doi:10.3390/cancers11091243 www.mdpi.com/journal/cancers219
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(PR), and the human epidermal growth factor receptor 2 (HER2) identifies three main subgroups:
Luminal or hormone receptor positive (HR-positive) BC, HER2-positive BC, and triple negative breast
cancer (TNBC) [4]. Despite new treatments and improved standard of care, metastatic breast cancer
(MBC) remains an incurable disease with a median survival of about 34 months, even if it varies
significantly among and within the subgroups [5]. Therefore, it is essential to identify tumor- and
patient-related factors able to predict aggressive biological behavior and treatment resistance. Recently,
several studies evaluated novel circulating biomarkers in BC, including inflammatory factors [6],
exosomes [7], circulating tumor DNA (ctDNA) [8], and circulating tumor cells (CTC) [9]. However,
even routinely used biomarkers (e.g., the neutrophil-to-lymphocyte ratio [10], lactate dehydrogenase
(LDH) [11], alkaline phosphatase (ALP) [12]) provide additional information on tumor biology and
should be further evaluated for their prognostic relevance.
LDH is a ubiquitous enzyme that plays a central role in anaerobic glycolysis, as it catalyzes
the reversible conversion of pyruvate into lactate [13]. LDH comprises a family of six tetrameric
isoenzymes [14,15] with a tissue-specific expression regulated by both physiological and pathological
conditions. The LDHA gene expression is upregulated in several types of cancers, especially in rapidly
growing tumors, to maintain glycolysis as an alternative source of energy during hypoxic stress and
subsequent high LDH level in cytoplasmic compartment. Notably, different extracellular factors, such
as hormones, growth factors, and cytokines can regulate LDH expression by receptor-dependent and
-independent intracellular signaling pathways (e.g., cAMP Response Element-Binding protein (CREB),
Hypoxia-Inducible Factor-1 (HIF-1), and c-Myc) [15]. Beyond its role in regulating cellular metabolism,
LDH is a well-known marker of tissue damage. Many pathological conditions, including cancer,
present with LDH elevation due to acute cell death or necrosis. Moreover, high plasmatic LDH levels
influence tumor progression and metastatic spread with a negative impact on outcome in various
cancer types [16–25].
The prognostic role of plasmatic LDH levels has been investigated in BC as well. The first piece of
evidence dates back to the late 1990s and early 2000s when three extensive studies found that elevated
plasmatic LDH levels were associated with poor outcome in MBC patients [26–28]. High plasmatic
LDH levels were also proven to be significantly associated with increased risk of disease recurrence and
death [12,29]. Notably, a recent meta-analysis confirmed these findings in both MBC and early BC [11].
Nevertheless, no data are available on the prognostic role of LDH dynamic response to first-line
treatment in unselected MBC patients. Thus, we conducted an exploratory study to identify
the prognostic impact of plasmatic LDH variation after 12 weeks of first-line treatment on both
progression-free survival (PFS) and overall survival (OS) in MBC.
2. Results
2.1. Patient’s Characteristics
A consecutive series of 392 women with MBC were included in the analysis, 219 with a plasmatic
LDH evaluation at baseline. The median age was 62 years (range 29–88), with 42.9% of patients older
than 65 years and 10.7% younger than 45 years. Invasive ductal carcinoma was the most common
histology (80.4%of cases), andpost-menopausalwomenaccounted for 59.4%ofpatients. Approximately
60.5% of patients had HR-positive tumors (11.2% were luminal A, 38.3% luminal B, and 11.0% luminal
HER2-positive; see Section 4.2. for classification details), 8.7% had HR-negative/HER2-positive disease,
and 9.4% TNBC. At MBC diagnosis, nearly half of the patients presented with a single metastatic site,
and about 20% had three or more localizations. Bone metastases were detected in half of the cases
(20% of patients had a bone-only disease), while patients with liver, lung, or central nervous system
localizations (CNS) were about 25%, 28%, and 6.4%, respectively. Overall, nearly 60% of patients
received chemotherapy as first-line treatment, and the remaining 40% received hormonal therapy.
Additional baseline clinical and pathologic characteristics of patients are listed in Table 1.
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Table 1. Baseline patients’ clinical and pathologic characteristics.
Characteristics Number of Patients(Total = 392) %
Age
<45 years 42 10.71
45–65 years 182 46.43
>65 years 168 42.86
Menopausal state
Pre-menopausal 114 29.08
Post-menopausal 233 59.44
Unknown 45 11.48
Histotype
Ductal 315 80.36
Lobular 59 15.05
Other 12 3.06
Unknown 6 1.53
Profile
Luminal A 44 11.22
Luminal B 150 38.27
Luminal HER2 43 10.97
HER2-positive 34 8.67
Triple negative 37 9.44
Unknown 84 21.43
ECOG PS
0 201 51.28
1 150 38.26
≥2 34 8.67
Unknown 7 1.79
Number of metastatic
sites
1 212 54.08
2 104 26.53
≥3 76 19.39
Site of metastases *
Bone 199 50.77
Bone only 79 20.15
Liver 99 25.26
CNS 25 6.38
Lung 110 28.06
Lymph nodes 133 33.93
Firs-line treatment
Chemotherapy 231 58.93
Hormonal
therapy 161 41.07
Baseline LDH level
High 1 69 17.60
Normal 150 38.27
Unknown 173 44.13
Baseline ALP level
High 2 124 31.63
Normal 245 62.50
Unknown 23 5.87
Legend: CNS, Central Nervous System; LDH, Lactate dehydrogenase; ALP, alkaline phosphatase; ECOG PS, Eastern
Cooperative Oncology Group Performance Status. 1 LDH > 480 IU/L; 2 ALP > 104 IU/L; * Patients may present
more than one metastatic site.
2.2. Prognostic Role of Pre-Treatment Plasmatic LDH
After a median follow-up of 52.77 months, median OS was 30.87 months (25–75th percentile:
13.50–62.80), and median PFS was 9.21 months (25–75th percentile: 3.95–20.70). At baseline, 31.5%
of evaluable patients (69/219) had elevated pre-treatment LDH levels according to the centralized
laboratory cut-off (>480 UI/L). Through univariate analyses, baseline elevated plasmatic LDH emerged
as an unfavorable prognostic factor in terms of PFS and OS. More specifically, patients with baseline
elevated LDH experienced shorter median PFS (6.87 vs. 13.12 months, HR 1.81, 95% CI: 1.31–2.51,
p = 0.0003) and OS (19.23 vs. 46.19 months, HR 2.23, 95% CI: 1.55–3.19, p < 0.0001) compared to patients
with normal LDH (Figure 1). The prognostic role of LDH plasma levels was also confirmed when
evaluated as a continuous variable for both PFS (p = 0.0002) and OS (p < 0.0001).
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Figure 1. Kaplan–Meier curves for progression-free survival (PFS) and overall survival (OS) according
to baseline lactate dehydrogenase (LDH).
These findings were confirmed for both PFS (HR 1.51, 95% CI: 1.02–2.26, p = 0.039) and OS
(HR 1.64, 95% CI: 1.05–2.55, p = 0.027) after multivariate adjustment for molecular profiles, Eastern
Cooperative Oncology Group Performance Status (ECOG PS), baseline ALP level, number of metastatic
sites, central nervous system (CNS), and liver and bone localizations (Tables 2 and 3).
Table 2. Baseline prognostic factors for PFS according to univariate and multivariate Cox model.
Covariates Number ofPatients
Univariate
Analysis(HR, 95% CI) p
Multivariate
Analysis(HR, 95% CI) p
Age
<45 years 42 0.80 (0.54–1.17) 0.25
45–65 years 182 Ref. -
>65 years 168 0.95 (0.75–1.20) 0.68
Profile
Luminal A 44 Ref. - Ref. -
Luminal B 150 1.27 (0.87–1.87) 0.20 1.10 (0.66–1.84) 0.68
Luminal HER2 43 0.73 (0.44–1.19) 0.21 0.58 (0.31–1.10) 0.09
HER2-positive 34 1.17 (0.71–1.92) 0.52 0.92 (0.44–1.92) 0.84
Triple negative 37 3.19 (1.96–5.17) <0.0001 2.81 (1.44–5.48) 0.002
ECOG PS
0 201 Ref. - Ref. -
1 150 1.25 (0.98–1.58) 0.06 1.35 (0.90–2.02) 0.13
≥2 34 1.70 (1.12–2.59) 0.01 2.45 (1.18–5.07) 0.01
Number of
metastatic
sites
1 212 Ref. - Ref. -
2 104 1.35 (1.04–1.75) 0.02 1.51 (0.97–2.35) 0.06
≥3 76 0.97 (0.71–1.34) 0.89 0.61 (0.35–1.04) 0.07
Site of
metastases *
Bone 199 0.93 (0.74–1.16) 0.54 1.07 (0.71–1.61) 0.73
Liver 99 1.14 (0.88–1.47) 0.29 0.92 (0.58–1.47) 0.75
CNS 25 1.38 (0.86–2.20) 0.17
Lung 110 0.90 (0.70–1.16) 0.44
Baseline
LDH level
High 1 69 1.81 (1.31–2.51) 0.0003 1.51 (1.02–2.26) 0.039
Normal 150 Ref. - Ref. -
Baseline
ALP level
High 2 124 1.45 (1.14–1.85) 0.002 1.11 (0.73–1.66) 0.61
Normal 245 Ref. - Ref. -
Legend: CNS, Central Nervous System; LDH, Lactate dehydrogenase; ALP, alkaline phosphatase; ECOG PS, Eastern
Cooperative Oncology Group Performance Status; Ref., Reference. 1 LDH cut-off: 480 IU/L; 2 ALP cut-off: 104 IU/L;
* Patients may present more than one metastatic site.
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Table 3. Baseline prognostic factors for OS according to univariate and multivariate Cox model.
Covariates Number ofPatients
Univariate
Analysis(HR, 95% CI) p
Multivariate
Analysis(HR, 95% CI) p
Age
<45 years 42 0.82 (0.52–1.29) 0.41
45–65 years 182 Ref. -
>65 years 168 1.16 (0.89–1.53) 0.25
Profile
Luminal A 44 Ref. - Ref. -
Luminal B 150 1.63 (1.01–2.62) 0.04 2.26 (1.16–4.38) 0.01
Luminal HER2 43 1.14 (0.63–2.03) 0.65 1.73 (0.81–3.70) 0.15
HER2-positive 34 1.61 (0.88–2.96) 0.12 1.24 (0.49–3.15) 0.64
Triple negative 37 4.31 (2.45–7.59) <0.0001 7.19 (3.11–16.5) <0.0001
ECOG PS
0 201 Ref. - Ref. -
1 150 1.92 (1.45–2.55) <0.0001 1.88 (1.18–2.99) 0.007
≥2 34 2.61 (1.72–3.97) <0.0001 1.76 (0.84–3.70) 0.13
Number of
metastatic
sites
1 212 Ref. - Ref. -
2 104 1.40 (1.03–1.89) 0.02 2.04 (1.20–3.46) 0.008
≥3 76 1.36 (0.95–1.94) 0.08 0.70 (0.35–1.41) 0.32
Site of
metastases *
Bone 199 0.95 (0.73–1.23) 0.74 1.19 (0.73–1.96) 0.47
Liver 99 1.33 (1.00–1.78) 0.046 0.58 (0.68–1.93) 0.58
CNS 25 2.72 (1.68–4.42) <0.0001 22.05 (4.38–110.94) 0.0002
Lung 110 1.10 (0.82–1.47) 0.51
Baseline
LDH level
High 1 69 2.22 (1.55–3.19) <0.0001 1.64 (1.05–2.54) 0.027
Normal 150 Ref. - Ref. -
Baseline
ALP level
High 2 124 1.84 (1.40–2.41) <0.0001 1.48 (0.94–2.31) 0.08
Normal 245 Ref. - Ref. -
Legend: CNS, Central Nervous System; LDH, Lactate dehydrogenase; ALP, alkaline phosphatase; ECOG PS, Eastern
Cooperative Oncology Group Performance Status; Ref., Reference. 1 LDH cut-off: 480 IU/L; 2 ALP cut-off: 104 IU/L;
* Patients may present more than one metastatic site.
The role of LDH as an adverse prognostic factor was consistent in all examined subgroups: Age,
profile, number of metastatic sites, type of first-line treatment (hormonal therapy or chemotherapy),
baseline ALP level, and liver and bone involvement (Figure 2). Aside from baseline LDH level,
other independent prognostic factors for PFS were triple negative profile (HR 2.81, 95% CI: 1.44–5.48,
p = 0.002) and ECOG PS (2 vs. 0, HR 2.45, 95% CI: 1.18–5.07, p = 0.015), while for OS, they were luminal
B profile (HR 2.26, 95% CI: 1.16–4.38, p = 0.015), triple negative profile (HR 7.19, 95% CI: 3.11–16.58,
p < 0.0001), ECOG PS (1 vs. 0, HR 1.88, 95% CI: 1.18–2.99, p = 0.007), tumor burden (2 vs. 1 localizations,
HR 2.04, 95% CI: 1.20–3.46, p = 0.008), and CNS localizations (HR 22.05, 95% CI: 4.38–110.94, p = 0.002).
The complete Cox regression model is reported in Tables 2 and 3.
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2.3. Prognostic Role of Plasmatic LDH Response during First-Line Treatment.
LDH value after 12 weeks of first-line treatment was available in 126 patients (32%). Among them,
54.7% had stable low LDH levels, 15.0% had stable high levels, and in approximately 30% of cases,
LDH levels changed over time across the upper normal limit (12% had a drop under the upper normal
limit, while 18.2% had a rise over the upper normal limit).
According to plasmatic LDH variation, we were able to detect significant differences of both
median PFS (stable low levels: 18.71 months, high-to-low levels: 10.92 months, low-to-high levels: 5.13
months, stable high levels: 4.27 months, p < 0.0001) and median OS (stable low levels: 54.64 months,
high-to-low levels: 30.87 months, low-to-high levels: 29.49 months, stable high levels: 14.83 months,
p < 0.0001) (Figure 3 and Table 4).
 
Figure 3. Kaplan–Meier curves for PFS and OS according to plasmatic LDH variation after 12 weeks of
first-line treatment.
Table 4. OS and PFS according to plasmatic LDH variation after 12 weeks of first-line treatment.
LDH Variation 1
Number of
Patients(Total = 126) %
Median PFS(25–75th
Percentile)
Median OS(25–75th
Percentile)
Stable low 69 54.76 18.71 (8.09–58.65) 54.64 (26.76–88.18)
High-to-low 15 11.91 10.92 (7.76–14.43) 30.87 (14.53–40.08)
Low-to-high 23 18.25 5.13 (2.79–12.43) 29.49 (14.01–72.26)
Stable high 19 15.08 4.27 (2.60–10.06) 14.83 (8.78–47.38)
Legend: LDH, Lactate dehydrogenase. 1 LDH cut-off: 480 IU/L.
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The prognostic relevance of LDH response to first-line treatment was then assessed using a Cox
regression multivariate model. Stable elevated LDH levels after 12 weeks of first-line treatment was
confirmed as an independent negative prognostic factor for both PFS (HR 2.88, 95% CI: 1.40–5.89,
p = 0.0038) and OS (HR 2.61, 95% CI 1.16–5.86, p = 0.02) after multivariate adjustment for molecular
profile, ECOG PS, number of metastatic sites, CNS, liver, bone localizations, and plasmatic ALP
variation at 12 weeks. Moreover, a rise in plasmatic LDH levels after 12 weeks of first-line treatment
(low-to-high variation) also emerged by multivariate analysis as an independent negative prognostic
factor for PFS (HR 3.96, 95% CI 2.00–7.82, p = 0.0001) with a trend for worse OS (HR 2.02, 95% 0.89–4.56,
p = 0.08). The complete Cox regression model is reported in Table 5.
Table 5. LDH variation after 12 weeks of first-line treatment: Prognostic impact on PFS and OS
according to multivariate Cox model.
Covariates Number ofPatients
Multivariate Analysis
(HR, 95% CI)
PFS
p
Multivariate Analysis
(HR, 95% CI)
OS
p
Profile
Luminal A 44 Ref. - Ref. -
Luminal B 150 0.88 (0.43–1.80) 0.73 1.39 (0.57–3.36) 0.46
Luminal HER2 43 0.37 (0.17–0.81) 0.01 0.75 (0.30–1.86) 0.54
HER2-positive 34 1.12 (0.41–3.03) 0.12 0.66 (0.18–2.40) 0.53
Triple negative 37 2.90 (1.16–7.22) 0.02 7.81 (2.66–22.9) 0.0002
ECOG PS
0 201 Ref. - Ref. -
1 150 1.68 (0.90–3.14) 0.10 1.78 (0.84–3.79) 0.13
≥2 34 4.19 (1.48–11.85) 0.006 2.29 (0.81–6.47) 0.11
Number of
metastatic
sites
1 212 Ref. - Ref. -
2 104 1.86 (0.92–3.73) 0.08 1.75 (0.79–3.88) 0.16
≥3 76 0.71 (0.32–1.56) 0.40 0.67 (0.25–1.79) 0.43
Site of
metastases *
Bone 199 1.46 (0.76–2.81) 0.25 2.35 (1.05–5.23) 0.036
Liver 99 0.88 (0.44–1.76) 0.72 1.53 (0.71–3.31) 0.26
CNS 25 1223.5 (42.5–35225.6) <0.0001
ALP
variation at
12 weeks 1
Stable low 20262 Ref. - Ref. -
High-to-low 44 0.82 (0.35–1.87) 0.63 0.62 (0.25–1.52) 0.30
Low-to-high 13 0.88 (0.22–3.42) 0.86 2.39 (0.57–10.0) 0.23
Stable high 62 0.98 (0.45–2.12) 0.96 1.24 (0.53–2.88) 0.60
LDH
variation at
12 weeks 2
Stable low 69 Ref. - Ref. -
High-to-low 15 1.27 (0.50–3.23) 0.60 2.35 (0.82–6.77) 0.11
Low-to-high 23 3.96 (2.00–7.82) 0.0001 2.02 (0.89–4.56) 0.08
Stable high 19 2.88 (1.40–5.89) 0.003 2.61 (1.16–5.86) 0.02
Legend: CNS, Central Nervous System; LDH, Lactate dehydrogenase; ALP, alkaline phosphatase; Ref., Reference;
ECOG PS, Eastern Cooperative Oncology Group Performance Status. 1 ALP cut-off: 104 IU/L; 2 LDH cut-off: 480
IU/L; * Patients may present more than one metastatic site.
3. Discussion
Many studies reported elevated plasmatic LDH levels to be associated with poor outcomes
in various tumors [30]. A recent meta-analysis, including 76 studies conducted in patients with
several cancer types, confirmed that high LDH plasmatic levels were associated with shorter PFS and
OS [31]. Although the prognostic role of LDH in cancer is well-established, the underlying biological
mechanisms are still unclear, and some possible explanations have been hypothesized. Firstly, high
LDH plasmatic concentrations sustain anaerobic metabolism during tumor growth and metastatic
spread, supporting the energetic requirements in hypoxic conditions [32]. Secondly, LDH exerts
an inflammatory action on tumor microenvironment, activating interleukin (IL)-23 and IL-17 and
modulating the activity of arginase I. It inhibits CD8+ T lymphocytes and natural killer (NK) activation,
allowing cancer cells to evade immune response [33]. Moreover, high LDH levels promote tumor
angiogenesis, cell migration, and metastatization by inhibiting the degradation of HIF-1 alpha and
increasing the production of vascular endothelial growth factor (VEGF) [34]. Thirdly, preliminary
evidence suggests that increased LDHA expression and lactate overproduction might also play a role
in drug resistance [35].
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The present study investigated the prognostic impact of plasmatic LDH levels on survival
outcomes in MBC patients at first-line treatment.
Approximately 31% of evaluated patients had high baseline LDH levels and about 32% had an
LDH variation during first-line treatment. In particular, 15% of patients had a stable high LDH and
18% had a low-to-high variation.
The results confirmed that elevated baseline LDH levels were independently associated with
shorter PFS (6.87 vs. 13.12months, adjustedHR 1.51, 95%CI: 1.02–2.26, p= 0.039) andOS (19.23 vs. 46.19
months, adjusted HR 1.64, 95% CI: 1.05–2.55, p = 0.027). These data were also confirmed when LDH
plasma levels were evaluated as a continuous variable (PFS, OS), so our results were not dependent on
the pre-specified cut-off for normal LDH plasmatic concentrations. To the best of our knowledge, this
is the first study to demonstrate that LDH changes during first-line treatment significantly impact both
PFS and OS in unselected MBC patients. Specifically, patients with elevated baseline plasmatic LDH
who maintained high LDH levels after 12 weeks of first-line treatment experienced worse PFS and
OS compared to patients with stable normal LDH levels, even after adjustment for other prognostic
factors (HR 2.88, 95% CI: 1.40–5.89, p = 0.0038 and HR 2.61, 95% CI 1.16–5.86, p = 0.02 for OS and
PFS, respectively). Interestingly, since elevated plasmatic LDH levels may also reflect the presence of
high tumor burden, bone localizations, liver metastases, and ALP levels variations, it is noteworthy
that their prognostic value was maintained after including these covariates in the multivariate Cox
regression model.
Additionally, plasmatic LDH elevation during first-line treatment emerged as an independent
prognostic factor for PFS (HR 3.96, 95% CI 2.00–7.82, p = 0.0001) with a trend for OS (HR 2.02, 95%
0.89–4.56, p = 0.08). In accordance with our findings, a recent study conducted in TNBC patients
confirmed that LDH changes after two cycles of first-line chemotherapy correlate with objective
response rate and PFS [36].
Therefore, LDH can predict survival in patients with MBC and provides independent and dynamic
prognostic information during first-line treatment. Given our results, patients with stable high LDH
levels or with LDH elevation during first-line therapy may be monitored more frequently for disease
progression, as they might experience shorter PFS. Conversely, patients with stable normal LDH
levels will experience prolonged PFS and OS. Nevertheless, since these findings are not prospectively
validated, LDH variation must not be considered an indirect proof of tumor progression or response,
even if it offers additional prognostic information.
In our study, LDH-A tissue expression was not tested. However, its relationship with plasmatic
LDH may be useful to define whether LDH plasmatic elevation is primarily tumor-related or not,
exploring the biological significance and the prognostic value of their concordance or discordance.
According to previous studies, elevated tissue LDH-A expression is associated with elevated Ki-67,
high proliferation rates, and CNS metastases in TNBC [37].
The main strength of our study is the identification of a dynamic, easy-to-use, inexpensive, and
reproducible prognostic biomarker in patients with unselected MBC. However, this is a retrospective
and single-center study. Thus, prospective and external validation is mandatory. Moreover, the LDH
cut-off value for normality implemented in this study may differ in other centers; consequently,
its reproducibility has to be confirmed. Lastly, we did not consider the potential interaction of several
other non-neoplastic diseases (e.g., heart failure, anemia, hypothyroidism, autoimmune, and lung
disorders), which might influence plasmatic LDH levels.
On the basis of these observations, it would be of great value to prospectively evaluate the potential
correlation between LDH variation and response to treatment in MBC, and explore the prognostic role
of this long-standing biomarker in the modern era of immunotherapy and targeted therapy.
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4. Materials and Methods
4.1. Study Design
This observational, retrospective, no-profit, monocentric cohort study examined data of 392
consecutive MBC patients treated between 2007 and 2017 at the Department of Oncology of the
University Hospital of Udine (Italy). The study was conducted under the Declaration of Helsinki,
and the Regional Ethics Committee approved the protocol (N◦ Protocol 14571 ratified in May 2018).
Informed consent was obtained for the use of clinical data, rendered anonymous, for purposes of
clinical research, epidemiology, training, and study of diseases.
4.2. Data Source
Clinicopathological information and blood sample data were collected from electronic health
records. We defined MBC subgroups as follows: Luminal A (ER or PR positive, HER2-negative, Ki-67
≤ 14%), luminal B (ER or PR positive, HER2-negative, Ki-67 > 14%), luminal HER2 (HER2-positive and
ER or PR positive), HER2-positive (ER and PR negative, HER2-positive), and triple negative (ER and
PR negative, HER2-negative) [4].
4.3. Blood Sample Analysis
Serum LDH and ALP data were retrospectively evaluated. Blood samples data were eligible for
review if performedwithin onemonth before first-line treatment administration (baseline pre-treatment
sample) and after 12weeks± 1week after first treatment dose (post-treatment sample). The quantitative
determination of LDH and ALP was performed using the Roche Cobas 8000 c702 system (Roche
Diagnostics, Indianapolis, IN, USA). The LDH and ALP cut-off value for normality was the normal
upper limit (NUL) defined by the analytical system used (480 IU/L and 104 IU/L, respectively).
4.4. Statistical Analysis
The study was designed in order to explore the prognostic role of LDH response after 12 weeks
of first-line treatment in unselected MBC, with a hierarchical design: The independent prognostic
impact of plasmatic LDH was first evaluated at baseline and then for its variation at 12 weeks, using
a multivariate Cox regression model for both PFS and OS with 95% confidence interval (95% CI).
A two-sided p < 0.05 was considered statistically significant. The multivariate model included the
following covariates: The molecular profile, ECOG PS, number of metastatic sites, CNS, liver and
bone localizations, and plasmatic ALP levels (at baseline and its variation at 12 weeks). Baseline
clinicopathological characteristics were summarized through descriptive analysis. OS was defined
as the time elapsed between the start of first-line treatment and death or last follow-up. PFS was
defined as the interval between the start of first-line treatment and disease progression or death for
any cause. Differences in survival were tested by a log-rank test and represented by Kaplan–Meier
survival curves. Statistical analysis was performed with STATA (StataCorp, www.stata.com (2015)
Stata Statistical Software: Release 14.2. College Station, TX: StataCorp LP).
5. Conclusions
LDH is a routinely used biomarker with a well-established prognostic role in several solid tumors
and hematological malignancies. Our study confirmed that LDH is an independent prognostic factor
also in MBC and explored its value as a dynamic biomarker. To the best of our knowledge, this is
the first study to demonstrate that LDH response to first-line treatment significantly impacts both
PFS and OS in unselected MBC patients. If validated in prospective studies, LDH could represent a
cost-effective biomarker to stratify patient’s prognosis, monitor treatment efficacy, and to implement
treatment strategies in MBC.
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Abstract: This study examined the effects of exercise intervention on the quality of life (QoL),
social functioning (SF), and physical functioning (PF) of breast cancer survivors, and identified the
responsible and optimal exercise characteristics for amelioration of outcomes. Randomized controlled
trials (RCTs) that adopted exercise intervention and measured the QoL, SF, and PF of breast cancer
patients were included. We used meta-analysis to calculate the pooled effect, and meta-regression
to identify the responsible exercise characteristics (type, frequency, duration, and time). Subgroup
analysis assessed the optimal “time of session” for an improved QoL. The Cochrane risk-of-bias tool
was used to determine the quality of studies. In the systematic review, we included 26 RCTs with a
total of 1892 breast cancer patients, whilst 18 trials were considered for meta-analysis (exercise = 602;
control = 603). The pooled effect showed that exercise intervention substantially improved the
QoL (standardized mean difference (SMD) = 0.35; I2 = 61%; 95% confidence internal (CI): 0.15–0.54;
p = 0.0004), SF (SMD = 0.20; I2 = 16%; 95% CI:0.08–0.32; p = 0.001), and PF (SMD = 0.32; I2 = 32%;
95% CI:0.20–0.44; p < 0.00001). Meta-regression analysis showed that improved QoL was associated
(p = 0.041) with the “time of session”. More specifically, sessions conducted for medium-time (>45 to
≤60 min; p = 0.03) and longer-time (>60 to 90 min; p = 0.005) considerably improved the QoL, whilst
shorter-time (≤45 min; p = 0.15) did not. To summarize, exercise interventions improved the QoL, SF,
and PF of breast cancer survivors, where the “time of session” appeared to be crucial for an effective
improvement in the QoL.
Keywords: physical activity; breast cancer survivors; physical function; social well-being; exercise
characteristics
1. Introduction
Breast cancer is the most commonly diagnosed cancer in women worldwide. The number of
newly diagnosed breast cancer patients reached 2.1 million in 2018, accounting for one quarter of
female cancer cases [1]. Globally, the number of newly diagnosed breast cancer patients is predicted
to reach 3.2 million by 2050 [2,3]. Currently, the highest incidence of breast cancer is found in
the developed regions, including Western Europe, Northern Europe, Australia and New Zealand,
and North America [1]. Owing to advancements in medical care and treatment, the number of
post-treatment cancer survivors has also increased worldwide. The 5-year survival rate for breast
Cancers 2019, 11, 706; doi:10.3390/cancers11050706 www.mdpi.com/journal/cancers233
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cancer patients is 90.2% in the USA, 89.5% in Australia, and 83.2% in China, while it is only 66.2% and
65% for patients in India and Malaysia, respectively [4]. Despite this, after treatment or prognosis,
most cancer survivors suffer from a series of psychological and physical adverse symptoms, including
nausea, insomnia, depression, anxiety, and fatigue. These side effects eventually impair the social
functions (SF) and physical functions (PF) of the women, and lead to a decrease in their overall quality
of life (QoL). For instance, negative outcomes, such as decreased expectations for the future, breakdown
in social relations, limitation of daily activities, and a decline in self-care ability, were commonly
observed in breast cancer survivors [5,6].
In recent decades, there has been a significant increase in the prescription of exercise to cancer
survivors as a means to overcome treatment-induced adverse effects [7,8]. Based on the evidence
from several randomized controlled trials (RCTs), the American College of Sports Medicine (ACSM)
roundtable concluded that exercise training is safe both during and after treatment, and it can improve
the QoL and PF, as well as reduce depression, anxiety, and fatigue in breast cancer survivors [9].
However, some studies using exercise intervention reported equivocal results in various clinical
outcomes in breast cancer patients. For instance, an RCT of 500 breast cancer survivors reported no
change in the QoL (all domains), depression, or fatigue after a 12 month exercise (60 min) program [10].
In contrast, another RCT showed that a 12 week supervised exercise program (>60 min) improved the
functional and global health scores linked to the QoL, whilst home-based exercise (30 min) improved
only the global health score of the QoL in breast cancer patients [11]. Moreover, resistance exercise
(45min, under an 8-week program) or aerobic exercise (60min, under a 17-week program) interventions
were found to be ineffective in improving the QoL in breast cancer patients [12,13]. To address the type
and dose response of exercise (~16 weeks) on PF, Courneya et al. reported that neither high-intensity
aerobic exercise (50 to 60 min) nor combined aerobic–resistance exercise (50 to 60 min) were superior to
standard aerobic exercise (25 to 30 min) in breast cancer survivors [14].
From these RCTs, it appears that the beneficial effects of exercise on the health outcomes (QoL, SF,
PF) should be moderated using one or more exercise characteristics, such as frequency (F), intensity (I),
type (T), and time (T) (i.e., the FITT factors). Therefore, to enhance the beneficial effects of exercise, it is
necessary to better understand the influences of exercise variables on the QoL, SF, and PF of breast
cancer patients. In this context, a systematic review and meta-analysis of 16 RCTs found that shorter
workouts improved both the physical and social functioning, whilst longer workouts only improved
the PF in patients with cancer. In addition, the optimal FITT factors to improve patients’ QoL remained
unanswered in that study [15]. A recent meta-analysis of 34 RCTs reported a significantly improved
QoL and PF of breast cancer patients after exercise. However, it was claimed that these improvements
were not moderated by the exercise characteristics [16]. Another meta-analysis of eight RCTs showed a
non-significant improvement in the QoL from exercise intensity or any type of exercise in breast cancer
patients [17]. In contrast, a recent systematic review of 36 trials concluded that all types of exercise
interventions improved the QoL in patients with breast cancer. Combined exercise was specifically
cited as being more efficient than aerobic or resistance exercise alone, although no meta-analysis data
were provided [7].
These systematic reviews and meta-analyses attempted to delineate the influence of exercise
characteristics on patients’ clinical outcomes. However, none of these studies revealed the efficacy of
individual exercise variables (i.e., type, frequency, duration, and time of session) on improving the QoL,
SF, or PF of breast cancer survivors. Most importantly, the conclusions are debatable with regards to
the optimal exercise variables on clinical outcomes. As such, in order to prescribe exercise intervention
as an alternative medicine, it is crucial to identify the effective and optimal exercise variables that
may effectively improve a patient’s clinical outcomes. Therefore, in the current systematic review
and meta-analysis, we seek to examine the effects of exercise intervention on the QoL, SF, and PF of
breast cancer survivors. We further sought to explore the most effective exercise characteristics (type,
frequency, duration, time, and total exercise time) using a meta-regression analysis, whilst the optimal
dose of exercise (time) for an improved QoL was determined using a subgroup analysis.
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2. Results
2.1. Search Results and the Selection of Studies
In the initial search, a total of 1251 articles were identified, with 1245 from electronic databases
(PubMed, Web of Science, ScienceDirect, EMBASE, SportDiscus, Google Scholar) and six from a manual
search (i.e., the reference list of included studies and other reviews). After removing 449 duplicates,
802 records were retrieved for further assessment. The titles and abstracts of the retrieved studies were
screened using EndNote and a one by one reading, which also led to an exclusion of 667 articles. Then,
the full-text of the remaining 135 articles was evaluated for the inclusion criteria, and 109 articles were
excluded based on the reasons detailed in Figure 1. Finally, 26 articles that met our study’s criteria were
included in the systematic review. Of these, articles with no information on exercise frequency [18–21],
time of session [22–25], and with wide ranges in the time of session [26,27] were excluded. Finally,
16 studies possessing sufficient information regarding exercise characteristics and clinical outcomes
were included in the meta-analysis. The detailed steps for article selection and the corresponding
number of included and excluded articles in our study are presented as a flowchart in Figure 1.
Figure 1. Flowchart of the study selection according to the Preferred Reporting Items for the Systematic
Review and Meta-Analysis (PRISMA) method.
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2.2. Summary of the Included Studies
According to the criteria, 26 articles (RCTs) were included for the systematic review, and 16 of
them were used for the meta-analysis. The RCTs were intercontinental, that is, from Australia,
Canada, China, England, France, Germany, Italy, Kosovo, Spain, and the United States. All the
participants (1892 in total) in these RCTs were women with breast cancer. The number of patients
in the trials (exercise and control) ranged from 16 to 220, and their cancer stages were from 0
to IV. For the systematic review, the included studies had conducted various types of exercise
interventions, including aerobic exercise [24,25,27–33], resistance exercise [33–36], a combination of
both [18,22,23,37–40], yoga [19–21,41,42], and Qigong [26,43]. The details of the patients and exercise
characteristics are presented in Table 1.
For the meta-analysis, we included 16 studies that contained 18 trials, with a total of 1205 patients
(exercise = 602; control = 603). Of these studies, seven trials performed aerobic exercises [28–33],
four trials performed resistance exercises [33–36], four trials underwent a combination of aerobic and
resistance exercises [37–40], two trials practiced yoga [41,42], and one trial performed Qigong [43],
with durations of 6 to 26 weeks. The frequency of exercise varied from 2 to 7 times per week, and the
length of each exercise session ranged from 25 to 90 min.
2.3. Patient-Reported Clinical Outcomes and Scales
The RCTs included in our meta-analysis used well-validated questionnaires (scales) to measure
the patient-reported clinical outcomes, such as the QoL, SF, and PF. For the assessment of the QoL,
the European Organization for Research and Treatment of Cancer-quality of life questionnaire-C30
(EORTC-QLQ-C30) was used in five studies [33–35,38,39], the functional assessment of cancer
therapy-general (FACT-G) scale was adopted in eight studies [28,30,32,36,37,40,42,43], the functional
assessment of cancer therapy-breast (FACT-B) scale was used in two studies [29,31], and the short
form-36 (SF-36) scale was employed in one study [41]. Further information on the scales used to
measure the SF and PF of breast cancer survivors is presented as supplementary data (Tables S1 and S2).
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2.4. Exercise Intervention Improves the QoL in Breast Cancer Survivors
The effect of exercise intervention on the QoL of breast cancer survivors was evaluated for 18 trials.
The meta-analysis results showed that the change in QoL was extremely (p = 0.0004) influenced by
exercise intervention, with heterogeneity: Tau2 = 0.10; Chi2 = 43.68; degrees of freedom (df) = 17; and
I2 = 61% (Figure 2). Then, a meta-regression analysis was performed to identify the effective exercise
variables that improved the QoL. Information regarding exercise type, time of session, frequency,
duration, and total exercise time was entered into the meta-regression analysis. In the results, we found
that except for the “time of session”, all other exercise characteristics (type, duration, frequency,
and total time) were not associated with a change in QoL of breast cancer survivors. However, the “time
of session” was significantly (p = 0.041) correlated with an improved QoL in breast cancer survivors
following exercise intervention (Table 2).
Figure 2. Changes in the quality of life (pooled outcomes) after exercise intervention in patients
with breast cancer. SD, standard deviation; IV, inverse variation; CI, confidence internal; df, degrees
of freedom.
Table 2. Meta-regression analysis to identify the effective exercise moderators on an improved quality
of life in breast cancer survivors.
Exercise Characteristics Coefficient Standard Error T Value p-Value
Type of exercise −0.3471926 0.3498219 −0.99 0.339
Time of session 0.0121459 0.0054789 2.22 0.041 *
Frequency −0.1384031 0.0839449 −1.65 0.119
Duration −0.006877 0.0171193 −0.40 0.693
Total time of exercise −0.0000111 0.0000583 −0.19 0.851
* Represents a significant correlation between the quality of life and exercise variable (time of session).
2.5. Longer Time of Session Profoundly Improves the QoL in Women with Breast Cancer
To identify the optimal “time of session” for an improvedQoL, the trials with “time of session” data
were categorized into three subgroups, that is, shorter-time of session (≤45 min; 7 trials), medium-time
of session (>45 to ≤60 min; 7 trials), and longer-time of session (>60 to 90 min; 4 trials). In the
subgroup analysis, we found that both the sessions over the medium-time (standardized mean
difference (SMD) = 0.30; I2 = 48%; 95% confidence internal (CI): 0.04 to 0.56, p = 0.03) and longer-time
(SMD = 0.83; I2 = 61%; 95% CI: 0.26 to 1.40, p = 0.005) significantly improved the QoL of the breast
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cancer patients. However, a shorter-time of session showed no significant improvement in the QoL
(SMD = 0.22; I2 = 65%; 95% CI: −0.08 to 0.52, p = 0.15). Furthermore, patients that engaged in longer
exercise sessions (>60 to 90 min) appeared to achieve greater improvements (a bigger effect size) to
their QoL, compared to the medium-time of session (>45 to ≤60 min) (Figure 3).
 
Figure 3. Forest plot of the quality of life (QoL) changes (subgroup analysis) with different times
of exercise sessions in patients with breast cancer. SD, standard deviation; IV, inverse variation;
CI, confidence internal; df, degrees of freedom.
2.6. Beneficial Effects of Exercise on SF amongst Breast Cancer Survivors
Cancer or cancer treatment affects the social functioning of women with breast cancer. To address
the influence of exercise on the SF, we included 15 eligible trials consisting of 1073 breast cancer patients
(535 exercise; 538 control), and a meta-analysis was also performed. The test for the overall effect
revealed that exercise interventions substantially (p = 0.001) improved SF in women with breast cancer.
The SF outcome extremely favored exercise, citing the SMD = 0.20, I2 = 16%, and 95% CI: 0.08 to 0.32.
Our data further indicated that none of the other specified exercise variables were correlated with
improving SF in female patients (Figure 4).
2.7. Beneficial Effects of Exercise on PF amongst Breast Cancer Survivors
A total of fifteen trials addressed the effects of exercise on the PF of female breast cancer survivors.
The pooled outcome of meta-analysis also showed that exercise interventions improved the PF of
breast cancer survivors (p < 0.00001). The pooled SMD of the enhanced PF was 0.32 (0.20 to 0.44), at a
95% CI, and where the I2 was 32% after the interventions (Figure 5).
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Figure 4. Pooled outcome of the changes in social function after exercise intervention in patients
with breast cancer. SD, standard deviation; IV, inverse variation; CI, confidence internal; df, degrees
of freedom.
Figure 5. Pooled outcome of changes in physical function after exercise intervention in patients
with breast cancer. SD, standard deviation; IV, inverse variation; CI, confidence internal; df, degrees
of freedom.
2.8. Risk of Bias of Included Studies
The risk of biased judgments in the 26 articles is shown in Figure 6. For the selection bias, most of
the studies (i.e., 20 trials) reported a low risk of random sequence generation, and seven studies were
judged to have a high risk of allocation concealment. Several studies (i.e., 18 trials) were judged to
have a high risk of bias in the blinding of participants towards exercise performance. Specifically, in the
studies with exercise interventions, it may not feasible to blind patients in the participation of exercise.
It is stated that reporting such a high risk of performance bias does not necessarily compromise the
study quality [44]. Nevertheless, we identified seven trials with detection bias and six trials with an
attrition bias. Only four studies were judged to have a selective reporting bias. These results indicated
that most of the included studies were not found to possess a high risk of selection, adherence, attrition,
and reporting bias.
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Figure 6. Risk of bias summary of the included studies. Green indicates a low risk of bias (+),
red indicates a high risk of bias (−), and yellow indicates unclear risk (?).
3. Discussion
For the first time, our systematic review and meta-analysis demonstrated the influence of exercise
intervention on the QoL, SF, and PF in female breast cancer survivors, and the “time of session” was
identified as a crucial exercise variable for an improved QoL. Previous meta-analyses have stated that
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exercise promotes a better QoL in breast cancer survivors; however, the intervention effect concerning
the exercise type, frequency, duration, or time of session was inconclusive [15–17]. In this study,
we included 26 RCTs and addressed the efficacy of exercise characteristics on the patient-reported
clinical outcomes. Pooled outcomes revealed that the exercise intervention significantly improved the
QoL, SF, and PF of breast cancer survivors. Our subsequent meta-regression analysis showed that
an improved QoL was significantly correlated with the “time of session” and not with other exercise
variables (i.e., type, frequency, duration, and total exercise time). Specifically, exercise sessions for a
longer-time (>60 to 90 min) appeared to be superior to the sessions for a medium-time (>45 to ≤60 min)
in improving the QoL, whilst shorter-time sessions (≤45 min) had no significant effect on the QoL.
Despite the incidence of breast cancer, the number of survivors has increased [4] owing to
advanced medical care and facilities. However, this greater number of survivors are still suffering from
treatment-induced adverse effects, such as impairments to social functioning, physical functioning,
and QoL [5,6]. In post-treatment survivors, poor subjective well-being and impaired health-related
QoL, along with extreme financial distress, could be vital risk factors of mortality [45]. A study on the
Brazilian female population revealed that physical inactivity was responsible for more deaths (~12%)
due to breast cancer, whilst other modifiable risk factors contributed for ~5% of deaths [46]. Evidence
from a cohort study emphasized the importance of exercise in the reduction of all-cancer mortality,
and it was reported to extend lifespan by ~3 years in both women and men [47]. In general, exercise
interventions are aimed at improving the health-related physical fitness and overall well-being of
cancer survivors.
Exercise prescription has gained significant attention in recent decades as a way to overcome
treatment-induced adverse effects and to promote overall well-being. Several trials have adopted
various exercise protocols, and these trials have demonstrated the practical applications of such
interventions in improving the clinical outcomes in breast cancer survivors [31,37,48]. Prior to
establishing this evidence, patients receiving cancer treatment were advised to stay rested and to
avoid physically challenging activities that may cause additional burden and fatigue, instead of
alleviating the cancer-related fatigue [49]. This conceptual notion was eventually ruled-out as studies
revealed the beneficial effects of exercise interventions on the improved physiological and psychological
domains of cancer survivors. In our systematic review, we synthesized the data from 26 RCTs that
adopted various types of exercise patterns and with different frequencies, durations, or time of session.
We found that exercise intervention significantly improved the clinical outcomes, including the QoL,
PF, and SF in breast cancer survivors. Although the overall response of the outcomes towards the
exercise interventions was favorable, the adopted exercise protocols in the RCTs were dissimilar in their
type [26,33,38,42], duration [32,43], time and dose [30,39] or frequency [28,33]. Therefore, identification
of the responsible exercise moderators and the optimal time and dose of exercise is required in order to
shed light on the best exercise prescription for breast cancer survivors.
QoL is a subjective andmultidimensional outcome, encompassing physical function, psychological
state and emotional well-being, and social well-being [50]. Much has been done to address the
influence of exercise interventions on a patients’ QoL, and several studies have also found either
an unchanged or slightly improved QoL in breast cancer survivors. This inconsistent result in the
QoL outcome from exercise interventions might be linked to several factors associated with the
exercise characteristics, such as the type, frequency, duration, or time of session [10,26,28,51]. In our
meta-analysis, the pooled outcome of 18 trials showed a profoundly improved QoL following exercise,
where the heterogeneity was high. Similarly, a previous meta-analysis of 34 RCTs reported an improved
QoL with exercise, although this improvement was not moderated by the exercise type or any other
exercise characteristics [16]. Another meta-analysis of eight RCTs found a non-significant improvement
in theQoL, linked to the intensity or type of exercise [17]. On the other hand, the practice of conventional
exercises, such as yoga and qigong, was also reported to improve the QoL and well-being of female
breast cancer survivors [26,41,48]. It indicates that either the type or duration of exercise could
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influence the QoL scores in breast cancer survivors, although the optimal duration for this promising
amelioration is still inconclusive.
The strength of our study was that we identified the “time of session” as a promising variable,
which we considered to be responsible for the improved QoL in female breast cancer survivors.
Our meta-regression analysis revealed a significant correlation between the “time of session” and
an improved QoL, whereas other variables (i.e., type, frequency, duration, and total exercise time)
were not associated with the QoL. A further subgroup analysis demonstrated that a shorter-time
of session (≤45 min) did not contribute to better a QoL. However, both the medium-time (>45 to
≤60 min) and longer-time of sessions (>60 to 90 min) profoundly improved the QoL, where longer-time
sessions showed a bigger effect size. In contrast to our findings, a prior meta-analysis found that
exercise intervention durations of ≤45 min (five trials) and >45 min (three trials), had improved the
QoL in patients with mixed types of cancer [15]. Another study showed that a longer time (higher
dose) of either aerobic or combined exercise (50 to 60 min) was not superior to a standard aerobic
exercise (25 to 30 min) program, in terms of the physical functioning of breast cancer survivors [14].
Another meta-analysis reported that neither the exercise time nor its duration significantly influenced
the QoL of patients with cancer [16]. Similarly, a recent meta-analysis showed an improved QoL in
cancer patients after supervised exercise, although no statistical difference was noted for the other
exercise variables, including time of session [8]. Nevertheless, our findings were in agreement with the
recommendations of the European Society for Clinical Nutrition and Metabolism (ESPEN), which cite
that cancer patients should be engaged in exercise sessions for 45 to 60-min per day [52]. Therefore,
to achieve the maximum benefits from exercise interventions, breast cancer patients should participate
in any type of exercises for >45 min per session.
To the best of our knowledge, this is the first systematic review and meta-analysis to address
the effects of exercise on the SF of female breast cancer survivors. Despite the etiology of cancer and
cancer treatment, there is still a limited understanding of cancer-related consequences, especially
of patients’ social domains. Either the diagnosis or treatment can cause sequential damages to
the social functioning of women with breast cancer [53]. In the overall health-related QoL, family
well-being and social well-being are the most considerable social domains for female breast cancer
patients. Therefore, it is necessary to study the impacts of cancer on the family and social relationships
following diagnosis, treatment, and during survival [54]. Group exercise interventions were said
to foster an improved overall QoL in survivors, because the group exercises provided access to
other survivors, and therefore could address the issues related to stained social relationships, stigma,
and isolation [55]. In view of this, a meta-analysis using mixed types of cancer reported improved
SF in cancer patients after exercise interventions. To be specific, the improved SF was observed with
more exercise frequency (3–5 times/week) and with shorter workouts, but this effect was not observed
with longer workouts [15]. Another meta-analysis of nine trials attempted to address the association
between exercise and social well-being in breast cancer survivors. However, we noticed a discrepancy
between that study’s explanations and the pooled data. In addition, the role of exercise variables
was not fully disclosed and the data were not extracted from several eligible studies [51]. In our
meta-analysis, we included all eligible studies (15 trials) and we found an extremely improved SF
after exercise. However, this beneficial effect might not be correlated with the exercise characteristics,
based on the heterogeneity.
Next, we found that exercise interventions substantially improved the PF of female cancer
survivors. Previous meta-analyses have also indicated that physical activity was correlated with
an improved PF and decreased fatigue symptoms in breast cancer survivors [17,56]. A recent
meta-analysis by Juvet and colleagues [57] concluded that there were improvements to the PF in
breast cancer trials with exercise intervention. The study’s subgroup analysis for aerobic, resistance,
and mixed interventions showed no significant group differences. However, the greater beneficial
effects of mixed interventions appeared to be inconsistent with the data provided in their study [57].
In another meta-analysis, the improved physical fitness of cancer patients was said to be connected
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with their exercise frequency (i.e., 5 times/week) and the duration of each intervention (shorter and
longer) [15]. However, with a relatively higher number of studies (15 trials), we found no involvement
of exercise characteristics on the improved PF. Furthermore, the pooled outcome from our study
was consistent with previous meta-analyses and RCTs, which affirmed the benefits of exercise on an
improved PF in cancer survivors. It is interesting to note that improved PF in breast cancer survivors
was not superior with a higher dose of aerobic or combined exercise as compared to a standard dose
of aerobic exercise [14]. Moreover, other meta-analyses have revealed that an improved PF was not
moderated by the patient’s demographic, clinical, and exercise characteristics or the FITT factors [8,16].
Considering these points, in order to maximize the benefits of exercise interventions on PF, the type of
exercise with the most optimal frequency, duration, or time still needs to be further established.
Significance of Exercise Intervention, Scales, and the Included Trials
To address the importance of the “time of session” in cancer survivors, one study showed an
improved QoL with both a shorter and longer “time of sessions” [15], whilst another study claimed no
influence of “time of session” on the QoL [16]. Our study found that the “time of session” is primarily
associated with an improved QoL in breast cancer survivors. The improved PF, SF, and overall QoL
in cancer survivors following exercise intervention could be explained by several possible aspects.
Exercise has been shown to increase the lean body mass of breast cancer patients, and decrease the fat
percentage, body mass index, and insulin level with improved muscle strength and cardiopulmonary
functions [25,51]. Moreover, by participating in group or supervised exercise programs, patients
can interact with the researcher or other patients that are facing similar issues. This setting allows
patients to obtain health advice on their overall well-being, and it also helps to decrease their sense of
isolation, social stigma, as well as improve their self-esteem [55,58]. The clinical outcomes reported
in our study were self-reported and measured using various scales, including the EORTC-QLQ-C30,
FACT-G, FACT-B, and SF-36. These self-reported questionnaires and scales are designed to provide
robust and meaningful measurements, which are determined by objectivity, reliability, and validity.
All the scales used in the included trials were well-validated, feasible, and are widely accepted in
cancer clinical trials [59–62]. The empirical evidence from previous studies and the data from our
meta-analysis emphasized that the implementation of exercise interventions is crucial in ameliorating
the clinical outcomes in breast cancer survivors. Based on the location of the included studies, it might
not be irrelevant to state that most of these RCTs were from Europe and North America. Therefore,
we assume that this observation not only indicates the higher breast cancer survival rates in those
regions, but it also implies the need for significant efforts and studies targeted towards the Asian
region, where post-treatment cancer rehabilitation is relatively lower than the incidence.
4. Materials and Methods
4.1. Search Strategy and the Identification of Studies
Comprehensive article searches were performed using the PubMed (Medline), Web of Science,
ScienceDirect, EMBASE, SportDiscus, and Google Scholar databases to identify the relevant articles
(until February 2019). The keywords used for the article search were, “breast cancer”, OR “breast
tumor”, OR “breast neoplasms”, OR “breast carcinoma”, AND “exercise”, OR “aerobic exercise”,
OR “aerobic training”, OR “resistance exercise”, OR “resistance training”, OR “strength training”,
OR “physical activity”, OR “kinesitherapy”, OR “motor activity”, OR “sports”, OR “yoga”, OR “Tai
chi”, OR “Qigong”, AND “quality of life”, OR “QoL”, OR “outcomes”. The keywords denoting
breast cancer and exercise were separately used again to search for studies with “social function” and
“physical function” outcome measures. In addition, a manual search was conducted using the reference
list of retrieved articles, systematic reviews, and meta-analyses to identify the relevant studies.
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4.2. Selection Criteria
Two investigators (Feng Hong and Weibing Ye) independently screened the titles and abstracts of
all the identified articles, and the duplicates were removed. The full-text articles were then evaluated
for inclusion in the systematic review and the meta-analysis. The inclusion criteria were as follows:
(1) All the studies were RCTs; (2) the participants were adults diagnosed with breast cancer; (3) the
experimental group (breast cancer patients) had undergone any type of exercise intervention, whilst
the control group (breast cancer patients) had not undergone any exercise intervention; (4) the trials
measured the QoL, PF, SF, or all these factors of the cancer patients; (5) the data of the outcomes was
provided before and after the interventions; and (6) the study was published in English. The exclusion
criteria were: (1) Inadequate statistical information or poor quality information; (2) insufficient
information about the exercise characteristics; (3) the trials included other types of cancer patients or
the studies were without a control trial; and (4) the data were provided as mean change within the trial.
Two of the authors (Feng Hong and Weibing Ye) carefully reviewed the studies, and then selected
the articles that met the inclusion criteria. Then, a further in-depth review and additional information
on the clinical outcomes and exercises was provided by other authors (Chia-Hua Kuo, Yong Zhang,
and Yongdong Qian). Potential discrepancies regarding the inclusion or exclusion of the articles were
discussed and resolved by another author (Mallikarjuna Korivi). The article review and selection
process was performed using the Preferred Reporting Items for Systematic Review and Meta-Analysis
(PRISMA) guidelines [63], and a detailed flowchart was provided (Figure 1).
4.3. Quality Assessment
The quality assessment procedure for the included RCTs was performed using the Cochran
Collaboration risk of bias tool as in a previous study [64]. Each included study was evaluated for
the source of bias, including: (1) random sequence generation and allocation concealment (selection
bias); (2) blinding of study participants and personnel (performance bias); (3) blinding of outcome
assessments (detection bias); (4) incomplete outcome data (attrition bias); (5) selective reporting
(reporting bias); and (6) other sources of bias. The quality of each domain was rated as “low risk”,
“high risk”, or “unclear”, and they were indicated using green (+), red (−), and yellow (?), respectively.
The quality assessment of the trials was independently performed by two of the three researchers, and
then compared (Feng Hong, Weibing Ye, and Yongdong Qian). The disagreements were resolved by
discussing with another review author (Mallikarjuna Korivi).
4.4. Data Extraction
Data from all the included trials were extracted by two independent authors (Feng Hong and
Weibing Ye), and they were verified by another review author (Mallikarjuna Korivi). All the data were
presented as mean with standard deviations (SD). Any data provided as standard error in the trials
were converted to SD. Details of the included articles, such as authors, year, and country of publication,
were recorded. Demographics of the patients (i.e., mean age, sample size, and cancer stage), as well as
the characteristics of the exercise (i.e., type, time of session, frequency, duration, and total exercise time)
were extracted from the included trials. The type of questionnaire used to determine the outcome
measures (QoL, PF, SF) was also obtained, and the details are presented in Table S1.
4.5. Outcome Measures
All the clinical outcomes, including the QoL (general health, global, and overall QoL), PF,
and SF, were self-reported. The general health, PF, and SF subscales from the generic short-form 36
(SF-36) [61] were used as the measures for self-reported QoL, self-reported PF, and self-reported SF,
respectively. The global QoL, PF, and SF scales from the disease-specific European Organization for
Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire [65] and the cancer rehabilitation
evaluation system short form [66] were used as the measures for self-reported QoL, self-reported
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PF, and self-reported SF. The total scores from the functional assessment of cancer therapy (FACT-G,
FACT-B) [62,67] were used as a measure for the self-reported QoL, whilst the physical well-being scale
was used as a measure of the self-reported PF, and the social and family well-being scale was used as a
measure of SF.
4.6. Subgroup Division and Analysis
The identified trials with sufficient “time of session” data were categorized into three subgroups,
including the shorter-time of session (≤45 min), medium-time of session (>45 to ≤60 min),
and longer-time of session (>60 to 90 min). This division was based on the time of each exercise session
that the cancer patients performed during the course of intervention. The European Society for Clinical
Nutrition and Metabolism (ESPEN) has recommended that cancer patients should engage in 45 to
60 min exercise sessions per day [59]. Based on the ESPEN recommendations and several other studies,
we intended to examine the effects of shorter- and longer-times of exercise sessions on the clinical
outcomes. Other exercise characteristics (i.e., type, frequency, duration, and total exercise time) were
not correlated with the change of outcomes in patients with breast cancer.
4.7. Statistical Analysis
The Cochrane Collaboration’s Review Manager (RevMan 5.3., Copenhagen, Denmark) program
was used to analyze the effects of exercise characteristics on the clinical outcome measures (QoL,
SF, PF) in breast cancer survivors. Owing to the different measurement scales, we calculated the
standardized mean difference (SMD) at 95% confidence intervals (CI). The I2 statistic was reported as
an indicator of heterogeneity, with I2 ≥50% representing high heterogeneity and I2 <50% representing
low heterogeneity. If the heterogeneity was low, the fixed-effects model was used for the meta-analysis.
If heterogeneity was high, then the random-effects model was used for the meta-analysis. Based on the
heterogeneity significance (pooled outcome), meta-regression analysis was performed to identify the
correlations between the exercise characteristics (type, time, frequency, duration, and total exercise
time) and the outcome measures (QoL, SF, PF) of breast cancer patients. We used the STATA version 12
(StataCorp, College Station, TX, USA) for the meta-regression analysis. In the analysis, the exercise
“time of session” was found to be associated with an improved QoL. Hence, the eligible trials containing
“time of session” data were assigned into three subgroups, as described above. Then, the subgroup
analysis was conducted to identify the effective “time of exercise session” to improve the QoL in female
breast cancer patients.
5. Conclusions
Our findings convincingly demonstrated that exercise intervention (of any type) is beneficial to
improving the QoL, SF, and PF of female breast cancer survivors. However, the improved QoL from
exercise intervention was specifically associated with the length of the exercise session. Participation
in the exercise sessions for more than 45 min (medium- or longer-time) effectively improved the QoL,
whilst a shorter-time of session (<45 min) did not contribute to a significant improvement. Our findings
suggest that the “time of session” could be the most decisive factor in improving the overall QoL
in cancer survivors. Therefore, prescribing exercise programs with >45 min per session would be a
promising approach to promoting the overall health-related QoL of breast cancer survivors.
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